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ABSTRACT 
Replacement of standard chemotherapy with targeted therapy for the cure of 
cancer would be a desirable way to improve treatment, especially for those 
tumors with low survival rates, giving patients longer life expectancy and better 
quality of life with a reduction of the severity of side effects. Progress in the 
fields of genomics and proteomics and increased understanding of the 
mechanisms leading to cancer have allowed many potential biological targets to 
be identified for therapeutic intervention. The projects described herein aim to 
identify small molecules that interact with proteins that are relevant in 
pathways related to either uncontrolled proliferation or evasion of apoptosis in 
tumor cells. 
Endosulfatases Sulf1 and Sulf2 are located in the extracellular matrix and the 
cell surface. They modify the sulfation state of heparan sulfate proteoglycans, 
which affect a number of cellular signaling events, ultimately resulting in 
proliferation and cell growth. Although there is evidence of the involvement of 
Sulf1 and Sulf2 in cancer processes, their action is not clearly understood. 
Therefore, the development of potent (low micromolar range) inhibitors of 
these endosulfatases is desirable for target validation and hit discovery 
purposes. Published experimental evidence suggests that sulfatases have some 
degree of arylsulfatase activity and that sulfamates are often efficacious for the 
inhibition of this enzyme class. Therefore, a range of aromatic-based tertiary 
(35 and 37) and primary (38) sulfamates were synthesized and tested in a 
biochemical assay against Sulf2 and counter-screened against ARSA and ARSB. 
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The tumor suppressor p53 is a transcription factor activating a number of 
genes responsible for cell growth arrest, senescence and apoptosis. Tumor cells 
evade apoptosis and proliferate by subverting the p53 pathway, either by 
mutation of the TP53 gene, resulting in the expression of inactive p53 (50% of 
cancers), or through amplification or overexpression of proteins responsible for 
p53 regulation, most notably MDM2 and MDMX. As such, modulators of the 
interaction of MDM2 and MDMX with p53 are of potential interest as antitumor 
agents and are being actively pursued by many research groups. 
More recently, evidence that MDMX provides a mechanism of resistance when 
inhibiting the MDM2:p53 interaction has focused efforts towards dual 
MDM2/MDMX:p53 inhibitors. Surprisingly, even though MDM2 and MDMX have 
a high sequence homology within the p53 binding domain (>53%), most of the 
small molecules designed to bind MDM2 show much lower binding affinity 
towards MDMX. Arising from a project aimed at developing inhibitors of the 
MDM2:p53 interaction, a small panel of isoindolinones showed low micromolar 
activity when counterscreened against MDMX. One of these compounds, 153, 
containing two stereogenic centres, was utilized as the starting point for further 
structure-activity relationships, SAR, investigation to identify either dual 
inhibitors of the MDM2/MDMX:p53 or selective MDMX:p53 antagonists. 
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CHAPTER 1. TARGETED CANCER THERAPY AND DRUG 
DISCOVERY 
 Cancer 1.1
There are more than two hundred disease forms that are designated as 
‘cancer’, affecting organs or tissues in the body.1 All are characterized by several 
common features, such as uncontrolled cellular replication and irregular 
growth with respect to normal tissues. At later stages, metastasis, the outspread 
and invasion of other tissues distinct from the primary site, is often observed 
and represents a leading cause of death from the disease.2 In 2012 
approximately 14.1 million cancers were diagnosed worldwide3-4 and, in the 
same year, it was estimated that 8.2 million people died as a consequence of the 
condition. According to projections, by 2030 the number of new cases 
worldwide will reach 20.3 million and the number of deaths will escalate to 
13.2 million, with a steep rise in developing countries driven by changes in 
lifestyle and increasing industrialization.5 In the United Kingdom, cancer is the 
leading cause of death, mainly as a result of the increase in life expectancy 
observed in the last decades.6 Incidence rates have risen over the last four 
decades (Figure 1.1) and in 2011 331,4877 people were diagnosed with cancer 
in the UK, while 159,178 died as a consequence of the disease.  
Primary factors triggering the development of neoplasms are genetic 
predisposition, a number of infectious agents, such as viruses (e.g. Human 
Papilloma Virus), occupational exposures to carcinogens, age and lifestyle. In 
this regard, it has been suggested that a lack of exercise, obesity, alcohol 
consumption, smoking and excessive exposure to UV radiation may be 
responsible for up to 42% of all cases.7 Cancer research is currently among the 
most prolific fields in scientific disciplines as the achievement of both a 
thorough understanding of the disease and more effective and safer treatments 
are required. 
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Figure 1.1 - European age-standardized incidence rates per 100,000 
population, by sex, Great Britain (1975-2011). 
Reproduced from Cancer Research UK.7 
 Key steps in cancer pathogenesis 1.2
In 2000, Hanahan and Weinberg8 described the ‘hallmarks’ of cancer, a set of 
acquired features that allow the gradual evolution of normal cells to the most 
aggressive form of malignant tumor. In their review, they identified six 
characteristics acquired by cancer cells (Figure 1.2): 
1. Self-sufficiency in growth signals: unlike normal cells, whose replication is 
activated by external signaling events, cancer cells may develop the ability 
to mimic those signals themselves. 
2. Insensitivity to antigrowth signals: in addition to low stimulation by growth 
inducers, normal cells are kept in a quiescent state by the release of 
antiproliferative signals that tumor cells are able to avoid. 
3. Evasion of apoptosis: programmed cell death is one of the tools used to limit 
the progression of neoplasms. Under physiological stress conditions, such 
as those found in the tumor environment, pathways leading to apoptosis 
should be activated but are evaded by cancer cells. 
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Figure 1.2 - The hallmarks of cancer. 
Reproduced from Hanahan, 2011.9 
4. Limitless replicative potential: normal cells are able to replicate only a 
limited number of times, proportional to the length of the telomeres, 
hexanucleotide TTAGGG repetitive units found at the end of chromosomes. 
To become immortalized, tumor cells overexpress the enzyme telomerase 
or activate an alternative lengthening of telomeres (ALT) mechanism to 
elongate telomere units at the end of DNA strands. 
5. Sustained angiogenesis: tumors require a blood supply to provide oxygen 
and nutrients and to allow the discharge of carbon dioxide and other wastes 
produced during the metabolic cycle. To satisfy these requirements, tumor 
cells induce new blood vessels to grow from the existing quiescent ones 
after activation of an ‘angiogenic switch’. Angiogenesis, the formation of 
new blood vessels, is regulated by several factors having either a positive 
(e.g. vascular endothelial growth factor-A, VEGF-A; acidic and basic 
fibroblast growth factors, FGF 1/2) or negative (e.g. thrombospondin-1, 
TSP-1) effect on the development of new vessels. 
6. Invasion and metastasis: these represent the stepwise process by which 
tumors spread into the body and originate secondary neoplasms. Starting 
from the localized invasion of neighbouring tissues, malignant cells 
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propagate through the circulatory and lymphatic systems and form 
micrometastatic outgrowths that ultimately lead to the formation of 
secondary tumors in other organs. 
In a more recent review,9 Hanahan and Weinberg identified two new 
hallmarks to be added to the six previously described (Figure 1.2): 
1. Reprogramming energy metabolism: cancer cells undergo a metabolic 
switch and provide themselves with energy through alternative pathways 
that are not yet completely understood. 
2. Evading immune destruction: a well-functioning immune system should 
detect and destroy tumors at an early stage of development and the reasons 
why this does not always happen are still to be elucidated. 
Two new features, or ‘enabling characteristics’, that allow tumor cells to 
acquire the aforementioned set of capabilities (Figure 1.2) were also 
introduced: 
1. Genome instability and mutation: to acquire the hallmarks of cancer, cells 
need to accumulate a number of mutations. This is made possible by cell 
sensitization to carcinogens, impairment of DNA repair pathways and 
breakdown of the tumor suppressor mechanisms that should trigger 
senescence or apoptosis to prevent propagation of damaged DNA. This may 
lead to acquisition of hyper-mutated phenotypes which allow mutations 
conferring other hallmarks to be accumulated more rapidly. 
2. Tumor-promoting inflammation: it has been recently found that tumor-
related inflammation processes can play a role in fostering tumor 
progression. It has become clear that growth and proangiogenic factors, as 
well as other bioactive molecules, are provided to the tumor 
microenvironment as a consequence of the inflammatory state, thus 
contributing to the expansion of the malignancy. Further mutation of 
neoplastic cells can also be promoted by reactive oxygen species or other 
chemicals produced by inflammatory cells. 
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 Cancer treatment 1.3
The first written record of cancer dates back 5000 years in ancient Egypt. 
Hippocrates (460-370 BC) in Greece and the Roman Celsus (50-28 BC), 
described tumors using the word ‘crab’, carcinos and cancer in ancient Greek 
and Latin, respectively. Later, Galen (130-200 AD), another Roman physician, 
referred to cancer with the Latin word for ‘swelling’, oncos, which is still found 
in medical terminology.10 One of the first attempts at treating cancer was the 
excision of the outgrowth that could result in deadly infections and blood loss 
or, if the patient survived, could end up in remanifestation of the disease, 
accounting for a low rate of success. It was not until the modern age that 
significant progress has been accomplished in the knowledge and treatment of 
cancer. With a deeper understanding of the mechanisms leading to the onset, 
development and spread of tumors, and with a larger range of techniques useful 
both for diagnosis (ultrasound, computer tomography, magnetic resonance 
imaging) and treatment (cryosurgery, radiofrequency ablation, X-rays, proton 
beam radiation) many are the tools currently available in the battle against 
cancer.10-11 
In addition to surgery and radiotherapy, pharmacotherapy has become 
increasingly important over the last sixty years. Following the discovery that 
some synthetic substances, for example nitrogen mustard, widely used during 
World War I, had cytotoxic effects towards rapidly-dividing cells, including 
cancer cells, several drugs were developed. This kind of pharmacologic 
approach to cancer treatment is referred to as chemotherapy and the drugs 
used can be classified into three main categories, depending on their mode of 
action. The first class includes alkylating agents, such as temozolomide 1, and 
platinum-based drugs, e.g. carboplatin 2, which disrupt DNA replication and 
induce DNA damage triggering apoptosis.12-13 
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Another strategy involves the use of antimetabolites, chemotherapeutic 
agents structurally similar to endogenous biomolecules, to inhibit metabolic 
pathways. 5-Fluorouracil 3, a uracil and thymine mimic often used for the 
treatment of colorectal cancer, is converted in vivo to three active metabolites. 
5-fluorodeoxyuridine monophosphate 4 (FdUMP) inhibits thymidylate 
synthase, the enzyme producing the nucleotide deoxythymidine 
monophosphate. 5-fluorodeoxyuridine triphosphate 5 (FdUTP) and 
fluorouridine triphosphate 6 (FUTP), instead, are misincorporated in RNA and 
DNA and lead to dysfunctional chains.14 
 
A third typology of therapeutic drugs includes natural products, such as the 
antimitotic agent taxol (Paclitaxel, 7) from Taxus brevifolia, which counteracts 
the depolymerization of microtubules during cell division by binding to the β-
tubulin subunits. 
 
Unfortunately, the administration of chemotherapeutic agents often leads to 
debilitating side effects (nausea, vomiting, hair loss, etc.) due to the lack of 
selectivity towards target tumor cells and their more generalized action on all 
rapidly dividing cells in the body, such as cells in the bone marrow, skin, hair 
follicles, and digestive tract. To avoid harming healthy cells, new strategies have 
been recently conceived, including targeted cancer therapy.11 This approach 
exploits recent significant progress in the field of molecular biology to identify 
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molecular pathways directly linked to the onset and/or progression of tumors 
and aims to develop drugs addressing specific cellular mechanisms. Because 
these molecular pathways may be found in smaller subgroups of patients 
affected by a certain type of cancer, a stratified, or personalized, approach to the 
administration of drugs is required. The most remarkable success obtained with 
this strategy is Glivec™ (imatinib, 8), a tyrosine kinase inhibitor approved by 
the Food and Drug Administration (FDA) in 2001, designed for the treatment of 
chronic myelogenous leukaemia (CML) and targeting a fusion tyrosine kinase 
originating from reciprocal translocation between the ABL gene (Abelson 
murine leukemia viral oncogene homolog 1) on chromosome 9 and the BCR 
(breakpoint cluster region protein) gene on chromosome 2215 resulting in an 
abnormally long chromosome 9+ and a short chromosome 22-, also known as 
the Philadephia chromosome, carrying a BCR-ABL fusion gene.16 The fusion 
gene encodes for a BCR-ABL fusion oncoprotein with an elevated tyrosine 
kinase activity that ultimately enhances cell proliferation. After five years of 
treatment with Glivec, the survival rate is 89% (17% estimated relapse rates), 
considerably higher than the 30% achieved with treatments available before 
the drug entered the market.17 
 
In most cases, the co-administration of several agents is required to overcome 
the heterogeneity of cancerous cells within a tumor and resistance mechanisms 
that are likely to arise. Combination therapies commonly include the use of both 
cytotoxic and targeted agents, or the administration of two drugs acting on two 
different targets, either in the same pathway or in parallel pathways.18 
 The stages of drug discovery 1.4
The modern scientific approach to drug discovery (Figure 1.3)19 starts when 
fundamental research provides evidence for the identification of a suitable 
target, a protein-protein interaction or a biomolecule, such as an enzyme or a 
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receptor, linked to a condition for which no efficacious cure is available or 
better treatments are needed. To be suitable for drug discovery, the 
relationship between the disease and the biological target needs to be proved 
and validated. Additionally, the target must be ‘druggable’, meaning that it must 
possess features, such as catalytic or allosteric pockets, likely to interact with a 
small-molecule modulator. The safety of addressing a particular target has to be 
considered and a profound knowledge of the pathways in which it might play a 
role is desirable. 
Once a target has been identified, more studies are required to validate it, 
often using a tool compound active against the target. In order to minimize 
failure of a drug in the clinic due to the lack of desired effect, once a lot of money 
and effort have already been invested, target identification and target validation 
are crucial stages of drug discovery. In these phases, studies include both data 
mining of information in the literature (bioinformatics) and experimental 
models at all levels, starting from genetic models up to in vivo studies (e.g. 
genetic validation, cell-based systems, animal models). 
 
Figure 1.3 - Flow chart representing the stages of drug discovery. 
The stage of hit identification for a validated target requires development of 
an assay to test for modulation of the target. The primary assay can be either a 
Approval 
Clinical evaluation 
Preclinical evaluation 
Lead optimization 
Lead generation 
Hit identification 
Target validation 
Target identification 
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cell-based assay, frequently applied for receptors and ion channels, or a cell-
free biochemical assay that will only include the biochemical entity in question, 
more often used for enzyme targets. An efficient assay is highly reproducible, 
gives good quality data and is cost-effective. Common ways of identifying a hit 
compound include virtual screening, screening of compound libraries (either 
high-throughput or focused), fragment screening and structure-based drug 
design, if a crystal structure of the target is available.19 
Once a hit has been discovered and validated, usually by re-synthesis and re-
testing, further development of the active pharmacophore is carried out. During 
the lead generation phase, extensive structure-activity relationship (SAR) 
studies are carried out aiming to increase potency against the desired target 
and selectivity over similar biological entities. At this stage, the physicochemical 
(e.g. molecular weight, rotatable bonds, hydrogen bond donors/acceptors, 
ionization state, solubility) and pharmacokinetic properties (absorption, 
distribution, metabolism, elimination, or ADME, properties) are also evaluated. 
Early assessment of toxicity (e.g. behavioral effects, cardiotoxicity, 
mutagenicity) is also performed. Once a lead compound, a ‘drug-like’ molecule, 
has been selected, optimization is required for the identification of a clinical 
candidate satisfying all the requirements.19 
Safety and efficacy of the drug candidate are usually assessed in pre-clinical 
studies on animal models before administration to healthy human volunteers in 
phase I clinical trials, principally to assess the dose-response of the drug. Some 
candidates will enter Phase II for efficacy and safety studies and, if successful at 
this stage, larger scale Phase III clinical trials to provide data on side-effects.13 
The entire process leading to the discovery of a drug generally can last about 
12-15 years, with costs of the order of billions of pounds. Failure is possible at 
each stage and it is, therefore, critical to recognize the weaknesses of a drug 
discovery project as early as possible. 
The projects discussed herein are both at the target validation stage, and 
medicinal chemistry efforts were started in order to provide better chemical 
tools for validation than the compounds available from the literature and to 
start building a confident SAR for hit discovery. 
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CHAPTER 2. INTRODUCTION TO SULF2 
 Sulfatases 2.1
Sulfatases are a class of hydrolase enzymes that catalyze the cleavage of sulfate 
esters to release the corresponding alcohol or phenol and an inorganic sulfate 
(Scheme 2.1). 
 
 
Scheme 2.1 - Sulfatases catalyze the hydrolysis of sulfate esters. 
The nature of sulfatase substrates is diverse and they are involved in many 
different signaling pathways within the cell. Some sulfatases are specific for the 
desulfation of sulfated carbohydrates, for example in the context of saccharide 
residues on glycosaminoproteoglycans, while others recognize and cleave the 
sulfate group appended to lipophilic scaffolds, such as steroidal sulfates.20 
Fifteen human sulfatases are currently known, in addition to further sulfatases 
from invertebrates, lower eukaryotes and prokaryotes.20 In most cases, these 
enzymes are membrane bound and located in the endoplasmic reticulum or the 
Golgi network. Two sulfatases, Sulf1 and Sulf2, and several others found in lower 
eukaryotes are secreted into the extracellular matrix and exist as soluble 
proteins.20 Studies on this class of enzymes have highlighted the high degree of 
conservation of primary structure across the known sulfatases (ranging from 
prokaryotic to human), particularly in the N-terminal region containing the 
catalytic site. As reviewed by Hanson and co-workers,20 this part of the peptide 
chain contains two key motifs, referred to as sulfatase signature sequences I and II. 
The former is a consensus sequence involved in the recognition event necessary 
for the post-translational modification required for catalytic activity, while the 
latter sequence plays a role in the catalytic mechanism of the enzyme.21 The 
signature sequence I for known sulfatases is shown in Figure 2.1.20-21 As 
highlighted in black, approximately six out of twelve residues in the motif are 
usually conserved in both prokaryotic and eukaryotic enzymes. 
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Figure 2.1 - Conservation of sulfatase signature sequence I in the majority of 
known sulfatases. 
Reproduced from Hanson, 2004.20 
The pentapeptide at the beginning of the signature sequence is almost invariable 
among human sulfatases and is generally well conserved in other species. The 
arginine residue at position 5 of the pentapeptide was found to be critical both in 
the formation and stabilization of a formylglycine (FG, 9; Figure 2.2) residue which 
is critical for the activity of all sulfatases.20 During biosynthesis, sulfatases undergo 
extensive post-translational modifications including one conferring catalytic 
activity. Active sulfatases exhibit the unusual formylglycine residue, which 
originates from oxidation of a conserved cysteine (or, in some cases, serine) 
through the action of a formylglycine-generating enzyme (FGE).20 Under 
1 2 3 4 5 6 7 8 9 10 11 12
Position 
of FG
Length
Human sulfatases
ARSA C T P S R A A L L T G R 69 507
ARSB C T P S R S Q L L T G R 75 533
ARSC C T P S R A A F M T G R 83 583
ARSD C T P S R A A F L T G R 89 593
ARSE C T P S R A A F L T G R 86 589
ARSF C S P S R S A F L T G R 79 591
ARSG C S P S R A S L L T G R 82 525
GalN6S C S P S R A A L L T G R 79 522
GlcN6S C C P S R A S I L T G K 91 552
GlcNS C S P S R A S L L T G L 70 502
IdoA2S C A P S R V S F L T G R 84 550
Sulf1 C C P S R S S M L T G K 87 871
Sulf2 C C P S R S S I L T G K 88 870
Invertebrate and
lower eukaryotic sulfatases
HeARS C T P S R S A I M T G R 106 559
HpArs C T P S R S A I M T G R 100 551
SARS C T P S R S A I V T G R 115 567
HpSulf1 C T P T R S Q L M S G R 80 508
PGSS C S P A R T A V L T G K 70 532
CARS C C P S R T N L C A A S 73 646
NARS C C P A R V S L W T G K 89 639
VARS C C P R T N L W R G Q 72 649
Prokaryotic sulfatases
FHS2S C T P S R S A I F S G K 82 464
KARS S A P A R S M L L T G N 72 577
PARS C S P T R S M L L T G T 51 533
PMdS S T P A R A C L L T G L 79 517
SChoS C A P A R A S F M A G Q 54 512
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physiological conditions, FG may be hydrated to give hydroxyformylglycine (HFG, 
10; Figure 2.2). Sulfatases lacking the formylglycine residue are catalytically 
inactive.22 Organisms having non-functional FGE suffer from an autosomal 
recessive disorder called multiple sulfatase deficiency. This rare disorder 
originates from mutations on the SUMF1 gene encoding for FGE, leading to a 
deficiency of this important post-translational modifying enzyme.20 
 
 
Figure 2.2 - The formylglycine residue. 
a) Biosynthesis of the catalytically active formylglycine (FG) residue in the 
sulfatase active site; b) equilibrium between formylglycine and its hydrated form, 
hydroxyformylglycine (HFG). Adapted from Spencer, 2013.23 
The location and physiological substrate of each of the fifteen human sulfatases is 
described in Table 2.1.20 The most extensively studied enzyme of this family is 
steroid sulfatase (STS), also known as aryl sulfatase C (ARSC) or estrone sulfatase, 
which has risen in interest over the last two decades due to its crucial role in 
hormone-dependent cancers, such as breast and prostate cancers. 
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Table 2.1 - Physiological substrate and subcellular location of known human 
sulfatases. 
Reproduced from Hanson, 2004.20 
Sulfatase Abbr. Physiological substrate 
Subcellular 
location 
Aryl sulfatase A ARSA Sulfatide Lysosome 
Aryl sulfatase B ARSB 
Dermatan sulfate, chondroitin 
sulfate 
Lysosome 
Aryl sulfatase C, Steroid 
sulfatase 
ARSC, 
STS 
Steroid sulfates ER 
Aryl sulfatase D ARSD Unknown ER 
Aryl sulfatase E ARSE Unknown 
Golgi 
network 
Aryl sulfatase F ARSF Unknown ER 
Aryl sulfatase G ARSG Unknown ER 
Galactosamine-6-sulfatase GalN6S 
Chondroitin sulfate, keratan 
sulfate 
Lysosome 
Glucosamine-3-sulfatase GlcN3S Heparan sulfate Lysosome 
Glucosamine-6-sulfatase GlcN6S Heparan sulfate, keratan sulfate Lysosome 
Glucuronate-2-sulfatase GlcA2S Heparan sulfate Lysosome 
Heparan-N-sulfatase GlcNS Heparan sulfate Lysosome 
Iduronate-2-sulfatase IdoA2S 
Heparan sulfate, dermatan 
sulfate 
Lysosome 
Endo sulfatase 1 Sulf1 Heparan sulfate ECM 
Endo sulfatase 2 Sulf2 Heparan sulfate ECM 
ER: endoplasmic reticulum. ECM: extracellular matrix. 
STS is one of four sulfatases whose X-ray crystal structure has been solved, in 
addition to two human sulfatases, aryl sulfatase A (ARSA) and aryl sulfatase B 
(ARSB), and a prokaryotic aryl sulfatase from Pseudomonas aeruginosa (PARS). 
Superposition of the four crystal structures highlights the degree of conservation 
of the globular domain folding (Figure 2.3).24 The STS crystal structure exhibits an 
additional transmembrane domain not present in the other structures, consisting 
of two antiparallel -helices, which anchors the enzyme to the membrane of the 
endoplasmic reticulum and is also believed to play a role in STS substrate 
recognition.24 
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Figure 2.3 - Structural data on human sulfatases. 
Superposition of the crystal structure of ARSA (blue), ARSB (magenta), STS (green) 
and PARS (yellow). Reproduced from Ghosh, 2007.24 
Despite the fact that no structures of sulfatases co-crystallized with their 
endogenous substrates have been reported, the available structural data and a 
series of mutagenesis studies are a valuable source of information to acquire an 
insight into the active site of these enzymes. It is postulated that the 
hydroxyformylglycine residue is stabilized by a number of positively charged 
residues (ArgA, HisA and LysA in Figure 2.4) and one of its hydroxyl groups makes 
an ionic interaction with a divalent metal cation (Ca2+ or Mg2+); the metal ion is 
additionally coordinated by a sulfate and by the electron-donor group on the side 
chain of AspA, AsnA, AspB and AspC. The metal cation may play a role in stabilizing 
the formylglycine, in binding the substrate and in activating the substrate for 
sulfate hydrolysis. Studies in which the residues significant for metal coordination 
were mutated showed decrease in binding and catalytic activity, confirming the 
globular domain 
active site 
STS membrane 
anchoring domain 
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importance of these active site residues.25 A further set of protonated basic 
residues (LysB and HisB) in the active site may be involved in protonation of the 
alcohol leaving group of the substrate and in binding to inorganic sulfate formed 
during the reaction.20,24 
 
Figure 2.4 - Representation of the active site of sulfatases. 
Reproduced from Hanson, 2004.20 
The lack of structural data for sulfatases interacting with their physiological 
substrates prevents a clear understanding of substrate recognition events and the 
enzyme domains involved. Nevertheless, since many sulfatases are able to 
hydrolyze small aryl sulfates, it is reasonable to infer that residues distinct from 
the active site may also be implicated in substrate recognition.20 
While it is widely agreed that the formyglycine residue is involved in the catalytic 
mechanisms, there has been much debate about the mechanism of the catalytic 
event.20 Initially, an addition-hydrolysis mechanism was proposed (Scheme 2.2a). 
This invoked nucleophilic attack of an oxy-anion of the sulfate substrate on the 
carbonyl carbon of the formylglycine, followed by a second nucleophilic attack 
carried out by a molecule of water on the sulfur to release the desulfated substrate 
alcohol (ROH). Subsequent loss of bisulfate ion would restore the active site 
formylglycine residue for subsequent entry into the catalytic cycle. 
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Scheme 2.2 - Proposed mechanisms for the desulfation of substrates by 
sulfatases. 
a) Addition-hydrolysis mechanism; b) transesterification-elimination mechanism; 
c) loss of sulfate and tautomerization of the enol to formylglycine. Reproduced 
from Hanson, 2004, and Bojarová, 2008.20,26 
The second proposed mechanism involves the hydration of the formylglycine to 
hydroxyformylglycine, whose second hydroxyl group would be necessary for 
sulfate cleavage. According to this theory, hydrolysis may proceed via a 
transesterification-elimination mechanism (Figure 2.2b):20 one of the two hydroxyl 
groups of the gem-diol of HFG attacks the sulfur atom of the sulfate thus releasing 
the desulfated substrate alcohol (ROH) in an SN2-like mechanism. Subsequently, 
the second hydroxyl group drives an α-elimination step that generates 
formylglycine and inorganic sulfate. Finally, a molecule of water re-hydrates the FG 
residue and regenerates the active HFG side chain. In the third proposed 
mechanism, after elimination of the alcohol following either pathway a or b, loss of 
an α-proton triggers elimination of the sulfate and subsequent tautomerization of 
the enol re-establishes the formylglycine moiety (Figure 2.2c). 
Unlike the wild-type enzymes, when [35S]-p-nitrocatechol sulfate is hydrolyzed 
by mutated ARSA and ARSB enzymes carrying a serine in place of the catalytic 
formylglycine, the labelled sulfur atom was not eliminated from the enzyme, 
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suggesting that the contribution of the oxygen lone pair of the second hydroxyl of 
HFG is required for the elimination step to occur. These data support the 
transesterification-elimination pathway.20 
 The importance of sulfation 2.2
To understand the role of sulfatases, it is necessary to examine in more detail the 
process of sulfation and its relevance in biological systems. 
The enzymes responsible for the sulfation of alcoholic and phenolic hydroxyl 
groups in vivo are sulfotransferases (SULTs) and, in eukaryotes, these rely on 3’-
phosphoadenosine 5’-phosphosulfate (PAPS, 11) as sulfate donor (Figure 2.5). The 
assertion that sulfation is a key biochemical reaction is supported by two main 
observations. Firstly, enzymes involved in sulfation and desulfation events 
(sulfotransferases and sulfatases) have been found across a wide range of (if not 
all) species. Secondly, PAPS is a high energy molecule requiring two molecules of 
ATP for its biosynthesis, making sulfation an expensive process for the cell in 
terms of energy balance.27 
 
 
ATP+ SO4
2- →  APS + PPi 
APS+ ATP →  PAPS + ADP 
 
Figure 2.5 - Bioynthesis of PAPS. 
In the first step, a molecule of adenosine 5'-phosphosulfate (APS) is formed from 
ATP and inorganic sulfate with release of pyrophosphate (PPi). Further 
phosphorylation of APS by a second molecule of ATP yields 3’-phosphoadenosine 
5’-phosphosulfate (PAPS, 11) which is used as a co-enzyme by sulfotransferases. 
On the basis of the current knowledge, three main roles of sulfation have been 
identified. First, the involvement of sulfation in the protection of organisms from 
xenobiotics has been long known.28 Lipophilic molecules of exogenous source are 
rapidly sulfated in order to obtain a) a less active and potentially less harmful 
compound and/or b) a water soluble counterpart which is rapidly excreted via the 
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urine or the bile (phase II metabolism). In addition to its crucial role in the 
preservation of the cellular environment, sulfation is also an important tool used 
both in the biosynthesis of hormones and in the activation of biomolecules.27 These 
aspects will be discussed in more detail below. 
 Steroid sulfatase inhibitors 2.3
Due to its involvement in hormone-dependent cancers, steroid sulfatase has been 
widely studied and considerable effort has focused on the design of small 
molecules that would efficiently inhibit its action. STS activates steroid hormones, 
for example estrone and dehydroepiandrosterone, by catalyzing the hydrolysis of 
the sulfate group from inactive sulfated precursors (Figure 2.6) 
 
Figure 2.6 - Hydrolysis of a sulfate group from a generic steroid catalyzed by 
STS. 
This desulfation route represents the major source of estrogen in estrogen-
dependent breast cancer where STS activity is elevated. Several publications by 
Potter and co-workers describe the synthesis and structure-activity relationship 
(SAR) evaluation of STS inhibitors.29-37 In these studies the sulfate moiety on a 
steroid scaffold was replaced by a range of functional groups with the potential of 
mimic the sulfate (phosphonate, H-phosphonate, thiophosphonate, sulfonate, 
sulfonamide, amide, urea). The best inhibition of sulfatase activity was obtained by 
molecules bearing a primary sulfamate moiety on an estrogen or estrogen-
mimicking fragment.30,33 
Key examples of steroid sulfatase inhibitors are estrone sulfamate (EMATE, 12)33 
and estradiol 3-O-sulfamate (E2MATE or PGL2001, 13).38 EMATE shows high 
potency against STS (IC50 < 0.1 nM in an intact MCF-7 cell assay).30 Additionally, 
EMATE has been shown to act as an irreversible inhibitor, with a time-dependent 
inhibition being observed upon formation of a covalent bond between the enzyme 
and the sulfamate group of the inhibitor. E2MATE 13, which is rapidly oxidized in 
 
 
19 
 
vivo to give EMATE 12, is also a potent inhibitor of STS (IC50 = 16 nM in placental 
microsomes).38 Unfortunately, both compounds show estrogenic effects that 
prevented their entry into clinical trials for estrogen-dependent breast cancer. 
Another therapeutic application was found for E2MATE, which is currently in a 
phase II clinical trial for the treatment of endometriosis in pre-menopausal 
women.23 
 
Subsequently, to avoid the side effects of steroid-based drugs and to improve 
biological selectivity and stability to human metabolism, Potter and co-workers 
focused their efforts on non-steroidal cores. They identified 667-COUMATE 14 
(STX 64 or irusostat) as an example of a potent coumarin-based irreversible 
inhibitor of STS (IC50 = 8 nM in placental microsomes). 667-COUMATE was 
unsuccessful in a number of clinical trials and is not currently under further 
development.23 
While primary sulfamates (-OSO2NH2) are irreversible inhibitors of STS, mono- 
or di- substitution on the sulfamate nitrogen to give a secondary  
(-OSO2NHR) or tertiary sulfamate (-OSO2NR2), respectively, yields reversible 
inhibitors. Such substituted sulfamates were also found to be significantly less 
active against STS (both having 87% inhibition at 1 µM).33 Taken together, the 
findings reported by Potter and his team suggest that the primary sulfamate 
moiety is an efficacious pharmacophore in the inhibition of STS and is crucial for 
the irreversible inhibition of steroid sulfatase while secondary and tertiary 
sulfamates reversibly bind to the target and show lower potency. 
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The cyclic sulfamate 15 was a potent inhibitor of STS and gave positive results in 
vivo in mice xenograft model. In contrast, the five-membered cyclic sulfamate 16 
was inactive.23 This may be explained by postulating in situ hydrolysis of the 
imino-sulfamate 15 to generate an ortho-formyl primary sulfamate which may be 
the agent inhibiting the enzyme.23 
Due to the conserved catalytic site, it is reasonable to assume that specifically 
designed sulfamate-based inhibitors may also have activity against other 
sulfatases. 
 Human endosulfatases (Sulf1 and Sulf2) 2.4
Interest in the field of sulfatases was increased by the discovery of two human 
sulfatases,39 Sulf1 and Sulf2, and their possible implication in cancer (see Section 
2.5).40 Similar to other sulfatases, Sulf1 and Sulf2 contain a cysteine residue, Cys87 
and Cys88, respectively,39 that is post-translationally modified to the active 
formylglycine counterpart. These enzymes have several characteristics that 
distinguish them from other known human sulfatases. Firstly, they have an amino 
acid sequence which is ~800 residues long, while most sulfatases have between 
500 and 600 residues.20 Sulf1 and Sulf2 are also the only known human sulfatases 
located in the extra-cellular matrix, as shown in Table 2.1.20 Finally, the other 
sulfatases that act on unbranched polysaccharide glycosaminoglycans (e.g. 
heparan sulfate, chondroitin sulfate or keratan sulfate) are exosulfatases, 
preferentially removing sulfate groups from the non-reducing termini of the 
polysaccharide chains. In contrast, Sulf1 and Sulf2 are endosulfatases that can 
hydrolyze sulfate esters internal to the polysaccharide chain. The natural substrate 
of these endosulfatases is heparan sulfate (HS, 17, Figure 2.7), a highly sulfated 
extracellular polysaccharide making up the hydrophilic part of proteoglycans. The 
structure and functions of heparan sulfate will be discussed in Section 2.4.1. In 
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their seminal work, Morimoto-Tomita and co-workers also reported low 
arylsulfatase activity of Sulf1 and Sulf2.39 Consistent with their extracellular 
localization, the activity of the endosulfatase enzymes is optimal at neutral pH.39 
 
Figure 2.7 - Example of a fragment of heparan sulfate, 17. 
Positions which are likely to undergo desulfation by Sulfs are marked in red. 
Sulf1 and Sulf2 are closely related in structure (63-65% sequence homology)39 
and their roles appear to overlap.41-42 Sulf1 or Sulf2 (Sulf1-/- or Sulf2-/-) knock-out 
mice do not exhibit major abnormalities and present no phenotype when 
compared to the wild-type animals. Double knock-out mice lacking both Sulf1 and 
Sulf2 genes, on the other hand, result in perinatal lethality and low long term 
survival frequency (15%). Taken together, these data suggest that Sulf1 and Sulf2 
may possess mutually redundant but essential roles during development.43 
Consistent with other sulfatases, the primary structure of the endosulfatases can 
be divided into two domains: an N-terminal domain bearing catalytic activity and a 
C-terminal domain. The latter, highly hydrophilic, domain is unique to Sulf1 and 
Sulf2 and is believed to be involved in recruiting the substrate.44 Indirect evidence 
that the C-terminal domain may be involved in recognition of the substrate 
heparan sulfate comes from the observation that there are several conserved 
sequences in this domain that are also present in the exosulfatase glucosamine 6-
sulfatase (which hydrolyses glucosamine 6-sulfate residues belonging to heparan 
sulfate).20 
Human endosulfatases are initially translated as a pre-proprotein.a A small 
peptide is post-translationally cleaved from the N-terminus generating the 
proprotein which is further processed by a furin-type protease. This cleaves the 
                                                        
a Precursor to an inactive protein precursor, which is called proprotein. 
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proprotein within the hydrophilic domain to form the Sulf protein as a 
heterodimer. These two subunits are subsequently linked together by a disulfide 
bridge (Figure 2.8).41 
 
 
Figure 2.8 - Post-translational process that brings to mature Sulf enzymes. 
A signal peptide at the N-terminus is cleaved from the pre-proprotein to originate 
the proprotein. Furin-type enzymes cleave the proprotein generating two 
fragments linked by a disulfide bridge. Reproduced from Rosen, 2010.41 
Several splice variants of Sulf1 have been identified in quail,45 human, dog and 
cat,46 and different splice variants of Sulf2 have also been reported.47 In both 
enzymes the shorter splice variants do not contain the Cys87 or Cys88 residue, 
respectively, and are, therefore, catalytically inactive. The splice variants of Sulf1 
have been shown to have opposing effects: the active full length variant of the 
enzyme appeared to prevent angiogenesis, while in the embryo the shorter form is 
predominant and showed an angiogenic effect possibly by binding to heparan 
sulfate and preventing the cleavage of 6-O-sulfates on which VEGF and FGF 
signaling pathways rely. The Wnt pathway (see Section 2.4.3) is affected by Sulf1 
splice variants in an opposite way: full length enzyme activates the pathway, while 
the shorter splice variant inhibits it.46 
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2.4.1 Heparan sulfate: the endogenous substrate of Sulf enzymes 
Heparan sulfate 17 (HS, Figure 2.7) is a linear polysaccharide, belonging to the 
family of glycosaminoglycans (GAGs), in which dimeric repetitive units consist of 
D-glucosamine (GlcN, 18) residues and either a D-glucuronic acid (GlcA, 19) or a L-
iduronic acid residue (IdoA, 20), shown in Figure 2.9.41 
 
Figure 2.9 - Structures of monosaccharide monomers 18, 19, and 20 which 
constitute heparan sulfate chains. 
Positions which are liable to sulfation are marked in blue. 
A heparan sulfate chain on average contains approximately 150 disaccharides44 
and has a half-life of 4-24 h.48 A heparan sulfate proteoglycan (HSPG) is formed 
when heparan sulfate is covalently associated to a protein core (syndecan, 
glypican, perlecan, agrin or collagen VIII). Characterization of HSPGs, both in 
structure and function, is complicated by their chemical heterogeneity, with the 
structure depending both on length and functionalization of the long 
polysaccharide chains and on the nature of the protein core. HSPGs are found on 
the outside of cell membranes or in the extra-cellular matrix. 
The biosynthesis of HS is non-template driven49 and takes place in the Golgi 
apparatus by elongation of a tetrasaccharide through progressive addition of 
glucuronic acid-N-acetylglucosamine (GlcA-GlcNAc) disaccharide units by glycosyl 
transferase.50 The newly synthesized precursor of heparan sulfate, called 
heparosan,51 is edited by the action of several enzymes. The polysaccharide chain 
may undergo enzyme-mediated sulfation on the N-position of glucosamine 
residues, epimerization of D-glucuronic acid residues to L-iduronic acid and 
sulfation of the 2-O position of the uronic acid residues and 3-O and 6-O positions 
of glucosamine residues.50 The pattern of functionalization of HS is complex and 
can vary depending, for instance, on the type of cell expressing the biopolymer and 
on the extracellular signals reaching the cell surface.51 
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Figure 2.10 - Cartoon depicting the structure of heparan sulfate 
proteoglycans. 
Reproduced from Rosen, 2010.41 
Heparan sulfate chains alternate rigid highly sulfated regions (S-domains) and 
flexible regions, characterized by lower or no sulfation (N-acetylated domains),51 
as shown in Figure 2.10.41 Heparan sulfate plays an active role in many biological 
processes. HSPGs are able either to bind or release a wide range of protein ligands 
(growth factors, cytokines, etc.), which are involved in numerous cascade events as 
a result of the modulation of their sulfation state by sulfatases and 
sulfotransferases. 
The roles of HS include the mediation of protein-protein interactions, for 
example by stabilizing the conformation of a protein. Also, heparan sulfate acts as a 
co-receptor, promoting the interaction between proteins by binding them on a 
template glycosaminoglycan chain (e.g. FGF-receptor tyrosine kinase 
interaction).52 Finally, HS sequesters signaling molecules and prevents the 
activation of signaling cascades.48 
As mentioned above, Sulf1 and Sulf2 are endosulfatases and cleave sulfate groups 
from the 6-O position of glucosamine residues (GlcN, 18) found in the disaccharide 
repetitive unit of the heparin/heparan sulfate glycosaminoglycan. The enzymes 
showed greatest activity towards the trisulfated disaccharide units made up of 2-
O-sulfated L-iduronic acid and N-sulfate-glucosamine 6-O-sulfate (IdoA2S-
GlcNS6S).39 A recent study by Staples et al., provided experimental evidence that 
Core protein 
Heparan sulfate chain 
S-domain Flexible spacer 
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the pattern of heparan sulfate needs to satisfy certain structural requirements to 
enable binding and editing by the endosulfatases.49 The study determined that 
removal of the 6-O-sulfates lowers the affinity of Sulf1 and Sulf2 for HS, thus 
allowing the substrate to be released. 
2.4.2 Proposed model for the action of Sulf1 and Sulf2  
At the time when this project was initiated, no information was available 
concerning the shape (pocket or groove), size or location of the active site of Sulf1 
and Sulf2. A recent biochemical study focused on the C-terminal hydrophilic 
domain, which is unique to the extracellular endosulfatases. This portion of the 
enzyme contains a high number of basic residues regularly arranged along the 
primary amino acid sequence. Within the hydrophilic domain of Sulf1, the authors 
were able to identify at least two binding sites for heparan sulfate. Following their 
observations, Milz et al. postulate a cooperativity between the catalytic (primary 
binding site) and the hydrophilic domain (secondary binding site or exosite), in 
which the hydrophilic domain binds to the heparan sulfate chain in at least two 
sites, while the catalytic domain hydrolyzes the sulfate group from a proximal 
disaccharide. Once the sulfate has been cleaved, the hydrophilic domain presents 
the next 6-O-sulfate group to the active site while the enzyme moves along the 
polysaccharide chain (Figure 2.11).44 
 
Figure 2.11 - Schematic description of the proposed processive action of 
Sulf1 on heparan sulfate chains. 
HD: hydrophilic domain. Cat Dom: catalytic domain. CT: C-terminal domain. 
Endosulfatases can bind other glycosaminoglycans, such as chondroitin sulfate and 
dermatan sulfate, but is not able to desulfate them. Adapted from Milz, 2013.44 
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The loss of sulfatase activity shown by Sulf1 when the hydrophilic domain is not 
present, supports the hypothesis of the binding function of the hydrophilic domain. 
A homology model of Sulf1 based on the structure of ARSB was reported in the 
same study and suggested that the hydrophilic domain could be positioned in the 
proximity of the active site (Figure 2.12).44 Given the great degree of homology 
between Sulf1 and Sulf2, it is likely that Sulf2 could function in an analogous 
manner. 
 
 
Figure 2.12 - Homology model of Sulf1. 
The catalytic domain is depicted in red, the hydrophilic domain in grey; Cys87 is 
highlighted in yellow; the dark spheres are the amino acid residues that mark the 
end of the N-terminal domain and the beginning of the HD. This model suggests 
that the hydrophilic domain is close enough to the active site to participate to 
recognition and binding of the substrate. Reproduced from Milz, 2013.44 
2.4.3 Endosulfatases and their role in signaling pathways 
By means of their sulfate groups, heparan sulfate proteoglycans interact with a 
variety of growth factors and cytokines modulating a number of signaling 
pathways, such the wingless/int (Wnt) pathway and the pathways downstream of 
the fibroblast growth factor (FGF) receptor (e.g. mitogen-activated protein kinase, 
MAPK, pathway).51,53 Because of the desulfating action exerted on HSPGs, Sulf1 and 
Sulf2 also have an active role in the regulation of signal transduction. 
Sulf1 has been shown to repress fibroblast growth factor (FGF) receptor tyrosine 
kinase signaling.54 The highly sulfated domains of heparan sulfate act as a co-
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receptor and facilitate the interaction between FGF-2 and the fibroblast growth 
factor receptor (FGFR) by formation of a ternary complex. This promotes 
dimerization of FGFR and activation of the receptor tyrosine kinase activity, with 
consequent transphosphorylation. The signal activates a phosphorylation cascade 
through the MAPK pathway (Ras-Raf-MEK-ERK, Figure 2.13), leading to increased 
cell proliferation, angiogenesis and survival.55-56 Desulfation of the heparan sulfate 
chain by Sulf1 reduces affinity for its partners and disrupts the ternary complex, 
effectively down-regulating the MAPK signaling pathway. As a result, cell 
proliferation, angiogenesis and survival are also diminished.56 With different HSPG 
selectivity, Sulf2 has an opposing effect to that of Sulf1, showing enhanced FGF 
signaling. Flow cytometry of human hepatocyte carcinoma Hep3B cells, either in 
the presence or in the absence of Sulf2, using biotinylated FGF-2 suggests that  
FGF-2 binding to the receptor is increased by the action of Sulf2.54 
 
Figure 2.13 - FGF signaling pathway. 
Formation of a ternary FGF:FGFR:heparan sulfate complex leads to FGFR 
dimerization and transphosphorylation with activation of the MAPK pathway. 
Reproduced from Goetz, 2013.55 
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The canonical Wnt/-catenin pathway, which promotes cell adhesion and cell 
proliferation through activation of target genes, is positively regulated by 
endosulfatases. As depicted in Figure 2.14, heparan sulfate proteoglycans 
sequester Wnt ligands on the cell surface by interaction with sulfate groups and 
prevent binding to the trans-membrane Frizzled receptor. As a result, β-catenin is 
sequestered by a destruction complex, phosphorylated and degraded. However, 
endosulfatase-catalyzed desulfation of HS chains releases the Wnt peptide which 
binds to Frizzled receptor, leading to disruption of the destruction complex and 
stabilization of β-catenin, which enters the nucleus where it contributes to gene 
expression. 
 
 
Figure 2.14 - The Wnt signaling pathway. 
The desulfation of HSPG by Sulf1 and Sulf2 causes the release of Wnt ligand that 
binds Frizzled receptor and leads to the activation of the Wnt target genes via 
stabilization of β-catenin. Reproduced from Rosen, 2010.41 
There is a wide range of growth factors and chemokines interacting with heparan 
sulfate with potential implications on other signaling pathways. Similar to the FGF 
pathway the hepatocellular growth factor (HGF), heparin-binding growth factor 
(HB-GF) and vascular endothelial growth factor (VEGF) signaling pathways are 
influenced by Sulf1.56 ELISA studies by Uchimura et al. proved that Sulf2 mobilized 
VEGF165 and the chemokines stromal cell-derived factor 1 (SFD-1) and secondary 
lymophoid tissue chemokine (SLC).57 
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Recently, Sulf2 was identified as a downstream effector of p53. No comment on 
Sulf1 were made by the authors.58 
 The role of Sulf1 and Sulf2 in cancer 2.5
As a consequence of their active role in the dynamic modulation of the sulfation 
state of heparan sulfate chains in the extracellular matrix and of the relevance of 
HS in regulating important cellular signaling pathways,42 Sulf1 and Sulf2 have been 
found to play an important role in a range of diseases, such as arthritis,59 
atherogenic dyslipidemia,60 chronic renal fibrosis61 and cancer.41 
An increasing body of literature reports altered levels of Sulf1 and Sulf2 in 
several subtypes of cancer, including brain cancer, breast and ovarian cancer, 
melanoma and cancers related to the gastro-intestinal tract, such as hepatocellular 
carcinoma, pancreatic adenocarcinoma, gastric and colorectal cancer.41 Despite the 
high sequence homology between the two enzymes and their apparently 
redundant functions, they may have contrasting roles in the regulation of cancer 
processes.56 In the case of hepatocellular carcinoma, for example, the negative 
regulation exerted by Sulf1 on the FGF pathway appears to have a tumor 
suppressor effect reducing cell proliferation.56 By contrast, Sulf2 activates the 
pathway and acts as an oncogene, resulting in proliferation and migration.56 
Immunocytochemistry and confocal microscopy experiments revealed that 
overexpression of Sulf2 correlates with increased levels of the heparan sulfate 
proteoglycan glypican 3 (GPC3), which is involved in upregulation of the Wnt 
pathway54 and has been reported as an oncoprotein.56 
Consistent with opposing effects on the FGF pathways, Sulf1 is downregulated in 
30% of hepatocellular carcinoma (HCC) primary tumors, while Sulf2 is 
overexpressed in 60% of cases. Poor prognosis was also observed in patients with 
HCC having high Sulf2 levels (Figure 2.15).42 Recurrence after surgery is also 
accelerated compared to patients with low Sulf2 levels.54 In addition to 
hepatocellular carcinoma, up-regulation of Sulf2 protein correlates on the 
pathological level to onset of pancreatic62 and breast cancers and non-small cell 
lung carcinoma.41 
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Figure 2.15 - Kaplan-Meier plots for patients affected by hepatocellular 
carcinoma. 
High Sulf2 levels translate in poor prognosis. Reproduced from Lai, 2008.56 
The current understanding of the processes the endosulfatases participate in is 
limited and, to further complicate the picture, there is the possibility of different 
splicing variants of both enzymes being implicated. On the whole, the role of Sulf1 
and Sulf2 is complex and further investigation is required to fully elucidate the 
roles of human endosulfatases in cancer. Such studies would be assisted by 
selective inhibitors of the respective enzymes. Both the endosulfatase activity and 
the extracellular localization of Sulf1 and Sulf2 may reduce the chances of 
selectivity issues against other intracellular sulfatases with exogenous inhibitors, 
thus making them an attractive target for drug discovery. 
 Targeting Sulf1 and Sulf2 with small-molecule inhibitors 2.6
Aiming to characterize the composition of heparan sulfate, Saad and co-
workers63 developed an electrospray ionization-mass spectrometry (ESI-MS) 
based assay and tested Sulf2 activity against heparin oligomers. Little catalytic 
activity was observed towards digested heparin fragments smaller than a 
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trisulfated tetrasaccharide, suggesting that it might be difficult to inhibit these 
enzymes with molecular weights typical for small-molecule modulators. In 2009, 
Hossain et al.64 reported that both Sulf1 and Sulf2 are inhibited by PI-88 
(phosphomannopentose sulfate), a heparin mimetic antiangiogenic and 
antimetastatic agent, and gave further experimental evidence that a minimum of a 
tetrameric unit is required for binding to the target. Using a theoretical approach 
based on the structural data available on thirteen sulfatases, Lai et al.56 observed 
that the residues in close proximity to the active formylglycine (5 Å radius) are 
equivalent in both Sulf1 and Sulf2. They therefore postulated that the site for 
substrate recognition in the endosulfatases might be located distant from the 
active site, in agreement with the model proposed by Milz.44 
A recent communication by Schelwies et al. in the context of research on 
inflammatory processes,59 reported the synthesis and activity of the first small 
molecule saccharide-based inhibitors of Sulf1 and Sulf2. Their work was based on 
the incorporation of a sulfamate moiety, which had proven effective in the 
inhibition of the extensively studied steroid sulfatase. Schelwies and co-workers 
chose the small aryl sulfamates 21 and 22 as a starting point for their studies, as 
well as the sulfamoylated monosaccharides 24-27, which can be regarded as 
heparan sulfate mimics. Finally, they tested a number of intermediates, 28-32. The 
assay exploited the aryl sulfatase activity of Sulf1 and Sulf2 on 4-
methylumbelliferyl sulfate (4-MUS, 23) as a reporter substrate (see Chapter 4) to 
evaluate the inhibitory effect of the synthesized molecules. The resulting inhibition 
profiles of Sulf1 and Sulf2 (Table 2.2) did not differ considerably between the two 
enzymes, in agreement with what postulated by Lai et al.56 
Both the aryl sulfamate 21 and 22 and the monosaccharide molecules 24-32 
proved to inhibit the human endosulfatases. The most potent compounds reported 
were the N-sulfated monosaccharides 24 (Sulf1: IC50 = 95 μM; Sulf2: IC50 = 130 μM) 
and 25 (Sulf1: IC50 = 180 μM; Sulf2: IC50 = 240 μM) which were more active than 
their acetamido-analogues 26 and 27. The phenyl-based sulfamates 21 and 22 and 
the unsubstituted amines 28 and 29 were all less potent than the monosaccharides 
24 and 25. Interestingly, even though primary sulfamates were more potent than 
the N,N-dimethyl analogues, N-alkylation seemed to be well tolerated.  
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Table 2.2 - Structure and Sulf1/Sulf2 activities of aryl and monosaccharide 
sulfamates.59 
 
# Compound R R’ Sulf1 activity Sulf2 activity 
1 21 - - ~30% inhibition at 5 mM ~30% inhibition at 5 mM 
2 22 - - ~50% inhibition at 5 mM ~50% inhibition at 5 mM 
3 24 H SO3Na IC50 = 95 μM IC50 = 130 μM 
4 25 CH3 SO3Na IC50 = 180 μM IC50 = 240 μM 
5 26 H Ac 40% inhibition at 5 mM 30% inhibition at 5 mM 
6 27 CH3 Ac ~50% inhibition at 5 mM ~50% inhibition at 5 mM 
7 28 H H ~10% inhibition at 5 mM ~10% inhibition at 5 mM 
8 29 CH3 H ~10% inhibition at 5 mM ~18% inhibition at 5 mM 
9 30 H SO3Na ~85% inhibition at 5 mM ~65% inhibition at 5 mM 
10 31 CH3 SO3Na ~70% inhibition at 5 mM ~80% inhibition at 5 mM 
11 32 - - ~10% inhibition at 5 mM ~10% inhibition at 5 mM 
This study provides experimental evidence that inhibition of Sulf1 and Sulf2 by 
low molecular weight templates may be possible. It also represents the first 
structure-activity relationship (SAR) study on these enzymes in the literature and 
suggests that N-sulfation and 6-O-sulfamoylation of the monosaccharides appear 
to be crucial for inhibition of human endosulfatases. However, these results 
suggest that obtaining selectivity between Sulf1 and Sulf2 could be problematic 
with small molecules. The most active molecule in the series, monosaccharide 24, 
was re-synthesized in the Medicinal Chemistry laboratories of the Northern 
Institute for Cancer Research by Duncan Miller65 and tested in the assay developed 
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by Gary Beale and Sari Alhasan.66-68 The results published in the literature could 
not be reproduced and compound 24 proved inactive against Sulf2 (<10% 
inhibition at 1 mM). 
 Project aims and design of potential novel inhibitors 2.7
The present work is focused on the identification of a tool compound to enable 
target validation studies for the inhibition of the cancer-related extracellular 
sulfatase Sulf2, which seems to play an important role in hepatocellular carcinoma 
determining low survival rates and high frequency of recurrence after excision.54 
Following the communication by Schelwies et al.,59 the synthesis of 
monosaccharide-based inhibitors was also successfully undertaken within the 
group.65 
Due to issues, both synthetic and pharmacokinetic, of developing and 
synthesizing saccharide-based inhibitors, it was desirable to undertake the 
development of non-saccharide inhibitors. Although no crystal structure of the 
target enzyme was available, a large amount of data concerning another sulfatase 
linked to cancer, steroid sulfatase (STS), was available in the literature 
demonstrating the key role of the sulfamate group as a sulfate isoster. The most 
potent known inhibitor of steroid sulfatase, EMATE 12 (IC50 <0.1 nM in an intact 
MCF-7 cell-based assay), bears a primary sulfamate moiety on an estrogen scaffold. 
In contrast, the tertiary sulfamate analogue 33 effectively inhibits STS with a 
reversible mode of action, but is less potent than EMATE 12 (90%, 87% and 79% 
inhibition at 10, 1.0 and 0.1 µM, respectively, in MCF-7 cells).33 In further lead 
discovery studies, the primary sulfamate moiety was retained while changing the 
estrogenic scaffold to avoid undesirable off-target effects. 
 
In the current study, a similar approach was taken with the aim of understanding 
SARs for low molecular weight aromatic sulfamates. The design and synthesis of 
compounds bearing a sulfamate attached to a diversely substituted aromatic ring 
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(34 and 35) was undertaken in an attempt to investigate whether a well-designed 
aromatic molecule could efficiently bind to the active site of Sulf2. 
Introduction of substituents onto the aryl scaffold allowed determination of SAR 
for steric and electronic requirements for effective inhibition of Sulf1 and Sulf2.65 
To further explore the scope of arylsulfamate-based motifs, a second set of 
potential tool molecules was devised based on the 3D structure of the dimeric 
repetitive units of heparan sulfate. As shown in Figure 2.16, the sulfamate moiety 
was retained at the 3-position of phenyl ring A, while incorporation of a range of 
substituents, such as carboxylic acids, esters, amines and N-sulfates, in different 
positions on phenyl ring B was explored to attempt to identify binding interactions 
that might be exploited in the further development of a tool compound (36 and 
37). Finally, since the HS substrate consists of saturated heterocyclic rings, a non-
aromatic B ring was attached to the 3-position of the aromatic ring A to explore 
whether this could improve inhibition. This non-aromatic B ring was further 
functionalized with hydroxyl and N-sulfate moieties in the 2- or 4-position to 
attempt to identify beneficial polar interactions within the enzyme active site. 
 
Figure 2.16 - Generation of three scaffolds of tool molecules for preliminary 
studies on the inhibition of Sulf2. 
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CHAPTER 3. RESULTS AND DISCUSSION - SULF2 
No structural data were available for Sulf2 at the start of the project but a review 
of the literature of sulfatase inhibitors revealed that the sulfamate group is a 
common pharmacophoric feature in inhibitors of sulfatases.20,33,35,59,69 The first 
targets were designed as tool molecules aiming to build an understanding of 
structural features important for Sulf2 inhibition to direct the more focused design 
of potential inhibitors. Assay development was investigated in parallel with 
compound synthesis. Unfortunately, the isolation of catalytically active protein 
proved challenging, and inhibition data were generated after the synthesis of all 
compounds had been completed. 
 Synthesis of N,N-dimethylsulfamates 3.1
3.1.1 Synthesis of a library of phenyl N,N-dimethylsulfamates 
The endogenous substrate of Sulf2 is heparan sulfate, a polysaccharide. As most 
sulfatases are able to catalyze desulfation of small aryl sulfate substrates, it was 
therefore desirable to investigate the activity of the target enzyme towards 
aromatic systems. Compared to carbohydrates, the chemistry of aromatic rings 
offers a number of advantages, such as the presence of a chromophore, ease of 
synthesis because of the absence of stereochemistry, commercial availability of a 
variety of starting materials and a wide scope of reactions for further manipulation 
of the building blocks. A small library of phenyl N,N-dimethylsulfamates was 
synthesized to be screened against Sulf2 for developing SARs. In parallel, Duncan 
Miller synthesized a similar set of primary aryl sulfamates 65. While these works 
were carried out, the communication by Schelwies et al.59 confirmed the 
hypothesis that small aryl sulfamates weakly inhibit Sulf2. 
To enable the synthesis of a group of diversely substituted aromatic tertiary 
sulfamates the limited number of procedures available in the literature were used 
as a starting point. Woo et al.36 reported the synthesis of N,N-dimethylsulfamates 
from phenols using a large excess of triethylamine (10 equiv.) and N,N-
dimethylsulfamoyl chloride, (Me2NSO2Cl, 14 equiv.) in DCM. The sulfamoylating 
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agent, Me2NSO2Cl, is classified as a potential carcinogen and proved to be stable to 
an aqueous work-up (TLC monitoring; petrol ether 100%), prompting the pursuit 
of a safer procedure to avoid having to handle crude product and waste stream 
containing the toxic substance. Quasdorf and co-workers70 were able to use just 1.2 
equiv. of dimethylsulfamoyl chloride in their synthesis of aryl dimethylsulfamates, 
employing sodium hydride to obtain the reactive phenolate ion. In an attempt to 
identify safer conditions, an optimization study of the sulfamoylation reaction was 
undertaken prior to embarking in the synthesis of a library of aromatic 
dimethylsulfamates. 4-tert-Butylphenol 40 was chosen as a model system (Scheme 
3.1). 
 
Scheme 3.1 - Synthesis of N,N-dimethylsulfamates. 
Addition of N,N-dimethylsulfamoyl chloride (1.5 equiv.) to a suspension of the 
phenol and K2CO3 in acetonitrile at 0 °C yielded the desired (4-tert-butyl)phenyl 
dimethylsulfamate 41 in 24% yield. The reaction proceeded without formation of 
side products and the sulfamate 41 was obtained pure after work-up without 
further purification. Nonetheless, the product was obtained in modest yield. 
 
Table 3.1 - Optimization of the sulfamoylation of 4-t-butylphenol. 
# Base Solvent 
Phenol 
(equiv.) 
Base 
(equiv.) 
Heating 
method 
Time T (°C) 
Conversiona 
% 
1 K2CO3 MeCN 1.5 1.7 C 8 d up to 40 65 
2 NaH  DMF 1.5 1.7 C 3 d up to 35 68 
3 Cs2CO3 MeCN 1.5 1.7 C 22 h 18 > 99 
4 Cs2CO3 MeCN 1.5 1.7 M 30 
min 
up to 
150 
66 
C = conventional heating. M = microwave heating. a Determined by LC-MS UV 
trace. 
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The effect of the base was investigated for the sulfamoylation of 4-tert-
butylphenol 40 (Table 3.1). Complete conversion of the starting material was only 
obtained using cesium carbonate in acetonitrile at room temperature (Table 3.1 - 
Entry 3) while potassium carbonate and sodium hydride did not lead to a 
conversion higher than 70%, even upon gentle heating over several days (Table 
3.1 - Entries 1 and 2). Aiming at reducing the reaction time, microwave heating 
was applied to the most successful reaction conditions, but the reaction did not 
proceed to completion under these conditions. The conditions in Entry 3 were 
chosen as standard for the synthesis of the library of aryl dimethylsulfamates. 
Isolated yields are summarized in Table 3.2. 
 
Table 3.2 - Summary of yields for the sulfamoylation of phenols 
Reagents and conditions: phenol, base, Me2NSO2Cl, MeCN, 0 °C then RT, 18 h. 
 
# Compound R 
Yield
% 
 
# Compound R 
Yield
% 
1 41 4-t-Bu 24a,c 11 51 4-CF3 33b 
2 42 4-OMe 74a 12 52 3-CF3 47b 
3 43 3-OMe 63b 13 53 2-CF3 52b 
4 44 2-OMe 43b 14 54 4-Cl 93b 
5 45 4-CN 71b 15 55 4-Ph 90a 
6 46 3-CN 58b 16 56 3-Ph 75b 
7 47 2-CN 92b 17 57 2-Ph 72b 
8 48 4-NO2 49b 18 58 H 27b 
9 49 3-NO2 >99b 19 59 3-Br 73b 
10 50 2-NO2 94b  
a  Base was potassium carbonate. 
b Base was cesium carbonate. 
c Phenol was the limiting reagent. 
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The optimized sulfamoylation conditions gave good yields for most compounds. 
Moderate yields were obtained with methoxy- at the 2-position 44 (Table 3.2 - 
Entry 4), nitro- at the 4- position 48 (Table 3.2 - Entry 8) and in general when a 
trifluoromethyl substituent was present anywhere on the ring (Table 3.2 - Entries 
11-13). 
3.1.2 Attempted synthesis of a library of benzyl N,N-dimethylsulfamates 
With the purpose of mimicking the 6-O-sulfate group of the endogenous 
substrate of Sulf2, a second small library of benzylic tertiary sulfamates was 
targeted from benzyl alcohols using a similar synthetic approach to that described 
for the phenyl series (Scheme 3.2). 
 
Scheme 3.2 - Approach to the synthesis of benzyl N,N-dimethylsulfamates. 
To investigate this reaction, 3-methoxybenzyl alcohol 60 was selected as a model 
system to obtain the product 61. The reaction conditions tested are summarized in 
Table 3.3. Using the procedure optimized for phenols described above (Table 3.3- 
Entry 1) no products were formed. This is likely to be explained by the Cs2CO3 
(conjugate acid pKa ~10) being too weak base to deprotonate the benzylic alcohol 
(conjugate acid pKa ~16) required for reaction with the dimethylsulfamoyl 
chloride. Stronger bases, such as sodium hydride (conjugate acid pKa ~35), sodium 
bis(trimethylsilyl)amide (conjugate acid pKa ~26) and potassium tert-butoxide 
(conjugate acid pKa ~17), were therefore investigated, but in each case a complex 
mixture was obtained with no evidence of formation of the desired product (Table 
3.3 - Entries 2 to 4). A pyridine/DMAP system led to the formation of two products 
by LC-MS, but purification on silica led to degradation with only several minor 
impurities being recovered (Table 3.3 - Entry 5). Similar results were obtained 
following a literature procedure71 in the absence of base (Table 3.3 - Entry 6). 
These observations suggest that the desired benzyl dimethylsulfamate 61 may be 
chemically unstable and, as a consequence, these targets were not pursued further. 
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Table 3.3 - Screening of reaction conditions for the synthesis of 3-
methoxybenzyl dimethylsulfamate 61. 
Reagents and conditions: base (1.7 equiv.), Me2NSO2Cl, solvent, 0 °C then RT, 18 h.  
 
# Base Solvent 
Temperature 
(°C) 
Result 
1 Cs2CO3 MeCN 0 Complex mixture 
2 NaH (60%) THF -30 Complex mixture 
3 NaHDMS THF -30 Complex mixture 
4 KOtBu THF 0 Complex mixture 
5 Py/DMAP THF 0 2 main peaks 
6 No base PhCH3/DMA 0 2 main peaks 
 
3.1.3 Synthesis of a library of biphenyl N,N-dimethylsulfamates 
The structure of the endogenous substrate of Sulf2 was used as a template to 
guide the design of a second round of phenyl sulfamates. The observation by 
Hossain et al.64 (see Section 2.6) that an oligosaccharide may be required for 
binding to Sulf2 suggested that it may be necessary to develop higher molecular 
weight scaffolds to allow further interaction between the inhibitor and the Sulf2 
protein in order to obtain potent Sulf2 inhibitors. With an optimized procedure for 
the introduction of the dimethylsulfamate group onto phenols, it was desirable to 
build onto the phenyl core in an attempt to incorporate features which may mimic 
the dimeric unit of heparan sulfate. Molecular modelling by Duncan Miller 
suggested that 3-substituted biphenyls of the class shown in Figure 3.1 might 
effectively reproduce the three-dimensional arrangement of substituents in a 
heparan sulfate disaccharide. 
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Figure 3.1 - Overlap of a heparan sulfate disaccharide unit with the primary 
[1,1'-biphenyl]-3-yl sulfamate analogues of 63, 64 and 73, respectively. 
It was envisaged introducing the second aryl ring via palladium-catalyzed 
formation of a carbon-carbon bond under Suzuki-Miyaura conditions by coupling 
of 3-bromophenyl dimethylsulfamate 59 to a series of phenyl boronic acids. A 
publication by Macklin and Snieckus72 reported the coupling of bromoaryl N,N-
diethyl sulfamates with retention of the sulfamate moiety, and reaction taking 
place at the bromo centre. However, a growing body of literature reported 
reactions in which the boronic acid coupling-partner may substitute the sulfamate 
group in the presence of nickel-based catalysts.70,73-74 More recently, examples of 
palladium-catalyzed Suzuki-Miyaura reaction at the sulfamate centre have also 
been described, using either boronic acids75 or potassium organofluoroboranes as 
coupling partners.75-76 Thus, for the palladium-catalyzed reaction between 
sulfamate 59 and phenylboronic acid, two pathways were deemed possible, to 
form either biphenyl sulfamate product 56 or the bromo-biphenyl 62 (Scheme 
3.3). 
 
Scheme 3.3 - Alternative cross-coupling products. 
Reagents and conditions: phenylboronic acid, Na2CO3 (2 M, aq.), Pd(PPh3)4, DME, 
reflux, 18 h. 
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The cross-coupling was attempted under reaction conditions of Macklin and 
Snieckus for the re-synthesis of biphenyl sulfamate 56 using 1,2-dimethoxyethane 
(DME) as solvent and tetrakis(triphenylphosphine)palladium as catalyst at the 
presence of aqueous Na2CO3 as base. The desired sulfamate 56 was obtained in 
good yield (83%) with no evidence of coupling reaction at the sulfamate centre 
(62). A library of diversely substituted biphenyl dimethylsulfamates was designed 
aiming to introduce polar groups such as carboxyl (63, 64, 65), amino (69, 70, 71) 
and aminosulfates (72, 73, 74) around the B-ring. The methyl esters (66, 67, 68) 
and the acetanilide (75, 76, 77) analogues were also of interest to investigate 
whether these groups may form stabilizing interactions with Sulf2. The 
introduction of polarity via a pyridine B-ring (78, 79, 80) was also assessed. As the 
boronic acids were available in-house, the 3’-cyano-, 4’-methoxy- and 4’-
hydromethyl biphenyl sulfamates 81, 82 and 83, respectively, were included 
among the target compounds. The latter compound was subjected to sulfation to 
give the corresponding hydroxymethylsulfate 84 (Figure 3.2). 
 
Figure 3.2 - Library of diversely substituted [1,1'-biphenyl]-3-yl 
dimethylsulfamates. 
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Synthesis of 81, 82, 83 
Following the literature procedure described previously and using the 
appropriate commercially available boronic acids, 81, 82 and 83 were obtained in 
moderate yields (Table 3.4), with an overnight reaction (18 h) being required. 
Table 3.4 - Summary of yields for the synthesis of a range of 
biphenylsulfamates. 
Reagents and conditions: a) Cs2CO3, Me2NSO2Cl, MeCN, 0 °C then RT,  
18 h, 73%; b) boronic acid, Na2CO3 (2 M, aq.), (PPh3)4Pd(0), DME, reflux, 18 h. 
 
# Compound R 
Yield 
% 
1 81 3’-CN 38 
2 82 4’-OMe 63 
3 83 4’-CH2OH 37 
 
 
Scheme 3.4 - Model reaction for the optimization of C-C bond formation. 
 
The coupling of N,N-dimethyl 3-bromophenylsulfamate 59 with 4-
hydroxymethylboronic acid to give the hydroxymethylbiphenyl compound 83 
(previously obtained in 37% yield) was chosen as a model system to identify 
conditions which would allow high yields to be obtained for further analogues 
(Scheme 3.4). Starting material and product were well resolved by LC-MS, offering 
a rapid method for monitoring the reaction and to assess the degree of conversion. 
In an attempt to reduce reaction time, microwave heating was investigated. All 
 
 
43 
 
reactions were performed on a 20 mg-scale for a fixed time and analyzed by LC-MS 
of the reaction mixture. To investigate the effect of temperature, a reaction mixture 
prepared as described in the literature72 was heated for 5 min under microwave 
irradiation at increasing temperatures. 
Table 3.5 - Effect of temperature on the conversion in the Suzuki-Miyaura 
coupling step. 
Conversion is reported as the area of the product peak in the LC-MS chromatogram 
normalized for the area of the peaks analyzed. 
Reagents and conditions: 59 (1 equiv.), 4-hydroxymethylphenylboronic acid (1 
equiv.), Na2CO3 (aq., 2 M, 2 equiv.), Pd (PPh3)4 (0.05 equiv.), DME, μW, 5 min. 
# 
Temperature 
[°C] 
Conversion 
[normalised product %] 
1 60 0 
2 80 66 
3 100 54 
4 120 62 
5 140 62 
As shown in Table 3.5, temperatures below 80 °C gave no conversion. At a 
temperature of 100 C or above there was no improvement in conversion, and an 
increase in the number and amount of by-products was observed. For subsequent 
optimization reactions, the temperature was fixed at 80 C. In the second instance, 
the effects of both solvent and catalyst were examined (Table 3.6). Alongside 
standard conditions using 1,2-dimethoxyethane and tetrakis(triphenylphosphine) 
palladium, dioxane and acetonitrile were evaluated as solvents and four catalyst 
systems commonly used in Suzuki reactions were tested, i.e. Pd(dba)2/Xantphos, 
Pd(dppf)Cl2, bis(tri-tert-butylphosphine)Pd, and Pd(dtbpf)Cl2, thus generating an 
optimization matrix. The results are summarized in Table 3.6. Pd(dba)2/Xantphos 
did not effectively catalyze the reaction in any of the solvents used. All the other 
systems gave a conversion of 53-70%. However, Pd(dppf)Cl2 in DME gave an 
improved 82% conversion. As a consequence, this set of conditions was taken on 
to further optimization. 
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Table 3.6 - Effects of solvent and catalyst on the conversion in the Suzuki-
Miyaura coupling step. 
Conversion is reported as the area of the product peak in the LC-MS chromatogram 
normalized for the area of the peaks analyzed. 
Reagents and conditions: 59 (1 equiv.), 4-hydroxymethylphenylboronic acid (1 
equiv.), Na2CO3 (aq., 2 M, 2 equiv.), Pd catalyst (0.05 equiv.), solvent, μW 80 °C, 6 
min. 
Catalyst 
Solvent 
[Pd(PPh3)4] 
Pd(dba)/ 
Xantphos 
Pd(dppf)Cl2 
Bis(tri-t-Bu- 
phosphine)Pd 
Pd-118 
DME 66 0 82 54 70 
Dioxane 62 0 62 66 61 
Acetonitrile 53 0 58 60 63 
 
For optimization of the base, three carbonates were investigated (Table 3.7). 
Potassium carbonate led to a 52% of conversion while cesium carbonate, gave 
71% conversion. Sodium carbonate (Table 3.7 - Entry 1), the base used in the 
original procedure, resulted in the best conversion and on scale-up these 
conditions (DME, aq. Na2CO3 2 M, Pd(dppf)Cl2, μW 80 °C) gave the 4-
hydroxymethylbiphenyl sulfamate 83 in 76% isolated yield, which compared 
favorably with the 37% obtained following the literature protocol. A major 
advantage of the optimized procedure was the modification of the catalytic system. 
The use of tetrakis(triphenylphosphine)palladium, led to oxidation of the 
triphenylphosphine ligand to triphenylphosphine oxide and resulted in a difficult 
separation when isolating polar products, such as anilines and carboxylic acids. 
The newly optimized reaction conditions were applied to the synthesis of the 
majority of the compounds in the biphenylsulfamate library. 
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Table 3.7 - Effect of base on the conversion in the Suzuki-Miyaura coupling 
step. 
Conversion is reported as the area of the product peak in the LC-MS chromatogram 
normalized for the area of the peaks analyzed. 
Reagents and conditions: 59 (1 equiv.), 4-hydroxymethylphenylboronic acid (1 
equiv.), base (aq., 2 M, 2 equiv.), Pd(dppf)Cl2 (0.05 equiv.), DME, μW 80 °C, 6 min. 
# Base 
Conversion 
[normalised product%] 
1 Na2CO3 82 
2 K2CO3 53 
3 Cs2CO3 71 
Sulfation of 8377-78 
To synthesize the benzyl sulfate 84 a sulfation procedure published in a patent77 
and optimized by Tristan Reuillon79 was employed. The method uses sulfur 
trioxide pyridine complex as the sulfating agent and the desired sulfate is formed 
in DMF at room temperature and then converted to the more stable sodium salt by 
addition of a large excess of aqueous sodium hydroxide (10 equiv.). The desired 
sulfate 84 was isolated in moderate yield (33%; Table 3.5). 
 
Scheme 3.5 - Sulfation of 83. 
Reagents and conditions: a) i) SO3 · py, DMF, RT, 45 min; ii) aq. NaOH, RT, 1.5 h, 
33%. 
Synthesis of amino-[1,1'-biphenyl]-3-yl dimethylsulfamates and derivatives 
In parallel with the optimization studies, the o- and p- amino-[1,1'-biphenyl]-3-yl 
dimethylsulfamates (69 and 71) were synthesized in good to excellent yield 
following the literature procedure of Macklin and Snieckus. However, a moderate 
yield (35%) was observed for the synthesis of the meta-substituted analogue 70. 
Once the amino-compounds were available, it was intended to sulfate the aniline 
under the conditions described for the synthesis of 84. Sulfation of the amino-
group was first investigated using biphenyl aniline 86 as a model system lacking 
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the sulfamate group, with sodium [1,1'-biphenyl]-2-ylsulfamate 87 being obtained 
in 67% yield (Scheme 3.6). 
 
Scheme 3.6 - Synthesis of the sulfate 87. 
Reagents and conditions: a) i) SO3 · py, DMF, RT, 45 min; ii) aq. NaOH, RT, 1.5 h, 
67%. 
Sulfation of 69, 70 and 71 using this procedure gave high conversion for the o- 
and p-anilines (87% and 82%, respectively; isolated yield 73% and 58%), while 
conversion for 70 was lower (65%), as was the isolated yields (25%). The 
acetanilide analogues 75, 76 and 77 were obtained in moderate to high yield upon 
treatment of the anilines with acetic anhydride.80 Yields are summarized in Table 
3.8. 
Table 3.8 - Summary of yields for the synthesis of amino-[1,1'-biphenyl]-3-yl 
dimethylsulfamates and derivatives 
Reagents and conditions: a) boronic acid/pinacol ester, Na2CO3 (aq., 2 M), 
(PPh3)4Pd(0), DME, reflux, 18 h; b) i) SO3 · Py, DMF, RT, 45 min; ii) aq. NaOH, RT, 
1.5 h; c) Ac2O, DCM, RT, 1.5 h. 
 
#  
Product (isolated 
yield %) Step a 
Product (isolated 
yield %) Step b 
Product (isolated 
yield %) Step c 
1 o- 69 (>99) 72 (73) 75 (>99) 
2 m- 70 (35) 73 (76) 76 (69) 
3 p- 71 (81) 74 (58) 77 (83) 
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Synthesis of a set of biphenyl carboxylic acids and their derivatives 
The carboxy-functionalized biphenyl derivatives were synthesized by reaction of 
N,N-dimethyl 3-bromophenylsulfamate 59 under the optimized conditions for the 
microwave-assisted Suzuki-Miyaura cross-coupling. Commercially available 
boronic acids bearing either the free carboxy- group (m- and p-) or the 
corresponding methyl ester (o-) were used, according to availability. The methyl 
ester 66 was hydrolyzed using aqueous lithium hydroxide in THF at 40 °C, 
obtaining carboxylic acid 63 in quantitative yield. A microwave-assisted Fischer 
esterification (Procedure B) yielded the methyl ester 68 from acid 65 in moderate 
yield (57%). However, the same procedure applied to the carboxylic acid 64 gave 
low conversion with formation of by-products for the synthesis of 67. An 
alternative method described by Brook and Chan81 (procedure A) was therefore 
applied to obtain the ester 67 using chlorotrimethylsilane in MeOH at room 
temperature. Under these conditions, complete conversion was reached and the 
product was isolated in good yield.82-83 Yields are summarised in Table 3.9. 
Table 3.9 - Summary of yields for the synthesis of biphenyl sulfamates 
functionalized with a carboxylic acid or methyl carboxylate. 
Reagents and conditions: a) boronic acid, Na2CO3 (aq., 2 M), Pd(dppf)Cl2, DME, μW 
80 °C, 15 min; b) LiOH, H2O/THF, 50 °C, 72 h; c) procedure A: TMSCl, MeOH, RT, 40 
h; procedure B: MeOH, cat. H2SO4, μW 100 °C, 1.5 h. 
 
#  
Product (isolated 
yield %) Step a 
Product (isolated 
yield %) Step b 
Product (isolated 
yield %) Step c 
1 o- 66 (90) 63 (>99) - 
2 m- 64 (66) - 67 (73) 
3 p- 65 (68) - 68 (57) 
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Synthesis of (pyridyl)phenyl sulfamates 
The 3-(pyridin-4-yl)phenyl and the 3-(pyridin-3-yl)phenyl dimethylsulfamates 
79 and 80 were synthesized following the optimized Suzuki protocol (Table 3.10 - 
Entries 2 and 3). The use of thiol-functionalized polymer cartridges prior to 
purification was particularly important to remove all traces of catalyst which 
otherwise formed a complex with the pyridine nitrogen. 
 
Table 3.10 - Summary of yields for the synthesis of the pyridinylphenyl 
dimethylsulfamates. 
Reagents and conditions: a) K2CO3, Cu(OAc)2, Pd(dppf)Cl2, DMF, IPA, μW 100 °C, 40 
min; b) Na2CO3 (aq., 2 M), Pd(dppf)Cl2, DME, μW 80 °C, 20 min. 
 
# Ar 
Starting 
material 
Conditions 
Product (isolated 
yield %) 
1 
 
 
a 78 (48) 
2 
  
b 79 (93) 
3 
  
b 80 (49) 
 
The free 2-pyridylboronic acid was not commercially available because it is 
inherently unstable and, therefore, a different procedure was required to 
synthesize 78. The stable equivalent N-methyliminodiacetic acid (MIDA) ester of 2-
pyridylboronic acid was coupled to 59 under the conditions described by Knapp 
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and co-workers.84 This procedure used isopropanol as co-solvent in place of water 
and involves the slow release in situ of 2-pyridyl boronic acid isopropyl ester in the 
presence of a copper(II) co-catalyst added to enhance the cross-coupling. The 
desired product was isolated in moderate yield (Table 3.10 - Entry 1). A recent 
publication by the same group suggested the use of Cu(diethanolamine)2 in place 
of Cu(OAc)2, which may allow a further improvement in yield for this reaction.85 
 Stability studies on sample N,N-dimethyl sulfamates and sulfates 3.2
The stability of N,N-dimethylsulfamates to a range of different conditions was 
evaluated by means of HPLC and NMR analysis with a small number of the phenyl 
N,N-dimethylsulfamates synthesized. 
3.2.1 Stability of 4-(trifluoromethyl)phenyl dimethylsulfamate 51 
By virtue of the destabilizing effect of the inductively electron-withdrawing 
trifluoromethyl group at the 4-position, 4-(trifluoromethyl)phenyl 
dimethylsulfamate 51 was chosen as a sample molecule for HPLC stability tests of 
the N,N-dimethyl sulfamate moiety under basic (both aqueous and anhydrous), 
acidic and reductive conditions. The substrate 51 was treated with sodium 
hydroxide in EtOH, sodium borohydride in EtOH, sodium hydride in THF and neat 
trifluoroacetic acid for 72 or 96 h and the residual amount of substrate 51 was 
monitored by HPLC. The results obtained indicated that the dimethylsulfamate 
moiety is stable to bases, both aqueous and anhydrous, and reducing agents, but 
rapidly degrades in the presence of strong acids, such as TFA (Figure 3.3). 
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Figure 3.3 - HPLC stability studies on tertiary sulfamates. 
Stability of sulfamate 51 in (A) basic anhydrous conditions; (B) basic aqueous 
conditions; (C) reductive conditions; (D) acidic conditions. Concentration of 
substrate is reported as percentage of the amount at t = 0 h. Replicates: n=1 
3.2.2 Stability of N,N-dimethyl sulfamates in DMSO and MeOH 
The biological evaluation requires the compounds to be stable in DMSO or, 
alternatively, in MeOH. Therefore, a range of dimethyl sulfamates was chosen to 
assess stability in d6-DMSO and d4-MeOD. The solutions were monitored 
periodically by 1H-NMR spectroscopy over 24 h to assess for degradation. 
Four test compounds were selected from the phenyl sulfamates bearing strongly 
electron-withdrawing groups: 3-cyanophenyl dimethylsulfamate 56, 3-nitrophenyl 
dimethylsulfamate 49, 2-nitrophenyl dimethylsulfamate 50, and 3-(trifluoro-
methyl)phenyl dimethylsulfamate 52. Additionally, the stabilities of the sodium 
sulfate salts 84, 72 and 87 were evaluated. All molecules showed no evidence of 
degradation in both solvents over 24 h. 
 Suzuki-Miyaura cross-coupling of unprotected primary sulfamates 3.3
As described in Chapter 2, several studies on STS33,69 and the biological results 
published by Schelwies et al. on Sulf1 and Sulf259 suggested that tertiary 
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sulfamates (-OSO2NMe2) were less active as sulfatase inhibitors than their primary 
sulfamate counterparts (-OSO2NH2). To verify these observations and develop a 
SAR, matched pairs of primary and tertiary sulfamates in the phenyl and biphenyl 
series were required. A library of primary phenylsulfamates analogous to those 
discussed in Section 3.1.1 had been previously synthesized by Duncan Miller,65 and 
hence the interest was focused on the synthesis of primary biphenylsulfamate 
analogues. 
 
Scheme 3.7 Direct (unprotected) approach to the synthesis of biphenyl 
primary sulfamates. 
Reagents and conditions: a) i) HCO2H, ClSO2NCO, 0 °C then RT, 3 h; ii) NH2SO2Cl, 
DMA, 0 oC then RT, 18 h, 87% over two steps; b) AQUEOUS CONDITIONS: base (aq., 
2 M), Pd(dppf)Cl2, DME, μW 80 C, 4 min; c) ANHYDROUS CONDITIONS: base, 
Pd(dppf)Cl2, solvent, μW 80 °C, 4 min. 
Suzuki-Miyaura cross-coupling was investigated to obtain the target compounds 
by reaction of the 3-bromophenyl sulfamate 88, obtained through sulfamoylation 
of 3-bromophenol 85 with fresh sulfamoyl chloride, NH2SO2Cl, with the 
appropriate boronic acid in the presence of palladium catalyst and base (Scheme 
3.7). Unfortunately, the inherent lability of the –SO2NH2 group to basic conditions 
documented in the literature86 was confirmed by Duncan Miller65 by stability 
studies on the primary phenylsulfamate series.65 Mechanistic studies86 support the 
hypothesis that the parent phenol is generated via an E1Cb mechanism in the 
presence of base (Scheme 3.8). 
 
Scheme 3.8 - Proposed mechanism for the decomposition of primary 
sulfamates in the presence of base. 
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In an attempt to tune the cross-coupling conditions to allow carbon-carbon bond 
formation to occur before degradation of the sulfamate, the 3-bromophenyl 
sulfamate 88 was synthesized according to the conditions optimized by Duncan 
Miller.65 Thus reacting chlorosulfonyl isocyanate with formic acid generated fresh 
sulfamoyl chloride, which was used to sulfamoylate 3-bromophenol in DMA. 
Subsequently, a number of small-scale reactions of 88 with phenylboronic acid in 
the presence of a variety of bases were performed and the conversion of the 
bromosulfamate 88 into biphenyl sulfamate 89 was monitored by LC-MS (Table 
3.11 - Entries 1-7). In addition to the normal aqueous conditions, the Suzuki 
coupling was performed in absence of water using sodium or cesium acetate as a 
base following a procedure from a recent publication (Table 3.11 - Entries 8-10).87 
Table 3.11 - Study on the Suzuki-Miyaura cross coupling of primary 
sulfamates.  
 
# BASE Measured pHa % 89b Yield %c 
1 Sodium carbonate 11.9 29 22% 
2 Monobasic sodium phosphate 
dihydrate 
3.9 32 N/D 
3 Monobasic sodium phosphate 4.0 0 N/D 
4 Ammonium acetate 7.2 3 N/D 
5 Sodium acetate 7.8 65 12% 
6 Dibasic ammonium phosphate 8.5 0 N/D 
7 Dibasic sodium phosphate 9.00 (0.5 M) 62 N/D 
     
8 Sodium acetate in THF - 67 5% 
9 Sodium acetate in MeCN - 28 N/D 
10 Cesium acetate in THF - N/A N/D 
a pH was measured for a 2 M aqueous solution of base at RT. 
b Percentages of the desired product from the LC-MS chromatogram (UV trace). 
c Isolated yield from a scale up of the reaction. 
d Water solubility 12.5 g/100 mL at 25 C (0.88 M). 
When following the reaction by LC-MS, four peaks could be identified: 
unconverted starting material 88, desired product 89 and phenols 85 and 90 
originating by desulfamoylation of 88 and 89. Suzuki coupling under the 
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previously optimized reaction conditions using sodium carbonate reached 29% 
conversion and enabled isolation of the biphenylsulfamate 89 in 22% yield 
(Scheme 3.7). Weaker bases such as monobasic sodium phosphate and ammonium 
acetate did not improve conversion (Table 3.11 - Entries 2-4), while LC-MS 
chromatograms in the presence of slightly stronger bases, such as sodium 
phosphate dibasic and sodium acetate gave encouraging results (Table 3.11 - 
Entries 5 and 6). A scale-up of the reaction with sodium acetate was performed but 
difficulties in the separation of the four compounds found in the reaction mixture 
resulted in an isolated yield of only 12% with recovered starting material 
accounting for most of the remaining mass balance. Dibasic sodium phosphate also 
gave good conversion, but was not scaled-up as the same purification problems 
were foreseen. 
The results obtained in anhydrous conditions were initially encouraging. The  
LC-MS profile of the reaction with cesium acetate suggested the formation of a 1:1 
mixture of 89 and 90 (Table 3.11 - Entry 10), while sodium acetate seemed to be 
effective, as conversion reached 67% in THF (Table 3.11 - Entry 8) and 27% in 
MeCN (Table 3.11 - Entry 9). Again, a scale-up of the most successful anhydrous 
conditions resulted in poor isolated yield of the product 89. To exclude the 
hypothesis of substrate-specific purification difficulties, the conditions reported in 
Table 3.11 - Entry 5 were also applied to the coupling of 88 with 4-
hydroxymethylboronic acid but similar low isolated yields were obtained. 
Further analysis of the experimental results highlighted that this approach was 
affected by several issues. The high UV absorption of the product 89 (max 248 nm; 
 /dm3 mol-1 cm-1 49 000) compared to that of the starting material 88 (max 256sh;  
 /dm3 mol-1 cm-1 600) gave misleading conversion percentages. The formation of 
phenolic by-products made separation of the four compounds difficult due to the 
similar polarities of each sulfamate and its corresponding phenol. 
A protecting group strategy introducing a non-polar chromophore on the 
primary sulfamates was therefore investigated by Tristan Reuillon79 to improve 
base stability and to facilitate reaction monitoring and purification. 
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 Synthesis of cyclohexylphenyl primary sulfamate mimics of heparan 3.4
sulfate 
In the attempt to access different spatial positioning of the polar groups relative 
to the sulfamate, three sulfated cyclohexylphenyl primary sulfamate molecules 
were designed: the 4-(3-(sulfamoyloxy)phenyl)cyclohexyl sulfates 91 and 92, only 
differing for the relative cis- or trans- stereochemistry of the 1,4-substituents on 
the cyclohexyl ring, and trans-2-(3-(sulfamoyloxy)phenyl)cyclohexyl sulfate 93 
(Figure 3.4). 
 
Figure 3.4 - Cyclohexylphenyl primary sulfamate mimics of heparan sulfate. 
It was envisaged that sulfates 91 and 92 could be accessed, with or without 
dimethoxybenzyl (DMB) protection of the primary sulfamate, from the 
corresponding cyclohexanols cis- and trans- 95, each obtained via an appropriate 
stereocontrolled reduction from the parent cyclohexanone 96. The carbon-carbon 
bond between the aryl and the cyclohexane rings of 85 and 97 could be formed 
under Suzuki-Miyaura cross-coupling conditions from commercially available 3-
bromophenol 85 and the easily accessible 4,4,5,5-tetramethyl-2-(1,4-
dioxaspiro[4.5]dec-7-en-8-yl)-1,3,2-dioxaborolane 97 (Figure 3.5). 
 
Figure 3.5 - Retrosynthetic approach to the synthesis of 91 and 92. 
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Similarly, a route to the 2-sulfate analogue 98 (with or without protection) was 
investigated by sulfation of the 3-(2-hydroxycyclohexyl)phenylsulfamate 99 
obtained via hydroboration-oxidation of cyclohexene precursor 100 synthesized 
from phenol 85 and 2-(cyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane 101 (Figure 3.6). 
 
 
Figure 3.6 - Retrosynthetic approach to the synthesis of 93. 
 
3.4.1 Synthesis of the boronic esters 97 and 101 
The boronic ester 97 was obtained by formation of the vinyl triflate (103) of the 
commercially available 1,4-dioxaspiro[4.5]decan-8-one 102 using KHMDS and N-
phenylbis(trifluoromethanesulfonamide)88 followed by Miyaura borylation89 
(Scheme 3.9). 
 
Scheme 3.9 - Synthesis of the boronic acid 97. 
Reagents and conditions: a) KHMDS (0.5 M in toluene), PhN(Tf)2, THF, 96%;  
b) Pd(dppf)Cl2, (Bpin)2, KOAc, 1,4-dioxane, overnight, 80 °C, 94%. 
The same approach was used to form the ester 101 (Scheme 3.10). An initial low 
yield for synthesis was related to the high volatility of vinyl triflate 105 and 
boronic ester 101 and was improved by avoiding heating during evaporation. 
 
 
Scheme 3.10 - Synthesis of the boronic acid 101. 
Reagents and conditions: a) KHMDS (0.5 M in toluene), PhN(Tf)2, THF, 5 h, 65%;  
b) Pd(dppf)Cl2, (Bpin)2, KOAc, 1,4-dioxane, 80 °C, 3 h, 71%. 
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3.4.2 Attempted synthesis of 91 and 92 in the presence of an unprotected 
primary sulfamate moiety 
The synthesis of 91 and 92 was first attempted without the use of protecting 
groups on the primary sulfamate. To avoid exposure of the primary sulfamate to 
basic conditions, the Suzuki coupling of 85 and 97 was performed in the first step 
of the synthesis. Catalytic hydrogenation of the double bond and acidic hydrolysis 
of the ketal would lead to the ketone 108, which could be sulfamoylated on the 
phenolic OH to give sulfamate 109 (Scheme 3.11). The key step in the synthesis 
was the stereoselective reduction of the ketone to give either cis- stereoisomer 
110 or its trans-alcohol 111. Although one example of carbonyl reduction with 
sodium borohydride in the presence of a free primary sulfamate has been reported 
in a patent,90 the reproducibility of the procedure was uncertain. Sulfation of the 
hydroxyl using sulfur trioxide pyridine complex followed by ion exchange 
chromatography to convert the sulfate into its sodium salt would yield the final 
targets 91 and 92 in six steps (Scheme 3.11). 
 
 
Scheme 3.11 - Attempted route for the target compounds 91 and 92. 
Reagents and conditions: a) 97, Na2CO3 (aq., 2 M), Pd(dppf)Cl2, DME, μW 80 °C, 15 
min, 28%; b) H2, Pd/C 10%, EtOH, 60 °C; c) AcOH/H2O/THF 20:10:3, 45 °C;  
d) i) HCO2H, ClSO2NCO, 0 °C then RT; ii) NH2SO2Cl in toluene, DMA, 0 C then RT;  
e) NaBH4, THF/EtOH 3:1, -78 °C to RT; f) i) SO3 · py, DMF, RT; ii) ion exchange 
chromatography on Dowex 50W8200 Na form, H2O. 
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Suzuki-Miyaura cross-coupling of 3-bromophenol 85 was performed with the 
optimized conditions for bromophenylsulfamates. The reaction was difficult to 
monitor by both LC-MS and TLC because of the poor separation between starting 
material and product. After a problematic purification the desired product 106 
was isolated in an unsatisfactory 28% yield. 
In an attempt to obtain more synthetically useful yields at the start of the 
synthesis, three different approaches were undertaken. 
Suzuki-coupling: approach A 
Most of the examples of Suzuki coupling of phenols reported in the literature are 
performed with a benzyl- or methyl- protected phenol. In absence of a protecting 
group, yields tend to depend on reaction conditions and the nature of the coupling 
partners.91 Following a publication reporting the Suzuki coupling of free phenols in 
aqueous media using a ligandless Pd catalyst,92 the coupling of 85 and 97 was 
attempted using 10% palladium on carbon and aqueous potassium hydroxide as a 
base (Scheme 3.12). Although successful, the reaction yielded the desired product 
106 with insufficient purity and in less than 50% yield and, therefore, this 
approach was not pursued further. 
 
Scheme 3.12 - Suzuki coupling: approach A. 
Reagents and conditions: 97, 10% Pd/C, KOH (aq., 1 M), H2O/EtOH, 135 °C, 3.5 h, 
49%. 
Suzuki-coupling: approach B 
Protection of the phenolic OH of 85 with a benzyl group was investigated, as the 
protecting group could be removed by hydrogenation concurrently with the 
reduction of the alkene to give 107, thus reducing the number of steps in the 
synthesis. The resulting 1-(benzyloxy)-3-bromobenzene 112 was coupled with the 
boronic ester 97 to give ketal 113 in good yield with straightforward purification 
and, finally, catalytic hydrogenation of 113 yielded the desired phenol 107. The 
total yield of the desired ketal 107 was 52% over three steps (Scheme 3.13). 
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Scheme 3.13 - Suzuki coupling: approach B. 
Reagents and conditions: a) K2CO3, BnBr, acetone, 57 °C, 3 h, 89%; b) 97, Na2CO3 
(aq., 2 M), Pd(dppf)Cl2, DME, μW 80 °C, 15 min, 75%, c) H2, 10% Pd/C, EtOH, 60 °C, 
3.5 h, 78%. 
Suzuki-coupling: approach C 
The final strategy investigated (Scheme 3.14) involved reversing the coupling 
partners. Phenol 114, obtained via Miyaura borylation from 85, was the 
nucleophilic species reacting with triflate 103 (precursor of 97) to give ketal 106. 
Upon hydrogenation of the double bond, the overall yield to obtain the ketal 107 
was 55%. The yield of approach C was comparable to that of approach B, but the 
synthesis was one step shorter (the triflate 103 was used, as starting material 
instead of the boronic ester 97 and no protection was needed) and, therefore, less 
time consuming. For this reason, approach C was chosen to continue the synthesis. 
 
Scheme 3.14 - Suzuki coupling: approach C. 
Reagents and conditions: a) Pd(dppf)Cl2, (Bpin)2, KOAc, 1,4-dioxane, 80 °C, 18 h, 
91%; b) 103, Na2CO3 (aq., 2 M), Pd(dppf)Cl2, DME, μW 80 °C, 15 min, 64%; c) H2, 
Pd/C 10%, EtOH/THF 4:1, 40 °C, 1.5 h, 96%. 
Utilizing approach C, the new route to targets 91 and 92 is depicted in Scheme 
3.15. Once 107 was synthesized, the ketone was liberated under acidic conditions 
to obtain 108. Despite the sulfamoylation of the phenol apparently leading to 
formation of sulfamate 109, its purification proved troublesome and the product 
could not be isolated and fully characterized. 
Once more, purification in the presence of unprotected sulfamate groups was 
problematic. At this point the dimethoxybenzyl (DMB) sulfamate protecting group 
emerged from work by Tristan Reuillon79,93 and efforts switched to using this 
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methodology to avoid the isolation issues in the synthesis of the sulfates 91, 92 
and 93. 
 
Scheme 3.15 - Revised route for the target compounds 91 and 92.  
Reagents and conditions: a) (Bpin)2, Pd(dppf)Cl2, KOAc, 1,4-dioxane, 80 °C; b) 103, 
Na2CO3 (aq., 2 M), Pd(dppf)Cl2, DME, μW 80 °C, 15 min, 64%; c) H2, Pd/C 10%, 
EtOH/THF 4:1, 40 °C, 1.5 h, 96%; d) AcOH/H2O/THF 20:10:3, 45 °C, 4 h, 77%;  
e) i) HCO2H, ClSO2NCO, 0 °C then RT, 3 h; ii) NH2SO2Cl in toluene, DMA, 0 C then 
RT, 18 h; f) NaBH4, THF/EtOH 3:1, -78 °C to RT; g) L-selectride, THF, -78 C to RT; 
h) i) SO3 · py (2 equiv.), DMF, RT; ii) ion exchange chromatography on Dowex 
50W8200 Na form, H2O. 
3.4.3 Sulfamate-protecting strategy applied to the synthesis of 91, 92 and 93 
Each of the two primary sulfamate protons of the sulfamate moiety was 
protected with a dimethoxybenzyl (DMB) group to avoid desulfamoylation to the 
parent phenol. The presence of an apolar protecting group also facilitated isolation 
of the intermediates via column chromatography on silica. The protecting group 
can be removed at room temperature under mild acidic conditions. Upon synthesis 
of the common precursor 115 following the published route, Suzuki coupling with 
9793 would afford the ketal 116. Deprotection of the ketone followed by catalytic 
hydrogenation would generate intermediate 118. Subsequent stereoselective 
reduction would yield either trans-alcohol 120 or cis-alcohol 119 that could be 
deprotected to give sulfamates 111 and 110, respectively. Sulfation of the alcohol 
moiety would afford the desired target molecules 91 and 92 (Scheme 3.16). 
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Scheme 3.16 - Proposed route to the synthesis of 91 and 92.  
Reagents and conditions: a) 97, Na2CO3 (aq., 2 M), Pd(dppf)Cl2, DME, μW 80 °C;  
b) p-TSA, acetone/H2O, µW 60 C; c) H2, Pd/C 10%, EtOH/THF 4:1, 40 °C;  
d) NaBH4, THF/EtOH 3:1, -78 °C to RT; e) L-selectride, THF, -78 °C to RT;  
f) TFA/DCM 9:1, RT; g) i) SO3 · py (2 equiv.), DMF, RT; ii) ion exchange 
chromatography on Dowex 50W8200 Na form, H2O. 
Similarly, coupling of 115 with the boronic ester 101 followed by hydroboration-
oxidation of the cyclohexene intermediate 121 would yield the alcohol 122. 
Finally, deprotection of the sulfamate group and sulfation of the 2-hydroxy group 
would afford the target sulfate 93 (Scheme 3.17). 
 
 
Scheme 3.17 - Proposed route to the synthesis of 93. 
Reagents and conditions: a) 101, Na2CO3 (aq., 2 M), Pd(dppf)Cl2, DME, μW 80 °C;  
b) i) BH3 · THF (1.0 M), 0 C; ii) NaOH, H2O2, RT; c) TFA/DCM 9:1, RT; d) i) SO3 · py 
(2 equiv.), DMF, RT; ii) ion exchange chromatography on Dowex 50W8200 Na 
form, H2O. 
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Synthesis of the protected 3-bromophenylsulfamate precursor 117 
The bis(2,4-dimethoxybenzyl) protected 3-bromophenyl precursor 115 was 
synthesized by reaction of 2-methylimidazole 124 with sulfuryl chloride, followed 
by displacement of one of the imidazole groups of 125 by 3-bromophenol to obtain 
intermediate 126. Methylation of the imidazole 3-nitrogen using 
trimethyloxonium tetrafluoroborate yielded the salt 127, which was not isolated 
and was coupled directly with bis(2,4-dimethoxybenzyl)amine 131 to displace the 
dimethylimidazole (Scheme 3.18). The amine 131 was obtained by reductive 
amination from 2,4-dimethoxybenzylamine and 2,4-dimethoxybenzaldehyde 
(Scheme 3.19). 
 
Scheme 3.18 - Synthesis of the bis(2,4-dimethoxybenzyl) protected  
3-bromophenyl primary sulfamate 128. 
Reagents and conditions: a) SO2Cl2, DCM, 0 °C to RT, 24 h, 68%; b) 3-bromophenol, 
Cs2CO3, MeCN, μW 120 °C, 15 min, 90%; c) Me3OBF4, DCM, 0 °C to RT, 18 h; d) 131, 
MeCN, RT, 8 h, 55% over two steps. 
 
Scheme 3.19 - Synthesis of 2,4-dimethoxybenzylamine 131. 
Reagents and conditions: a) i) EtOH, 78 °C, 5 h; ii) NaBH4, RT, 18 h, 75%. 
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Synthesis of sulfates 91 and 92 
The palladium-catalyzed coupling of boronic ester 97 and protected  
3-bromophenylsulfamate 115 following the previously optimized Suzuki 
conditions led to the formation of acetal 116 in excellent yield. Deprotection of the 
ketone without removal of the DMB group was obtained in mild acidic conditions 
using an adapted literature procedure94 to give cyclohexenone 117. It was 
observed that the latter intermediate was not stable, probably because of 
aromatization of the cyclohexenone ring in air, and it was therefore decided to 
perform the catalytic hydrogenation of the double bond prior to deprotection of 
the ketone. Once the stable acetal 132 was obtained, a milder acid (AcOH) was 
utilized for the deprotection. A literature procedure using acetic acid in a mixture 
of water and THF at 45 C95 successfully afforded ketone 118 in good yield 
(Scheme 3.20). 
 
Scheme 3.20 - Synthesis of the intermediate 132. 
Reagents and conditions: a) 97, Na2CO3 (aq., 2 M), Pd(dppf)Cl2, DME, μW 80 °C, 15 
min, 99%; b) p-TSA (1 equiv.), acetone/H2O, µW 60 C, 1 h, 72%; c) H2, Pd/C 10%, 
EtOH/THF 4:1, 40 °C, 96%; d) AcOH/H2O/THF 20:10:3, 45 °C, 87%. 
The position of the equilibrium between the two chair conformers of 4-
substituted cyclohexanone 118 is such that, to minimize 1,3-diaxial interactions, 
the predominant form has the aryl ring occupying an equatorial position, thus 
facilitating the stereoselective reduction of the ketone. A hydride attacking the 
carbonyl from the same face of the equatorial 4-aryl group will give the trans-
cyclohexanol (±)-120 as major product, while attack coming from the opposite 
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face will prevalently lead to the cis-cyclohexanol (±)-119. When approaching the 
carbonyl, a small hydride source, such as NaBH4, can overcome the unfavorable 
1,3-diaxial interactions with the two hydrogens on C3 and C5 and lead to 
formation of the most stable trans-4-arylcyclohexanol (±)-120 product, in which 
the hydroxyl is in equatorial position (Scheme 3.21). Equatorial attack is preferred 
by the more hindered L-Selectride to avoid 1,3-diaxial interactions resulting in cis-
4-arylcyclohexanol (±)-119 being the major product, even though it is the least 
favored in terms of free energy due to the hydroxyl being in an axial position 
(Scheme 3.22). As shown in Table 3.12, in both cases a roughly 8:1 ratio of the 
desired and the unwanted isomers was observed by LC-MS. The stereochemistry 
was confirmed by 1H-NMR analysis of the splitting patterns (see discussion below 
regarding (±)-92 and (±)-91). 
 
Scheme 3.21 - Axial attack by an unhindered hydride source on a  
4-arylcyclohexanone. 
Reagents and conditions: NaBH4, THF/EtOH, -78 °C to RT, 1.5 h, 78%. 
 
Scheme 3.22 - Equatorial attack by a hindered hydride source on a  
4-arylcyclohexanone. 
Reagents and conditions: L-selectride, THF, -78 °C to RT, 1 h, 69%. 
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Table 3.12 - Stereoselective reduction of a 4-arylcyclohexanone. 
Hydride source 
trans/cis ratio 
(LC-MS) 
trans 120 
isolated yield 
cis 119 
isolated yield 
NaBH4 8.6 : 1 78% 5.5% 
L-selectride 1 : 8.2 - 69% 
Deprotection of the sulfamate group of (±)-120 using 10% TFA in DCM under 
anhydrous conditions93 led to the formation of both the desired sulfamate (±)-111 
and the corresponding trifluoroacetate side product (±)-133. The use of a lower 
concentration of TFA (5% in DCM) did not prevent esterification of the alcohol. 
The by-product (±)-133 could be isolated and converted to the desired trans-
alcohol (±)-120 upon treatment with sodium borohydride (Scheme 3.23). 
 
Scheme 3.23 - Deprotection of 120. 
Reagents and conditions: a) TFA/DCM 9:1, RT, 2.5 h, 111: 46%, 133: 39%;  
b) NaBH4, THF/EtOH 3:1, -78 °C to RT, 2.5 h, quant. 
Sulfation of the hydroxyl was performed with sulfur trioxide pyridine complex in 
DMF using the conditions described previously. To form the more stable sodium 
sulfate salt (±)-92, ion exchange chromatography79 at pH 7 was preferred to 
treatment with sodium hydroxide to avoid hydrolysis of the primary sulfamate 
group (Scheme 3.24). 
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Scheme 3.24 - Sulfation of the alcohol 111. 
Reagents and conditions: a) i) SO3 · py (2 equiv.), DMF, RT, 30 min; ii) ion exchange 
chromatography on Dowex 50W8200 Na form, H2O, 84%. 
The same procedure was applied to the synthesis of the cis-isomer (±)-91 from 
alcohol 119 (Scheme 3.25). 
 
Scheme 3.25 - Synthesis of 91. 
Reagents and conditions: a) TFA/DCM 9:1, RT, 2.5 h, 110: 53%, 134: 25%; b) 
NaBH4, THF/EtOH 3:1, -78 °C to RT, 2.5 h, 66%; c) i) SO3 · py, DMF, RT, 1 h; ii) ion 
exchange chromatography on Dowex 50W8200 Na form, H2O, 98%. 
To confirm the predicted stereochemistry the 1H-NMR coupling constants were 
analyzed and compared with those expected from the Karplus equation.96 For an 
axial proton, coupling constants 3Jax-ax are expected to be 9-13 Hz and 3Jax-eq should 
be 2-4.5 Hz. Consistent with these values, the coupling constants observed in the 
triplet of triplets corresponding to the axial proton H-4 of 111 were 11.0 and  
4.3 Hz, respectively (Figure 3.7a). For an equatorial proton, 3Jeq-ax and 3Jeq-eq are 
expected to be in the range between 2 Hz and 4.5 Hz. Smaller coupling constants 
leading to the distinct multiplet observed in Figure 3.7b are consistent with the 
equatorial position of proton H-4 of 110. 
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Figure 3.7 - Splitting patterns of the proton on the 4-position of the 
cyclohexyl ring. 
Larger coupling constants are observed for the trans-sulfate 111 (a) while small 
coupling constants are found for the cis-product 110 (b), in agreement with the 
Karplus equation. 
Synthesis of sulfate (±)-93 
To obtain sulfate 93, Suzuki coupling of boronic ester 101 with protected 3-
bromophenylsulfamate 115 led to the formation of the 1-substituted cyclohexene 
121, which was deprotected to yield 135 (Scheme 3.26). 
 
Scheme 3.26 - Synthesis of 135. 
Reagents and conditions: a) 101, Na2CO3 (aq., 2 M), Pd(dppf)Cl2, DME, μW 80 °C,  
15 min, 96%; b) TFA/DCM 9:1, RT, 3 h, 74%. 
  
a b 
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The optimized Suzuki-Miyaura conditions were also used to synthesize the 
tertiary sulfamate analogue 136 (Scheme 3.27). 
 
Scheme 3.27 - Synthesis of 2',3',4',5'-tetrahydro-[1,1'-biphenyl]-3-yl 
dimethylsulfamate. 
Reagents and conditions: a) 1-cyclohexen-1-yl boronic acid pinacol ester, Na2CO3 
(aq., 2 M), Pd(dppf)Cl2, DME, μW 80 °C, 15 min, 49%. 
Hydroboration-oxidation of the double bond of the cyclohexene ring of 121 gave 
122 as a racemate, with attack occurring from either face of the double bond. A 
small amount of the regioisomer 137 was also isolated (ratio 122:137 3.4:1). 
Deprotection of the sulfamate group of 122, conversion of the trifluoroacetate 
ester side-product 138 back to the alcohol 123, and sulfation of the latter followed 
by ion exchange chromatography yielded desired target 93 (Scheme 3.28). The low 
yield of the sulfation may be due to both steric hindrance and problematic 
purification. 
 
Scheme 3.28 - Synthesis of 93. 
Reagents and conditions: a) i) BH3 · THF (1.0 M), 0 °C, 1 h; ii) NaOH, H2O2, RT, 18 h, 
122 55%; 137 16%; b) TFA/DCM 9:1, RT, 18 h, 123: 35%, 138: 32%; c) NaBH4, 
THF/EtOH 3:1, -78 °C to RT, 5 h, 95%; d) i) SO3 · py, DMF, RT, 1 h; ii) ion exchange 
chromatography on Dowex 50W8200 Na form, H2O, 32%. 
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 Conclusions 3.5
The synthesis of three small libraries of potential inhibitors of Sulf2 was 
reported. A library of aryl tertiary sulfamates 35 was synthesized in one step 
following an improved literature procedure for the sulfamoylation of appropriately 
substituted phenols which used an excess of phenol and base (Cs2CO3) with 
respect to the N,N-dimethylsulfamoyl chloride. The target compounds were 
obtained from commercially available starting materials in variable yields. 
   
Subsequently, a library of 3-biaryl tertiary sulfamates 37 was designed on the 
model of the disaccharide unit of heparan sulfate. The B-ring was functionalized 
with polar moieties such as carboxylic acids, sulfates and aminosulfates. Starting 
from a literature procedure for the Suzuki-coupling of sulfamates with appropriate 
boronic acids, the optimization of the reaction conditions led to an improved yield 
and a reliable methodology for the formation of the C-C bond between the two 
aromatic rings. Further elaboration of the resulting biaryls led to the desired target 
molecules. 
The synthesis of an analogue library of biaryl primary sulfamates following the 
same strategy was attempted but resulted in the partial hydrolysis of the -OSO2NH2 
moiety to the parent phenol to give a complex mixture that proved difficult to 
purify and from which the desired product could be isolated in poor yield (20%). 
Several bases were tested in Suzuki-Miyaura cross coupling conditions but none of 
them led to an improvement, pointing out the need for a primary sulfamate 
protecting strategy which was therefore devised within the research group by 
Tristan Reuillon. 
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Using this protecting strategy, a third set of target molecules was synthesized 
which was characterized by an aryl primary sulfamate substituted at the  
3-position by a cyclohexyl ring bearing an hydroxyl or a sulfate group either at the 
2- or at the 4- position. Appropriate choice of the hydride source allowed the 
stereoselective reduction of the 4-cyclohexanone moiety to obtain either the cis- or 
the trans-cyclohexanol derivatives 119 and 120 which were then deprotected and 
sulfated to yield the target compounds 91 (14 steps; total yield 7%) and 92 (14 
steps; total yield 10%), respectively. Hydroboration of the 1’-cyclohexene 
intermediate 121 followed by deprotection and sulfation led to primary sulfamate 
93 (12 steps; total yield: 2%). 
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CHAPTER 4. SUMMARY OF THE BIOLOGICAL RESULTS OBTAINED 
FOR SULF2 POTENTIAL CHEMICAL TOOLS 
 Activity of the synthesized sulfamates against Sulf2, ARSA and ARSB 4.1
The compounds prepared were screened in a biochemical assay against Sulf2 at a 
single concentration to obtain a value of percentage inhibition of the desulfation of 
4-methylumbelliferone sulfate (4-MUS, Figure 4.1a). The sulfatase-catalyzed 
desulfation of 4-MUS releases the parent phenol 4-methylumbelliferone (4-MU), a 
fluorescent indicator (Figure 4.1b). In the presence of an inhibitor, the decrease in 
fluorescence is proportional to the inhibitory activity (Figure 4.1c). 
 
 
Figure 4.1 - Desulfation of 4-MUS (potassium salt). 
a) Desulfation reaction of 4-methylumbelliferone sulfate; b) removal of the sulfate 
group by immobilized Sulf2 releases 4-methylumbelliferone, a fluorescent 
indicator; c) in the presence of an inhibitor, Sulf2 cannot catalyze the desulfation of 
4-MUS, resulting in a decrease in fluorescence proportional to the amount of 
inhibited enzyme. 
The assay was developed by Gary Beale66 and Sari Alhasan67-68 who also tested 
all the compounds. In the Sulf2 project, the inhibitor working concentration in the 
assay was 1 mM, due to the low activity of the compounds analyzed. An IC50 was 
measured only for compounds with percentage inhibition higher than 50%. 
Initially, the benchmark compound used for assay development was the sulfated 
a) 
b) c) 
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monosaccharide 24 (lit. IC50 = 130 µM; in house <10% inhibition at 1 mM), 
reported in the literature59 and resynthesized by Duncan Miller.65 At a more 
advanced stage, the positive and negative control compounds used were 
trichloromethyl {3'-(sulfamoyloxy)-[1,1'-biphenyl]-3-yl}sulfamate (IC50 = 156 µM) 
and 3-(sulfamoyloxy)benzoic acid (16% inhibition at 1 mM), which emerged from 
the SAR studies conducted by Tristan Reuillon.79 
Selectivity of the compounds against sulfatases was assessed by means of a 
counter-screen against aryl sulfatase A (ARSA) and aryl sulfatase B (ARSB), again 
using 4-MUS as substrate. 
 Activities of a library of sulfamates against Sulf2 4.2
4.2.1 The monocyclic substituted phenyl sulfamate series 
All the tertiary phenylsulfamates had no significant inhibitory activity against 
Sulf2. 
4.2.2 The substituted biphenyl sulfamate series 
In the biphenyl series (all measured at 1 mM concentration), the 3’-cyano 
analogue 81 was the most potent, achieving 29% inhibition. The 4’-substituted 
aniline 71 exhibited weak inhibition of Sulf2 (21% inhibition), while the 2’- and 3’-
anilines (69 and 70, respectively) had no inhibitory activity. Sulfated anilines 74 
(10%), 73 (17%) and 72 (11%) all showed low levels of activity. The 4’-carboxylic 
acid 65 (19%) and its 3’-regioisomer 64 (16%) demonstrated superior inhibition 
than 2’-carboxyl 63 (3%). The 4’-hydroxymethylsulfate 84 was the second most 
potent compound (27%) and more potent than its parent alcohol 83 (5%). The 
pyridyl compounds had low activity, with the most active regioisomer being 4-
pyridyl 80 (13%). Apolar compounds, such as the 4’-methoxyphenyl 82, the 
acetanilides 75, 76 and 77 and the methyl esters 66, 67, 68 were all weakly active. 
Overall these results suggest that a polar group at the 4-position of the B-ring may 
contribute to activity against Sulf2 (Figure 4.2). However, it would appear that the 
biphenyl tertiary sulfamate scaffold in general does not confer good Sulf2 
inhibition. 
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Figure 4.2 - Percentage inhibition of the substituted biphenyl sulfamate 
series against Sulf2. The assay was performed by Sari Alhasan.68 Replicates: n=2. 
Error bars represent standard deviation. 
A similar set of primary sulfamates was prepared by Tristan Reuillon79 and found 
to have higher activity, again measured at 1 mM concentration. For example, the 
primary sulfamate analogue of 73, had Sulf2 inhibition of 31% (compared to just 
17% of 73). 
4.2.3 Compounds with a non-aromatic B-ring 
The most active compound synthesized was the cyclohexene-containing primary 
sulfamate 135 (49% inhibition at 1 mM). Its tertiary sulfamate analogue 136 had 
much weaker Sulf2 activity, further supporting the superiority of primary over 
tertiary sulfamates. The trans-sulfate 92 was more active than the corresponding 
alcohol 111, whereas no statistically significant difference was found between the 
corresponding cis-compounds 91 and 110, respectively, and between 93 and 123. 
The trans-4-cyclohexyl sulfate 92 was the most active among the sulfates (35%) 
followed by the trans-2-cyclohexyl sulfate 93 (14% at 1 mM). The results obtained 
with the cyclohexylsulfates initially suggest that a polar group at the 4-position 
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may be beneficial. It appears that a better interaction with the target is obtained 
when the polar substituent at the 4 position of the B-ring is equatorial and trans to 
the A-ring. Nonetheless, polarity does not seem to be a strict requirement for 
binding, as the most potent compound synthesized was the unsubstituted 
cyclohexene primary sulfamate 135 (Figure 4.3). 
 
Figure 4.3 - Percentage inhibition of the non-aromatic B-ring series against 
Sulf2. The assay was performed by Sari Alhasan.68 Replicates: n=2. Error bars 
represent standard deviation. 
 Activities of a library of sulfamates against ARSA and ARSB 4.3
As mentioned in Section 2.1, the active site of sulfatases is highly conserved and 
it is therefore necessary to probe the synthesized inhibitors against a selection of 
sulfatases to exclude the possibility of non-selective sulfatase inhibition. The 
commercially available aryl sulfatase A, ARSA, and arylsulfatase B, ARSB, were 
chosen for the counterscreen and, as for Sulf2, 4-MUS was used as a substrate. 
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4.3.1 The monocyclic substituted phenyl sulfamate series 
The compounds synthesized in the phenyl series were more active against ARSA 
and ARSB than against Sulf2. In most cases higher activity was shown against 
ARSB. 
Several compounds exhibited high selectivity for ARSB. For example, 
unsubstituted phenylsulfamate 58 only inhibited ARSB (59% inhibition at 1 mM), 
as did the 3-bromo analogue 59 (59%). A lipophilic substituent at the 4-position 
such as chloro- in 54 (ARSA: 38%; ARSB 66) or t-butyl- in 41 (ARSA 28%; ARSB 
67%), appeared to confer some ARSA activity inhibition. Methoxy-substituted 
phenyls 42, 43 and 44 were all active against ARSB (68, 71 and 68% inhibition, 
respectively) but much less active towards ARSA (12, 41 and 24%, respectively). 
The cyano- and trifluoromethyl- subgroups were also active against both enzymes. 
The selectivity was reversed only when nitro- was present in the 4- position of the 
phenyl ring, 48 (ARSA: 79%; ARSB 61%, Figure 4.4). 
 
Figure 4.4 - Percentage inhibition of the monocyclic substituted phenyl 
sulfamate series against ARSA and ARSB. The assay was performed by Sari 
Alhasan.68 Replicates: n=2. Error bars represent standard deviation. 
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4.3.2 The substituted biphenyl sulfamate series 
In the biphenyl sulfamates, inhibitors with high selectivity for ARSA over ARSB 
were obtained. For example, the Sulf2-active 3’-cyano compound 81 was an 
effective inhibitor of ARSA at 1 mM (94%) but had low activity against ARSB 
(12%). A good example of the effect of regiochemistry on selectivity is observed in 
the case of carboxyl, where the 4’-carboxylic acid 65 (ARSA: 96%; ARSB <5%) is 
selective for ARSA and 2’-carboxyl 63 (ARSA: <5%; ARSB: 72%) is selective for 
ARSB. The corresponding methyl esters do not show such selectivity, which may 
indicate the establishment of interactions involving the carboxylate. 1,1’-Biphenyl 
3-sulfamate 56 was active against both sulfatases (97 and 98% against ARSA and 
ARSB, respectively) and more active than the 2- and 4- isomers. The 4-methoxy-
substituted compound was weakly active against either enzyme. 
 
Figure 4.5 - Percentage inhibition of the substituted biphenyl sulfamate 
series against ARSA and ARSB. The assay was performed by Sari Alhasan.68 
Replicates: n=2. Error bars represent standard deviation. 
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When 4’-amino substitution was present on 71, both ARSA (98%) and ARSB 
(79%) were inhibited, while the 3’- and 2’- regioisomers, 70 and 69, respectively, 
were inactive. The 4’- and 2’- sulfated anilines 74 and 72 were found to be more 
effective inhibitors of both ARSA and ARSB than the 3’-sulfated analogue 73 
(Figure 4.5). The 3’-acetanilide 76 was more active against ARSB (88%) than the 
other acetanilide regioisomer. The 4’-hydroxymethyl sulfate 84 was active against 
both enzymes, but its parent alcohol 83 (ARSA: 98%; ARSB: 94%) only inhibited 
ARSB (ARSA: 4%; ARSB 82%). Both targets were not affected by the 4-pyridyl 80, 
but were inhibited by the 2- and 3-regioisomers 78 (ARSA: 76%; ARSB: 87%) and 
79 (ARSA: 15%; ARSB: 62%), with a stronger effect observed on ARSB. Finally, the 
sulfated aniline 87 only weakly inhibited ARSB. 
 
4.3.3 Compounds with a non-aromatic B-ring 
 
Figure 4.6 - Percentage inhibition of the non-aromatic B-ring series against 
ARSA and ARSB. The assay was performed by Sari Alhasan.68 Replicates: n=2. 
Error bars represent standard deviation. 
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In this series, results were not obtained for all compounds, with data only being 
generated for 136, 111 and 110. The cyclohexenyl tertiary sulfamate 136 showed 
some activity against both the enzymes, whereas the primary sulfamates 111 and 
110 did not show any inhibition of either ARSA or ARSB (Figure 4.6). 
The results highlight that tertiary sulfamates are not good inhibitors of Sulf2 but 
they do exhibit greater inhibition of ARSA and ARSB. The available data are 
insufficient to draw definite conclusions, but replacement of the tertiary sulfamate 
group with a primary sulfamate appears to reduce activity towards the aryl 
sulfatases and improve binding to Sulf2. 
 
 Conclusions 4.4
All compounds synthesized within the Sulf2 project were tested for Sulf2, ARSA 
and ARSB activity using the assay developed by Gary Beale and Sary Alhasan. The 
results of the SAR are summarized schematically in Figure 4.7. 
 
 
 
 
 
 
Figure 4.7 - Summary of the SAR for Sulf2, ARSA and ARSB. 
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CHAPTER 5. INTRODUCTION TO MDMX 
 p53, MDM2, and MDMX 5.1
5.1.1 The p53 tumor suppressor 
In their reviews, Hanahan and Weinberg included evasion of apoptosis among 
the hallmarks of cancer.8-9 Common mechanisms by which neoplasms elude 
programmed cell death include the inactivation of the TP53 gene, or the inhibition 
and reduction of cellular levels of p53 protein by Murine Double Minute 2 (MDM2) 
and Murine Double Minute X (MDMX).8-9 p53 mutations are found in up to 50% of 
human cancers (Figure 5.1); moreover, in tumors where wild-type p53 is retained, 
alterations in its regulation are frequently observed.97 
 
Figure 5.1 - Occurrence of p53 mutations in common cancers. 
Adapted from Petitjean, 2007, last database update R17, November 2013.98 
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Protein 53, or p53, is a transcription factor involved in a large number of 
processes including differentiation, ageing, mitochondrial respiration, 
angiogenesis and glycolysis. The importance of p53, also known as ‘guardian of the 
genome’ and ‘cellular gatekeeper’,98-101 is linked to its ability to activate cell cycle 
arrest, DNA repair, senescence and apoptosis in response to cellular stress signals 
(Figure 5.2) with the aim of preserving the integrity of genetic information. It is, 
therefore, unsurprising that p53 is one of the most commonly mutated proteins in 
cancer.102 p53 was first reported in 1979 and was at first believed to be an 
oncogene.103 It was only after establishing that the clones used to ‘prove’ 
tumorigenic properties of p53 were, in fact, p53 mutants and after determining the 
sequence of wild-type p53, that the scientific community acknowledged the tumor-
suppressor role of this protein. It was formally proven in 1991 that p53 is capable 
of inducing apoptosis.104 Subsequently, improved understanding of the p53 
pathway has been achieved. 
 
Figure 5.2 - The p53 pathway. 
Upstream signals cause activation of p53 trancriptional activity leading to 
downstream effects according to the severity of DNA damage. Reproduced from 
Levine, 2009.104 
Consisting of 395 amino acid residues, p53 is a small protein (actually 43.7 kDa 
and not 53 kDa as originally claimed) undergoing several post-translational 
modifications including phosphorylation, acetylation and ubiquitination.105-106 
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Notably, active p53 binds to DNA as a homotetramer.107 Together with p67 and 
p73, p53 belongs to a small family of transcription factors.108 Functional domains 
in p53 include (Figure 5.3): the N-terminal transactivation domain, responsible for 
transcriptional activity, as well as for MDM2 and MDMX binding; a central DNA-
binding domain which is commonly a target for mutations in cancer; a C-terminal 
domain containing a negative regulation domain and an oligomerization domain 
(4D), the latter comprised of a nuclear export signal (NES) and three nuclear 
localization signals (NLS).109 
 
Figure 5.3 - Schematic representation of p53 primary structure. 
The N-terminal transactivation domain, NTD, contains the two sub-domains TAD1, 
transactivation domain 1, TAD2, transactivation domain 2. p53 also includes a DNA 
binding domain, DBD, and a tetramerization domain, TET, located at the  
C-terminus. Adapted from Follis, 2014.110 
Cellular stress conditions such as hypoxia, oxidative stress, starvation or 
alteration of mitochondrial and ribosomal biogenesis, trigger a number of signals 
which ultimately results in the activation of p53 for its nuclear and cytoplasmic 
functions. In the nucleus, p53 binds to specific DNA sites and promotes the 
transcription of target genes involved in processes designed to preserve DNA 
integrity, such as apoptosis (BAX, NOXA, PUMA), senescence (p21), cell-cycle arrest 
(14-3-3α, p21), DNA repair (MSH2) and autophagy (AMPK, BAX, PUMA). 
Additionally, other downstream effects of p53 transcriptional activity are related 
to metabolism, antioxidant activity, angiogenesis, fertility and pigmentation. p53 is 
also involved in its own regulation (activation of genes such as MDM2, COP1, 
CYCLIN G, PIRH2 and WIP1), establishing a negative feedback loop.101,111 
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It has been demonstrated that p53 can induce apoptosis in cells in which the 
nucleus has been removed (enucleated cells). One of the most plausible 
explanations for this phenomenon is that alongside the transactivation of genes 
involved in mitochondrial-related apoptosis (e.g. Bax, PUMA, NOXA), cytoplasmic 
p53 is capable of promoting mitochondrial outer member permeabilization 
(MOMP), which is linked to the mitochondrial (or intrinsic) pathway of apoptosis 
through interaction with proteins of the Bcl-2 family.101,111 
5.1.2 MDM2 and MDMX 
MDM2 and MDMX are two structurally similar proteins that are involved in the 
regulation of p53. Loss-of-function studies in mutant mice suggested the roles of 
MDM2 and MDMX to be non-redundant, as they are both necessary for embryo 
development.112 The interplay of MDM2 and MDMX in p53 regulation is currently 
not fully understood but it is clear that both proteins play a crucial role in the 
degradation of p53 through the ubiquitin-proteasome pathway.113 
The ubiquitin-proteasome pathway 
The conjugation of ubiquitin, a small protein highly conserved in eukaryotic cells, 
is a multi-step process relying on three classes of enzymes. Initially, the adenylated 
carboxy-terminal residue of ubiquitin is attached to a cysteine of an ubiquitin-
activating enzyme, classified as an E1 enzyme. Subsequently, ubiquitin is 
transferred to an ubiquitin-conjugation enzyme, E2. A third enzyme, E3, acts as a 
scaffold for the E2 enzyme and the target protein and catalyzes the formation of an 
isopeptide bondb between the C-terminal carboxyl of ubiquitin and the lysine  
ε-amino group of the protein to be degraded. A single ubiquitin molecule is usually 
not sufficient to trigger degradation and, frequently, ubiquitin chains need to be 
formed by conjugation of multiple ubiquitin units onto lysine side chains for the 
target protein to be recognized by the proteasome.114 Ubiquitination can occur on 
multiple lysine residues of a protein (multi-ubiquitination) or onto ubiquitin lysine 
residues to form an extended ubiquitin chain (polyubiquitination).115 
                                                        
b Peptide bond involving a side chain and resulting in a branch point from the main protein chain. 
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MDM2 
MDM2, a 491-amino acid protein (90 kDa on SDS-PAGE), was first reported in 
1992.116 At first believed to be an oncogene, it was shown to have E3 ligase activity 
towards p53, promoting its own ubiquitination117 and subsequent degradation by 
the 26S proteasome. In addition to promoting p53 degradation, MDM2 also masks 
the N-terminal transactivation domain of p53, thus preventing DNA binding and 
transcription promoting activity. MDM2 also promotes the export of p53 from the 
nucleus to the cytoplasm.118 
 
Figure 5.4 - MDMX (a) and MDM2 (b) functional domains.  
Reproduced from Macchiarulo, 2011.119 
MDM2 comprises three main functional domains (Figure 5.4.b).119 The N-
terminal domain contains the p53-binding cleft, consisting of a hydrophobic region 
that accommodates three key residues of a p53 ligand α-helix: Phe19, Trp23 and 
Leu26 (Figure 5.5). This triad of amino acid residues accounts for most of the 
energy of binding representing the so-called ‘hot spot’ of the interaction (see 
Section 5.4). The central domain includes a zinc finger, whose function is yet to be 
elucidated, and a signal sequence for caspase cleavage. The C-terminal RING 
(Really Interesting New Gene) domain is responsible for both dimerization (either 
homodimerization, or heterodimerization with MDMX) and E3 ligase activity.119 
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The MDM2-MDMX heterodimer is more stable than the homodimer of each 
protein120 and seems to promote a more effective ubiquitination of p53 than 
MDM2.121 
 
Figure 5.5 - The three key residues of p53 α-helix (green) accommodate into 
a hydrophobic binding cleft on MDM2. 
Reproduced from Khoury, 2011.108 
MDMX 
MDMX (also known as MDM4) is a 490 amino acid homolog of MDM2. Similarly, 
it has three functional domains with analogous roles, with highest sequence 
identity being in the p53-binding N-terminal domain (53.6%).119 Approximately 
70% of the MDMX polypeptide chain is intrinsically disordered.122 Structural data 
suggests that the MDMX binding site for p53 is smaller than for MDM2. This is due 
to structural reasons: firstly, a leucine is replaced by a methionine in MDMX and, 
secondly, unlike the Tyr100 in MDM2, the MDMX Tyr99 adopts a closed 
conformation (see Section 5.4).123 These differences may explain the large 
difference in binding affinity usually exhibited by MDM2 inhibitors towards these 
two closely related proteins.124 More recently, Yu et al. showed that an opened 
conformation of Tyr99 (see Section 5.4 for more details) in MDMX is also possible, 
indicating that the binding surface is dynamic and that ligand-induced fit must be 
taken into account in the design of inhibitors.125 MDMX and MDM2, through 
interaction of their RING domains, form a heterodimer with enhanced 
ubiquitination activity with respect to the MDM2 homodimer, as frequently 
observed for other E3 ligases.113 Although the mechanism of activation has not 
been elucidated, MDM2:MDMX heterodimers tend to promote polyubiquitination 
of the substrate, rather than its mono-ubiquitination.121 
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Figure 5.6 - Known splice variants of MDMX. 
Reproduced from Mancini, 2009.126 
Several MDMX splice variants have been identified to date (Figure 5.6)126-128 
stemming from removal of a different set of non-coding RNA sequences (introns) 
from the same pre-mRNA transcript by the spliceosome to generate mature mRNA. 
A total of seven shorter transcript variants of MDMX have been characterized, 
although not all are known to be translated into proteins, some being cancer-
specific.126-127 Among the most interesting isoforms there is a shorter version of 
MDMX (MDMX-S)128 whose estimated affinity towards the transactivation domain 
of p53 is approximately 70-fold higher than that of the full-length protein (Table 
5.1, entries 1 and 5).  
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Table 5.1 - Binding affinities of MDMX for the formation of protein-protein 
interactions. 
The binding affinity of the interactions between full length MDMX and both the N-
terminal domain of p53 (entry 1) and full length p53 (entry 2) are comparable, 
suggesting that the association of the N-terminal domains drives the formation of 
the complex. The KD of the association of the WWW autoinhibitory domain (MDMX 
181-211) to MDMX N-terminal domain (1-111) is in a similar range (entry 3). 
Deletion of the WWW element improves binding affinity (entries 4 and 5). Adapted 
from Bista, 2013.122 
# Complex KD (nM) 
1 Full length MDMX + p53 17-32 2,870 ± 558 
2 Full length MDMX + full length p53 1,110 ± 101 
3 MDMX 1-111 + MDMX 181-211 1,290 ± 641 
4 MDMX 1-111 + p53 17-32 30.3 ± 3.9 
5 MDMX-S + p53 17-32 40.3 ± 6.3 
 
 
Figure 5.7 - Alignment of the WWW sequence across a range of species. 
Adapted from Bista, 2013.122 
In a recent publication, Bista and co-workers described the identification of an 
intrinsically disordered area of full-length MDMX which contains a sequence that is 
highly conserved across species (Figure 5.7) and that is not found in MDM2. They 
demonstrated that this sequence, called the WWW element, by virtue of the 
presence of three key tryptophan residues, intramolecularly inhibits the N-
terminal domain of MDMX, accounting for a 100-fold difference in p53 binding 
affinity between full-length MDMX and N-terminal domain MDMX. Active MDMX is 
obtained either by alternative splicing engendering MDMX-S, which does not 
include the autoinhibitory domain, or through binding of accessory regulators to 
the WWW element causing the N-terminal domain to be released (Figure 5.8).122 
| | | | |
Human (Homo sapiens ) L G F E E W D V A G L P W W F L G N L R S N Y T P R S N
Mouse (Mus musculus ) L D F E E W D V A G L P W W F L G N L R N N C I P K S N
Chicken (Gallus gallus ) L V F E E W D V A G L P W W F L G N L R S N Y K S R S N
Green anole (Anolis carolinenesis ) S V L E E W D V P G L P W W F L G N L R N N Y K S R S N
Clawed frog (Xenopus levis ) F I F E E W D E A G L P W W F L G N L R T N Y N L Q S I
Zebrafish (Danio renio ) V T L E E W D L S G L P W W F L G N L R S N Y T R R S N
Elephant shark (C. millii ) S V S D H W D A A G L P W W F I K S L Q S N Y G S R K S
MDM2 Human (Homo sapiens ) S I S L S F D E S L A L C V I R E I C C E R S S S S S E
190 210
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Figure 5.8 - Full-length MDMX contains an autoinhibitory sequence (WWW 
sequence). 
The protein is activated either by a) alternative splicing giving a shorter version 
(MDMX-S) or b) pathway accessory regulators which bind the WWW sequence. 
Reproduced from Bista, 2013.122 
Despite the high homology with MDM2, MDMX does not have E3 ligase activity 
per se, as it lacks an essential cysteine residue in the RING domain that allegedly 
binds ubiquitin.129-130 The cellular localization of MDM2 and MDMX is also 
different, with MDM2 principally being located in the nucleolus, whereas MDMX is 
mainly found in the cytoplasm.128 Furthermore, Wade and Wahl observed that the 
relative amount of MDMX in normal cells is only 10-20% of that of MDM2. Given 
that MDM2 has higher affinity for dimerizing with a molecule of MDMX rather than 
recruiting a second MDM2 unit, the authors suggested that most MDMX exists as 
MDM2:MDMX heterodimers in normal cells.113 
A number of post-translational modification sites have been reported for MDMX. 
Multiple serine residues on the protein are phosphorylated by cyclin-dependent 
kinase 1 (CDK1/Cdcp34), Casein Kinase 1α (CK1α), Checkpoint kinases 1 and 2 
(Chk1/Chk2), Akt and ataxia teleangiectasia mutated (ATM).126 Recently, AMP-
activated protein kinase (AMPK) was found to phosphorylate MDMX at Ser342, 
thus enhancing MDMX binding to the regulatory protein 14-3-3. This pathway 
seems to be important for cell response to mild stress, such as glucose 
deprivation.131 MDMX is ubiquitinated by MDM2 to be tagged for degradation. 
a b 
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Another less common modification is conjugation of the protein SUMO at Lys254 
and Lys379, whose effects are still to be identified.118 
5.1.3 Cellular levels of p53 are finely tuned 
Given the number and the relevance of its functions, it is not surprising that p53 
transcriptional activity in normal cells is tightly regulated by a large number of 
enzymes, proteins and growth factors (Figure 5.9) and by a series of elegantly 
interconnected autofeedback loops. Regulation of p53 has been extensively studied 
but comprises such a complex network of signals that it is still far from fully 
understood. 
 
Figure 5.9 - Scheme showing the proteins known to influence p53 activity. 
Reproduced from Lavin, 2006.106 
As anticipated, the cellular stability of p53 is prevalently influenced by MDM2 
and MDMX.121 The relative amounts of p53, MDM2 and MDMX are cell-line 
dependent, as are the p53 regulatory processes.132 Under normal (i.e. unstressed 
cell) conditions, levels of p53 are kept low by MDM2 which, through its E3 ligase 
activity, promotes p53 degradation via the ubiquitin-proteasome pathway. 
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Additionally, ubiquitinated p53 is translocated from the nucleus to the cytoplasm, 
away from the target DNA. Finally, p53 transcriptional functions are inhibited by 
interaction of its transactivation domain with MDM2 and MDMX. The constant 
presence of low cellular levels of short-lived p53 (half-life 5-20 min)133 ensures a 
rapid response in the unfortunate event of DNA damage. When the cell is subjected 
to stress conditions, phosphorylation of MDM2 and MDMX113 triggers a response 
ranging from cell cycle arrest, to allow DNA repair, through to apoptosis, if the cell 
is highly compromised (Figure 5.10). 
 
Figure 5.10 - Regulation of p53 by MDM2 and MDMX. 
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In response to stressors, such as hypoxia, UV radiation, activation of oncogenes, 
cells will activate the p53 pathway to arrest replication until the appropriate 
repair processes are completed. p53 is released by MDM2 and MDMX and is able to 
bind DNA and exert its transcriptional activity. At this point, the preferred 
substrates targeted for ubiquitination by MDM2 are MDM2 itself and MDMX, thus 
allowing p53 accumulation. The MDM2 gene is one of the target genes induced by 
p53, originating a negative feedback loop and bringing p53 down to normal levels 
after the appropriate response has been achieved. 
Early studies showed that MDMX is not transcriptionally activated by p53 in 
stressed cells.134 Interestingly, a new promoter of the human MDMX gene has been 
recently discovered. Upon p53 binding to this new promoter, a longer version of 
MDMX, with reduced affinity for p53 itself, is expressed (MDMX-L isoform, 
containing an extra N-terminal 18-aminoacid sequence; Figure 5.11a). This adds 
another level of complexity to the network of feedback loops that regulates p53, 
MDM2 and MDMX, and further studies are required to fully understand the role of 
this isoform.121 
A question may arise at this stage: what is the molecular switch which makes 
MDMX a better substrate for ubiquitination by MDM2:MDMX dimer? Cellular stress 
causes MDMX to be phosphorylated by ATM/ATR and c-Abl kinases, resulting in 
nuclear MDMX localization. Phosphorylated MDMX is now the preferred substrate 
for MDM2:MDMX E3 ligase and is quickly degraded by the 26S proteasome, leaving 
p53 free to exert its transcriptional function (Figure 5.11c).121,135 Upon stress 
relief, phosphatase-catalyzed dephosphorylation of MDM2 and MDMX restores 
normal conditions and the p53 concentration lowers to basal levels. 
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Figure 5.11 - The p53 network. 
a) p53 promotes transcription of MDM2 and MDMX-L genes; p53 is inactivated 
upon binding to MDM2 or MDMX proteins. b) Mono-ubiquitinated p53 is 
translocated to the cytoplasm and further ubiquitinated for subsequent 
proteasomal degradation. There are deubiquitinases, both in the nucleus and in the 
cytoplasm, which are able to remove the tag. c) Stress signals promote 
polyubiquitination of p53 by MDM2/MDMX heterodimers, resulting in 
proteasomal degradation. The process is inverted by a panel of deubiquitinases. At 
the same time, MDM2/MDMX ligase leads to polyubiquitination and degradation of 
MDMX. Reproduced from Wang.121 
 MDMX as a target for cancer therapy 5.2
As previously described, tumors retaining wild-type p53 often display a severely 
impaired p53 regulation which can be achieved via either amplification or 
overexpression of the MDM2 and MDMX genes.119,136 The role of MDM2 in cancer 
has been studied for over 20 years and it is currently well established that, in 
cancer cells characterized by MDM2 overexpression and wild-type p53, 
antagonists of the MDM2:p53 interaction lead to p53 reactivation and tumor 
suppression.100 Although MDMX was also found to be amplified or overexpressed 
in many cancer types, its role is yet to be completely unravelled. As shown in Table 
5.2, increased MDMX levels are found predominantly in retinoblastoma, 
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melanoma, breast, head and neck cancers and in hepatocellular carcinoma,113 
lending support to the idea that MDMX acts as an oncogene. 
Table 5.2 - Frequency of amplification or overexpression of MDMX in a panel 
of cancers. 
Adapted from Wade, 2009.113 
Tumor type % of cases 
Retinoblastoma 60 
Glioblastoma 4 
Colon 19 
Lung 18 
Breast 19 
Melanoma 14 
Hepatocellular carcinoma 50 
Head and neck 50 
Sarcoma 22 
Bladder cancer 25 
All cell lines 40 
 
In MCF-7 breast cancer cells (characterized by wild-type p53), it has been shown 
that the knock-down of MDMX leads to increased levels of the p53-activated gene 
p21 not accompanied by a variation in p53 levels, suggesting that MDMX 
sequesters p53 to prevent its transcriptional activity.120 
Gembarska and co-workers showed that MDMX is highly expressed in 
melanomas and has an active role in the evasion of p53-induced apoptosis leading 
to cell proliferation.137 In gliomas, high levels of the MDMX-S splice variant were 
observed120 and a recent paper identified, within the same tumor type, a new 
splice variant (MDMX-B) whose expression was found to correlate directly to 
tumor stages.127 
The role of MDMX in cancer is still controversial, as other studies could find no 
correlation between MDMX overexpression and tumor development.136 Following 
a recent study by Carrillo et al., a p53-independent role of MDMX in genomic 
instability and tumorigenesis was hypothesized. The research team demonstrated 
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that transformation occurs in MDMX-overexpressing p53-devoid cells, suggesting 
an evolutionary advantage of the simultaneous increase in MDMX and decrease in 
active p53.138 
 
Figure 5.12 - Inhibition of MDM2 and MDMX and cancer cell susceptibility. 
Reproduced from Bernal, 2010.132 
The current knowledge suggests that simultaneous inhibition of MDMX and 
MDM2 would be more effective in the reactivation of p53.120 In particular, dual 
inhibition could be advantageous when targeting cancers with pathologically low 
levels of p53.132 As shown in Figure 5.12, the cellular susceptibility to MDM2 and 
MDMX inhibitors seems to depend on the relative amounts of the three proteins, 
MDMX, MDM2 and p53. Single-agent MDM2 inhibitors successfully lead to 
apoptosis in the absence of MDMX (Figure 5.12a), but cells show resistance in the 
presence of MDMX (Figure 5.12b). If MDMX is overexpressed and there is a high 
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concentration of MDMX:p53, MDMX inhibition reactivates p53 (Figure 5.12c). 
Nonetheless, if p53 levels are not sufficiently high, no effect is observed upon 
inhibition of MDMX (Figure 5.12d). In a situation where MDMX levels are high and 
p53 levels are low, dual inhibition is thought to be the solution to the problem of 
resistance (Figure 5.12e).132 
Unfortunately, as Hu et al. reported in 2006,139 MDMX binding affinity to the 
inhibitors designed for MDM2 is low or negligible. As a consequence, when treated 
with these drugs, patients who overexpress MDMX are likely to have no benefit 
from the treatment because p53 levels remain low. It is, therefore, very important 
to achieve a deeper understanding of the differences in the binding cleft of the two 
homolog proteins and rationally design MDMX inhibitors for combination therapy 
or, ideally, dual MDM2/MDMX inhibitors. 
 Protein-protein interaction inhibition 5.3
In recent years the importance of protein-protein interactions, PPIs, in the 
regulation of most physiological and pathological biological processes has become 
apparent, as ca. 650,000 PPIs are predicted to be involved in human cellular 
biology. It follows that, in the quest for new medications, interest in disrupting 
protein-protein associations has increased among medicinal chemists. 
The effect of common drugs, developed for mimicking enzyme (or receptor) 
endogenous inhibitors (or antagonists/agonists), is due to the establishment of 
strong directional interactions with a few key residues in the target protein, such 
as either amino acid side chains or backbone peptide bonds, that are located in a 
defined cavity or active site. Such interactions include ionic binding (21-42 kJ/mol 
in a biological system140) and hydrogen bonds (4-29 kJ/mol140). By contrast, it has 
been an established belief in medicinal chemistry that, to prevent two proteins 
from coming in contact with one another, a large number of weak hydrophobic 
interactions, e.g. the interaction between two methylene groups which is as weak 
as 1.5 kJ/mol,140 covering a broad surface is necessary (Figure 5.13). However, 
Clackson and Wells observed that the interaction with a few key residues, the so-
called ‘hot spots’, accounts for most of the free energy gain in some PPIs.141 The 
interactions that are more likely to be antagonized by small molecules are those in 
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which recognition occurs via an α-helix, as in MDM2:p53 and MDMX:p53 
interactions. Generally, this kind of PPIs involve 3-4 amino acid side chains, 
branching off on the same face of the helix and a suitable binding cleft on the 
partner protein.142 
 
Figure 5.13 - Surface engaging interaction with p53 (left) and with a small 
molecule inhibitor (right). 
MDM2 is shown in grey. The structure of the interacting molecule is represented in 
yellow sticks. The contact surface between the receptor and its ligand is 
highlighted in green. Reproduced from Khoury.108 
There are three main strategies in the development of small molecules able to 
engage the binding cleft competitively: 
1. Type I mimetics: oligopeptides mimicking the interacting surface of the 
endogenous substrate, i.e. stapled peptides, β-peptides; 
2. Type II mimetics: non-peptide small molecules engineered to fill effectively the 
acceptor protein binding cleft via a set of interactions, which are not 
necessarily overlapping to that of the endogenous substrate, i.e. Nutlins; 
3. Type III mimetics: non-peptide molecules simulating the characteristic of the 
interacting side chains in the α-helix recognition element, i.e. 3,2’,2’’-terphenyl 
derivatives. 
In his review on the topic,143 Wilson stresses that, due to the particular nature of 
the targeted interaction, Lipinski’s rule of five144 is not always applicable to PPI 
inhibition. He also points out that ligand efficiency is constitutionally lower in PPI 
inhibitors compared to classic enzyme inhibitors.143 From a drug discovery point 
of view, it is very important to bear in mind these two observations when targeting 
a PPI. 
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 Overview of small-molecule MDMX inhibitors 5.4
In the large and growing body of literature concerning MDM2:p53 protein-
protein interaction inhibitors (over 20 different chemotypes developed145), only a 
few molecules are also active against MDMX, often with not excellent binding 
affinities. Here follows an overview of the most representative known small 
molecule inhibitors of MDMX. 
The cis-imidazoline Nutlin-3 (140), patented by Hoffman-La Roche and current 
benchmark compound for the inhibition of the MDM2:p53 protein-protein 
interaction (KD = 0.7 µM), only weakly binds to MDMX (KD = 25 µM) and does not 
reactivate p53 in MDMX-overexpressing cancer cells in vitro.136 Further 
development in the Nutlin series led to the discovery of RG7112 (141) which is a 
very potent inhibitor of MDM2 (IC50 = 18 nM), but has been reported as inactive 
against MDMX:p53.146 RG7388 (142), a second generation MDM2 inhibitor 
developed by Roche and currently in phase I clinical trials, showed low micromolar 
activity when tested in-house (MDMX IC50 = 8.04 µM; MDM2 IC50 = 0.4 nM,  
lit. 6 nM).147 
 
 
In the imidazo-indole series, WK298 (143) is worth mentioning, as it is the only 
small-molecule whose co-crystal structure with MDMX has been solved and 
published (PDB 3LBJ; see Section 5.5).148 
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At St. Jude’s Children Research Hospital, a selective inhibitor of MDMX was 
developed which enhanced the effect of Nutlin-3 in in vitro tests (SJ-172550, 144: 
IC50 = 0.84 µM).136 
Zhuang et al. reported pyrrolidone 145 as a nanomolar inhibitor of MDM2:p53 
and a low micromolar inhibitor of MDMX:p53. To our surprise, the pyrrolidone 
145 was inactive against either target in the ELISA assay available in-house 
(MDM2 17% inhibition at 200 M; MDMX no activity at 200 mM). Consistent with 
the ELISA data, the pyrrolidone 145 did not show any growth-inhibitory activity 
against either MDM2 or MDMX overexpressing cell lines (data not shown).149 
 
RO-2443 (146) and RO-5963 (147) are low nanomolar inhibitors of both MDM2 
and MDMX showing an unusual mechanism of action, as demonstrated by X-ray 
crystallography150 (see Section 5.5). The compounds were synthesized and 
examined in our laboratories as part of the target validation process.151 
Surprisingly, both the hydantoin compounds RO-2443 and RO-5963 were found to 
 
 
97 
 
be three orders of magnitude less potent in our biochemical assay compared with 
the values reported in the literature.152 
 
 
MDMX 
IC50 (µM) 
MDM2 
IC50 (µM) 
 
 
MDMX 
IC50 (µM) 
MDM2 
IC50 (µM) 
Published 0.041 0.033  Published 0.0247 0.0173 
In-house 13.7 6.9  In-house 20.2 17.2 
The most promising class of MDM2/MDMX dual inhibitors is that of stapled-
peptides, short peptide sequences comprising a hydrocarbon crosslink, the ‘staple’, 
to promote the chain to adopt the active α-helix conformation. The most potent 
molecule in this series is SAH-p53-8 (MDMX KD= 0.0023 µM; MDM2 KD = 0.055 µM 
in a fluorescence polarization assay), whose sequence is based on that of the  
N-terminal of p53. 
 Structural data on MDMX 5.5
The crystal structure of zebrafish MDMX in complex with a p53 peptide (15 
residues) reveals that the folding and the arrangement of the domains in MDMX 
are comparable to those of MDM2.153 In MDMX, the tryptophan binding pocket 
seems to be less deep than in MDM2. This is due mainly to the presence of the 
neutral residue Met50and to the open conformation adopted by Tyr96 (directing 
the hydroxyl away from the binding cleft), as opposed to the closed conformation 
observed in MDM2 (hydroxyl going into the binding cleft). The shallower pocket 
possibly results in a non-optimal interaction with one of the chlorophenyl rings of 
Nutlin-3a and can account for the low affinity of the inhibitor for MDMX. Although 
the transition of Tyr96 from an open to a closed conformation is believed to be 
achievable in MDMX, an energetic penalty would apply due to a steric clash with 
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Glu20 and the hydrophobicity requirements for an effective inhibitor may be 
significantly different.153 
 
Figure 5.14 - WK298 bound to MDMX (PDB: 3LBJ). 
Reproduced from Popowicz, 2010.154 
Although structural data of a number of peptides bound to human MDMX are 
available in the public domain, the co-crystal structures of only two small molecule 
inhibitors had been published so far. In 2010, Popowicz and co-workers obtained 
the crystal structure of MDMX bound to WK298 (PDB: 3LBJ).154 This compound 
occupies the same space as the endogenous ligand p53, with the 6-chloroindole 
penetrating the tryptophan binding pocket, the 4-chlorobenzyl going into the 
leucine pocket and the phenyl ring filling the phenylalanine pocket. As shown in 
Figure 5.14, hydrogen bonds are established with His54 and Met53. The N,N-
dimethylpropylamine side chain of WK298 does not point straight out to the 
solvent but wraps over the core and the phenyl ring. There is no significant change 
in the folding of the protein upon binding of the inhibitor compared to p53, 
although induced fit is observed, for example around the bulky 6-chloroindole. 
Interestingly, the Tyr99 is in a conformation, that is neither open nor closed. The 
interactions of the inhibitor with the other pockets, Leu26 and Phe19, are weak. 
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The authors also observe that the mode of binding of WK298 to MDMX is similar to 
that of an earlier analogue, WK23, to MDM2. 
 
Figure 5.15 - Structure of RO-2443 inducing dimerization of MDMX. 
Reproduced from PDB (3U15).150 
Another co-crystal structure was reported by Graves et al. in 2012 in which 
humanized-zebrafish MDMX is bound to RO-2443. As described in Section 5.4, RO-
2443 displays a fairly unique binding mode (Figure 5.15), in which two molecules 
of inhibitor interact with one another triggering the dimerization of MDMX. The 
inhibitor does not interact with all three pockets. The phenylalanine pocket is 
occupied by the indole-hydantoin group where it can also interact with Tyr63 (π-
stacking). The tryptophan binding pocket is occupied by the difluorophenyl moiety 
of the second inhibitor molecule and the leucine pocket is left empty. It is 
reasonable to assume that the same mode of binding is adopted also by the more 
potent RO-5963. 
 The isoindolinone series and its potential for inhibition of MDMX 5.6
In the Medicinal Chemistry Laboratories of the Newcastle Cancer Centre, within a 
project aimed at the inhibition of the MDM2:p53 protein-protein interaction, a 
series of pyrroles was developed showing dual inhibition against the target PPIs, 
but was discontinued because of poor solubility and off-target effects.155 In a 
second series, a large number of diversely substituted isoindolinones were 
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synthesized and tested against MDM2. Activity against MDMX was also measured 
for some of the most potent compounds in order to assess selectivity. Several 
compounds proved to be low micromolar inhibitors of MDMX, thus offering the 
chance to elucidate the differences in the binding interactions with the two 
proteins and, potentially, to lead to the development of selective MDMX inhibitors 
or dual MDM2/MDMX inhibitors. 
The isoindolinones with the lowest IC50 against MDMX:p53 are: 
1. Compound 148 (MDMX IC50 = 6.22 µM; MDM2 IC50 = 0.218 µM): characterized 
by the presence of a 3-hydroxyisoxazole as a carboxylic acid replacement at 
the extremity of the side chain, this isoindolinone shows a  
21-fold increase in potency compared to its parent compound 149. The 
enantiomers were not resolved. 
  
2. Compound 150 (MDMX IC50 = 6.54 µM; MDM2 IC50 = 0.071 µM): bears a 
pyrrole ring at the 7-position and a carboxylic acid moiety on the side chain. Its 
potency as a racemate is significantly higher than both its parent racemic 
alcohol 151 (MDMX IC50 = 55 µM) and the correspondent active enantiomer of 
the latter, 152 (MDMX IC50 = 30 µM). 
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3. Compound 153 (MDMX IC50 = 16.7 µM; MDM2 IC50 = 0.036 µM): a methyl 
group was added at the benzylic position, alpha to the isoindolinone nitrogen, 
to enable the separation of diastereoisomers by traditional column 
chromatography using an enantiopure starting material α-methylbenzylamine. 
This approach was advantageous compared to time-consuming chiral HPLC for 
separating enantiomers. As already seen for 150, the potency of each of the 
four diasteroisomers bearing the free alcohol moiety 154-157 is not excellent 
(ranging from 60 to 130 µM), but when the carboxylic acid is introduced, an 
increase in activity is observed for the (3R,1’S) isomer (153). The latter 
compound was chosen as a benchmark in the context of the development of 
MDMX inhibitors (see Section 5.7). 
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Structural data156 show that isoindolinones bind to MDM2 so that the core is 
accommodated in the Phe19 pocket, the 4-chlorophenyl occupies the Trp23 pocket 
and the 4-chlorobenzyl enters the Leu26 pocket, while the cyclopropyl side chain 
points out towards the solvent. In the light of the results published by Popowicz et 
al. regarding the imidazoyl-indole scaffold,154 it is reasonable to assume that the 
mode of binding of the isoindolinones with MDMX is similar to the one observed 
with MDM2. 
 Project aims and design of selective MDMX inhibitors 5.7
The current literature suggests that inhibition of the MDM2:p53 interaction alone 
may not be enough to treat wild-type p53 cancer effectively. In addition to its low 
nanomolar potency against MDM2, the isoindolinone scaffold would become more 
valuable if dual inhibition could be achieved. The objective of the work described 
herein was to identify an isoindolinone with a submicromolar IC50 against both 
MDMX and MDM2. Key to this was the achievement of a deeper understanding of 
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the interaction of the isoindolinones with MDMX through SAR studies and/or a co-
crystal structure. 
 
Figure 5.16 - SAR studies of the isoindolinone scaffold against MDMX:p53. 
 
For the SAR studies, a structural minimization approach was undertaken to 
quickly and effectively assess what parts of the molecule are necessary for binding. 
The 1’-methyl isoindolinone 153 was chosen as a starting point, offering the 
opportunity to investigate both the contribution to binding of each one of the three 
chloro substituents and the stereochemical preference of the two proteins. 
Compound 159, with its (3R,1’R) configuration at the stereocentres and lack of the 
4-chloro substituent on the 3-phenyl ring, showed selectivity towards MDMX and 
was therefore selected as a benchmark compound for further studies. The 
contribution to binding of each part of the molecule was assessed by sequential 
removal of the benzyl (160), simplification of the cyclopropane side chain (161) 
and by minimization of the isoindolinone core (162). 
Following some promising inhibition data against MDMX in the library of 
compounds designed to target MDM2, nitrogen-containing heterocycles were 
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introduced at the 7-position of 159. For the same reason, the side chain was 
extended with a 3-hydroxyisoxazole (164), trying to achieve the same 20-fold 
jump in potency observed in the des-methyl series. Exploration of the Leu26 
pocket was attempted by replacement of the chlorine at the 4-benzyl position with 
a variety of substituents with different electronic and steric requirements. 
When possible, the synthesized compounds were tested against both MDMX:p53 
and MDM2:p53. 
 
With regard to the structural biology aspects of the project, a group of 
isoindolinones having either good potency (low micromolar range) or good 
selectivity against MDMX was selected from the available library to perform co-
crystallization trials with three constructs of both MDMX and MDM2. 
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CHAPTER 6. RESULTS AND DISCUSSION - MDMX 
 Sequential chlorine deletion 6.1
6.1.1 Rationale for the targets 
The first aims of the project were to investigate a) the contribution to binding of 
each one of the chlorine atoms present in 153 and b) the absolute configuration 
preferred by MDMX at the two stereocentres. Although previous results obtained 
in the MDM2:p53 project showed that a terminal carboxylic acid on the side chain 
improves potency against both MDMX and MDM2, the synthesis was stopped at the 
(1-hydroxymethyl-cyclopropyl)methoxy side chain for the purposes of this study. 
Twelve analogues of 157, a precursor of 153, in which a single chloro-group was 
replaced with a hydrogen atom were synthesised in all four diastereomeric forms 
(Figure 6.1 ‒ 165-167). The set of diastereoisomers lacking all three chlorines was 
also synthesized (Figure 6.1 ‒ 168). 
    
Figure 6.1 - Sequential chlorine deletion from the initial hit 153. 
6.1.2 Synthetic route to the targets 
The synthesis of the sixteen target isoindolinones was accomplished following 
the route previously used by Sarah Cully156 and Bian Zhang157 to obtain 157 and its 
diastereoisomers. This 5-step regiospecific synthetic pathway was developed 
within the MDM2:p53 inhibition project and is based on work of Jacq et al.158 for 
the synthesis of 2-benzoylbenzoic acids.159 As shown in Scheme 6.1, coupling of 3-
chloro-2-hydroxybenzaldehyde 169 and 4-chlorobenzhydrazide 170 in acetic acid 
yielded the N-aroylhydrazone 171.158 A lead tetraacetate-mediated 
rearrangement158 yielded the aldehyde 172, which was oxidized to the 
corresponding carboxylic acid 173 following the Pinnick procedure.160 The 
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formation of the isoindolinone core was performed via thionyl chloride-promoted 
formation of the acid chloride, followed by reaction with the appropriate 
enantiopure 4-chloro-α-methylbenzylamine: the (R)-α-methylbenzylamine yielded 
isoindolinones 174 and 175, while the mirror image isoindolinones 176 and 177 
were obtained using (S)-α-methylbenzylamine. Vilsmeier reagent was reacted in 
situ with each pair of intermediate 3-hydroxyisoindolinones to form the ether 
linkage between the (1-hydroxymethylcyclopropyl)methoxy side chain and to 
obtain the target compounds 154 and 155, 156 and 157 (Scheme 6.1).157 The 
diastereoisomers were separated by column chromatography on silica in the last 
step. 
 
Scheme 6.1 - Synthesis of four isoindolinone diastereoisomers by B. Zhang. 
Reagents and conditions: a) acetic acid, RT, 1 h, 97%; b) Pb(OAc)4, THF, RT, 3 h, 
79%; c) sodium chlorite, sulfamic acid, MeCN/H2O, RT, 2 h, 94%; d) i) SOCl2, cat. 
DMF, THF, RT, 4 h; ii) (R)-4-chloro-α-methylbenzylamine, DIPEA, THF, RT, 18 h, 
61%; e) i) SOCl2, cat. DMF, THF, RT, 4 h; ii) (S)-4-chloro-α-methylbenzylamine, 
DIPEA, THF, RT, 18 h, 35%; f) i) SOCl2, cat. DMF, THF, RT, 4 h; ii) 1,1-
bis(hydroxymethyl)cyclopropane, K2CO3, THF, RT, 18 h, 154 6%, 155 13%;  
g) i) SOCl2, cat. DMF, THF, RT, 4 h; ii) 1,1-bis(hydroxymethyl)cyclopropane, K2CO3, 
THF, RT, 18 h, 156 8%, 157 32%. 
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During the synthesis of the abovementioned sixteen analogues, all steps were 
found to be highly reproducible. A higher yielding InBr3-promoted ether linkage 
formation optimized by Timothy Blackburn161 was used to add the side chain to 
the isoindolinone core. The N-aroylhydrazone did not require any purification and 
could be used directly in the second step. The desired carboxylic acid 
intermediates were obtained in very good to excellent yields (Table 6.1). The lower 
yield for compound 186 was due to poor recovery following recrystallization. 
Table 6.1 - Summary of yields for the synthesis of benzoylbenzoic acids. 
Reagents and conditions: a) acetic acid, RT, 1 h; b) Pb(OAc)4, THF, RT, 3 h;  
c) sodium chlorite, sulfamic acid, MeCN/H2O, RT, 2 h. 
 
# R1 R2 
Product 
(isolated 
yield %) Step a  
Product 
(isolated 
yield %) Step b 
Product 
(isolated 
yield %) Step c 
1 Cl Cl 178 (86) 179 (95) 180 (95) 
2 Cl H 181 (95) 182 (90) 183 (96) 
3 H Cl 184 (97) 185 (93) 186 (57) 
4 H H 187 (86) 188 (90) 189 (95) 
 
The formation of the isoindolinone core was performed using the appropriate 
enantiopure α-methylbenzylamine (Table 6.2 ‒ Step a). In some cases, the two 
isoindolinone diastereoisomers were separated at this stage, but epimerization 
was observed by polarimetry when compounds were solubilized in ethanol. To 
allow reliable optical rotation measurements, the compounds were dissolved in 
EtOAc. Ring-chain tautomerism occuring at the isoindolinone stereocentre with 
formation of a sp2 (planar) carbon is probably responsible for this phenomenon 
(Scheme 6.2). Following this observation, the two diastereoisomers were taken to 
the next step without attempting any separation during the purification.  
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Table 6.2 - Summary of yields for the synthesis of the target isoindolinones. 
Reagents and conditions: a) i) SOCl2, cat. DMF, THF, RT, 4 h; ii) amine, DIPEA, THF, 
RT, 18 h; b) InBr3, 1,1-bis(hydroxymethyl)cyclopropane, DCE, 80 °C, 18 h. 
 
# R1 R2 R3 (3,1’) 
Product 
(isolated 
yield %) 
step a 
Product 
(isolated 
yield %) 
step b 
1 Cl Cl H R,R 190 (20) 191 (24) 
2 Cl Cl H S,R 192 (23) 193 (23) 
3 Cl Cl H S,S 194 (40) 195 (35) 
4 Cl Cl H R,S 196 (30) 197 (26) 
5 Cl H Cl R,R 
198 (88) 
159 (36) 
6 Cl H Cl S,R 199 (44) 
7 Cl H Cl S,S 
200 (94) 
201 (43) 
8 Cl H Cl R,S 202 (50) 
9 H Cl Cl R,R 
203 (96) 
204 (40) 
10 H Cl Cl S,R 205 (38) 
11 H Cl Cl S,S 
206 (94) 
207 (39) 
12 H Cl Cl R,S 208 (38) 
13 H H H R,R 209 (16) 210 (24) 
14 H H H S,R 211 (11) 212 (23) 
15 H H H S,S 213 (34) 214 (20) 
16 H H H R,S 215 (36) 216 (9) 
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Scheme 6.2 - Ring-chain tautomerism of isoindolinones in protic solvents. 
With regard to the indium bromide-promoted addition of the side chain, the low 
yields for the unsubstituted isoindolinones 210, 212, 214, and 216 (Scheme 6.2 ‒ 
Step b ‒ Entries 13-16) were caused by poor separation during purification on 
silica, due to similar retention factors probably caused by the absence of 
substituents reducing the difference in polarity of the two diastereoisomers. 
6.1.3 Determination of the absolute configuration at the isoindolinone 
stereocentre 
The absolute configuration of 155 had previously been unambiguously assigned 
by X-ray crystallography and was found to be (S) at the 3-position of the 
isoindolinone ring and confirmed to be (R) at the benzylic position, in agreement 
with the stereochemistry of the α-methylbenzylamine used for the synthesis. Once 
the absolute stereochemistry of 155 had been assigned, the configuration of the 
stereocentres of the remaining three diastereoisomers could be deduced by virtue 
of the stereochemical relationships among the four compounds (Figure 6.2 and 
Table 6.3). The isomer present in the same mixture, 154, must have the opposite 
configuration at the isoindolinone stereocentre (R), while retaining the same 
configuration at the benzylic position (R). The other pair of diastereoisomers had 
been obtained using enantiopure (S)-4-chloro-α-methylbenzylamine, and were 
therefore expected to have (S) configuration at the benzylic position. By 
comparison of physicochemical properties such as polarity, optical rotation and 
1H-NMR, 157 was found to be enantiomer of 155, and 156 to be enantiomer of 
154.157 Epimerization at the 3-position can be excluded after addition of the side 
chain. 
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Figure 6.2 - Stereochemical relationship between the four diasteroisomers of 
157. 
Each framed pair of diastereoisomers was generated in the same reaction. 
Initially, the absolute configuration of the isoindolinone stereocentre of the 
twelve dichloro- and the four des-chloro- analogues in Table 6.2 was arbitrarily 
assigned by comparison of their physicochemical properties, such as polarity and 
optical rotation data, with those of the trichloro-analogues 154-157. The data 
available for 155 and its diastereoisomers, allowed two main observations to be 
made: a) the (3R,1’R) and (3S,1’S) isomers were more lipophilic and b) an (R) 
configuration at the benzylic stereocentre caused polarized light to rotate 
clockwise ([α] > 0°). The absolute configurations of the sixteen new isoindolinones 
were assigned on the basis of such evidence (Table 6.3). Subsequently, the 
stereochemistry predicted for compounds 199 and 208 was confirmed by X-ray 
crystallography (Figure 6.3 and Figure6.4). 
  
 
 
111 
 
Table 6.3 - Table for the arbitrary assignment of the configuration at the two 
stereocentres of the compounds synthesized. 
# Compound Rf Optical rotation (3,1’) 
1 154 0.54 (33% EtOAc/petrol) [𝛼]D
24 +60 (c 0.100, EtOH) R,R 
2 155 0.37 (33% EtOAc/petrol) [𝛼]D
24 +59 (c 0.100, EtOH) S,R 
3 156 0.54 (33% EtOAc/petrol) [𝛼]D
24 -65 (c 0.100, EtOH) S,S 
4 157 0.37 (33% EtOAc/petrol) [α]D
24 -56 (c 0.100, EtOH) R,S 
 
5 159 0.25 (25% EtOAc/petrol) [𝜶]𝐃
𝟐𝟒 +118° (c 0.764, EtOAc) R,R 
6 199 0.14 (25% EtOAc/petrol) [𝛼]D
24 +35° (c 0.747, EtOAc) S,R 
7 201 0.25 (25% EtOAc/petrol) [𝛼]D
24 -115 (c 0.745, EtOAc) S,S 
8 202 0.14 (25% EtOAc/petrol) [𝛼]D
24 -35 (c 0.878, EtOAc) R,S 
9 204 0.17 (25% EtOAc/petrol) [𝛼]D
30 +105 (c 0.502, EtOAc) R,R 
10 205 0.09 (25% EtOAc/petrol) [𝛼]D
30 +21° (c 0.210, EtOAc) S,R 
11 207 0.17 (25% EtOAc/petrol) [𝛼]D
30 -105° (c 0.477, EtOAc) S,S 
12 208 0.09 (25% EtOAc/petrol) [𝛼]D
30 +22° (c 0.200, EtOAc) R,S 
  
 
Figure 6.3 - X-ray crystal structure of the isoindolinone 199. 
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Figure 6.4 - X-ray crystal structure of the isoindolinone 208. 
In the light of the X-ray data, the analysis of the 1H-NMR of pairs of enantiomers 
allowed making a few interesting observations. Figure 6.6 shows the spectra for 
compounds 159 and 199 in CDCl3. The protons of the cyclopropyl ring are more 
shielded in the (3R,1’R) diastereoisomer 159 (‒0.07-‒0.04 and 0.14-0.25 ppm) 
than they are in the (3S,1’R) isomer 199 (0.51-0.71 ppm). The same applies to the 
two side chain methylene groups (double doublets between 2.89 and 3.75 ppm). In 
the aromatic region, the protons of the benzyl and the phenyl rings are more 
shielded in 199 (δH < 7.26 ppm), in which both rings point in the same direction. 
  
Figure 6.5 - Model of two isoindolinone stereoisomers. 
Model of 159 (a) and 199 (b) obtained by iterative calculation of the mimimum 
conformational energy using ChemBio3D Ultra. 
The crystal structure of the (3S,1’R) diastereoisomer 199 shown in Figure 6.3 
confirms the prediction obtained using ChemBio3D Ultra by iterative minimization 
of the conformational energy (Figure 6.5b) and suggests that the aromatic rings of 
a b 
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the benzyl and the phenyl form a π-stacking interaction which cannot be achieved 
with opposite configuration at the 3 stereocentre, as in (3R,1’R)-159, where they 
point away from each other as predicted by the model (Figure 6.5a). The 
establishment of such an interaction may be responsible for the shielding effect on 
the benzyl and phenyl protons observed in 199. 
The rotation of the phenyl ring was slow compared to the NMR time scale, 
resulting in a broad signal for its protons; this was more evident for 
diastereoisomer 199. In support of this analysis, a variable temperature 1H-NMR in 
DMSO-d6 showed that when the temperature was raised, and therefore molecular 
mobility was increased allowing the phenyl to rotate, the peak at 7.12 ppm 
increased in intensity and became sharper (Figure 6.7). A similar trend for the 
(3R,1’R) and (3R,1’S) diastereoisomers (and their enantiomers) could be found in 
the 1H-NMR of all the other compounds. In the light of the data shown here, it was 
considered reasonable to perform subsequent assignments of the configuration at 
the isoindolinone stereocentre on the basis of polarity, 1H-NMR and optical 
rotation data. 
 
Figure 6.6 - NMR analysis of isoindolinone diastereoisomers. 
Comparison between the 1H-NMR of the (3R,1’R) isomer 159 (red) and the (3S,1’R) 
isomer 199 (blue). 
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Figure 6.7 - Variable temperature 1H-NMR of 199. 
Aromatic region. 
6.1.4 Biological evaluation 
The activities of the sixteen isoindolinones were measured by Yan Zhao162 
against both full length MDMX and full length MDM2 (produced by in vitro 
transcription/translation) in an ELISA assay format (Figure 6.8) using DMSO as 
negative control and AP-B peptide163 as positive control. Unless otherwise stated, 
one replicate was performed for each inhibitor. As shown in Table 6.4, activities 
are reported either as percentage inhibition at 200 µM or as half maximal 
inhibitory concentration (IC50) for compounds with percentage inhibition lower 
than 50%. For comparison, entries 1-4 report the IC50 values for the trichloro 
compounds synthesized by Bian Zhang. 
Core Phenyl ring  Benzyl ring  
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Figure 6.8 - Schematic representation of the ELISA for MDMX and MDM2. 
a) Biotinylated IP3 peptide164 is immobilized on a streptavidin-coated plate;  
b) protein (MDMX or MDM2) binds the the IP3 peptide; c) the target protein is 
recognized by a primary antibody to which a secondary antibody conjugated to 
horseradish peroxidase (HRP) binds. Addition of hydrogen peroxide causes 
oxidation of HRP and emission of light; d) in the presence of an inhibitor, only a 
fraction of protein binds to the IP3 peptide leading to e) decreased light emission. 
Adapted from Sarah Cully.165 
Removal of the chlorine from the benzyl group (Table 6.4 ‒ Entries 5-8) did not 
lead to an increase in neither MDMX nor MDM2 activity. Removal of the chlorine 
from the chlorophenyl group (Table 6.4 ‒ Entries 9-12) caused a significant drop in 
MDM2 activity, whereas the (3R,1’R) diastereoisomer 159 (entry 9) showed a  
4-fold increase in the activity against MDMX (IC50 = 25.9 µM), which led to an 
inversion in the selectivity (MDMX/MDM2 0.14). The efficiency of the binding of 
159 to MDMX, expressed as ligand efficiency (LE) was the highest in the 
isoindolinone series (LE = 0.19). Its enantiomer 201 (entry 11) also had a 
preference towards MDMX (MDMX/MDM2 0.86), although it was 6-fold lower 
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than that of 159. A possible explanation is that the 4-chlorophenyl is likely to make 
a favourable interaction with MDM2, e.g. halogen bond, and loss of the chloro-
substituent results in reduced potency against this target. However, the relatively 
high potency observed for 202 (entry 12; IC50 = 1.98 µM) is in contradiction with 
this theory. Nonetheless, it seems reasonable to postulate that a favourable 
interaction is formed when 159 interacts with MDMX. Replacement of the chlorine 
at the 4-position of the isoindolinone core with a hydrogen (Table 6.4 ‒ Entries 13-
16) also reduced affinity against MDM2, apart from the (3S,1’R) isomer, but did not 
seem to affect greatly MDMX binding. The simultaneous removal of the three 
chlorines (Table 6.4 ‒ Entries 17-20) was overall detrimental to activity against 
both targets, with the only exception being the (3S,1’S) diastereoisomer 214, 
which retained some activity against MDM2. 
By virtue of its potency, comparable to that of the carboxylic acid-bearing 153, its 
selectivity towards MDMX and its ligand efficiency, the highest in the isoindolinone 
series, 159 was chosen as a benchmark compound for further structure-activity 
relationship studies. 
Table 6.4 - Results of the ELISA for the sequential chlorine deletion set of 
compounds. 
 
# R1 R2 R3 (3,1’) Compound 
MDMX IC50 
(µM) 
MDM2 IC50 
(µM) 
MDMX % 
Inhibition 
at 200 µM 
MDM2 % 
Inhibition 
at 200 µM 
1 Cl Cl Cl R,R 154 102a 1.71±0.13c   
2 Cl Cl Cl S,R 155 132a 1.15±0.32c   
3 Cl Cl Cl S,S 156 N/A 11.4±1.6c 40%  
4 Cl Cl Cl R,S 157 59.6a 0.0394±0.0051c   
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# R1 R2 R3 (3,1’) Compound 
MDMX IC50 
(µM) 
MDM2 IC50 
(µM) 
MDMX % 
Inhibition 
at 200 µM 
MDM2 % 
Inhibition 
at 200 µM 
5 Cl Cl H R,R 191 114a 2.54a   
6 Cl Cl H S,R 193 N/A 22.4a 37%  
7 Cl Cl H S,S 195 N/A 95.3a 47%  
8 Cl Cl H R,S 197 N/A 0.880a 46%  
9 Cl H Cl R,R 159 25.9a 180±10b   
10 Cl H Cl S,R 199 182a 171±90b   
11 Cl H Cl S,S 201 173a 202±23b   
12 Cl H Cl R,S 202 118a 1.98±0.85b   
13 H Cl Cl R,R 204 82.2a 57.9±0.2b   
14 H Cl Cl S,R 205 52.9a 0.347±0.114b   
15 H Cl Cl S,S 207 56.6a 85.0±27.5b   
16 H Cl Cl R,S 208 135a 3.62±1.02b   
17 H H H R,R 210 N/A N/A 24% 24% 
18 H H H S,R 212 N/A N/A 3% 25% 
19 H H H S,S 214 N/A 40.5a 41%  
20 H H H R,S 216 N/A N/A 7% 41% 
a n = 1; b n = 2; c n = 3.  
The ELISA was performed by Yan Zhao162 against full length MDMX and MDM2 
using DMSO as negative control and active AP-B peptide (IC50 = 5 nM)163 (100 µM) 
as positive control. IC50 values were measured when the percentage inhibition at 
200 µM was less than 50% (if not measured, the field is marked as N/A, not 
available). Percentage inhibition is not reported for compounds whose IC50 is 
available. 
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 Sequential chlorine deletion from 159 6.2
To further investigate the role of the 4-chloro substituent on the isoindolinone 
core in binding, a second chlorine atom was replaced with hydrogen. Only the 
(3R,1’R) and the (3S,1’R) diastereoisomers were synthesized. The four target 
compounds were obtained using the general synthetic pathway described above 
using the appropriate benzoylbenzoic acid and amine to form the isoindolinone. 
Yields are reported in Table 6.5. Unfortunately, the biological evaluation for these 
compounds was not performed (see Chapter 7). 
 
Table 6.5 - Summary of yields for the synthesis of the target isoindolinones 
with a second chlorine deletion. 
Reagents and conditions: a) i) 183 or 189 SOCl2, cat. DMF, THF, RT, 4 h; ii) amine, 
DIPEA, THF, RT, 18 h; b) InBr3, 1,1-bis(hydroxymethyl)cyclopropane, DCE, 80 °C, 
18 h. 
 
# R1 R2 * 
Product 
(isolated yield %) 
step a 
Product 
(isolated yield %) 
step b 
1 Cl H R 
217 (87) 
218 (20) 
2 Cl H S 219 (21) 
3 H Cl R 
220 (85) 
221 (33) 
4 H Cl S 222 (21) 
 Structural minimization of the core structure 6.3
To provide information on the Phe19 binding pocket of MDMX and its interaction 
with the A-ring of isoindolinones, the core was minimized and replaced with either 
a 1,5-dihydropyrrol-2-one or a cyclohexene isoindolinone analogue (Figure 6.9). 
Both targets were obtained using a synthetic approach devised in the past by Anna 
Watson for the synthesis of analogues similar in structure.166-167 
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Figure 6.9 - Minimization of the isoindolinone core. 
To synthesize the 1,5-dihydropyrrol-2-ones 223 and 228 (Scheme 6.3), the 
maleimide 226 was obtained from 2,3-dimethylmaleic anhydride 225 and (R)-4-
chloro-α-methylbenzylamine according to the procedure described by 
Punniyamurthy et al.168 Steric hindrance caused by the α-methyl group may be 
responsible for both the long reaction time and the modest yield of this step. 
 
Scheme 6.3 - Synthesis of 223 and 228. 
Reagents and conditions: a) (R)-4-chloro-α-methylbenzylamine, THF, reflux, 4 days, 
59%; b) PhMgBr, THF, -78 °C to RT, 2 h, 54%; c) InBr3, 1,1-
bis(hydroxymethyl)cyclopropane, DCE, 80 °C, 18 h, 223 38%; 228 30%. 
Addition of an excess of phenylmagnesium bromide to one of the imide carbonyls 
afforded the dihydropyrrolone 227. The desired compound 223 and its 
diastereoisomer 228 were obtained upon formation of the ether linkage with  
1,1-bis(hydroxymethyl)cyclopropane. Starting from 3,4,5,6-tetrahydrophthalic 
anhydride, a similar approach was used to synthesize the cyclohexene 
isoindolinone analogues 224 and 232 (Scheme 6.4). 
 
 
120 
 
 
Scheme 6.4 - Synthesis of 224 and 232.  
Reagents and conditions: a) (R)-4-chloro-α-methylbenzylamine, THF, reflux,  
37 h, 72%; b) PhMgBr, THF, -78 °C, 2 h, 71%; c) InBr3, 1,1-
bis(hydroxymethyl)cyclopropane, DCE, 80 °C, 18 h, 224 28%; 232 14%. 
6.3.1 Biological evaluation 
As summarized in Table 6.6, both dihydropyrrolones 223 and 228 were weakly 
active against MDM2 and MDMX in the ELISA. The cyclohexene isoindolinone 
analogues 224 and 232, instead, showed a moderate inhibitory effect against both 
MDMX and MDM2. Interestingly, as previously observed for the benchmark 
compound 159, the (3R,1’R) diastereoisomer 224 was more potent against MDMX 
(IC50 = 55.2 µM) than MDM2 (IC50 = 192 µM). 
Table 6.6 - Results of the ELISA for the 1,5-dihydropyrrol-2-one and the 
cyclohexene isoindolinone analogues. 
# * Compound 
MDMX 
IC50 
(µM) 
MDM2 
IC50 
(µM) 
MDMX % 
inhibition 
at 200 µM 
MDM2 % 
inhibition 
at 200 µM 
1 R 223 N/A N/A 37% 39% 
2 S 228 N/A 200 28%  
3 R 224 55.2 192   
4 S 232 117 51.3   
The ELISA was performed by Yan Zhao162 against full length MDMX and MDM2 
using DMSO as negative control and active AP-B peptide (IC50 = 5 nM)163 (100 µM) 
as positive control. IC50 values were measured when the percentage inhibition at 
200 µM was less than 50% (if not measured, the field is marked as N/A, not 
available). Percentage inhibition is not reported for compounds whose IC50 is 
available. 
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 Variations at the 3-position 6.4
The next targets were designed to investigate the role of the side chain at the  
3-position. Previously obtained structural data156 showed that the cyclopropyl of 
the side chain interacts with a small lipophilic pocket on the outer surface of 
MDM2 while the terminal hydroxyl reaches out to solvent. 
The main aims of the next phase of the study were: a) to probe whether the side 
chain was required for MDMX binding; b) to verify whether the cyclopropyl 
interacts with MDMX in a way similar to that observed for MDM2. 
6.4.1 Removal of the side chain 
As mentioned above (see Section 6.1.2), isoindolinones with a free OH at the  
3-position undergo ring-chain tautomerism with consequent epimerization of the 
C-3 stereocentre. In order to assess purely the effect of the removal of the side 
chain, the hydroxyl- was replaced with a small methoxy-group whose presence 
prevents tautomerism. 
The target compound 233 and its isomer 234 were obtained from the 
intermediate 198 following the indium bromide procedure and using MeOH to 
form the ether (Scheme 6.5). 
 
Scheme 6.5 - Synthesis of 233 and 234. 
Reagents and conditions: a) InBr3, MeOH, DCE, 80 °C, 1 h, 233 39%, 234 33%. 
6.4.2 Removal of the cyclopropyl motif 
With a view to simplifying the molecule, it was envisaged that the cyclopropane 
motif would be removed and simple alkyl chains would be introduced. Propane-
1,3-diol and ethane-1,2-diol were chosen to form the ether linkage at the 
isoindolinone 3-position to probe the area interacting with the side chain. Knowing 
from previous results (see Section 5.6) that a carboxylic acid moiety is beneficial to 
binding, biological evaluation of the carboxylic acid analogues was also desirable. 
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The alcohols 235 and 236 were obtained by reaction of the isoindolinone 198 
with indium bromide and the appropriate diol, as shown in Table 6.7. At this stage, 
diastereoisomers were resolved and each of the alcohols was oxidised with sodium 
periodate and ruthenium chloride to afford the corresponding carboxylic acid. The 
yields for the reactions are summarized in Table 6.7. 
Table 6.7 - Summary of yields for the synthesis of isoindolinones bearing 
carboxylic acid side chains. 
Reagents and conditions: a) OH(CH2)nCH2OH, InBr3, DCE, 80 °C, 4.5 h; b) NaIO4, 
RuCl3, MeCN/EtOAc/H2O, RT, 15-20 min. 
 
 
# n * 
Product 
(isolated yield %) 
step a 
Product 
(isolated yield %) 
step b 
1 1 R 235 (50) 237 (53) 
2 1 S 238 (45) 239 (70) 
3 2 R 236 (49) 240 (61) 
4 2 S 241 (37) 242 (58) 
6.4.3 Biological evaluation 
Both diastereoisomers 233 and 234 were weakly active against both targets, 
providing evidence for the need of a side chain at the 3-position (Table 6.8 ‒ 
Entries 1-2). Among the alcohols, 235 (n=2, (3R,1’R) configuration) and 236 (n=3, 
(3R,1’R) configuration) retained some activity against MDMX. By virtue of its low 
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molecular weight, 235 is the isoindolinone with the highest ligand efficiency  
(LE = 0.20). All the alcohols were weakly active against MDM2. Activity against 
MDM2 was retrieved by oxidation of the hydroxyl to the correspondent carboxylic 
acid and was at maximum with n=3 and (3S,1’R) configuration of the stereocentres. 
Overall these results suggest that a) the side chain is a requirement for binding;  
b) the cyclopropyl motif is beneficial but not essential in isoindolinones with 
(3R,1’R) configuration; c) the carboxylic acid has to be at a certain distance from 
the core in order to contribute most effectively to the binding energy. 
Table 6.8 - Results of the ELISA for isoindolinones bearing a range of 
simplified side chains. 
 
# R * Compound 
MDMX 
IC50 (µM) 
MDM2 
IC50 (µM) 
MDMX % 
inhibition 
at 200 µM 
MDM2 % 
inhibition 
at 200 µM 
1 -Me R 233 N/A N/A 41% 6% 
2 -Me S 234 N/A N/A 26% 25% 
3 -(CH2)2OH R 235 42.9 N/A  44% 
4 -(CH2)2OH S 238 N/A N/A 36% 41% 
5 -(CH2)3OH R 236 61.8 N/A  40% 
6 -(CH2)2OH S 241 N/A N/A 38% 44% 
7 -CH2CO2H R 237 N/A 185 31%  
8 -CH2CO2H S 239 N/A 103 36%  
9 -(CH2)2CO2H R 240 N/A 75.7 36%  
10 -(CH2)2CO2H S 242 122 14.7   
The ELISA was performed by Yan Zhao162 against full length MDMX and MDM2 
using DMSO as negative control and active AP-B peptide (IC50 = 5 nM)163 (100 µM) 
as positive control. IC50 values were measured when the percentage inhibition at 
200 µM was less than 50% (if not measured, the field is marked as N/A, not 
available). Percentage inhibition is not reported for compounds whose IC50 is 
available. 
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 Structural minimization at the 2-position 6.5
Finally, the interaction of the isoindolinone scaffold with the Leu26 binding 
pocket was assessed. A panel of amines was chosen to synthesize a variety of 
isoindolinones according to the general synthetic pathway described above. When 
only one stereocentre was present, the enantiomers were not resolved. The α-
methylbenzyl moiety was initially replaced with an ethyl group (Table 6.9 ‒ Entry 
1). Subsequently, larger alkyl chains were introduced, such as isopropyl, 
cyclopropylmethyl and cyclohexylmethyl (Table 6.9 ‒ Entries 2-4). Aromaticity 
was reintroduced with benzyl and 4-chlorobenzyl substituents lacking the second 
stereocentre (Table 6.9 ‒ Entries 5-6). Finally, an analogue of 159 was synthesised 
in which the 4-chloro-α-methylbenzyl group was replaced by a 3-chloro-α-
methylbenzyl. 
 
Table 6.9 - Summary of yields for the synthesis of isoindolinones with a panel 
bearing a panel of R groups at the 2-position. 
Reagents and conditions: a) i) SOCl2, THF, cat. DMF, RT, 4 h; ii) amine, THF, DIPEA, 
RT, 18 h; b) i) InBr3, 1,1-bis(hydroxymethyl)cyclopropane, DCE, 80 °C, 18 h. 
 
# R Configuration 
Product 
(isolated yield %) 
step a 
Product 
(isolated yield %) 
step b 
1 
 
(3RS) 243 (54) 244 (76) 
2 
 
(3RS) 245 (67) 246 (76) 
3 
 
(3RS) 247 (55) 248 (85) 
4 
 
(3RS) 249 (77) 250 (69) 
5 
 
(3RS) 251 (90) 252 (69) 
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# R Configuration 
Product 
(isolated yield %) 
step a 
Product 
(isolated yield %) 
step b 
6 
 
(3RS) 253 (74) 254 (70) 
7 
 
(3R,1’R) 
255 (77) 
256 (27) 
(3S,1’R) 257 (38) 
8 
 
(3R,1’R) 
258 (93) 
259 (30) 
(3S,1’R) 260 (20) 
 
6.5.1 Biological evaluation 
The results of the ELISA for the above compounds are summarized in Table 6.10. 
All the isoindolinones bearing an alkyl substituent only showed low activity 
against both MDM2 and MDMX (Table 6.10 ‒ Entries 1-4). The same applied to 
252, bearing a simple benzyl group (Table 6.10 ‒ Entry 5). The N-(4-chlorobenzyl) 
substituent resulted in the isoindolinone 254, fairly active against MDM2 but still 
unable to inhibit the MDMX:p53 interaction (Table 6.10 ‒ Entry 6). Reintroduction 
of the α-methyl motif in conjunction with the change of position of the chloro- 
group from the 4- to the 3-position resulted in partial recovery of the MDMX 
activity and selectivity (Table 6.10 ‒ Entries 7-8). 
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Table 6.10 - Results of the ELISA for isoindolinones bearing a range of alkyl 
and benzyl chains at the 2-position. 
 
# R Configuration Compound 
MDMX 
IC50 
(µM) 
MDM2 
IC50 
(µM) 
MDMX % 
inhibition 
at 200 µM 
MDM2 % 
inhibition 
at 200 µM 
1 
 
(3RS) 244 N/A N/A 12% 34% 
2 
 
(3RS) 246 N/A N/A 15% 24% 
3 
 
(3RS) 248 N/A N/A 9% 35% 
4 
 
(3RS) 250 N/A 140 45%  
5 
 
(3RS) 252 N/A N/A 16% 37% 
6 
 
(3RS) 254 N/A 1.75 38%  
7 
 
(3R,1’R) 256 47.6 N/A  42% 
8 
 
(3S,1’R) 257 156 N/A  32% 
The ELISA was performed by Yan Zhao162 against full length MDMX and MDM2 
using DMSO as negative control and active AP-B peptide (IC50 = 5 nM)163 (100 µM) 
as positive control. IC50 values were measured when the percentage inhibition at 
200 µM was less than 50% (if not measured, the field is marked as N/A, not 
available). Percentage inhibition is not reported for compounds whose IC50 is 
available. 
 Introduction of a range of substituents at the 4-benzyl position 6.6
To probe further the Leu26 binding pocket, the replacement of the 4-chloro 
group with an array of substituent with diverse electronic and steric requirements 
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at the 4-position of the benzyl was desired. The availability of enantiopure starting 
materials and ease of synthesis were key to the choice of the replacement moieties 
shown below. The trifluoromethylsulfonamide 263 was of particular interest 
because in parallel series the -NHSO2CF3 group substantially improved  
potency.169-170 Molecular modelling by Martin Noble also suggests that mode of 
binding for this scaffold is such that the abovementioned group enters the Leu26 
pocket with potential for interactions.171 
 
From the commercially available (R)-4-methoxy-α-methylbenzylamine, the 
target isoindolinone 259 and its diastereoisomer 260 were synthesized starting 
from 183 following the general synthetic pathway, as described in Table 6.9. In 
this case, the polarities of the two diastereoisomers 259 and 260 was very similar, 
therefore, after purification on silica was attempted few times in different 
conditions, HPLC was used to obtain the pure products. Similarly, the 4-nitro 
compound 261 could be obtained from the appropriate enantiopure α-
methylbenzylamine. Once 261 was available, the aniline 262 could be accessed by 
catalytic hydrogenation. Subsequent trifluoromethylsulfonylation (triflation) of the 
NH2 led to the trifluoromethylsulfonamide 263 (Scheme 6.6). Further optimization 
is required for the last step, as the use of triflic anhydride in the presence of DIPEA 
resulted in low isolated yield. This could be explained as a consequence of 
competition of the free hydroxyl in the triflation, although no bis-triflated side 
product was isolated. Optimization could be achieved by: a) lowering the 
temperature to ensure that the only group reacting is the more nucleophilic 
aniline; b) changing the base (e.g. Et3N is commonly used in this kind of reaction); 
c) using a different triflating agent, such as N-phenylbis(trifluoromethyl-
sulfonimide), successfully used in the Sulf2 project described above (see Chapter 
3). 
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Scheme 6.6 - Synthesis of 263. 
Reagents and conditions: a) (i) 183, SOCl2, cat. DMF, THF, RT, 4 h; (ii) DIPEA, THF, 
RT, 18 h, 87%; b) InBr3, 1,1-bis(hydroxymethyl)cyclopropane, DCE, 80 °C, 261 
37%; 266 54%; c) H2, Pd/C, RT, 3 h, 99%; d) (CF3SO2)2O, DIPEA, DCM, 0 °C to RT,  
1 h then NaOH, MeOH, 30 min, 16% (impurity present). 
To enable a matched pair comparison, the des-methyl analogues were also 
obtained following a similar route. The trifluoromethylsulfonamide 271 was 
obtained in low yield following the same procedure described above (Scheme 6.7). 
 
Scheme 6.7 - Synthesis of 271. 
Reagents and conditions: a) (i) 183, SOCl2, cat. DMF, THF, RT, 4 h; (ii) DIPEA, THF, 
RT, 18 h, 74%; b) InBr3, 1,1-bis(hydroxymethyl)cyclopropane, DCE, 80 °C, 82%;  
c) H2, Pd/C, RT, 3.5 h, 60%; d) (CF3SO2)2O, DIPEA, DCM, 0 °C to RT, 1 h then NaOH, 
MeOH, 30 min, 21%. 
Unfortunately, the biological evaluation for this set of compounds was not 
performed (see Chapter 7). 
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 Introduction of a 5-hydroxyisoxazole moiety 6.7
As shown in Chapter 5, the most potent compound in the isoindolinone series 
against MDMX is 148, which features a 3-hydroxyisoxazole motif linked to the 
terminal hydroxyl of the side chain. One of the main aims of this project was to 
synthesize 164, an analogue of 148 based on the substituent pattern and 
stereochemical configuration of the benchmark compound 159, and its (3S,1’R) 
diastereoisomer 276. 
 
It was envisaged to obtain the target compound in four steps by slightly 
modifying the approach used by Sarah Cully for her synthesis of 148.156 Using a 
literature procedure,172 the free hydroxyl of the commercially available isoxazole 
272 would be protected by benzylation followed by reduction of the ester moiety 
using sodium borohydride to obtain the alcohol 274. The next steps would involve 
a Williamson synthesis between the pre-formed mesylate of alcohol 274 and the 
appropriate isoindolinone and subsequent removal of the benzyl to yield the target 
compound. Alcohol 274 was obtained as previously described by Sarah Cully. The 
Williamson etherification was attempted using the (3S,1’R) diastereoisomer 199, 
but did not yield the desired isoindolinone 275 and a mixture of the mesylate and 
the alcohols 274 and 199 was recovered (Scheme 6.8). 
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Scheme 6.8 - Proposed route to the synthesis of 276. 
Reagents and conditions: a) BnBr, K2CO3, MeCN, 0 °C then 70 °C, 5 h, 84% b) NaBH4, 
MeOH, 0 °C, 18 h, 92%; c) i) methanesulfonyl chloride, Et3N, DCM, RT, 15 min; ii) 
199, NaH, DCM, 0-65 °C, 16 h; d) Pd(OAc)2, Et3SiH, Et3N, DCM. 
It was then decided to follow the same synthetic scheme used for the synthesis of 
148 from 274 by Williamson reaction with 1,1-bis(hydroxymethyl)cyclopropane 
to give the alcohol 277. At this stage, the side chain 277 could be introduced on the 
isoindolinone 198 using the InBr3 protocol and, upon separation of the 
diastereoisomers and removal of the benzyl, the target compounds 164 and 276 
could be obtained in parallel. Unfortunately, the Williamson reaction was again 
unsuccessful. Although the reported yield for this exact step was 23%, the reaction 
was difficult to reproduce. An attempt to replace sodium hydride with potassium 
bis(trimethylsilyl)amide as base and dichloromethane with tetrahydrofuran as 
solvent led to the formation of the desired product 277 in 10% yield, but this step 
was not reproducible. The low yields and poor reproducibility of this reaction are 
probably due to the steric hindrance around the hydroxyl moiety in 
bis(hydroxymethyl)cyclopropane. 
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Scheme 6.9 - Attempted route for the synthesis of 164 and 276. 
Reagents and conditions: a) BnBr, K2CO3, MeCN, 0 °C then 70 °C, 5 h, 84%;  
b) NaBH4, MeOH, 0 °C, 18 h, 92%; c) i) methanesulfonyl chloride, Et3N, DCM, RT, 15 
min; ii) 1,1-bis(hydroxymethyl)cyclopropane, NaH, DCM, 0 to 65 °C, 16 h; d) 198, 
InBr3, DCE, 80 °C; e) Pd(OAc)2, Et3SiH, Et3N, DCM, RT. 
At this stage, it was clear that a new reliable approach to the synthesis of 277 
was needed. Rychnovsky and co-workers173-175 proposed a new route to the 
synthesis of ethers from hindered alcohols, such as t-butanol. This was achieved in 
a 2-step net deoxygenation via reductive acetylation of an ester to an α-
acetoxyether, which was reduced to an ether with triethylsilane in the presence of 
boron trifluoride. This sequence was attempted using 273 as model system and led 
to the formation of the desired ether 280 and the aldehyde 281 (Scheme 6.10). 
 
Scheme 6.10 - Reductive acetylation using 273 as model system. 
Reagents and conditions: a) i) DIBALH (2 equiv.), DCM, -78 °C, 45 min;  
ii) pyridine, DMAP, Ac2O, DCM, -78 °C for 14 h then 0 °C for 30 min, 33%;  
b) BF3 · Et2O, Et3SiH, DCM, -78 °C, 280 20%, 281 38%. 
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Although requiring a certain degree of optimization to favor the formation of the 
desired ether over the aldehyde side product, this approach was considered 
promising and, therefore, a new route to the synthesis of 164 and 276 was devised 
(Scheme 6.11). 
 
Scheme 6.11 - Synthesis of alcohol 277. 
Reagents and conditions: a) TBDPS-Cl, Et3N, DCM, 0 °C to RT, 2 h, 99%; b) BnBr, 
K2CO3, MeCN, 0 °C then 70 °C, 5 h, 84%; c) LiOH, H2O/THF, RT, 30 min, quant.; d) i) 
SOCl2, cat. DMF, THF, RT, 4 h; ii) 283, DIPEA, THF, RT, 16 h, 72%; e) i) DIBALH (3 
equiv.), DCM, -78 °C, 45 min; ii) pyridine, DMAP, Ac2O, DCM, -78 °C for 14 h then 
0 °C for 30 min, quant.; f) cat. TMSOTf, Et3SiH, DCM, 0 °C, 30 min, 69%; g) TBAF, 
THF, 0 °C to RT, 10 h, 98%. 
Monoprotection of the diol 282 with TBDPS following a literature procedure176 
yielded alcohol 283, easier to handle than the starting material by virtue of its 
higher molecular weight and better UV absorption. The benzyl-protected isoxazole 
273 was obtained as earlier described and underwent saponification to obtain the 
carboxylic acid 284, which was treated with Vilsmeier reagent followed by 
addition of the alcohol 283 to give ester 284. The latter was subjected to reductive 
acetylation by treatment with DIBAL followed by pyridine, DMAP and acetic 
anhydride to yield quantitatively the α-acetoxyether 277. 
In the light of the results obtained with the model system 273 and after an 
unsuccessful attempt with 277, the deacetoxylation step was optimized. 
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Replacement of boron trifluoride with other Lewis acids, such as InBr3, ZnCl2 and 
CuI, led to either no conversion or degradation of the starting material. Variation of 
the number of equivalents of either triethylsilane or boron trifluoride did not 
improve the LC-MS profile of the reaction. Interestingly, when 10 equiv. of 
triethylsilane were used, the isoxazole 288 was isolated as major product (35% 
compared of 6% of desired product 287) probably originating from the addition of 
a side chain alkoxide to the oxonium ion formed after departure of the acetoxy 
group (Scheme 6.12). 
 
Scheme 6.12 - Proposed mechanism for the formation of 288. 
In the attempt to obtain ether 287 from the by-product 288, a procedure by 
Noyori was followed, which uses catalytic amounts of TMSOTf and trimethylsilane 
to generate ethers from benzaldehyde acetals. Under these conditions, ether 287 
was formed from 288 in 18% yield. An even more satisfying yield of 69% was 
obtained when the α-acetoxyether 286 was used as starting material allowing 
completion of the scheme (Scheme 6.11). With 287 accessible via a reproducible 
and good yielding synthetic pathway, the desired side chain 277 was easily 
obtained through removal of the TBDPS protecting group using TBAF. Despite the 
number of steps required to obtain 277, this route is made advantageous by its 
high reproducibility and its good overall yield (40% over seven steps). As 
previously done in the synthesis of 148,156 the benzyl protection was removed 
under mild catalytic conditions via the Birkofer reaction, according to a literature 
procedure,177 in order to avoid dechlorination and ring-opening of the 
cyclopropane. Yields are reported in Table 6.11. 
Unfortunately, the compounds could not be tested in the ELISA. 
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Table 6.11 - Summary of yields for the removal of the benzyl protection. 
Reagents and conditions: a) Pd(OAc)2, Et3SiH, Et3N, DCM, RT, 18 h. 
 
# Configuration Starting material 
Product 
(isolated yield %) 
step a 
1 (3R,1’R) 278 164 (26) 
2 (3S,1’R) 275 276 (73) 
 
 Introduction of nitrogen containing heteroaromatics at the 7-position 6.8
The final aim of this work was to introduce a range of heterocycles at the  
7-position of the isoindolinone core following the route devised by Benoit 
Carbain160 for the synthesis of 150, the second most potent compound in the 
isoindolinone series against MDMX (see Section 5.6). 
 
Scheme 6.13 - Retrosynthetic scheme for the 7-heteroaromatic compounds. 
Envisaging exploitation of Suzuki chemistry to introduce heterocycles at the 
desired position, a bromo-substituent was needed at the 7-position of the 
isoindolinone core. The non-commercially available hydroxybenzaldehyde 290 
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required to generate the desired bromo-intermediate 289 was obtained via 
Reimer-Tiemann reaction in 25% yield, in line with what reported for this reaction 
using halophenols.178 The general route was then followed to obtain 289 (Scheme 
6.14). 
 
Scheme 6.14 - Synthesis of 7-bromo isoindolinone 289. 
Reagents and conditions: a) CHCl3, NaOH, H2O, 75 °C, 3 h, 25%; b) acetic acid, RT, 1 
h, 81%; c) Pb(OAc)4, THF, RT, 3 h, 81%; d) sodium chlorite, sulfamic acid, 
MeCN/H2O, RT, 2 h, 97%; e) (i) SOCl2, THF, cat. DMF, RT, 4 h; (ii) (R)-4-chloro-α-
methylbenzylamine, DIPEA, THF, RT, 18 h, 98%; f) InBr3, 1,1-
bis(hydroxymethyl)cyclopropane, DCE, 80 °C, 18 h, 289 41%, 297 44%. 
The pyrrole targets 299 and 301 were obtained in good overall yield by Suzuki 
reaction of each of the intermediates 289 and 297 with silyl-protected pyrrole 
boronic acid followed by deprotection with TBAF following the procedure 
previously used by Benoit Carbain (Table 6.12).160 
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Table 6.12 - Summary of yields for the synthesis of 7-pyrroloisoindolinones. 
Reagents and conditions: a) [Pd(PPh3)4], Na2CO3, MeCN, H2O, 85 °C, 6 h; b) TBAF, 
THF, 0 °C to RT, 3h. 
 
# * 
Product 
(isolated yield %) 
step a 
Product 
(isolated yield %) 
step b 
1 R 298 (67) 299 (77) 
2 S 300 (59) 301 (74) 
 
The pyrazolo-regioisomers were prepared only in the (3R,1’R) configuration. The 
isoindolinone 289 was coupled with either 1H-pyrazol-3-yl boronic acid or 1H-
pyrazole-4-boronic acid to obtain in good yield the target compounds 302 and 
303, respectively. Microwave heating was required for these reactions to go to 
completion (Table 6.13). 
 
Table 6.13 - Summary of yields for the synthesis of 7-pyrazoloisoindolinones. 
Reagents and conditions: a) [Pd(PPh3)4], Na2CO3, MeCN, H2O, µW 120 °C, 1 h. 
 
# X Y 
Product 
(isolated yield %) 
step a 
1 N CH 302 (76) 
2 CH N 303 (59) 
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The 1H-NMR of 302 in DMSO showed two exchangeable protons at 13.1 and 14.2 
ppm. This could be explained by considering that pyrazole 302 can exist in two 
non-equivalent tautomeric forms, 302A and 302B, one of which can, in theory, 
form an intramolecular hydrogen bond with the carbonyl group of the 
isoindolinone core. The same phenomenon was not observed with 303, whose 
tautomers are structurally equivalent upon rotation about a 180° angle along the 
C7-C4’’’’’ axis (Figure 6.10). 
 
  
Figure 6.10 - Tautomerism of the pyrazole targets 302 and 303. 
 
6.8.1 Biological evaluation 
The 7-substituted isoindolinones described above were tested against MDM2 and 
MDMX and they all showed moderate activity against MDMX with IC50s ranging 
from 31 to 56 µM. The most active compounds were the pyrazoles 302 and 303, 
which were almost equipotent to the benchmark compound 159, although with 
ligand efficiency lowered by the presence of the additional heterocycle (LE = 0.16). 
While 303 also inhibited MDM2, 302 was only weakly active against this target 
(Table 6.14). 
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Table 6.14 - Results of the ELISA for 7-substituted isoindolinones. 
 
# R * Compound MDMX IC50 (µM) MDM2 IC50 (µM) 
1 -Br R 289 40.1 124 
2 -Br S 297 41.7 65.9 
3 
 
R 299 56.4 78.1 
4 
 
S 301 44.1 26.8 
5 
 
R 302 30.8 200 
6 
 
R 303 34.2 13.3 
The ELISA was performed by Yan Zhao162 against full length MDMX and MDM2 
using DMSO as negative control and active AP-B peptide (IC50 = 5 nM)163 (100 µM) 
as positive control. IC50 values were measured when the percentage inhibition at 
200 µM was less than 50% (if not measured, the field is marked as N/A, not 
available). Percentage inhibition is not reported for compounds whose IC50 is 
available. 
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 Conclusions 6.9
The α-methyl isoindolinone 153 (MDMX IC50 = 16.65 µM) was selected as a 
starting point for SAR investigations aming to achieve dual inhibitors of 
MDM2/MDMX or selective MDMX inhibitors. 
 
Using the 5-step route developed within the research group for the synthesis of 
isoindolinones (Scheme 6.15), a number of analogs were synthesized using 
enantiopure α-methylbenzylamines and the diastereoisomers were separated by 
chromatography. The absolute configuration of the initial sets of compounds was 
assigned by solving the X-ray structure of at least one diastereoisomer. Once a 
considerable amount of data was available, the stereochemistry was predicted 
after careful analysis of the physicochemical properties (polarity, specific rotation, 
1H-NMR). 
 
 
Scheme 6.15 - Synthetic route to isoindolinones. 
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The synthesis of 164, the α-methyl analog of 148, was undertaken and a high 
yielding and reliable method to form the 3-hydroxyisoxazole side chain 277 was 
devised (7 steps; 40% yield). The desired compound 164 was obtained in 3% yield 
over a total of 13 steps. 
A minimization approach was used to investigate what parts of the core are 
necessary for binding. Finally, modifications at the 7-position and at the 4’’-benzyl 
position were performed by introducing nitrogen-containing heterocycles and 
moieties with a variety of stereoelectronic properties, respectively. The SAR for the 
library of compounds synthesized is summarized in Figure 6.11. 
 
Figure 6.11 - Summary of the SAR of the isoindolinone library synthesized for 
the MDMX project. 
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CHAPTER 7. STRUCTURAL BIOLOGY INVESTIGATIONS  
WITH MDMX AND MDM2 
7.1 Aims 
In line with literature results,148 the MDMX structure-activity relationship data 
around the isoindolinone series highlight the difficulty of obtaining sub-
micromolar selective inhibitors of MDMX or dual MDM2/MDMX inhibitors. 
Although MDMX selectivity was achieved to some extent with compound 159 (IC50 
MDMX/IC50 MDM2 = 0.14), any modification performed around this structure did 
not lead to an increase in potency against the desired target. To enable a deeper 
understanding of the reasons underlying the large MDM2 selectivity, a co-crystal 
structure of an isoindolinone bound to MDMX was highly desired. Previous studies 
by Sarah Cully156 had resulted in the solution of the structure of an isoindolinone, 
304, bound to MDM2 but, despite efforts,179 no structural data of MDMX with an 
inhibitor from the isoindolinone series had been obtained. A 3-month placement in 
Structural Biology at the Northern Institute for Cancer Research was therefore 
undertaken aiming at obtaining a co-crystal structure of an isoindolinone with 
MDMX. 
 
7.2 Protein crystallography and its challenges 
Structural data represent an extremely powerful tool in drug discovery that can 
greatly accelerate the identification of clinical candidates through structure-based 
drug design. Unfortunately, despite the scientific and technical advances of the last 
decades, protein crystallography is still limited by the high number of variables 
influencing crystallization and an empirical approach to protein production is still 
required. The molecule of interest must be organized into a highly ordered three-
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dimensional lattice to result in interpretable X-ray diffraction data. However, 
proteins are large biopolymers characterized by a certain degree of flexibility and 
micro-heterogeneities (i.e. conformation variability, post-translational 
modifications) and therefore crystallization can prove difficult. When varying the 
conditions of the environment, protein degradation or denaturation can occur in a 
population of biomolecules, interfering with crystal growth.180 Additionally, some 
proteins may be intrinsically less prone to crystallization. Derewenda181 showed 
that in some cases large, flexible and hydrophilic side chains on the surface of the 
protein prevent molecules from packing. Their engineered mutation to smaller and 
more hydrophobic residues may enhance crystal formation (surface entropy 
reduction). 
 
Figure 7.1 
a) Crystallization phase diagram. Reproduced from McPherson, 2009.182 b) Sitting 
drop vapour diffusion crystallization method. Reproduced from Adachi, 2003.183 
Figure 7.1a shows the phase diagram for the crystallization process. In the 
undersaturated region, all the protein is soluble and no crystals will form. At 
equilibrium, molecules dynamically exchange from the aqueous solution (usually 
buffer) to the solid phase, preventing the formation of crystallization nuclei. At 
higher solute concentration, in the supersaturated phase, nucleation and growth 
may occur to generate crystals. As the concentration of protein increases, the 
further the system is from equilibrium, then the faster nucleation and growth take 
place, eventually resulting in the formation of precipitates. To allow the growth of 
suitable-sized and high-quality crystals, the system needs to be within the 
supersaturated region but relatively close to the equilibrium, in the so-called labile 
a b 
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zone.182 A number of techniques are available to reach the supersaturation 
conditions required for crystallization, such as the commonly used vapor diffusion 
method. Using automation for both sample preparation and monitoring, the 
preferred set-up for our studies was the sitting drop (Figure 7.1b), which involves 
a drop of solution, containing both the protein and a precipitating agent, sitting in a 
small well and equilibrating with a reservoir of precipitant at a higher 
concentration. In these conditions, water diffuses away from the droplet, thus 
increasing the concentration of protein and promoting the shift to a 
supersaturated state. 
Considering the size and quality requirements for the crystals and given that the 
near-native conformation of the protein needs to be preserved, several parameters 
can be varied in the attempt to establish optimum conditions for nucleation and 
crystal growth, including temperature, pH, ionic strength of the solution, nature of 
the precipitant, volume of samples. Thanks to the advances in genetic engineering 
rendering larger scale protein production more efficient and to the availability of 
accurate automated systems for the preparation and monitoring of samples, the 
high-throughput screening of thousands of conditions on a micro- or nano-litre 
scale can be performed. Unfortunately, this is often not enough to lead to success 
and many systems have yet to be crystallized. 
7.2.1 Selection of protein constructs for crystallization trials 
To allow a comparison of the binding mode adopted by isoindolinones to MDMX 
and MDM2, crystallization trials with both proteins were deemed most desirable. 
Full length MDMX and MDM2 contain intrinsically disordered regions that would 
decrease the chances of crystal formation.184 Additionally, the presence of the 
autoinhibitory domain on MDMX competing for the binding site122 (see Section 
5.1.2) is not desirable for obtaining a homogenous population of protein-inhibitor 
complex molecules. In line with other work reported in the literature,153-154,185 the 
present study was focused on the expression and purification of the N-terminal 
p53-binding domain of MDMX and MDM2 to be co-crystallized with inhibitors, 
whose binding promotes partial order in the N-terminal domain. Three constructs 
of the MDMX p53-binding domain encoding up to amino acid residue 111 were 
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selected in which the disordered N-terminal loop (residues 1-19) was not included 
and the sequences started from residues 18, 22 and 26, respectively (Appendix C). 
With regards to MDM2, three previously optimized constructs were selected 
lacking the N-terminal loop and bearing surface entropy mutations to remove long 
hydrophilic side chains from the protein surface. These MDM2 
constructs, MDM217−125
K51A , MDM217−108
E69K70Aand MDM217−125
E69K70A, are known to be prone 
to crystallization with inhibitors from the isoindolinone series.186 
7.2.2 Expression and purification 
To produce a recombinant protein, Escherichia coli cells are transformed by the 
introduction of a vector bearing the appropriate DNA sequence coding for that 
protein. The vector also includes an antibiotic resistance gene that allows for the 
selection of the cell strain of interest and the minimization of contaminant strains 
by addition of antibiotics to the cultures. It also bears a sequence encoding for an 
N-terminal 3C (PreScission protease)-cleavable glutathione S-transferase (GST) tag 
to allow affinity purification. To increase protein yield, expression is induced in the 
exponential phase of cell growth (optical density at λ = 600 nm, OD600, of 0.6-1.0) 
by addition of a non-hydrolysable lactose analogue, isopropyl β-D-1-
thiogalactopyranoside (IPTG). This effector molecule activates the lac operon on 
the vector and triggers expression of the desired protein, which is present 
downstream on the plasmid. 
To express MDMX and MDM2, the plasmid pGEX-6P-1 (Figure 7.2) was used as a 
vector for transformation. The plasmid was introduced into competent cells 
(RosettaTM BL21 (DE3) pLysS E. coli for the expression of all three MDMX 
constructs, BL21 (DE3) pLysS E. coli for MDM217−108
E69K70A, and E. coli BL21 (DE3) 
for MDM217−125
K51A  and MDM217−125
E69K70A) by heat shock and colonies were grown on 
Luria-Bertani broth (LB)-agar plates with selection from ampicillin (and 
chloramphenicol for pLysS-containing strains). Expression of the N-terminal 
tagged GST-fusion recombinant protein was induced by addition of 0.2 mM IPTG to 
cultures (1 L) originating from those colonies. 
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Figure 7.2 - Vector map of the pGEX-6P-1 expression vector. 
The vector map highlights the ampicillin resistance gene (ampr), the lac operon 
(lac Iq) and the N-terminal 3C (PreScission protease)-cleavable glutathione S-
transferase (GST) tag. Reproduced from GE Life Sciences.187 
The GST tag was exploited to perform an affinity chromatography and separate 
GST-tagged protein of interest from other substances present in the lysate (Figure 
7.3a) before being cleaved by 3C protease. A second purification by size-exclusion 
chromatography yielded the pure protein (Figure 7.3b and Figure 7.4). 
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Figure 7.3 - Expression and purification of MDMX18-111 
a) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of GST-
MDMX18-111 following expression in E. coli and purification by GST affinity 
chromatography (FT: flow-through; W1 & W2: wash 1 and wash 2; P: purified GST-
MDMX18-111); b) SDS-PAGE of 3C cleaved purified MDMX18-111 (CR: crude) and gel 
filtration fractions. 
 
Figure 7.4 - Size-exclusion chromatogram of MDMX18-111. 
a b 
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7.2.3 Crystallization trials 
The three MDMX constructs expressed well under the conditions described 
above (MDMX18-111 ~9.5 mg/L culture; MDMX22-111 ~9.9 mg/L; MDMX26-111 ~13.6 
mg/L). As expected from previous observations,186 two MDM2 constructs were 
obtained in good to moderate yield (MDM217−125
K51A  ~8.9 mg/L; MDM217−125
E69K70A ~6.8 
mg/L), while the final amount of MDM217−108
E69K70A was extremely poor (0.32 mg/L). 
Compounds from both the MDMX and the MDM2 projects were chosen within the 
isoindolinone series for the crystallization studies according to several parameters. 
Isoindolinones from the MDMX and the MDM2 projects with suitable activity 
against MDMX (IC50 < 35 µM) were selected according to their availability. Also, 
because of known solubility issues in aqueous systems with this series, compounds 
which had a range of clogD values were selected to maximize the chance of success 
(Table 7.1). 
Table 7.1 - Isoindolinone MDMX inhibitors selected for crystallization trials 
with MDMX. 
 
Structure 
 
 
 
 
Compound 148 159 305 306 
MDMX IC50 
(LE) 
6.2 µM (0.18) 26 µM (0.19) 20 µM (0.17) 26 µM (0.17) 
MDM2 IC50 
(LE) 
0.218 µM 
(0.22) 
181 µM (0.16) 0.007 µM (0.30) 
0.034 µM 
(0.28) 
MDMX/MDM2 28.9 0.14 2953 773 
clogD 6.13 5.87 5.61 3.29 
Crystallization 
trial with 
MDMX 
MDM2 
MDMX 
MDM2 
MDMX 
MDMX 
MDM2 
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Structure 
 
 
 
Compound 307 308 303 
MDMX IC50 
(LE) 
25 µM (0.18) 110 µM (0.14) 34 µM (0.16) 
MDM2 IC50 
(LE) 
0.745 µM 
(0.23) 
0.061 µM 
(0.25) 
13 µM (0.18) 
MDMX/MDM2 33 1809 2.57 
clogD 2.86 1.92 5.76 
Crystallization 
trial with 
MDMX 
MDM2 
MDMX 
MDM2 
MDM2 
The isoindolinones selected for co-crystallization with MDMX included the most 
potent in the series, 148, and the most MDMX selective, 159. Compound 305 
(synthesized by Ruth Bawn within the MDM2 project)188 was chosen because it 
bears two groups whose interaction with MDMX was considered worth 
investigating: the methyl group on the benzylic position and the carbinol group at 
the 6-position. The presence of the side chain carboxylic acid, which lowers the 
clogD, was the reason behind the choice of 306 (synthesized by Sarah Cully within 
the MDM2 project)156 and 307 (synthesized by Ruth Bawn within the MDM2 
project).188 The dicarboxylic acid 308 (synthesized by Ruth Bawn within the 
MDM2 project)188 was included in the crystallization trials despite its low activity 
against MDMX (IC50 = 110 µM) because it stood out in a parallel study performed 
by Santosh Adhikari152 as one of the few isoindolinones giving a dose-response 
curve in the homogenous time-resolved fluorescence (HTRF) assay (see Section 
7.3), probably by virtue of its low clogD. To enable a comparison between the 
binding modes in the two protein homologs, the same compounds were used for 
crystallization trials with MDM2, with the exception of the 6-carbinol 305, for 
which a co-crystal structure with MDM217−108
E69K70A was already available. Within the 
α-methyl series, the pyrazole 303 was therefore selected as an additional 
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compound with clogD and MDMX IC50 comparable to those of 305. The Roche 
compound RO-2443 was used as a positive control in trials with both proteins. 
The purified proteins were incubated with a 1.5 molar excess of selected 
inhibitor overnight at 4 C to allow binding before being concentrated to the 
concentration required for crystallization trials (5-10 mg/mL). A difference in 
behaviour could be observed between the two proteins. Achieving higher 
concentrations proved challenging with MDMX and protein precipitation was 
observed in the presence of the isoindolinones 148, 159 and 308 with all 
constructs at concentrations higher than 2-3 mg/mL. Precipitation was also 
observed with MDMX26-111 bound to RO-2443. However, when concentrating any 
of the MDM2 constructs, the process was quicker and precipitation did not occur, 
suggesting a more stable complex was formed. 
The protein:inhibitor complexes were mixed with two commercial screens 
(ninety-six precipitants per screen) in an attempt to find conditions suitable for 
crystallization. The AmSO4 Suite from Qiagen and the JCSG+ screen from Molecular 
Dimensions were used for the trials with all constructs of both proteins. In a 96-
well plate, a Mosquito liquid handling system (TTP Labtech) accurately dispensed 
the crystallization solution from the pre-pipetted reservoir and mixed it with the 
protein:inhibitor solution, generating two drops with ratios of 1:1 and 1:2. 
Approximately 6,900 conditions were screened for each protein. 
7.2.4 Crystal formation and data collection 
Upon preparation of the samples, the crystallization trays were incubated at  
4 C for up to five weeks and monitored periodically using an automated imaging 
system (Minstrel, Rigaku). Unfortunately, none of the three MDMX constructs 
crystallized in any of the conditions screened with any of the compounds selected, 
including the positive control RO-2443 and the formation of precipitates was 
mostly observed. However MDMX26-111 in the presence of isoindolinones 307 and 
308 generated small spheroidal masses of crystals called spherulites (Figure 7.5a 
and b), which may represent a starting point for further optimization of the 
crystallization conditions. 
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Figure 7.5 - Crystallization trials with MDMX26-111. 
Co-presence of spherulites and precipitate in drops containing MDMX26-111 with a) 
isoindolinone 307 and b) isoindolinone 308, both using JCSG+ screen, 0.2 M 
lithium sulfate, 50 v/v polyethylene glycol 400, 0.1 M sodium acetate, 200+100 nL 
precipitant:protein. 
As expected, crystallization trials with MDM2 were more satisfactory and a few 
conditions proved successful. Both MDM217−125
K51A  and MDM217−108
E69K70A formed crystals 
with 306 (Figure 7.6) and though diffraction data were obtained, a co-crystal 
structure could not be obtained from these samples due to crystal twinning (lattice 
points shared among two crystals). 
   
Figure 7.6 - Crystals of MDM2 with 306 (AmSO4 Suite screen). 
a) MDM217−125
K51A  with 306, 0.2 M ammonium iodide, 2.2 M ammonium sulfate, 
200+100 nL precipitant:protein; b) MDM217−125
K51A  with 306, 0.2 M lithium sulfate, 
2.2 M potassium thiocyanate, 200+100 nL precipitant:protein; c) 
MDM217−108
E69K70Awith 306, 0.2 M potassium iodide, 2.2 M ammonium sulfate, 
100+100 nL precipitant:protein. 
To our delight, crystals of MDM217−125
K51A  and the MDMX-selective isoindolinone 
159 were also grown (Figure 7.7), offering the chance to understand the reasons 
underlying the selectivity shown by this compound. The crystals were transferred 
in an appropriate cryo-protecting solution (reservoir supplemented with 30% 
a b 
a b c 
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ethylene glycol) and flash-cooled in liquid nitrogen. Diffraction data were collected 
at the Diamond Light Source. 
 
Figure 7.7 - Crystals of 𝐌𝐃𝐌𝟐𝟏𝟕−𝟏𝟐𝟓
𝐊𝟓𝟏𝐀  with 159. 
Crystallization conditions: AmSO4 Suite screen, 0.2 M potassium iodide, 2.2 M 
potassium nitrate, 100+100 nL precipitant:protein. 
7.2.5 Highlights of the X-ray structure of 159 bound to MDM2 
The data collected for MDM217−125
K51A  with 159 were processed by Martin Noble 
and Judith Reeks. The solved co-crystal structure was obtained at 2.5 Å resolution. 
In each asymmetric unit, six molecules of protein were found but only three of 
them were in complex with the inhibitor. The remaining three sites were occupied 
by peptide from the N-terminal region of other MDM2 molecules. The three 
molecules of 159 were present at low occupancy, probably due to the low potency 
of the ligand against MDM2 (IC50 = 181 µM), manifesting as poor but interpretable 
electron density. As observed for other isoindolinones, the A-ring of 159 enters the 
Phe19 pocket while the phenyl ring at the 3-position interacts with the Trp23 
pocket of MDM2. The Leu26 pocket is not occupied in this structure, apparently 
because of the stereochemistry of the ligand. In the (3R,1’R) configuration, the 
steric hindrance pushes the phenyl substituent at the 3-position and the 4-
chlorobenzyl at the 2-position in different directions, with the former entering the 
Trp23 pocket and the latter rotating outwards and away from the Leu26 pocket 
(Figure 7.8). 
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Figure 7.8 - Crystal structure of 159 bound to 𝐌𝐃𝐌𝟐𝟏𝟕−𝟏𝟐𝟓
𝐊𝟓𝟏𝐀 . 
The stereochemistry at the benzylic stereocentre forces the aromatic ring into a 
conformation that prevents it from entering the Leu26 binding pocket. 
Superposition of the structure of 305 with that of 159 (Figure 7.9) shows that 
with the α-methyl group in the opposite configuration (S) the benzyl enters the 
Leu26 pocket, while the (R) configuration leads to steric hindrance between the 
two aromatic rings forcing the benzyl out of the binding pocket. The conformation 
adopted by 305 upon binding to MDM2 is comparable to the low-energy 
conformation adopted by (3R,1’S)-208 in the small-molecule crystal structure 
shown in Section 6.1.3. The N-terminal region of MDM217−125
K51A , which is normally 
disordered in MDM2-isoindolinone structures, is ordered in the 159 structure and 
interacts with the 4-chlorobenzyl. However, it is not certain whether this 
interaction would be biologically relevant in a native system, because the N-
terminus of the protein construct MDM217−125
K51A  still possesses six non-native amino 
acid residues belonging to the cleaved GST tag. In the co-crystal structure, the 
isoindolinone core is substantially shifted outwards, resulting in a non-optimal 
occupancy of the Phe19 and Trp23 binding pockets by the isoindolinone A-ring 
and the phenyl ring, thus contributing to the low potency shown by 159 towards 
MDM2. This shift is also observed when comparing the structures of 159 with that 
of another isoindolinone analogue not bearing the carbinol moiety at the 6-
position as well as with an analogue with fluorine in the 4-position (data not 
shown). This suggests that the (R)-α-methyl group is the cause of the alternative 
binding mode. 
Phe19 
Trp23 
Phe19 
binding pocket 
Trp23 
binding pocket 
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Figure 7.9 - Superposition of the crystal structure obtained from the 6-
carbinol isoindolinone 305 (orange) bound to 𝐌𝐃𝐌𝟐𝟏𝟕−𝟏𝟎𝟖
𝐄𝟔𝟗𝐊𝟕𝟎𝐀 with that of 159 
(green) bound to 𝐌𝐃𝐌𝟐𝟏𝟕−𝟏𝟐𝟓
𝐊𝟓𝟏𝐀 . 
The image shows the alternative binding modes of the benzyl group dictated by the 
stereochemistry of the α-methyl. Figure provided by Judith Reeks. 
The MDM217−125
K51A :159 co-crystal structure was superposed with an MDMX crystal 
structure available from the Protein Data Bank (PDB 3U15),150 as shown in Figure 
7.10. The model suggests that a mode of binding comparable to that observed with 
MDM2 is also plausible with MDMX. The 4-chlorobenzyl would be in proximity to 
the side chain of Lys50 (Lys51 in MDM2, mutated to alanine in the construct that 
co-crystallized with 159) in the flexible loop, where a stabilizing interaction could 
potentially be established. 
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Figure 7.10 - Superposition of the MDM2:159 co-crystal structure to one of 
the MDMX crystal structures available in the PDB (PDB code 3U15).150 
The image suggests a potential interaction between the 4-chlorobenzyl group of 
159 and the side chain of Lys50 (Lys51 in MDM2). Figure provided by Judith 
Reeks. 
Although no definite conclusions can be drawn in the absence of a crystal 
structure of 159 in complex with MDMX, the data available suggest that for this 
inhibitor the interaction with MDM2 is compromised in three ways: a) the 
interaction of the 4-chlorobenzyl with the Leu26 pocket is abolished due to the 
steric hindrance originating from the stereochemical configuration of the 
isoindolinone forcing the phenyl and the benzyl groups in opposite directions; b) 
the interaction of the phenyl ring with the residues in the Trp23 pocket is weak 
due to the absence of the 4-chloro substituent; c) a putative interaction of the 4-
chlorobenzyl with a flexible loop causes a shift of the whole isoindolinone core, 
ultimately resulting in sub-optimal interactions between the inhibitor and the two 
occupied pockets of MDM2. The data suggest that the binding mode adopted by 
159 with MDMX is likely to be similar to that observed with MDM2. Therefore, it is 
reasonable to assume that either the lack of the 4-chloro substituent on the phenyl 
ring or the isoindolinone core shift, or a synergy of the two, are better tolerated by 
MDMX. 
Phe19 
binding pocket 
Trp23 
binding pocket 
Lys 50 
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7.3 HTRF Assay 
Fluorescence resonance energy transfer, FRET, is a physical phenomenon first 
described by the German physical chemist Theodor Förster in 1948. FRET involves 
the transfer of energy from an excited fluorophore (donor) to another suitable 
fluorophore (acceptor). The emission spectrum of the donor must overlap with the 
absorbance spectrum of the acceptor. FRET is a distance-dependent, non-radiative 
energy transfer and, for it to occur, the donor and acceptor must be in close 
proximity to one another (10-80 Å).189-191 
FRET is the basis of the high-throughput HTRF assay developed by Judith Reeks 
and Santosh Adhikari to evaluate the potency of compounds against the 
MDMX:p53 and the MDM2:p53 protein-protein interactions as a replacement for 
the ELISA. The need for an alternative way to measure the IC50 of the compounds 
synthesized stemmed from the anti-MDMX antibody used in the ELISA being 
discontinued by the manufacturer. As shown in Figure 7.11a, addition of 
fluorescein-labelled IP3 peptide164 to GST-tagged MDMX leads to the formation of 
an MDMX:IP3 complex. A terbium-labelled anti-GST antibody is added which binds 
to the GST-tag, bringing the terbium in close proximity to the fluorescein 
fluorophore. FRET excitation of terbium (donor) at a specific wavelength (320 nm) 
results in emission of energy from fluorescein (acceptor) at a different wavelength 
(520 nm). The presence of an inhibitor (Figure 7.11b) prevents the formation of 
the MDMX:IP3 complex and, consequently, FRET does not occur.  
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Figure 7.11 - Cartoon representing the principle behind the HTRF assay 
a) The interaction between MDMX and IP3 brings the two fluorophores in close 
proximity and, upon excitation of the donor (Tb), the acceptor (fluorescein) 
fluoresces at a different wavelength (FRET); b) the presence of an inhibitor 
prevents the formation of the MDMX:IP3 complex and FRET does not occur. 
Adapted from Judith Reeks. 
Validation of the HTRF assay for MDMX required a panel of compounds from the 
isoindolinone series with a range of potencies and clogD. Reportedly, solubility 
represented the main hurdle in the evaluation of the potency of compounds with 
both MDMX and MDM2.152,186 In addition to the seven compounds used for the 
crystallization studies (Table 7.1), six other isoindolinones were selected for HTRF 
validation (Table 7.2). Among these, the carboxylic acids 242 and 310 
(synthesized by Sarah Cully within the MDM2 project)156 were chosen because of 
their low clogD (2.53 and 2.66, respectively) and their alcohol analogues 236 and 
309 (synthesized by Anna Watson within the MDM2 project)166 were tested to 
verify the hypothesis that clogD is a key parameter to obtain meaningful results in 
the conditions required by the HTRF assay. In addition to the pyrazole 303 that 
was already included in the study (Table 7.1), the regioisomer 302 was also 
selected to compare the results obtained from the assay using equipotent close 
analogues. The α-methyl analogue of 148, 164, was included in the study as a 
sample compound with no measured IC50. 
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Table 7.2 - Isoindolinones selected for HTRF assay evaluation. 
Structure 
   
Compound 242 236 302 
MDMX IC50 
(LE) 
123 µM (0.18) 62 µM (0.19) 31 µM (0.16) 
MDM2 IC50 
(LE) 
15 µM (0.21) Not active 200 µM (0.13) 
MDMX/MDM2 8.4 - 0.15 
clogD 2.53 5.47 5.76 
Structure 
   
Compound 309 310 164 
MDMX IC50 
(LE) 
114 µM (0.15) 29 µM (0.16) N/A 
MDM2 IC50 
(LE) 
0.044 µM 
(0.29) 
0.057 µM 
(0.25) 
N/A 
MDMX/MDM2 2562 500 - 
clogD 4.99 2.67 6.14 
For the experiment, a number of positive controls were used, including two p53 
peptides, p5317–27 (provided by Pamela Williams, Astex) and p5317−30
N30F  (provided 
by David Lane, A*Star, Singapore), alongside two literature small molecule-
inhibitors, RO-2443 and WK298 (Figure 7.12). The measured IC50s were 9.33 µM 
for the p5317-27 peptide and 1.33 µM for the p5317−30
N30F  peptide. The dose-response 
curve generated for the small-molecule inhibitor RO-2443 corresponds to an IC50 
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of 4.31 µM (literature 0.041 µM;150 in-house ELISA 13.7 µM) and the one for 
WK298 to 13.9 µM, (literature 19.7 µM).148 
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Figure 7.12 - HTRF dose-response curves for GST-MDMX22-111 using positive 
controls. 
a) Peptides p5317–27 and p5317−30
N30F ; b) literature small-molecule inhibitors RO-2443 
and WK298. 
Suitable dose-response curves were obtained for the acids 310 (HTRF IC50 = 37.5 
μM; ELISA IC50 = 28.5 μM) and 242, although extrapolation of the IC50 for the latter 
compound was not possible because of the low potency of the compound (a 
plateau was not reached within the concentration range examined). The lipophilic 
alcohol analogues 310 and 236, instead, hit a solubility threshold in the assay 
conditions and did not reach 50% inhibition (Figure 7.13). 
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Figure 7.13 - HTRF curves for GST-MDMX22-111. 
a) 4-nitrobenzyl isoindolinones 309 and 310; b) des-cyclopropyl isoindolinones 
236 and 242. 
A dose-response curve was observed with the soluble carboxylic acids 306 
(HTRF IC50 = 40.2 μM; ELISA IC50 = 26.0 μM) and 307 (HTRF IC50 = 90.1 μM; ELISA 
IC50 = 24.9 μM). An IC50 value could not be extrapolated for isoindolinones 305, 
164, 148, 302, 303 and 159 (Figure 7.14). 
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Figure 7.14 - HTRF curves for GST-MDMX22-111. 
a) Dose-response curves for the carboxylic acids 306 and 307. The 6-carbinol 
isoindolinone 305 hits a solubility threshold at higher concentrations. b) The 
isoxazole compound 148 and its α-methyl analogue 164 did not give a dose-
response curve. c) Data obtained for the pyrazole compounds 302 and 303 show 
an anomalous behavior and could not be fitted. d) The curve corresponding to the 
benchmark compound 159 is entirely at negative values of inhibition. 
7.4 Differential scanning fluorimetry (DSF) 
The isoindolinones synthesized within the MDMX project, together with those 
used for the structural biology studies and HTRF validation, were all screened 
against the three MDMX constructs using differential scanning fluorimetry, DSF. 
The screen was performed in set conditions to identify compounds that are 
effective in stabilizing the protein constructs. Each protein, or protein construct, is 
characterized by a distinct melting temperature, Tm, at which 50% of the protein is 
unfolded due to the denaturing effect of a temperature increase. By measuring the 
difference between the Tm of the apo protein and that of the protein bound to an 
inhibitor (thermal shift, Tm), it is possible to evaluate whether the presence of the 
ligand has a stabilizing or a destabilizing effect on the protein. DSF experiments are 
performed with a temperature gradient in the presence of a dye (SYPRO orange) 
that binds to the hydrophobic sites of the protein that are exposed as a result of 
unfolding. The increasing fluorescence is proportional to the fraction of bound dye 
and is used to evaluate the stage of protein denaturation. Allowing for the 
a b 
c d 
 
 
160 
 
screening of a large number of compounds at the same time, DSF is a highly time-
efficient, inexpensive and informative technique.192 
The imidazo-indole WK298 143, the indolyl-hydantoins RO-2443 146 and  
RO-5963 147 and the p5317−30
N30F  peptide were included in the experiments as 
positive controls. Negative controls encompassed systems lacking of a) inhibitor, 
to determine the Tm of the apo protein; b) protein and inhibitor, to exclude the 
possibility of fluorescent contaminants; c) inhibitor and dye, to verify the absence 
of an interaction between the two compounds that would affect the fluorescence. 
Every condition was run in triplicate and average values and standard deviations 
were calculated. Example DSF curves are shown in Figure 7.15. The results of the 
experiments performed with the compound library using all three purified MDMX 
constructs are summarized in Figures 7.16–18. 
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Figure 7.15 - Example of thermal denaturation curves with MDMX22-111. 
a) Apo protein (Tm = 55.0 C); b) p5317−30
N30F  peptide (Tm = 57.0C); c) RO-5963 (Tm = 
55.6 C); d) 148 (Tm = 55.3C). 
a b 
d c 
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The p53 peptide stabilized all three constructs by 1.5-2.0 C. Among the 
literature compounds, the greatest effect was observed with the presence of 
WK298, especially with MDMX22-111 and MDMX26-111 (Tm = +2.19±0.09 and 
+1.32±0.71 C, respectively). With the only exception of 248 bound to MDMX22-111, 
all the isoindolinones synthesized within the project destabilized all three 
constructs. However, the result obtained with 248 must be interpreted with 
caution, due to the considerable error associated with the data (Tm = +0.33 ± 1.09 
C). Among the other isoindolinones included in the study, the 4-nitrobenzyl 
carboxylic acid 310 induced a stabilization of 0.44±0.09 C with construct 
MDMX18-111, 1.060.19 C with construct MDMX22-111 and 0.980.27 °C with 
MDMX26-111. The dicarboxylic acid 308 also had a favorable effect on protein 
stability, especially with MDMX22-111 (Tm = 1.56±0.26). The isoindolinones 306 
and 305 also showed a mild stabilizing effect on MDMX upon binding. 
7.5 Conclusions drawn from the structural biology studies on MDMX 
Crystallization trials were set up with a selection of ligands using three 
constructs of each protein aimed at achieving a clearer understanding of the 
differences between the mode of binding of isoindolinones to MDMX and to MDM2. 
Unfortunately, crystals of MDMX were not obtained. However, the structure of the 
MDMX-selective 159 in complex with MDM217−125
K51A  was solved and exhibited a 
peculiar mode of binding triggered by the conformation adopted by the ligand as a 
result of its (3R,1’R) stereochemistry. The crystal structure showed that the 4-
chlorobenzyl group at the 2-position of the isoindolinone core does not have 
access to the Leu26 binding pocket, but seems to interact with the flexible N-
terminal of the protein. An outward shift of the core is also observed, which 
reduces the extent of the interaction of the A-ring and the phenyl group with the 
Phe19 and Trp23 pockets, respectively. Superposition of the structure obtained 
with a MDMX structure available in the PDB suggests that a similar mode of 
binding is plausible to MDMX, although it is not possible to determine the reasons 
underlying the selectivity of 159 towards this target. Similarly to what was 
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previously achieved with MDM2, a surface entropy mutation approach could be 
attempted to promote the crystallization of MDMX. 
As a consequence of withdrawal from the market of the anti-MDMX antibody 
used for the ELISA, an HTRF assay was developed. A panel of isoindolinones was 
selected to validate it. The attainment of meaningful results was strongly 
dependent on the solubility of the ligands and only isoindolinones with clogD < 3 
were likely to show a dose-response curve. These findings suggest that most of the 
MDMX-active isoindolinones are not amenable for HTRF assay because of their low 
solubility. A library of isoindolinones was screened to measure the thermal shift 
induced on three MDMX constructs. Only the soluble carboxylic acids 308 and 310 
significantly stabilized the protein (Tm1 C) while 305 and 306 showed a 
moderate stabilizing effect. Taken together, these findings highlight the relevance 
of solubility as a parameter to be considered prior to the synthesis of any target 
molecule.  
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Figure 7. 16 
Thermal shift for a selection of isoindolinones and MDMX18-111. 
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Thermal shift for a selection of isoindolinones and MDMX22-111. 
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Thermal shift for a selection of isoindolinones and MDMX26-111. 
 
 
166 
 
CHAPTER 8. CONCLUSIONS 
Validation studies were undertaken on two different target classes potentially 
implicated in cancer survival and development, a sulfatase enzyme and a 
protein-protein interaction. In both cases, chemical tools of suitable potency 
were required, prompting the initiation of medicinal chemistry projects at the 
Northern Institute of Cancer Research. 
 The Sulf2 project 8.1
Up-regulation of the endosulfatase Sulf2 in hepatocellular carcinoma 
corresponds to a more aggressive tumor phenotype, with lower survival rate 
for patients and higher tumor recurrence after excision. The interplay between 
Sulf2 and its homologue Sulf1 is still not completely understood, as the two 
enzymes appear to have non-redundant functions and different substrate 
specificity in vivo.56 Additionally, Sulf1 may act either as a tumor suppressor or 
as an oncogene depending on the cellular context, making it difficult to evaluate 
whether a specific Sulf2 inhibitor would be desirable or if dual Sulf1 and Sulf2 
inhibition would be preferred. Nonetheless, specificity could prove difficult to 
achieve with small-molecules due to the high degree of homology in the 
catalytic domains of the two enzymes. 
Aiming to develop tool compounds for further target validation and 
rationalize interactions with the enzyme, three series of compounds were 
synthesized featuring either a tertiary or a primary sulfamate group on an 
aromatic template. 
The first series designed, including diversely substituted monocyclic aromatic 
tertiary phenylsulfamates, was essentially inactive in a biochemical assay 
against Sulf2, but more encouraging results were obtained with a tertiary 
biphenylsulfamate template. The second aromatic ring (B-ring) was introduced 
via an optimized Suzuki-Miyaura cross-coupling to allow exploration of 
substitution with polar functionalities (carboxylic acid, amine, aminosulfate) 
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which were appended to the B-ring aiming to mimic the position of polar 
groups on the disaccharide unit of heparan sulfate, the endogenous substrate. 
Polar substituents, such as aminosulfates, carboxylic acids and sulfated 
hydroxymethyl, as well as the electron-withdrawing cyano- showed some level 
of activity (up to ~30% inhibition at 1 mM), which tend to be higher with a 3’- or 
4’- substitution pattern. 
 
 
 
The third series of compounds featured a non-aromatic B-ring aiming to 
explore an area of space not accessible using a planar aromatic B-ring. The 
cyclohexene primary sulfamate 135 (49% inhibition at 1 mM) was more potent 
than its tertiary sulfamate counterpart (<5% inhibition at 1 mM) supporting the 
superiority of the non-alkylated primary sulfamate group. 
The trans-4-cyclohexylsulfate 92 (35% inhibition at 1 mM) was more potent 
than both the cis-isomer and the unsubstituted alcohol precursor. 
 
Due to difficulties in the scale-up of production of pure Sulf2 enzyme, the 
project was down-prioritized and the studies aiming at the identification of tool 
molecules are currently on hold. Nonetheless, the synthesis of the 2- and  
3-cyclohexene isomers of 135 would be required to investigate the preferred 
position of unsaturation. Further elaboration of the alkene of 135 would be 
desirable (e.g. dihydroxylation, epoxidation). 
 
 
168 
 
 
Also, different sizes of the B-ring could be explored, either in conjunction with 
the double bond or with the sulfate group. In the light of the results obtained by 
Tristan Reuillon, the introduction of an ether linkage as a spacer between the  
A- and B-rings would be worth investigating to generate more potent 
compounds. 
 
 The MDMX:p53 protein-protein interaction project 8.2
One of the most common ways adopted by cancer cells to evade apoptosis is to 
subvert the p53 pathway. When wild-type p53 is retained, this subversion is 
achieved through either amplification or overexpression of the two negative 
regulators MDM2 and MDMX. Although a number of candidates have reached 
the clinic as modulators of the MDM2:p53 protein-protein interaction, in vitro 
and in vivo studies indicate that in some cell-lines (low MDM2, high MDMX 
cellular levels) MDMX provides a mechanism of resistance to MDM2:p53 
inhibitors, thus raising interest in the search for MDMX:p53-selective or dual 
MDM2/MDMX:p53 inhibitors. Despite the effort, only one series has been 
reported, which showed potencies in the low nanomolar range, although these 
results were not replicated by the in-house ELISA. Following the low 
micromolar activity measured with ELISA against MDMX:p53 for isoindolinone 
153 (IC50 = 16.7 µM), a series of 2-(α-methyl)benzylisoindolinones was 
investigated. Serial deletion of the chloro- substituents and analysis of the pure 
diastereoisomers led to the identification of 159, a selective low micromolar 
MDMX inhibitor (MDMX IC50 = 25.9 µM; MDM2 IC50 = 180 µM), with (3R,1’R) 
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configuration and lacking the 4-chloro-substituent at the 3-phenyl group. 159 
was chosen as the benchmark compound for further SAR studies. 
 
A structural minimization approach was used, with removal or simplification 
of the 2-benzyl substituent, the side chain at the 3-position or the isoindolinone 
core. Each one of the three elements examined proved to be necessary for 
binding, but the SAR confirmed that, for almost all compounds, the (3R,1’R) 
configuration at the stereocenters confers selectivity towards MDMX versus 
MDM2. 
A panel of 7-substituted isoindolinones bearing nitrogen-based heterocycles 
was synthesized, ultimately resulting in potency to be either retained or slightly 
decreased (up to 2-fold). For 7-substituted compounds, the R and S 
configurations at the 3-stereocenter were almost equipotent against MDMX; 
only in the case of the 3-pyrazole 303, was MDM2-selectivity observed with an 
(3R,1’R) configuration. 
By analogy with the most potent compound in the isoindolinone series against 
MDMX, a 5-hydroxyisoxazole moiety was introduced at the free end of the side 
chain of 159 after a new reliable route to the ether linkage was devised. 
Unfortunately, the resulting compound 164 could not be tested by ELISA to 
compare the activities. 
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To investigate the Leu26 binding pocket, variations at the 4-benzyl position 
were introduced by replacement of the chloro- substituent with a methoxy- 
(259), nitro- (261), amino- (262) or trifluoromethylsulfonamide (263) group. 
Again, the compounds were not tested. 
 
To understand the reasons behind the apparent difficulties in obtaining sub-
micromolar IC50 values against MDMX with the isoindolinone scaffold, 
crystallization trials were set up with both proteins. These trials used different 
constructs, two commercial screens (the AmSO4 Suite and JCSG+ screen) and 
six isoindolinones with suitable potency against MDMX (preferably < 35 µM) 
and in a range of clogD values. None of the trials with the MDMX constructs gave 
a co-crystal structure, but the complex formed by MDM217−125
K51A  with 159 
resulted in a 2.5 Å-resolution structure revealing a peculiar mode of binding. 
The (3R,1’R) configuration forces the 2-benzyl out of the Leu26 binding pocket 
and makes it likely to induce an ordered structure of the N-terminal region of 
MDM2, which contains residues from the GST-tag used for protein purification. 
The isoindolinone core is shifted outwards and leads to sub-optimal occupation 
of the Phe19 and Trp23 binding pockets. This mode of binding may be adopted 
by 159 bound to MDMX and may lead to the formation of a stabilizing 
interaction with either the protein surface or N-terminal residues that would 
justify the selectivity observed towards this target. In light of these results, 
further investigation of the substitution pattern on the benzyl ring would be 
highly desirable. 
The validation of a new assay format (HTRF) was attempted using a selection 
of isoindolinones, but results were only obtained for compounds with  
clogD < 3.3, highlighting solubility issues in the assay conditions. 
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A library of isoindolinones, including all the compounds whose synthesis has 
been described herein, was screened against three MDMX constructs using 
differential scanning fluorimetry to measure the thermal shift induced. Only the 
soluble carboxylic acids 308 and 310 significantly stabilized the protein  
(Tm  1 C) while 305 and 306 showed a moderate stabilizing effect. The 
remaining compounds, including the potent 5-hydroxyisoxazole 148 and the 
selective 159, destabilized the protein upon binding. 
Due to the lack of progress in achieving sub-micromolar potency against the 
target, the difficulties in obtaining structural data of isoindolinones bound to 
MDMX and the lack of a suitable assay to measure the activity against the target 
protein-protein interaction, the project was discontinued. 
 
 
 
 
172 
 
CHAPTER 9. EXPERIMENTAL 
 Summary of generic synthetic, analytical and chromatographic 9.1
conditions 
9.1.1 Chemicals and solvents 
All commercial reagents were purchased from Acros, Alfa-Aesar, Avocado, 
BDH, Fluka, Lancaster, Sigma-Aldrich or Strem Chemicals at a degree of purity 
higher than 95%, unless otherwise stated. Anhydrous solvents were purchased 
from Sigma-Aldrich or Acros Organics. The solvents were enclosed in 
SureSealTM or AcroSealTM bottles and were handled under dry nitrogen 
whenever required. Microwave-assisted reactions were performed in a Biotage 
Initiator Sixty apparatus. 
9.1.2 Synthesis 
All water- and/or oxygen-sensitive reactions were carried out under strict 
anhydrous conditions with oven-dried glassware cooled under nitrogen. Metal 
catalyzed reactions were degassed by bubbling nitrogen through the reaction 
mixture prior to addition of the catalyst. 
Microwave assisted synthesis was performed using an Initiator Sixty Biotage 
apparatus. Hydrogenation reactions were carried out using a Thales H-cube® 
continuous-flow hydrogenation reactor. 
Thiol-functionalized polymer cartridges (Agilent Thiol MP SPE) were used to 
remove all traces of palladium-based catalysts. 
The risk of each reaction was assessed in agreement with Newcastle 
University guidelines and a Control of Substances Hazardous to Health (COSHH) 
form was completed before performing any new reaction. 
9.1.3 Chromatography 
Thin Layer Chromatography (TLC) monitoring of reactions was performed 
using Merck silica gel-coated (Silica Gel 60 F254, Silica Gel 60 RP-18 F254s or 
NH2F254s) plates aluminium-backed. Compounds were visualized by UV light 
(254 and 298 nm) or by use of potassium permanganate or 2,4-
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dinitrophenylhydrazine stains, as stated for each compound. LC-MS analyses 
were performed on a Waters Acquity UPLC system with PDA, and ELSD coupled 
with a Waters SQD with ESCi source in ES mode equipped with an Acquity UPLC 
BEH C18 column (17 µm, 2.1 × 50 mm) as the stationary phase. The samples 
were eluted using either a 2.0 or a 2.5 min gradient with a flow rate of 0.6 
mL/min, and the mobile phase was 0.1% v/v formic acid (aq.)/MeCN. 
All purifications were accomplished by medium pressure liquid 
chromatography (MPLC) using either a Biotage SP4 or a Varian 971-FP 
automated system, and the progress of the purification was followed by UV 
detection (collection wavelength: 254 nm). Varian silica pre-packed (Si50 or SF) 
cartridges were used, respectively, for normal phase and reverse phase 
purification. When semi-preparative HPLC was required, compounds were 
purified on Agilent 1200 Modular Preparative HPLC system using an ACE 5 
Phenyl 150 x 21.2 mm column. 
Purities of compounds were measured by analytical HPLC using either Waters 
XTerra RP18 5 µM, 150  4.6 mm or Waters Xselect CSH C18 3.5 µM, 4.6  100 
mm with a flow rate of 1 mL/min using up to three eluents (0.1% formic 
acid/MeCN, 0.1% ammonia/MeCN or water/MeCN). For bioassay, 
purities >95% were required. In some cases a discrepancy between acidic and 
basic eluents was ascribed to e.g. oxidative degradation or decomposition of the 
primary sulfamate moiety. 
9.1.4 Analytical techniques 
All melting points were measured with a Stuart Automatic Melting Point 
Apparatus Model SMP40 and are uncorrected. UV spectra were determined in 
ethanolic solution on a Hitachi U-2800A spectrophotometer (400 to 200 nm); 
unless reported, the extinction coefficient ε was not measured. Optical rotations 
were determined on an Optical Activity PolAAR 3001 polarimeter with a path 
length of 0.25 dm. [α]D values are given in 10-1 deg cm2 g-1. FTIR spectra were 
recorded as neat samples using a Bio-Rad FTS 3000MX diamond ATR or an 
Agilent Cary 630 FTIR. 1H, 13C and 19F nuclear magnetic resonance (NMR) 
spectra were obtained using a Bruker Avance III 500 spectrometer (operating 
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at 500 MHz, 125 MHz and 75 MHz, respectively) using CDCl3, DMSO-d6 or 
CD3OD as the solvent. Chemical shifts (δ) are reported in parts per million 
(ppm) and coupling constants (J) in Hertz. Homonuclear and heteronuclear 
two-dimensional NMR experiments were used where appropriate to facilitate 
assignment of chemical shifts. HR-MS spectra were determined by the ESPRC 
National Mass Spectrometry Service, University of Wales Swansea, Singleton 
Park, Swansea, SA2 8PP, using a Thermofisher LTQ Orbitrap XL coupled to an 
Advion TriVersa NanoMate or a Thermofisher DSQ-II coupled to a Trace GC 
Ultra gas chromatograph with Tri-plus auto-sampler and generating a list of 
possible elemental formulae. Data were compared with literature data for 
compounds which had been previously reported. 
Measurements of pH values were carried out at room temperature using a 
SevenEasy pH Mettler Toledo pH-meter equipped with a InLab Expert Pro pH 
combination electrode (reference system: ARGENTHALTM; reference electrolyte: 
XEROLYT Polymer). 
 SULF2 project experimental procedures 9.2
9.2.1 Sulfatase Biological Assay Protocols 
The sulfatase biological assays were performed by Dr Gary Beale and Dr Sari 
Alhasan (Northern Institue for Cancer Research, Paul O’Gorman Building, 
Framlington Place, Newcastle upon Tyne, Tyne and Wear NE2 4AD). 
Sulf-2 assay protocol 
Compounds were screened using 4-MUS as a substrate for Sulf-2 according to 
a protocol described by Morimoto-Tomita et al.39 Briefly, 293T cells were 
transiently transfected with pcDNA3.1/Myc-His(-)-HSulf-2 DNA (Addgene) and 
TransIT-LT1 Transfection Reagent (Mirus) using a transfection mixture at the 
ratio 1:3 (µg DNA: µL transfection reagent) in Opti-MEM I reduced serum 
medium (Gibco). Conditioned medium containing Sulf-2 was collected after 3 
days and bound to HIS-Select Nickel affinity gel (Sigma) overnight at 4 °C. Beads 
were washed three times with washing buffer containing 50 mM HEPES (pH 
7.5), 300 mM NaCl, 0.05% Tween 20, followed by washing once with washing 
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buffer containing no Tween. Beads were suspended in 50 mM Hepes (pH 7.5) 
and used in inhibition assays. 20 μL of bead slurry was incubated with 1 mM 
compound (in DMSO) plus 10X reaction buffer (500 mM HEPES pH 7.5, 100 mM 
CaCl2) for 1 h at 37 °C. The reaction was started by the addition of 20 μL of 20 
mM 4-MUS (final concentration of 8 mM) and incubated at 37 °C for 1 h. The 
reaction was stopped with 100 μL 1 M Tris buffer (pH 10.4) and read at 460 nm 
following excitation at 355 nm in FLUOstar Omega plate reader (BMG Labtech) 
using Omega data analysis software. 
ARSA and ARSB assay protocols 
Compounds were screened in a 96-well black plate (Sterilin) using 4-MUS as a 
substrate, using 50 μL reaction mixture containing 40 ng of the commercially 
available enzymes (ARSA or ARSB from R & D Systems), 50 mM HEPES (pH = 
4.5), 10 mM CaCl2, 1 mM test compound (dissolved in DMSO; final concentration 
of DMSO in reaction = 2%), and H2O (45 μL). The assay mixture was incubated 
for 1 h at 37 °C, followed by addition of 5 μL of 4-MUS (Km = 1.6 mM for ARSA 
and 612 μM for ARSB), and incubation for a further 1 h at 37 °C. The reaction 
was stopped with 100 μL of 1 M Tris (pH = 10.5) and read at 460 nm following 
excitation at 355 nm in FLUOstar Omega plate reader (BMG Labtech) using 
Omega data analysis software. 
9.2.2 General synthetic procedures 
General procedure A - Synthesis of N,N-dimethylsulfamates from phenols 
A mixture of the phenol (1.5 equiv.) and Cs2CO3 (1.7 equiv.) in dry acetonitrile 
(3 mL per mmol of phenol) was stirred at room temperature for 1 h. A solution 
of N,N-dimethylsulfamoyl chloride (1.0 equiv.) in dry acetonitrile (1.1 
mL/mmol) was added dropwise to the mixture at 0 °C under nitrogen 
atmosphere. After complete conversion, the reaction mixture was filtered over 
Celite and the solvent was removed in vacuo. The residue was dissolved in 
diethyl ether, washed with water, and the aqueous layer was extracted twice 
with Et2O. The combined organic phases were dried (MgSO4), filtered and 
evaporated. The crude product was purified by MPLC on C18 reversed phase 
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SiO2 with gradient elution, 20-80% acetonitrile/water, formic acid 0.1%, unless 
otherwise stated. 
General procedure B - Suzuki-Miyaura cross-coupling of N,N-dimethyl 3-
bromophenyl sulfamates with boronic acids72 
A 2.0 M aqueous solution of sodium carbonate (2.0 equiv.) was added to a 
solution of the sulfamate (1.0 equiv.) in 1,2-dimethoxyethane (4.0 mL/mmol), 
and the mixture was stirred and nitrogen was bubbled through it. The boronic 
acid (1.0 equiv.) and tetrakis(triphenylphosphine)palladium (0.05 equiv.) were 
added in one portion under an inert atmosphere. The mixture was heated at 
reflux overnight. Upon completion of the reaction, the solvent was removed in 
vacuo, water was added and the product was extracted with ethyl acetate. The 
combined organic layers were dried (MgSO4), filtered, and evaporated. The 
crude product was purified by MPLC as described for each compound. 
General procedure C - Acetylation of anilino-phenylsulfamates80 
The aniline was dissolved in dichloromethane (2.8 mL/mmol) under an inert 
atmosphere, and acetic anhydride (1.2 equiv.) was added. The solution was 
stirred overnight at RT before being diluted with DCM, and washed with a 
saturated aqueous NaHCO3 solution. The aqueous layer was extracted with 
DCM; the combined organic phases were dried (MgSO4), filtered and the solvent 
was removed in vacuo. Purification was performed by MPLC (gradient elution, 
0-100% EtOAc/petrol) to obtain the desired compounds. 
General procedure D - Preparation of sodium sulfate salts79 
Method 1 - Under an inert atmosphere, the aniline or phenol was dissolved in 
DMF (18 mL/mmol) and sulfur trioxide pyridine complex (3.0 equiv.) was 
added in one portion. The resulting solution was stirred at RT for 45 min. NaOH 
(2 M aq., 20 equiv.) was added, and the solution was stirred for 1.5 h. The 
solvent was removed under high vacuum, and the residue was dissolved in 
methanol and filtered through Celite. The crude product was purified by MPLC 
as described for each compound. 
 
 
177 
 
Method 2 - The alcohol (1.0 equiv.) was dissolved in DMF (2.7 mL/mmol) and 
SO3 · pyridine complex (2.0 equiv.) was added in one portion. The solution was 
stirred at RT for 1 h before removing the solvent in vacuo. The residue was 
dissolved in Milli-Q® water and charged on an ion exchange column (Dowex 
50WX2/Na+ form; pH adjusted to 7-8 by Milli-Q® flushing). The crude product 
was purified by MPLC (gradient elution, 0-10% MeOH/EtOAc) to yield the 
desired compounds. 
General procedure E - Microwave-assisted Suzuki-Miyaura cross-coupling 
Under an inert atmosphere, the appropriate boronic acid or ester (1.0 equiv.) 
was added to a solution of the N,N-dimethyl 3-bromophenylsulfamate (1.0 
equiv.) in DME (2.8 mL/mmol). Following addition of Na2CO3 (2 M aq., 2 equiv.) 
and [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium(II) DCM 
complex (0.05 equiv.), the reaction mixture was heated under microwave 
irradiation at 80 °C for 10-20 min. 
General procedure F - Ketone deprotection 
A solution of the acetal (1.0 equiv.) was dissolved in a mixture of THF (7 
mL/mmol), water (21mL/mmol) and acetic acid (43 mL/mmol). The solution 
was stirred for 4.5 hours at 40 °C. After removal of the solvents in vacuo, the 
residue was dissolved in EtOAc (40 mL) and washed with sat. aq. NaHCO3 (40 
mL). The aqueous layer was extracted with EtOAc (2  40 mL); the combined 
organic layers were washed with brine, dried (MgSO4), filtered and evaporated. 
If required, the crude product was purified by MPLC as specified for each 
compound. 
General procedure G - Sulfamate deprotection79,93 
The appropriate protected sulfamate (1.0 equiv.) was dissolved in a 10% 
(v/v) solution of TFA in DCM (10 mL/mmol). The reaction mixture was stirred 
at RT until complete conversion was reached. The solvent was removed in 
vacuo and the residue was dissolved in EtOAc (20 mL) and washed with aq. 
NaHCO3 (10% v/v, 10 mL). The aqueous layer was extracted with EtOAc (2  20 
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mL); the combined organic layers were dried (MgSO4), filtered, and evaporated. 
The crude product was purified by MPLC as described for each compound. 
General procedure H - Synthesis of vinyl triflate from a ketone 
A solution of KHMDS in toluene (0.5 M, 1.3 equiv.) was added dropwise to a 
solution of the appropriate ketone (1.0 equiv.) at -78 °C and N-phenyl 
bis(trifluoromethanesulfonamide) (1.3 equiv.) in THF (10 mL/mmol) and the 
resulting mixture was stirred for 3 h. Water (40 mL) was added and the product 
was extracted with Et2O (3  40 mL). The combined organic layers were washed 
with aq. Na2CO3 (10% v/v, 40 mL) and brine (40 mL), dried (MgSO4), filtered 
and evaporated. The crude product was purified by MPLC using the conditions 
as described below for each compound. 
General procedure I - Miyaura borylation 
Under an inert atmosphere, bis(pinacolato)diboron (1.2 equiv.), Pd(dppf)Cl2 · 
DCM (0.03 equiv.), and potassium acetate (3.0 equiv.) were added to a solution 
of the vinyl triflate/halide (1.0 equiv.) in 1,4-dioxane (5.0 mL/mmol). The 
reaction mixture was heated at 80 °C overnight. Upon completion of the 
reaction, water (20 mL) was added and the product was extracted with EtOAc 
(3  30 mL). The combined organic layers were washed with brine, dried 
(MgSO4), filtered and the solvent was removed in vacuo. The residue was 
dissolved in ethyl acetate and filtered through a Thiol MP SPE cartridge. The 
crude product was purified by MPLC according to the conditions described 
below. 
Procedure for assessment of stability by HPLC analysis 
Anhydrous basic conditions 
NaBH4 (3 mg, 79 μmol) was added to 4-(trifluoromethyl)phenyl 
dimethylsulfamate 51 (5 mg, 19 μmol) in EtOH (0.5 mL) and the resulting 
solution was stirred at RT. After 2, 24, and 96 h a sample was taken, diluted 
with MeOH (0.75 mL) and assayed by HPLC. 
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Aqueous basic conditions 
NaOH (2 M aq., 0.5 mL, 1 mmol) was added to 4-(trifluoromethyl)phenyl 
dimethylsulfamate 51 (5 mg, 19 μmol) in EtOH (0.5 mL) and the resulting 
solution was stirred at RT. After 2, 24, and 96 h a sample was taken, diluted 
with MeOH (0.75 mL) and assayed by HPLC. 
Reductive conditions 
NaH (60% dispersion in mineral oil, 3 mg, 75 μmol) was added to 4-
(trifluoromethyl)phenyl dimethylsulfamate 51 (5 mg, 19 μmol) in THF (0.5 mL) 
and the resulting solution was stirred at RT. After 2, 24, and 96 h a sample was 
taken, diluted with MeOH (0.75 mL) and assayed by HPLC. 
Anhydrous acidic conditions 
TFA (0.5 mL, 2.9 mmol) was added to 4-(trifluoromethyl)phenyl 
dimethylsulfamate 51 (5 mg, 19 μmol) and the resulting solution was stirred at 
RT. After 2, 24 and 72 h a sample was taken, diluted with MeOH (0.75 mL) and 
assayed by HPLC. The sample taken at 72 h was filtered before HPLC analysis 
due to the formation of a precipitate. 
9.2.3 SULF2 project - Synthesized compounds 
4-(tert-Butyl)phenyl dimethylsulfamate (41) 
 
4-t-Butylphenol (100 mg, 0.67 mmol) was dissolved in acetonitrile (2.0 mL) 
under an inert atmosphere and a solution of N,N-dimethylsulfamoyl chloride 
(143 mg, 0.11 mL, 1.0 mmol) in acetonitrile (0.5 mL) was added dropwise at 
0 °C followed by addition of potassium carbonate (143 mg, 1.0 mmol) in one 
portion. The reaction mixture was allowed to reach ambient temperature and 
stirred for 5.5 h. Water (3.0 mL) was added to quench the unreacted sulfamoyl 
chloride and the mixture was stirred at ambient temperature overnight. After 
addition of brine (3.0 mL), the mixture was neutralized by addition of HCl (aq., 1 
M), diluted with water and extracted with ethyl acetate (3 × 25 mL). The 
combined organic layers were dried over MgSO4, filtered and the solvent was 
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removed in vacuo to afford the desired sulfamate 41 as a white solid without 
further purification (41 mg, 24%). Rf 0.30 (50% MeCN (0.1% formic acid)/H2O); 
m.p. 77.2-78.2 °C; λmax (EtOH)/nm 261; νmax/cm-1 (neat) 1148 and 1176 (s, 
SO2sy), 1198 (m, C-O), 1356 (s, SO2as), 2871, 2926 and 2956 (w, aliphatic C-H 
stretching, t-Bu); 1H NMR (500 MHz; CDCl3) δH 1.31 (9H, s, C(CH3)3), 2.97 (6H, s, 
2 × N-CH3), 7.18-7.21 (2H, m, H-2 and H-6), 7.37-7.40 (2H, m, H-3 and H-5); 13C 
NMR (125 MHz; CDCl3) δC 31.5 (3 × C-CH3), 34.7 (C-CH3), 38.9 (2 × N-CH3), 121.3 
(C-2 and C-6), 126.8 (C-3 and C-5), 148.0 (C-4), 149.9 (C-1); LRMS (ES+) m/z 
258.2 [M+H]+; HRMS calcd for C12H20NO3S [M+H]+ 258.1158, found 258.1163; 
HPLC 97.9% in 0.1% formic acid (aq.)/MeCN (Rt 12.9 min); 97.9% in 0.1% 
ammonia (aq.)/MeCN (Rt 12.9 min). 
4-Methoxyphenyl dimethylsulfamate (42) 
 
4-Methoxyphenol (100 mg, 0.81 mmol) was dissolved in acetonitrile (2.4 mL) 
and potassium carbonate (167 mg, 1.21 mmol) was added. The mixture was 
stirred for 1 h at ambient temperature (18-20 °C). A solution of N,N-
dimethylsulfamoyl chloride (77 mg, 0.06 mL, 0.54 mmol) in acetonitrile (0.26 
mL) was added dropwise to the mixture at 0 °C. The system was allowed to 
reach ambient temperature and was stirred for 19 h. The mixture was filtered 
through Celite and acetonitrile was removed in vacuo. The residue was 
dissolved in diethyl ether and washed with water. The aqueous layer was 
extracted with diethyl ether (30 mL) and with DCM (30 mL). The combined 
organic phases were dried (MgSO4), filtered and evaporated. Purification by 
MPLC (C18 reversed phase SiO2 with gradient elution, 20-80% 
acetonitrile/water, formic acid 0.1%) yielded the title compound 42 as a yellow 
oil (92 mg, 74%). Rf 0.34 (50% MeCN (0.1% formic acid)/H2O); λmax (EtOH)/nm 
276; νmax/cm-1 (neat) 1147 and 1164 (s, SO2sy), 1193 (m, C-O), 1249 (m, C-O-
Cas), 1364 (s, SO2as), 1501 (s, C=C ring stretch); 1H NMR (500 MHz; CDCl3) δH 
2.96 (6H, s, 2 × N-CH3), 3.80 (3H, s, OCH3), 6.86-6.90 (2H, m, H-2 and H-6), 7.18-
7.26 (2H, m, H-3 and H-5); 13C NMR (125 MHz; CDCl3) δC 38.8 (2 × N-CH3), 55.7 
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(O-CH3), 114.8 (C-2 and C-6), 123.0 (C-3 and C-5), 143.7 (C-4), 158.2 (C-1); 
LRMS (ES+) m/z 232.1 [M+H]+; HRMS calcd for C9H14O4NS [M+H]+ 232.0638, 
found 232.0640; HPLC 96.9% in 0.1% formic acid (aq.)/MeCN (Rt 10.7 min); 
96.2% in 0.1% ammonia (aq.)/MeCN (Rt 10.7 min). 
NMR data match those previously reported for this compound.70 
3-Methoxyphenyl dimethylsulfamate (43) 
 
The sulfamate 43 was synthesized and purified as described in general 
procedure A, using 3-methoxyphenol (200 mg, 0.161 mmol.), cesium carbonate 
(578 mg, 1.77 mmol), N,N-dimethylsulfamoyl chloride (154 mg, 0.12 mL, 1.07 
mmol) and acetonitrile (5.0 and 1.2 mL). The desired compound was obtained 
as a colorless oil (157 mg, 64%). Rf 0.29 (50% MeCN (0.1% formic acid)/H2O); 
λmax (EtOH)/nm 271, 276; νmax/cm-1 (neat) 1119 (s, SO2sy), 1175 (s, C-O), 1261 
and 1285 (m, C-O-Cas), 1365 (s, SO2as), 1607 and 1588 (m, C=C ring stretch); 1H 
NMR (500 MHz; CDCl3) δH 2.90 (6H, s, 2 × N-CH3), 3.74 (3H, s, OCH3), 6.84 (1H, 
ddd, J = 0.8, 2.4, 8.1 Hz, H-6), 6.86 (1H, app. t, J = 2.4 Hz, H-2), 6.89 (1H, ddd, J = 
0.8, 2.4, 8.1 Hz, H-4), 7.30 (1H, t, J = 8.1 Hz, H-5); 13C NMR (125 MHz; CDCl3) δC 
38.9 (2 × N-CH3), 55.7 (OCH3), 107.8 (C-2), 112.7 (C-6), 113.8 (C-4), 130.2 (C-5), 
151.3(C-1), 160.8 (C-3); LRMS (ES+) m/z 232.2 [M+H]+; HRMS calcd for 
C9H14O4NS [M+H]+ 232.0638, found 232.0640; HPLC 99.3% in 0.1% formic acid 
(aq.)/MeCN (Rt 10.9 min); 99.4% in 0.1% ammonia (aq.)/MeCN (Rt 10.8 min). 
2-Methoxyphenyl dimethylsulfamate (44) 
 
General procedure A was followed to synthesize and purify compound 44, 
using 2-methoxyphenol (200 mg, 0.161 mmol), cesium carbonate (578 mg, 1.77 
mmol), N,N-dimethylsulfamoyl chloride (154 mg, 0.12 mL, 1.07 mmol) and 
acetonitrile (5.0 and 1.2 mL). The desired sulfamate was obtained as a white 
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solid (108 mg, 43%). Rf 0.30 (50% MeCN (0.1% formic acid)/H2O); m.p. 45.0-
45.6 °C (lit.193 38-42 °C); λmax (EtOH)/nm 271; νmax/cm-1 (neat) 1109 (s, SO2sy), 
1147 (s, C-O), 1281 (s, C-O-Cas), 1370 (s, SO2as), 1580 and 1602 (w, C=C ring 
stretch); 1H NMR (500 MHz; CDCl3) δH 2.97 (6H, s, 2 × N-CH3), 3.89 (3H, s, 
OCH3), 6.95 (1H, m, H-5), 6.98 (1H, dd, J = 1.6 and 8.0 Hz, H-3), 7.22 (1H, ddd, J = 
1.6, 7.7, 8.0 Hz, H-4), 7.36 (1H, dd, J = 1.6 and 8.0 Hz, H-6); 13C NMR (125 MHz; 
CDCl3) δC 38.8 (2 × N-CH3), 56.1 (OCH3), 113.0 (C-3), 121.1 (C-5), 123.9 (C-6), 
127.7 (C-4), 139.5 (C-2), 151.7 (C-1); LRMS (ES+) m/z 232.2 [M+H]+; HRMS calcd 
for C9H14O4NS [M+H]+ 232.0638, found 232.0640; HPLC 99.5% in 0.1% formic 
acid (aq.)/MeCN (Rt 10.6 min); 99.7% in 0.1% ammonia (aq.)/MeCN (Rt 10.5 
min). 
NMR data match those previously reported for this compound. 70 
4-Cyanophenyl dimethylsulfamate (45) 
 
Acetonitrile (2.5 mL) was added to 4-cyanophenol (96 mg, 0.806 mmol) and 
cesium carbonate (289 mg, 0.887 mmol) and the resulting mixture was stirred 
at RT for 1 h before adding a solution of N,N-dimethylsulfamoyl chloride (77 
mg, 0.06 mL, 0.537 mmol) in acetonitrile (0.6 mL) pre-cooled to 0 °C under an 
inert atmosphere. The mixture was allowed to reach ambient temperature and 
was stirred overnight. The temperature was maintained at RT for 24 h before 
addition of further sulfamoyl chloride (0.03 mL in 0.3 mL acetonitrile) and 
stirring overnight. Additional phenolate (1.7 equiv. of phenol and 2.4 equiv. of 
base in 2.6 mL acetonitrile) was added in two portions to the reaction mixture 
at 0 °C in order to react with the excess sulfamoyl chloride. The mixture was 
stirred at RT and then at 30 °C for 36 h before filtering through Celite. The 
filtrate was evaporated and the residual oil was dissolved in diethyl ether. The 
ethereal solution was washed with water. The aqueous layer was extracted 
twice with Et2O, the combined organic phases were dried (MgSO4), filtered and 
the solvent was removed in vacuo. The crude product was purified by MPLC 
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yielding the title compound as a light blue solid (129 mg, 71%). Rf 0.40 (50% 
MeCN (0.1% formic acid)/H2O); m.p. 74.2-75.4 °C; λmax (EtOH)/nm 232; 
νmax/cm-1 (neat) 1150 and 1173 (s, SO2sy), 1199 (s, C-O), 1363 (s, SO2as), 2237 
(m, CN); 1H NMR (500 MHz; CDCl3) δH 3.03 (6H, s, 2 × N-CH3), 7.39-7.44 (2H, m, 
H-2 and H-6), 7.70-7.75 (2H, m, H-3 and H-5); 13C NMR (125 MHz; CDCl3) δC 
38.9 (2 × N-CH3), 110.7 (-CN), 118.0 (C-4), 122.5 (C-2 and C-6), 134.2 (C-3 and 
C-6), 153.6 (C-1); LRMS (ES+) m/z 268.2 [M + MeCN + H]+; HRMS calcd for 
C9H10N2O3S [M+H]+ 226.0407, found 226.0407; HPLC >99.9% in 0.1% formic 
acid (aq.)/MeCN (Rt 10.4 min); >99.9% in 0.1% ammonia (aq.)/MeCN (Rt 10.3 
min). 
3-Cyanophenyl dimethylsulfamate (46) 
 
General procedure A was followed to synthesize and purify compound 46, 
using 3-cyanophenol (192 mg, 0.161 mmol), cesium carbonate (578 mg, 1.77 
mmol), N,N-dimethylsulfamoyl chloride (154 mg, 0.12 mL, 1.07 mmol) and 
acetonitrile (5.0 and 1.2 mL). The desired sulfamate was obtained as an oil (142 
mg, 58%). Rf 0.31 (50% MeCN (0.1% formic acid)/H2O); λmax (EtOH)/nm 221, 
274; νmax/cm-1 (neat) 1171 (s, SO2sy), 1224 (m, C-O), 1361 (s, SO2as), 2235 (w, 
CN); 1H NMR (500 MHz; CDCl3) δH 3.37 (6H, s, 2 × N-CH3), 7.82-7.95 (4H, m, H-
Ar); 1H NMR (500 MHz; DMSO-d6) δH 2.93 (6 H, s, 2 × N-CH3), 7.67-7.73 (2H, m, 
H-Ar), 7.83-7.87 (1H, m, H-Ar), 7.88-7.89 (1H, m, H-Ar); 13C NMR (125 MHz; 
CDCl3) δC 38.9 (2 × N-CH3), 114.1 (-CN), 117.6 (C-3), 125.5 (C-Ar), 126.7 (C-Ar), 
130.4 (C-Ar), 131.0 (C-Ar), 150.5 (C-1); LRMS (ES+) m/z 268.1 [M + MeCN + H]+; 
HRMS calcd for C9H14N3O3S [M+NH4]+ 244.0570, found 244.0573; HPLC >99.9% 
in 0.1% formic acid (aq.)/MeCN (Rt 10.4 min); >99.9% in 0.1% ammonia 
(aq.)/MeCN (Rt 10.4 min). 
  
 
 
184 
 
2-Cyanophenyl dimethylsulfamate (47) 
 
The sulfamate 47 was synthesized and purified as described in general 
procedure A, using 2-cyanophenol (192 mg, 0.161 mmol), cesium carbonate 
(578 mg, 1.77 mmol), N,N-dimethylsulfamoyl chloride (154 mg, 0.12 mL, 1.07 
mmol) and acetonitrile (5.0 and 1.2 mL). The title compound was obtained as 
colorless crystals (224 mg, 92%). Rf 0.32 (50% MeCN (0.1% formic acid)/H2O); 
m.p. 70.1-71.0 °C (lit.74 70-71 °C); λmax (EtOH)/nm 225, 276; νmax/cm-1 (neat) 
1164 (s, SO2sy), 1182 (m, C-O), 1368 (s, SO2as), 2235 (w, CN); 1H NMR (500 
MHz; CDCl3) δH 3.10 (6H, s, 2 × N-CH3), 7.32-7.39 (1H, m, H-4), 7.55-7.60 (1H, m, 
H-6), 7.61-7.70 (2H, m, H-5 and H-3); 13C NMR (125 MHz; CDCl3) δC 39.1 (2 × N-
CH3), 107.1 (-CN), 115.1 (C-2), 122.7 (C-6), 126.8 (C-4), 133.8 (C-3), 134.6 (C-5), 
151.3 (C-1); LRMS (ES+) m/z 227.1 [M+H]+; HRMS calcd for C9H14N3O3S 
[M+NH4]+ 244.0570, found 244.0573; HPLC 99.1% in 0.1% formic acid 
(aq.)/MeCN (Rt 10.4 min); 99.3% in 0.1% ammonia (aq.)/MeCN (Rt 10.4 min). 
4-Nitrophenyl dimethylsulfamate (48) 
 
Compound 48 was synthesized and purified according to general procedure A, 
using 4-nitrophenol (224 mg, 0.161 mmol), cesium carbonate (578 mg, 1.77 
mmol) in acetonitrile (5.0 mL) and N,N-dimethylsulfamoyl chloride (154 mg, 
0.12 mL, 1.07 mmol) in acetonitrile (1.2 mL). The title compound was obtained 
as pale yellow crystals (129 mg, 49%). Rf 0.27 (50% MeCN (0.1% formic 
acid)/H2O); m.p. 122.2-123.9 °C (lit.194 124 °C); λmax (EtOH)/nm 267; νmax/cm-1 
(neat) 1144 (s, C-O), 1172 and 1197 (s, SO2sy), 1344 (s, SO2as), 1361 (m, NOsy), 
1521 (m, NOas); 1H NMR (500 MHz; CDCl3) δH 3.04 (6H, s, 2 × N-CH3), 7.41-7.47 
(2H, m, H-2 and H-6), 8.26-8.32 (2H, m, H-3 and H-5); 13C NMR (125 MHz; 
CDCl3) δC 38.9 (2 × CH3), 122.2 (C-2 and C-6), 125.7 (C-3 and C-5), 155.1 (C-1). 
One quaternary carbon not detected; LRMS (ES+) m/z 247.2 [M+H]+; HRMS 
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calcd for C8H10O5N2S [M]+ 246.0305, found 246.0308; HPLC 98.6% in 0.1% 
formic acid (aq.)/MeCN (Rt 11.1 min); 98.8% in 0.1% ammonia (aq.)/MeCN (Rt 
11.0 min). 
NMR and IR data match those previously reported for this compound.76,195 
3-Nitrophenyl dimethylsulfamate (49) 
 
The sulfamate 49 was synthesized as described in general procedure A, using 
3-nitrophenol (224 mg, 0.161 mmol), cesium carbonate (578 mg, 1.77 mmol), 
N,N-dimethylsulfamoyl chloride (154 mg, 0.12 mL, 1.07 mmol) and acetonitrile 
(5.0 and 1.2 mL). The crude product was purified by MPLC (gradient elution, 0-
50% DCM/petrol) to yield the desired product as a white solid (297 mg, >99%). 
Rf 0.26 (50% MeCN (0.1% formic acid)/H2O); m.p. 84.6-85.2 °C (lit.193 85 °C); 
λmax (EtOH)/nm 256; νmax/cm-1 (neat) 1167 (s, SO2sy), 1199 (s, C-O), 1352 (s, 
SO2as), 1528 (s, N=Oas); 1H NMR (500 MHz; CDCl3) δH 3.05 (6H, s, 2 × N-CH3), 
7.59 (1H, t, J = 8.2 Hz, H-5), 7.65 (1H, ddd, J = 1.0, 2.2 and 8.2 Hz, H-6), 8.12 (1H, 
t, J = 2.2 Hz, H-2), 8.16 (1H, ddd, J = 1.0, 2.2 and 8.2 Hz, H-4); 1H NMR (500 MHz; 
CD3OD) 3.05 (6H, s, 2 × N-CH3), 7.71-7.78 (2H, m, H-Ar), 8.16-8.19 (1H, m, H-Ar), 
8.21-8.28 (1H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 38.9 (2 × N-CH3), 117.5 
(C-2), 121.6 (C-4), 128.1 (C-6), 130.6 (C-5), 149.1 (C-Ar), 150.7 (C-Ar); LRMS 
(ES+) m/z 288.1 [M + MeCN + H]+; HRMS calcd for C8H10N2O5S [M]+ 246.0305, 
found 246.0305; HPLC 97.9% in 0.1% formic acid (aq.)/MeCN (Rt 10.9 min); 
97.9% in 0.1% ammonia (aq.)/MeCN (Rt 10.9 min). 
2-Nitrophenyl dimethylsulfamate (50) 
 
General procedure A was followed to synthesize compound 50, using 2-
nitrophenol (224 mg, 0.161 mmol), cesium carbonate (578 mg, 1.77 mmol), 
N,N-dimethylsulfamoyl chloride (154 mg, 0.12 mL, 1.07 mmol) and acetonitrile 
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(5.0 and 1.2 mL). Purification by MPLC (gradient elution, 0-50% EtOAc/petrol) 
gave the title product as a yellow oil (250 mg, 94%). Rf 0.32 (50% MeCN (0.1% 
formic acid)/H2O); λmax (EtOH)/nm 251; νmax/cm-1 (neat) 1171 (s, SO2sy), 1207 
(m, C-O), 1351 (s, SO2as), 1523 (s, NOas); 1H NMR (500 MHz; CDCl3) δH 3.06 (6H, 
s, 2 × N-CH3), 7.40 (1H, m, H-Ar), 7.64 (2H, m, H-Ar), 7.97 (1H, m, H-Ar); 13C 
NMR (125 MHz; CDCl3) δC 38.9 (2 × N-CH3), 124.4 (C-Ar), 125.9 (C-Ar), 126.9 (C-
Ar), 134.4 (C-Ar), 142.8 (C-Ar); LRMS (ES+) m/z 247.1 [M+H]+; HRMS calcd for 
C8H11O5N2S [M+H]+ 247.0390, found 247.0387; HPLC 97.7% in 0.1% formic acid 
(aq.)/MeCN (Rt 10.7 min); 97.7% in 0.1% ammonia (aq.)/MeCN (Rt 10.7 min). 
4-(Trifluoromethyl)phenyl dimethylsulfamate (51) 
 
General procedure A was used to synthesize and purify compound 51, using 
4-(trifluoromethyl)phenol (261 mg, 0.161 mmol), cesium carbonate (578 mg, 
1.77 mmol) in acetonitrile (5.0 mL) and N,N-dimethylsulfamoyl chloride (154 
mg, 0.12 mL, 1.07 mmol) in acetonitrile (1.2 mL). The desired sulfamate was 
obtained as a pale yellow solid (95 mg, 33%). Rf 0.19 (50% MeCN (0.1% formic 
acid)/H2O); m.p. 38.8-40.9 °C; λmax (EtOH)/nm 258; νmax/cm-1 (neat) 1098 (s, C-
O), 1151 (s, SO2sy), 1319 (s, C-F), 1366 (m, SO2as); 1H NMR (500 MHz; CDCl3) δH 
3.02 (6 H, s, 2 × N-CH3), 7.38-7.42 (2 H, m, H-2 and H-6), 7.64-7.71 (2 H, m, H-3 
and H-5); 19F NMR (470 MHz; CDCl3) δF -62.33; 13C NMR (125 MHz; CDCl3) δC 
38.9 (2 × N-CH3), 122.1 (C-2 and C-6), 123.8 (q, J = 270.9 Hz, CF3), 127.3 (q, J = 
3.82 Hz, C-3 and C-5), 129.1 (C-4), 152.8 (q, J = 33.1, Hz, C-1); LRMS (ES+) m/z 
311.2 [M + MeCN + H]+; HRMS calcd for C9H11O3NF3S [M+H]+ 270.0406, found 
270.0400; HPLC 96.1% in 0.1% formic acid (aq.)/MeCN (Rt 12.0 min); 97.3% in 
0.1% ammonia (aq.)/MeCN (Rt 12.0 min). 
NMR data match those previously reported for this compound.70 
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3-(Trifluoromethyl)phenyl dimethylsulfamate (52) 
 
The sulfamate 52 was synthesized and purified as described in general 
procedure A, using 3-(trifluoromethyl)phenol (261 mg, 0.161 mmol), cesium 
carbonate (578 mg, 1.77 mmol), N,N-dimethylsulfamoyl chloride (154 mg, 0.12 
mL, 1.07 mmol) and acetonitrile (5.0 and 1.2 mL). The desired product was 
obtained as a colorless oil (136 mg, 47%). Rf 0.15 (50% MeCN (0.1% formic 
acid)/H2O); λmax (EtOH)/nm 263; νmax/cm-1 (neat) 1085 (m, C-O), 1171 (s, 
SO2sy), 1351 (s, C-F), 1363 (s, SO2as); 1H NMR (500 MHz; CDCl3) δH 3.02 (6H, s, 2 
× N-CH3), 7.46-7.57 (4H, m, H-Ar); 1H NMR (500 MHz; DMSO-d6) 2.94 (6H, s, 2 × 
N-CH3), 7.75-7.79 (2H, m, H-Ar), 7.71-7.79 (2H, m, H-Ar); 1H NMR (500 MHz; 
CD3OD) 3.02 (6H, s, 2 × N-CH3), 7.58-7.63 (2H, m, H-Ar), 7.65-7.70 (2H, m, H-
Ar); 19F NMR (470 MHz; CDCl3) δF -62.71; 13C NMR (125 MHz; CDCl3) δC 38.9 (2 
× NCH3), 119.1 (q, J = 3.7 Hz, C-Ar), 123.5 (q, J = 272.6 Hz, CF3), 123.6 (q, J = 3.4 
Hz, C-Ar), 125.4 (C-Ar), 130.6 (C-Ar), 132.5 (q, J = 33.0 Hz, C-3), 150.5 (C-1); 
LRMS (ES+) m/z 270.1 [M+H]+; HRMS calcd for C9H10F3NO3S [M]+ 269.0328, 
found 269.0324; HPLC 99.4% in 0.1% formic acid (aq.)/MeCN (Rt 11.9 min); 
99.8% in 0.1% ammonia (aq.)/MeCN (Rt 11.9 min). 
2-(Trifluoromethyl)phenyl dimethylsulfamate (53) 
 
The sulfamate 53 was synthesized and purified as described in general 
procedure A, using 2-(trifluoromethyl)phenol (261 mg, 0.161 mmol), cesium 
carbonate (578 mg, 1.77 mmol), N,N-dimethylsulfamoyl chloride (154 mg, 0.12 
mL, 1.07 mmol) and acetonitrile (5.0 and 1.2 mL). The title compound was 
obtained as a solid (152 mg, 52%). Rf 0.14 (50% MeCN (0.1% formic 
acid)/H2O);m.p. 39.5-40.9 °C; λmax (EtOH)/nm 264; νmax/cm-1 (neat) 1111 and 
1136 (s, C-O), 1162 (s, SO2sy), 1317 (s, C-F), 1376 (s, SO2as); 1H NMR (500 MHz; 
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CDCl3) δH 3.06 (6H, s, 2 × N-CH3), 7.29-7.36 (1H, m, H-Ar), 7.55-7.61 (1H, m, H-
Ar), 7.64-7.69 (1H, m, H-Ar), 7.69-7.73 (1H, m, H-Ar); 19F NMR (470 MHz; CDCl3) 
δF -60.69; 13C NMR (125 MHz; CDCl3) δC 38.9 (2 × NCH3), 121.5 (C-Ar), 123.0 (q, J 
= 271.7, CF3), 125.7 (C-Ar), 127.5 (q, J = 5.4 Hz, C-3), 133.7 (C-Ar). Two 
quaternary carbons were not visible; LRMS (ES+) m/z 270.2 [M+H]+; HRMS 
calcd for C9H10F3NO3S [M]+ 269.0328, found 269.0328; HPLC 98.1% in 0.1% 
formic acid (aq.)/MeCN (Rt 11.9 min); 99.0% in 0.1% ammonia (aq.)/MeCN (Rt 
11.9 min). 
4-Chlorophenyl dimethylsulfamate (54) 
 
Compound 54 was synthesized and purified according to the procedure 
described for the synthesis of compound 45, using 4-chlorophenol (104 mg, 
0.806 mmol) and cesium carbonate (289 mg, 0.887 mmol) in acetonitrile and 
N,N-dimethylsulfamoyl chloride (77 mg, 0.06 mL, 0.537 mmol), in acetonitrile 
(0.6 mL) to give the title compound as blue crystals (176 mg, 93%). Rf 0.19 
(50% MeCN (0.1% formic acid)/H2O); m.p. 48.1-49.5 °C (lit.196 46 °C); λmax 
(EtOH)/nm 267, 274sh; νmax/cm-1 (neat) 1089 (m, C-Cl), 1146 (s, C-O), 1169 and 
1188 (s, SO2sy), 1357 (s, SO2as); 1H NMR (500 MHz; CDCl3) δH 2.98 (6H, s, 2 × N-
CH3), 7.19-7.25 (2H, m, H-2 and H-6), 7.33-7.38 (2H, m, H-3 and H-5); 13C NMR 
(125 MHz; CDCl3) δC 38.9 (2 × N-CH3), 123.3 (C-2 and C-6), 130.0 (C-3 and C-5), 
132.4 (C-4), 148.8 (C-1); LRMS (ES+) m/z 236.1 and 238.1 [M+H]+; HRMS calcd 
for C8H14O3N435ClS [M+NH4]+ 253.0408, found 253.0412; HPLC 99.4% in 0.1% 
formic acid (aq.)/MeCN (Rt 11.7 min); 99.5% in 0.1% ammonia (aq.)/MeCN (Rt 
11.7 min). 
NMR data match those previously reported for this compound.76 
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[1,1’-Biphenyl]-4-yl dimethylsulfamate (55) 
 
Under an inert atmosphere, 4-phenylphenol (137 mg, 0.806 mmol) was 
dissolved in acetonitrile (2.4 mL) and potassium carbonate (167 mg, 1.21 
mmol) was added. The mixture was stirred for 1 h at RT. A solution of N,N-
dimethylsulfamoyl chloride (77 mg, 0.06 mL, 0.54 mmol) in acetonitrile (0.26 
mL) was added dropwise to the mixture at 0 °C. The reaction was allowed to 
reach ambient temperature and stirred for 19 h. The mixture was filtered 
through Celite and acetonitrile was removed in vacuo. The residue was 
dissolved in diethyl ether (35 mL) and washed with water (20 mL). The 
aqueous layer was extracted with DCM (25 mL) and with diethyl ether (2 × 35 
mL). The combined organic phases were dried (MgSO4), filtered and 
evaporated. The crude product was purified by MPLC (gradient elution, 0-50% 
EtOAc/petrol) to afford title compound as a white solid (134 mg, 90%). Rf 0.17 
(50% MeCN (0.1% formic acid)/H2O); m.p. 110.4-111.8 °C (lit.197 105-107 °C); 
λmax (EtOH)/nm 250; νmax/cm-1 (neat) 1149 (s, C-O), 1174 and 1187 (s, SO2sy), 
1359 (s, SO2as); 1H NMR (500 MHz; CDCl3) δH 3.01 (6H, s, 2 × N-CH3), 7.35-7.39 
(3H, m, H-Ar), 7.42-7.47 (2H, m, H-Ar), 7.54-7.58 (2H, m, H-Ar), 7.58-7.63 (2H, 
m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 38.8 (2 × N-CH3), 122.2 (C-3 and C-5), 
127.3 (C-2’ and C-6’), 127.7 (C-4’), 128.6 (C-2 and C-6), 129.0 (C-3’ and C-5’), 
139.9 (C-1 and C-1’), 149.8 (C-4); LRMS (ES+) m/z 278.2 [M+H]+; HRMS calcd for 
C14H16NO3S [M+H]+ 278.0845, found 278.0850; HPLC 98.5% in 0.1% formic acid 
(aq.)/MeCN (Rt 12.8 min); 98.8% in 0.1% ammonia (aq.)/MeCN (Rt 12.8 min). 
[1,1’-Biphenyl]-3-yl dimethylsulfamate (56) 
 
Procedure 1 -Product 56 was obtained according to general procedure A using 
3-phenylphenol (274 mg, 0.161 mmol), cesium carbonate (579 mg, 1.77 mmol), 
acetonitrile (5.0 mL) and N,N-dimethylsulfamoyl chloride (154 mg, 0.12 mL, 
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1.07 mmol) in acetonitrile (1.2 mL). Following MPLC, the desired product was 
obtained as a white solid (193 mg, 65%). Procedure 2 - The biphenyl sulfamate 
56 was also obtained following general procedure B, using 3-bromophenyl 
sulfamate (50 mg, 0.178 mmol), phenylboronic acid (22 mg, 0.178 mmol), 
sodium carbonate (2 M, aq., 1.0 mL), tetrakis(triphenylphosphine)palladium 
(10 mg, 8.92 µmol) and DME (0.7 mL). Purification by MPLC (gradient elution, 
0-20% EtOAc/petrol) yielded the desired product as a white solid (41 mg, 
83%). Rf 0.14 (50% MeCN (0.1% formic acid)/H2O); m.p. 51.1-54.6 °C; λmax 
(EtOH)/nm 249; νmax/cm-1 (neat) 1140 (s, SO2sy), 1178 (m, C-O), 1369 (s, SO2as); 
1H NMR (500 MHz; CDCl3) δH 3.01 (6H, s, 2 × N-CH3), 7.26-7.29 (1H, m, H-Ar), 
7.34-7.63 (8H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 38.8 (2 × CH3), 120.4 (C-
Ar), 120.5 (C-Ar), 125.5 (C-Ar), 127.2 (2 × C-Ar), 127.6 (C-Ar), 128.9 (2 × C-Ar), 
130.0 (C-Ar), 139.8 (C-Ar), 143.3 (C-Ar), 150.7 (C-Ar); LRMS (ES+) m/z 278.2 
[M+H]+; HRMS calcd for C14H16NO3S [M+H]+ 278.0845, found 278.0846; HPLC 
99.6% in 0.1% formic acid (aq.)/MeCN (General procedure A; Rt 12.8 min); 
99.7% in 0.1% ammonia (aq.)/MeCN (General procedure A; Rt 12.7 min). 
[1,1’-Biphenyl]-2-yl dimethylsulfamate (57) 
 
General procedure A was followed to synthesize and purify compound 57, 
using 2-phenylphenol (274 mg, 0.161 mmol), cesium carbonate (578 mg, 1.77 
mmol), N,N-dimethylsulfamoyl chloride (154 mg, 0.12 mL, 1.07 mmol) and 
acetonitrile (5.0 and 1.2 mL). The title compound was obtained as a white solid 
(213 mg, 72%). Rf 0.14 (50% MeCN (0.1% formic acid)/H2O); m.p. 76.2-77.8 °C 
(lit.193 78 °C); λmax (EtOH)/nm 240; νmax/cm-1 (neat) 1153 (s, SO2sy), 1186 (s, C-
O), 1356 (s, SO2as); 1H NMR (500 MHz; CDCl3) δH 2.53 (6H, s, 2 × N-CH3), 7.32-
7.43 (4H, m, H-Ar), 7.43-7.48 (2H, m, H-Ar), 7.50-7.54 (2H, m, H-Ar), 7.56-7.60 
(1H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 38.2 (2 × N-CH3), 122.9 (C-Ar), 
126.9 (C-Ar), 127.8 (C-Ar), 128.4 (2 × C-Ar), 128.9 (C-Ar), 129.9 (2 × C-Ar), 
131.3 (C-Ar), 135.1 (C-Ar), 137.3 (C-Ar), 147.4 (C-Ar); LRMS (ES+) m/z 278.2 
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[M+H]+; HRMS calcd for C14H16NO3S [M+H]+ 278.0845, found 278.0849; HPLC 
99.7% in 0.1% formic acid (aq.)/MeCN (Rt 12.6 min); 99.7% in 0.1% ammonia 
(aq.)/MeCN (Rt 12.5 min). 
NMR data match those previously reported for this compound.70 
Phenyl dimethylsulfamate (58) 
 
The sulfamate 58 was synthesized and purified as described in general 
procedure A, using phenol (152 mg, 0.161 mmol), cesium carbonate (578 mg, 
1.77 mmol), N,N-dimethylsulfamoyl chloride (154 mg, 0.12 mL, 1.07 mmol) and 
acetonitrile (5.0 and 2.0 mL). The title compound (88 mg, 27%) was obtained as 
a brown oil. Rf 0.88 (10% MeOH/DCM); λmax (EtOH)/nm 262; νmax/cm-1 (neat) 
1145 (s, C-O), 1169 and 1193 (s, SO2sy), 1366 (s, SO2as); 1H NMR (500 MHz; 
CDCl3) δH 2.97 (6H, s, 2 × N-CH3), 7.24-7.31 (3H, m, H-4, H-2 and H-6), 7.36-7.41 
(2H, m, H-3 and H-5); 13C NMR (125 MHz; CDCl3) δC 38.9 (2 × NCH3), 121.9 (C-2 
and C-6), 126.9 (C-4), 129.9 (C-3 and C-5), 150.4 (C-1); LRMS (ES+) m/z 202.2 
[M+H]+; HRMS calcd for C8H11NO3S [M+H]+ 202.0532, found 202.0539; HPLC 
98.7% in 0.1% formic acid (aq.)/MeCN (Rt 10.5 min); 99.6% in 0.1% ammonia 
(aq.)/MeCN (Rt 10.5 min). 
NMR data match those previously reported for this compound.70 
3-Bromophenyl dimethylsulfamate (59) 
 
General procedure A was used to synthesize and purify compound 59, using 
3-bromophenol (2.00 g, 11.6 mol), cesium carbonate (4.14 g, 12.7 mmol) in 
acetonitrile (35 mL) and N,N-dimethylsulfamoyl chloride (1.11 g, 0.83 mL, 7.71 
mmol) in acetonitrile (9 mL). The title compound was obtained as a colorless oil 
(1.58 g, 73%). Rf 0.16 (50% MeCN (0.1% formic acid)/H2O); λmax (EtOH)/nm 
267; νmax/cm-1 (neat) 1062 (m, arom. C-Br), 1154 (s, C-O), 1165 and 1193 (s, 
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SO2sy), 1368 (s, SO2as); 1H NMR (500 MHz; CDCl3) δH 2.99 (6H, s, 2 × N-CH3), 
7.21-7.30 (2H, m, H-Ar), 7.39-7.44 (1H, m, H-Ar), 7.44-7.48 (1H, m, H-Ar); 13C 
NMR (125 MHz; CDCl3) δC 38.9 (2 × NCH3), 120.62 (C-Ar), 120.7 (C-3), 125.3 (C-
Ar), 130.0 (C-Ar), 130.9 (C-Ar), 150.8 (C-1); LRMS (ES+) m/z 280.1 and 282.1 
[M+H]+; HRMS calcd for C8H1479BrN2O3S [M+NH4]+ 296.9903, found 296.9908; 
HPLC 99.3% in 0.1% formic acid (aq.)/MeCN (Rt 11.8 min); 99.2% in 0.1% 
ammonia (aq.)/MeCN (Rt 11.8 min). 
3'-Cyano-[1,1'-biphenyl]-3-yl dimethylsulfamate (81) 
 
The title compound 81 was synthesized according to general procedure B 
using dimethyl 3-bromophenylsulfamate (120 mg, 0.428 mmol), 3-
cyanophenylboronic acid (63 mg, 0.428 mmol), sodium carbonate (2 M aq., 0.42 
mL), tetrakis(triphenylphosphine)palladium (25 mg, 21.4 µmol) and DME (1.7 
mL). Purification by MPLC (gradient elution, 0-40% EtOAc/petrol) afforded the 
desired product as a colorless oil which solidified upon storage at RT (49 mg, 
38%). Rf 0.11 (50% MeCN (0.1% formic acid)/H2O); m.p. 73.8-75.0 °C; λmax 
(EtOH)/nm 250, 350; νmax/cm-1 (neat) 1150 (s, SO2sy), 1176 (m, C-O), 1363 (s, 
SO2as), 2238 (m, CN); 1H NMR (500 MHz; CDCl3) δH 3.03 (6H, s, 2 × N-CH3), 
7.31-7.36 (1H, m, H-Ar), 7.44-7.52 (3H, m, H-Ar), 7.53-7.59 (1H, m, H-Ar), 7.63-
7.68 (1H, m, H-Ar), 7.78-7.83 (1H, m, H-Ar), 7.84-7.87 (1H, m, H-Ar); 13C NMR 
(125 MHz; CDCl3) δC 39.0 (2 × NCH3), 113.4 (-CN), 118.7 (C-3’), 120.6 (C-Ar), 
121.7 (C-Ar), 125.5 (C-Ar), 129.9 (C-Ar), 130.6 (C-Ar), 130.9 (C-Ar), 131.5, (C-
Ar) 131.7 (C-Ar), 141.0 and 141.2 (C-1 and C-1’), 151.0 (C-3); LRMS (ES+) m/z 
344.2 [M+MeCN+H]+; HRMS calcd for C15H18N3O3S [M+NH4]+ 320.1063, found 
320.1068; HPLC 97.6% in 0.1% formic acid (aq.)/MeCN (Rt 12.1 min); 96.6% in 
0.1% ammonia (aq.)/MeCN (Rt 12.1 min). 
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4'-Methoxy-[1,1'-biphenyl]-3-yl dimethylsulfamate (82) 
 
The title compound 82 was synthesized according to general procedure B 
using dimethyl 3-bromophenylsulfamate (120 mg, 0.428 mmol), 4-
methoxyphenylboronic acid (65 mg, 0.428 mmol), sodium carbonate (2 M aq., 
0.42 mL), tetrakis(triphenylphosphine)palladium (25 mg, 21.4 µmol) and DME 
(1.7 mL). Purification by MPLC (gradient elution, 0-30% EtOAc/petrol) yielded 
the desired product as a yellow oil which solidified upon storage at RT (83 mg, 
63%). Rf 0.11 (50% MeCN (0.1% formic acid)/H2O); m.p. 75.3-76.0 °C; λmax 
(EtOH)/nm 264, 350; νmax/cm-1 (neat) 1141 (s, SO2sy), 1179 (s, C-O), 1244 (m, C-
O-Cas), 1359 (s, SO2as), 2845 (w, CH3s), 2928 (w, CH3as); 1H NMR (500 MHz; 
CDCl3) δH 3.00 (6H, s, 2 × N-CH3), 3.86 (3H, s, -OCH3), 6.96-7.01 (2H, m, H’-2 and 
H’-6), 7.20-7.24 (1H, m, H-Ar), 7.39-7.44 (1H, m, H-Ar), 7.45-7.49 (2H, m, H-Ar), 
7.50-7.55 (2H, m, H’-3 and H’-5); 13C NMR (125 MHz; CDCl3) δC 38.9 (2 × N-CH3), 
55.5 (-OCH3), 114.5 (C’-2 and C’-6), 119.8 (C-Ar), 120.1 (C-Ar), 125.1 (C-Ar), 
128.4 (C’-3 and C’-5), 130.1 (C-Ar), 132.4 (C-Ar), 143.0 (C-Ar), 150.8 (C-Ar), 
159.8 (C-Ar); LRMS (ES+) m/z 308.2 [M+H]+; HRMS calcd for C15H21N2O4S 
[M+NH4]+ 325.1217, found 325.1222; HPLC 99.5% in 0.1% formic acid 
(aq.)/MeCN (Rt 12.6 min); 98.6% in 0.1% ammonia (aq.)/MeCN (Rt 12.5 min). 
4'-(Hydroxymethyl)-[1,1'-biphenyl]-3-yl dimethylsulfamate (83) 
 
General procedure B was followed using dimethyl 3-bromophenylsulfamate  
(120 mg, 0.428 mmol), 4-hydroxymethylphenylboronic acid (63 mg, 0.428 
mmol), sodium carbonate (2 M aq., 0.42 mL), tetrakis(triphenyl-
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phosphine)palladium (25 mg, 21.4 µmol) and DME (1.7 mL). After purification 
by MPLC (gradient elution, 0-100% EtOAc/petrol), the desired product was 
obtained as a colorless oil which solidified upon storage at RT (49 mg, 37%). Rf 
0.54 (50% EtOAc/petrol); m.p. 50.5-51.7 °C; λmax (EtOH)/nm 253, 350; νmax/cm-
1 (neat) 1141 (s, SO2sy), 1178 (s, C-O), 1356 (s, SO2as), 2868 (w, CH2s), 2932 (w, 
CH2as), 3357 (w, O-H); 1H NMR (500 MHz; CDCl3) δH 1.68 (1H, br, OH), 3.01 (6H, 
s, 2 × N-CH3), 1.71 (1H, t, J = 6.0 Hz, OH), 4.76 (2H, d, J = 6.0 Hz, CH2), 7.25-7.30 
(1H, m, H-Ar), 7.43-7.48 (3H, m, H-Ar), 7.49-7.53 (2H, m, H-Ar), 7.57-7.60 (2H, 
m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 39.0 (2 × NCH3), 65.1 (CH2), 120.5 (C-
Ar), 120.5 (C-Ar), 125.5 (C-Ar), 127.5 (2 × C-Ar), 127.6 (2 × C-Ar), 130.2 (C-Ar), 
139.3 (C-Ar), 140.8 (C-Ar), 143.0 (C-Ar), 150.8 (C-Ar); LRMS (ES+) m/z 290.2 
[M–H2O+H]+; HRMS calcd for C15H21N2O4S [M+NH4]+ 325.1217, found 325.1222; 
HPLC 98.9% in 0.1% formic acid (aq.)/MeCN (Rt 10.8 min); 98.6% in 0.1% 
ammonia (aq.)/MeCN (Rt 10.7 min). 
3'-Amino-[1,1'-biphenyl]-3-yl dimethylsulfamate (70) 
 
General procedure B was followed using dimethyl 3-bromophenylsulfamate 
(60 mg, 0.214 mmol), 3-aminophenylboronic acid (30 mg, 0.214 mmol), sodium 
carbonate (2 M aq., 0.5 mL), tetrakis(triphenylphosphine)palladium (13 mg, 
10.7 µmol) and 1,2-dimethoxyethane (0.5 mL). After purification by MPLC 
(gradient elution, 0-10% MeOH/DCM), the title compound was obtained as a 
brown oil (22 mg, 35%). Rf 0.67 (10% MeOH/DCM); λmax (EtOH)/nm 235; 
νmax/cm-1 (neat) 1139 (s, SO2sy), 1174 (s, C-O), 1356 (s, SO2as), 3372 (m, N-H), 
3477 (m, N-H); 1H NMR (500 MHz; CDCl3) δH 2.92 (6H, s, 2 × N-CH3), 3.63 (2H, 
br, -NH2), 7.31-7.36 (1H, m, H-Ar), 7.49-7.55 (1H, m, H-Ar), 7.57-7.63 (1H, m, H-
Ar), 7.83-7.91 (2H, m, H-Ar), 8.03-8.08 (1H, m, H-Ar), 8.09-8.13 (2H, m, H-Ar); 
13C NMR (125 MHz; CDCl3) δC 38.9 (2 × NCH3), 114.0 (C-2’), 114.8 (C-4’), 117.7 
(C-6’), 120.4 (C-Ar), 120.5 (C-Ar), 125.5 (C-Ar), 129.9 (C-Ar), 130.0 (C-5’), 141.1 
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and 143.6 (C-1 and C-1’), 147.0 (C-3’), 150.7 (C-3); LRMS (ES+) m/z 293.1 
[M+H]+; HRMS calcd for C14H17N2O3S [M+H]+ 293.0954, found 293.0957; HPLC 
99.4% in 0.1% formic acid (aq.)/MeCN (Rt 10.4 min); 97.2% in 0.1% ammonia 
(aq.)/MeCN (Rt 11.7 min). 
2'-Amino-[1,1'-biphenyl]-3-yl dimethylsulfamate (69) 
 
The title compound was synthesized according to general procedure B using 
dimethyl 3-bromophenylsulfamate (500 mg, 1.78 mmol), 2-
aminophenylboronic acid pinacol ester (391 mg, 1.78 mmol), sodium carbonate 
(2 M aq., 1.8 mL), tetrakis(triphenylphosphine)palladium (103 mg, 89.2 µmol) 
and DME (4.2 mL). Purification by MPLC (gradient elution, 0-10% MeOH/DCM) 
yielded the desired product as a brown oil (518 mg, >99%). Rf 0.78 (10% 
MeOH/DCM); λmax (EtOH)/nm 226, 253sh; νmax/cm-1 (neat) 1139 (s, SO2sy), 1180 
(s, C-O), 1364 (s, SO2as), 3383 (m, N-H), 3468 (m, N-H); 1H NMR (500 MHz; 
CDCl3) δH 3.00 (6H, s, 2 × N-CH3), 3.70 (2H, br, NH2), 6.75 (1H, dd, J = 0.9 and 8.0 
Hz, H-3’), 6.82 (1H, td, J = 0.9 and 7.6 Hz, H-5’), 7.12 (1H, dd, J = 1.6, 7.6 Hz, H-6’), 
7.15-7.19 (1H, m, H-4’), 7.28 (1H, ddd, J = 1.3, 2.4, 8.3 Hz, H-6), 7.37-7.41 (2H, m, 
H-4 and H-2), 7.44-7.49 (1H, m, H-5); 13C NMR (125 MHz; CDCl3) δC 38.9 (2 × N-
CH3), 116.0 (C-3’), 118.9 (C-5’), 120.5 (C-6), 122.5 (C-2), 126.2 (C-2’), 127.6 (C-
4), 129.1 (C-4’), 130.3 (C-5), 130.5 (C-6’), 141.6 and 143.5 (C-1 and C-1’), 150.6 
(C-3); LRMS (ES+) m/z 293.1 [M+H]+; HRMS calcd for C14H17N2O3S [M+H]+ 
293.0954, found 293.0957; HPLC 99.5% in 0.1% formic acid (aq.)/MeCN (Rt 
11.9 min); 99.3% in 0.1% ammonia (aq.)/MeCN (Rt 12.0 min). 
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Sodium (3'-((N,N-dimethylsulfamoyl)oxy)-[1,1'-biphenyl]-4-yl)methyl 
sulfate (84) 
 
Compound 84 was synthesized according to general procedure D (method 1) 
using the benzyl alcohol 83 (125 mg, 0.407 mmol), sulfur trioxide pyridine 
complex (194 mg, 1.22 mmol), NaOH (2 M aq., 4.1 mL, 8.2 mmol) and N,N-
dimethylformamide (8.0 mL). After purification by MPLC (gradient elution, 0-
10% MeOH/DCM), the desired sulfate was obtained as yellow crystals (55.3 mg, 
33%). Rf 0.40 (10% MeOH/DCM); not clear m.p. (dec. 163-187) λmax (EtOH)/nm 
252; νmax/cm-1 (neat) 1143 (s, SO2sy), 1178 (s, C-O), 1212 (s, sulfate SO2as), 1362 
(s, sulfamate SO2as); 1H NMR (500 MHz; CD3OD) δH 2.98 (6H, s, 2 × N-CH3), 5.07 
(2H, s, CH2), 7.27-7.31 (1H, m, H-Ar), 7.48-7.55 (4H, m, H-Ar), 7.58-7.65 (3H, m, 
H-Ar); 13C NMR (125 MHz; CD3OD) δC 39.1 (2 × NCH3), 70.3 (CH2), 121.3 (C-Ar), 
121.7 (C-Ar), 126.4 (C-Ar), 128.0 (2 × C-Ar), 129.7 (2 × C-Ar), 131.3 (C-Ar), 
137.9 (C-Ar), 140.8 (C-Ar), 144.2 (C-Ar), 150.4 (C-3’); LRMS (ES–) m/z 386.1 [M-
Na]–; HRMS calcd for C15H16NO7S2 [M-Na]– 386.0374, found 386.0367; HPLC 
99.5% in 0.1% formic acid (aq.)/MeCN (Rt 8.6 min); 99.7% in 0.1% ammonia 
(aq.)/MeCN (Rt 6.5 min). 
Sodium {3'-[(N,N-dimethylsulfamoyl)oxy]-[1,1'-biphenyl]-2-yl}sulfamate 
(72) 
 
General procedure D (method 1) was followed to obtain the sulfate 72 using 
the aniline 69 (125 mg, 0.428 mmol), sulfur trioxide pyridine complex (204 mg, 
1.28 mmol), NaOH (2 M aq., 4.3 mL, 8.6 mmol) and N,N-dimethylformamide (8.6 
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mL). After purification by MPLC (gradient elution, 0-10% MeOH/DCM), the 
desired sulfate was obtained as a yellow solid (123 mg, 73%). Rf 0.17 (10% 
MeOH/DCM); m.p. 90-123 °C (dec.); λmax (EtOH)/nm 251sh, 293; νmax/cm-1 
(neat) 1142 (s, SO2sy), 1180 (s, C-O), 1363 (s, SO2as), 3524 (m, N-H); 1H NMR 
(500 MHz; CD3OD) δH 2.94 (6H, s, 2 × N-CH3), 7.02 (1H, td, J = 1.2, 7.6 Hz, H-5’), 
7.16 (1H, dd, J = 1.8, 7.6 Hz, H-6’), 7.28-7.32 (1H, m, H-4’), 7.33-7.38 (2H, m, H-2 
and H-4), 7.40-7.45 (1H, m, H-5), 7.55 (1H, dt, J = 0.5, 7.8 Hz, H-6), 7.74 (1H, dd, J 
= 1.2, 8.3 Hz, H-2’); 13C NMR (125 MHz; CD3OD) δC 39.1 (2 × N-CH3), 120.0 (C-3), 
122.2 (C-4’), 122.8 (C-5), 123.9 (C-2’), 129.0 (C-5’), 129.7 (C-4), 130.9 (C-2), 
131.0 (C-6), 131.5 (C-6’), 139.5 and 142.3 (C-1 and C-1’), 152.2 (C-3’); LRMS 
(ES–) m/z 371.1 [M-Na]–; HRMS calcd for C14H15N2O6S2 [M-Na]– 371.0377, found 
371.0372 (Rt 8.0 min); HPLC 96.8% in 0.1% formic acid (aq.)/MeCN; 96.2% in 
0.1% ammonia (aq.)/MeCN (Rt 6.5 min). 
Sodium [1,1’-biphenyl]-2-ylsulfamate (87) 
 
General procedure D (method 1) was followed to synthesize compound 87 
using 2-aminobiphenyl (108 mg, 0.6376 mmol), sulfur trioxide pyridine 
complex (307 mg, 1.93 mmol), NaOH (2 M aq., 6.4 mL, 12.8 mmol) and N,N-
dimethylformamide (12.0 mL). The crude product was purified by MPLC 
(gradient elution, 0-10% MeOH/DCM) to afford the product as a light brown 
solid (114 mg, 66%). Rf 0.29 (10% MeOH/DCM); m.p. 54-82 ° C (dec.); λmax 
(EtOH)/nm 224, 289; νmax/cm-1 (neat) 1194 (s, SO2sy), 1481 (s, SO2as), 3358 (m, 
N-H); 1H NMR (500 MHz; CD3OD) δH 7.00 (1H, td, J = 1.2, 7.5 Hz, H-5), 7.12-7.16 
(1H, m, H-6), 7.27 (ddd, J = 1.6, 7.5 and 8.3 Hz, H-4), 7.36-7.41 (1H, m, H-4’), 
7.41-7.45 (1H, m, H-Ar), 7.45-7.50 (1H, m, H-Ar), 7.71 (ddd, J = 0.3, 1.2 and 8.3 
Hz, H-3); 13C NMR (125 MHz; CD3OD) δC 119.3 (C-3), 122.6 (C-5), 128.6 (C-4’), 
129.1 (C-4), 130.0 (2  C-Ar), 130.3 (2  C-Ar), 130.9 (C-6), 132.1 (C-2), 139.3 
and 140.0 (C-1 and C1’); LRMS (ES–) m/z 247.8 [M-Na]–; HRMS calcd for 
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C12H12NO3S [M-Na]– 248.0387, found 248.0382; HPLC 99.5% in 0.1% formic 
acid (aq.)/MeCN (Rt 7.2 min); 99.4% in 0.1% ammonia (aq.)/MeCN (Rt 5.3 min). 
2'-Acetamido-[1,1'-biphenyl]-3-yl dimethylsulfamate (75)80 
 
The title compound was obtained following general procedure C using the 
aniline 69 (125 mg, 0.428 mmol), dichloromethane (1.2 mL), acetic anhydride 
(52 mg, 0.05 mL, 0.513 mmol) and NaHCO3 (sat. aq., 10 mL). Purification by 
MPLC afforded the title compound as a yellow oil (144 mg, >99%). Rf 0.20 (50% 
EtOAc/petrol); λmax (EtOH)/nm 250sh; νmax/cm-1 (neat) 1143 (s, SO2sy), 1182 (s, 
C-O), 1366 (s, SO2as), 1663 (m, C=O); 1H NMR (500 MHz; CDCl3) δH 2.07 (3H, s, 
CH3), 3.03 (6H, s, 2 × N-CH3), 7.15 (1H, br, NH), 7.17-7.22 (1H, m, H-Ar), 7.24-
7.26 (1H, m, H-Ar), 7.29-7.33 (2H, m, H-Ar), 7.33-7.36 (1H, m, H-Ar), 7.36-7.42 
(1H, m, H-Ar), 7.48-7.55 (1H, m, H-Ar), 8.20-8.26 (1H, m, H-Ar); 13C NMR (125 
MHz; CDCl3) δC 24.6 (CH3), 38.9 (2 × N-CH3), 121.4 (C-Ar), 122.5 (C-Ar), 123.0 
(C-Ar), 124.7 (C-Ar), 127.9 (C-Ar), 129.1 (2  C-Ar), 130.1 (C-Ar), 130.7 (C-Ar), 
134.8 and 140.2 (C-1 and C-1’), 150.4 (C-3), 168.7 (C=O); LRMS (ES+) m/z 335.2 
[M+H]+; HRMS calcd for C16H19N2O4S [M+H]+ 335.1060, found 335.1064; HPLC 
99.8% in 0.1% formic acid (aq.)/MeCN (Rt 10.5 min); 99.8% in 0.1% ammonia 
(aq.)/MeCN (Rt 10.5 min). 
4'-Amino-[1,1'-biphenyl]-3-yl dimethylsulfamate (71) 
 
General procedure B was followed to synthesize compound 71 using dimethyl 
3-bromophenylsulfamate 59 (400 mg, 1.43 mmol), 4-aminophenylboronic acid 
pinacol ester (313 mg, 1.43 mmol), sodium carbonate (2 M aq., 1.4 mL), 
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tetrakis(triphenylphosphine)palladium (82 mg, 71 µmol), and DME (3.3 mL). 
Purification by MPLC (gradient elution, 0-10% MeOH/DCM) yielded the desired 
product as a red solid (339 mg, 81%). Rf 0.79 (10% MeOH/DCM); m.p. 82.4-
83.1 °C; λmax (EtOH)/nm 290; νmax/cm-1 (neat) 1134 (s, SO2sy), 1177 (s, C-O), 
1361 (s, SO2as), 1476, 1627 (m, N-H bending), 3382 (m, N-H), 3480 (m, N-H); 1H 
NMR (500 MHz; CDCl3) δH 2.99 (6H, s, 2 × N-CH3), 3.77 (2H, br, NH2), 6.73-6.77 
(2H, m, H-2’ and H-6’), 7.16-7.20 (1H, m, H-Ar), 7.36-7.42 (3H, m, H-Ar, H-3’ and 
H-5’), 7.43-7.46 (2H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 39.0 (2 × N-CH3), 
115.5 (C-2’ and C-6’), 119.4 (C-Ar), 119.6 (C-Ar), 124.7 (C-Ar), 128.2 (C-3’ and C-
5’), 130.0 (C-Ar), 146.6 (C-Ar), 150.8 (C-3). Two carbons not detected; LRMS 
(ES+) m/z 293.3 [M+H]+; HRMS calcd for C14H17N2O3S [M+H]+ 293.0954, found 
293.0957; HPLC 98.9% in 0.1% formic acid (aq.)/MeCN (Rt 10.5 min); 97.2% in 
0.1% ammonia (aq.)/MeCN (Rt 11.6 min). 
3'-Acetamido-[1,1'-biphenyl]-3-yl dimethylsulfamate (76) 
 
Compound 76 was synthesized according to general procedure C using the 
aniline 70 (100 mg, 0.342 mmol) and acetic anhydride (42 mg, 0.04 mL, 0.410 
mmol) in DCM (0.92 mL, 2.7 mL/mmol). Purification by MPLC afforded the 
desired product as a colorless oil (79 mg, 69%). Rf 0.43 (50% EtOAc/petrol); 
λmax (EtOH)/nm 242; νmax/cm-1 (neat) 1141 (s, SO2sy), 1178 (s, C-O), 1365 (s, 
SO2as), 1548 (s, N-H bending + C-N stretching or amide II band), 1667 (m, C=O 
or amide I band), 3300 (w, N-H); 1H NMR (500 MHz; CDCl3) δH 2.21 (3H, s, CH3), 
3.01 (6H, s, 2 × N-CH3), 7.26-7.34 (3H, m, 2  H-Ar, NH), 7.36-7.41 (1H, m, H-Ar), 
7.42-7.46 (1H, m, H-Ar), 7.47-7.51 (2H, m, H-Ar), 7.51-7.55 (1H, m, H-Ar), 7.71-
7.74 (1H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 24.8 (CH3), 39.0 (2 × N-CH3), 
118.7 (C-Ar), 119.4 (C-Ar), 120.5 (C-Ar), 120.8 (C-Ar), 123.2 (C-Ar), 125.7 (C-
Ar), 129.8 (C-Ar), 130.3 (C-Ar), 138.6 (C-Ar), 140.8 (C-Ar), 142.9 (C-Ar), 150.8 
(C-3), 168.5 (C=O); LRMS (ES+) m/z 335.2 [M+H]+; HRMS calcd for C16H19N2O4S 
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[M+H]+ 335.1060, found 335.1063; HPLC >99.9% in 0.1% formic acid 
(aq.)/MeCN (Rt 11.3 min); >99.9% in 0.1% ammonia (aq.)/MeCN (Rt 11.2 min). 
4'-Acetamido-[1,1'-biphenyl]-3-yl dimethylsulfamate (77) 
 
Compound 77 was synthesized according to general procedure C using the 
aniline 71 (100 mg, 0.342 mmol) and acetic anhydride (42 mg, 0.04 mL, 0.410 
mmol) in DCM (0.92 mL, 2.7 mL/mmol). Purification by MPLC afforded the 
desired product as a white solid (95 mg, 83%). Rf 0.41 (50% EtOAc/petrol); 
m.p. 119.2-120.2 °C; λmax (EtOH)/nm 275; νmax/cm-1 (neat) 1143 (s, SO2sy), 1181 
(s, C-O), 1364 (s, SO2as), 1528 (s, N-H bending + C-N stretching or amide II 
band), 1665 (m, C=O or amide I band), 3314 (w, N-H); 1H NMR (500 MHz; 
CDCl3) δH 2.20 (3H, s, CH3), 3.01 (6H, s, 2 × N-CH3), 7.23-7.26 (1H, m, H-Ar), 
7.27-7.30 (1H, br, NH), 7.41-7.50 (3H, m, H-Ar), 7.51-7.56 (2H, m, H-Ar), 7.56-
7.61 (2H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 24.8 (CH3), 39.0 (2 × N-CH3), 
120.2 (C-Ar), 120.3 (2 C-Ar), 125.2 (C-Ar), 127.8 (2 C-Ar), 130.2 (C-Ar), 
135.7 (C-Ar), 137.9 (C-Ar), 142.7 (C-Ar), 150.8 (C-3), 168.4 (C=O); LRMS (ES+) 
m/z 335.3 [M+H]+; HRMS calcd for C16H19N2O4S [M+H]+ 335.1060, found 
335.1063; HPLC >99.9% in 0.1% formic acid (aq.)/MeCN (Rt 11.2 min); >99.9% 
in 0.1% ammonia (aq.)/MeCN (Rt 11.2 min). 
Sodium {3'-[(N,N-dimethylsulfamoyl)oxy]-[1,1'-biphenyl]-3-yl}sulfamate 
(73) 
 
Compound 73 was synthesized according to general procedure D (method 1) 
using the aniline 70 (100 mg, 0.342 mmol), sulfur trioxide pyridine complex 
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(163 mg, 1.03 mmol), DMF (6.8 mL, 18 mL/mmol), and NaOH (2 M aq., 3.4 mL, 
6.84 mmol). Purification by MPLC (gradient elution, 0-20% MeOH/DCM) 
afforded the desired product as a yellow solid (103 mg, 76%). Rf 0.01 (10% 
MeOH/DCM); m.p. 92-182 °C (dec.); λmax (EtOH)/nm 236; νmax/cm-1 (neat) 1142 
(s, SO2sy), 1365 (m, SO2as), 1604 (m, N-H bending), 3247 (N-H stretching); 1H 
NMR (500 MHz; CD3OD) δH 2.97 (6H, s, 2 × N-CH3), 7.12-7.16 (1H, m, H-Ar), 7.20 
(1H, ddd, J = 0.9, 2.2, 8.1 Hz, H-Ar), 7.26 (1H, ddd, J = 0.8, 2.4, 8.1, H-Ar), 7.30 
(1H, app. t, J = 7.6 Hz, H-Ar), 7.47 (1H, app. t, J = 7.9 Hz, H-Ar), 7.49-7.52 (2H, m, 
H-Ar), 7.55-7.59 (1H, m, H-Ar); 13C NMR (125 MHz; CD3OD) δC 39.1 (2 × N-CH3), 
117.4 (C-Ar), 118.5 (C-Ar), 120.6 (C-Ar), 121.4 (C-Ar), 121.6 (C-Ar), 126.6 (C-
Ar), 130.3 (C-Ar), 131.1 (C-Ar), 141.5 and 143.7 (C-1 and C-1’), 144.8 (C-3), 
152.1 (C-3’); LRMS (ES–) m/z 371.1 [M-Na]–; HRMS calcd for C14H15N2O6S2 [M-
Na]– 371.0377, found 371.0373; HPLC 95.6% in 0.1% formic acid (aq.)/MeCN 
(Rt 8.6 min); 95.5% in 0.1% ammonia (aq.)/MeCN (Rt 5.4 min). 
Sodium {3'-[(N,N-dimethylsulfamoyl)oxy]-[1,1'-biphenyl]-4-yl}sulfamate 
(74) 
 
General procedure D (method 1) was used for the synthesis of compound 74 
using the aniline 71 (100 mg, 0.342 mmol), sulfur trioxide pyridine complex 
(163 mg, 1.03 mmol), DMF (6.8 mL, 18 mL/mmol) and aq. NaOH (2 M, 3.4 mL, 
6.84 mmol). Purification by MPLC (gradient elution, 0-20% MeOH/DCM) 
afforded the desired product as a brown amorphous solid (79 mg, 58%). Rf 0.10 
(10%/MeOH/DCM); m.p. 66-105 °C (dec.); λmax (EtOH)/nm 284; νmax/cm-1 
(neat) 1141 (s, SO2sy), 1180 (s, C-O), 1365 (m, SO2as), 1608 (m, N-H bending), 
3226 (N-H stretching); 1H NMR (500 MHz; CD3OD) δH 2.95 (3H, s, CH3), 7.17-
7.22 (1H, m, C-2’), 7.26-7.30 (2H, m, H-2 and H-6), 7.40-7.47 (2H, m, H-Ar), 7.47- 
7.53 (3H, m, H-3 and H-5); 13C NMR (125 MHz; CD3OD) δC 39.0 (2 × N-CH3), 
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118.9 (C-2 and C-6), 120.5 (C-Ar), 120.7 (C-2’), 125.7 (C-Ar), 128.3 (C-3 and C-
5), 131.1 (C-Ar), 133.2 (C-Ar), 143.2 (C-Ar), 144.3 (C-Ar), 152.2 (C-3’); LRMS 
(ES–) m/z 371.1 [M-Na]–; HRMS calcd for C14H15N2O6S2 [M-Na]– 371.0377, found 
371.0370; HPLC 96.1% in 0.1% formic acid (aq.)/MeCN (Rt 8.5 min); 95.6% in 
0.1% ammonia (aq.)/MeCN (Rt 5.4 min). 
3'-[(N,N-Dimethylsulfamoyl)oxy]-[1,1'-biphenyl]-2-carboxylic acid (63) 
 
At RT, a solution of lithium hydroxide monohydrate (13.8 mg, 0.329 mmol) in 
water (1.0 mL, 3.3 mmol/mL) was added to a solution of the methyl ester 66 
(70.4 mg 0.210 mmol) in THF (1.5 mL, 7 mL/mmol), The reaction mixture was 
heated at 50 °C for 3 days. Upon completion of the reaction, the mixture was 
acidified to pH 5-6 by addition of aq. HCl (1 M), and extracted with EtOAc (3  
15 mL). The combined organic phases were washed with brine, dried (MgSO4), 
filtered, and the solvent was removed in vacuo. The crude product was purified 
by MPLC (gradient elution, 0-10% MeOH/DCM) to afford the title compound as 
a pale yellow solid (68 mg, quant.). Rf 0.45 (10% MeOH/DCM); m.p. 151-162 °C 
(dec.); λmax (EtOH)/nm 340; νmax/cm-1 (neat) 1140 (s, SO2sy), 1179 (s, C-O), 1374 
(m, SO2as), 1416 (m), 1681 (s, C=O), 1696 (s, C=O); 1H NMR (500 MHz; CDCl3) δH 
2.93 (6H, s, 2 × N-CH3), 7.22-7.25 (1H, m, H-6), 7.25-7.27 (1H, m, H-2), 7.28 (1H, 
ddd, J = 1.0, 2.4, 8.0 Hz, H-4), 7.33-7.36 (1H, m, H-6’), 7.39 (1H, app. t, J = 8.0 Hz, 
H-5), 7.46 (1H, td, J = 1.2, 7.6 Hz, H-4’), 7.57 (1H, td, J = 1.4, 7.6 Hz, H-5’), 7.96-
8.00 (1H, m, H-3); 13C NMR (125 MHz; CDCl3) δC 38.8 (2 × N-CH3), 120.8 (C-4’), 
122.3 (C-2’), 127.1 (C-6’), 128.0 (C-4), 129.1 (C-2), 129.6 (C-5’), 131.1 (C-3), 
131.3 (C-6), 132.4 (C-5), 142.2 (C-1), 143.3 (C-1’), 150.0 (C-3’), 171.5 (-CO2H); 
LRMS (ES–) m/z 320.2 [M-H]–; HRMS calcd for C15H14NO5S [M-H]– 320.0598, 
found 320.0590; HPLC 99.7% in 0.1% formic acid (aq.)/MeCN (Rt 11.0 min); 
N/A in 0.1% ammonia (aq.)/MeCN. 
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3'-[(N,N-Dimethylsulfamoyl)oxy]-[1,1'-biphenyl]-3-carboxylic acid (64) 
 
Compound 64 was synthesized following general procedure E using sulfamate 
59 (152 mg, 0.54 mmol), 3-carboxyphenylboronic acid (90 mg, 0.54 mmol), aq. 
Na2CO3 (2 M, 0.54 mL, 1.1 mmol), Pd(dppf)Cl2 · DCM (22 mg, 0.024 mmol), and 
DME (1.3 mL). The reaction mixture was diluted with ethyl acetate and water, 
and filtered through Celite. The organic solvent was removed in vacuo, and the 
aqueous residue was extracted with EtOAc (50 mL). The aqueous layer was 
acidified by addition of a solution of 10% aqueous HCl, and extracted with ethyl 
acetate (3  50 mL). The combined organic layers were dried (MgSO4), filtered, 
and evaporated. Purification by MPLC (gradient elution, 0-10% MeOH/DCM) 
afforded the product as a pale pink solid (113 mg, 66%). Rf 0.41 (10% 
MeOH/DCM); m.p. 130-147 °C (dec.); λmax (EtOH)/nm 250 nm; νmax/cm-1 (neat) 
1144 (s, SO2sy), 1182 (s, C-O), 1364 (m, SO2as), 1448, 1678 (s, C=O); 1H NMR 
(500 MHz; CDCl3) δH 3.03 (6H, s, 2 × N-CH3), 7.33 (1H, ddd, J = 1.1, 2.4, 8.0 Hz, H-
Ar), 7.50 (1H, app. t, J = 8.0 Hz, H-5’), 7.52-7.55 (2H, m, H-Ar), 7.58 (1H, app. t, J 
= 7.8 Hz, H-5), 7.84 (1H, ddd, J = 1.1, 1.7, 7.8 Hz, H-6), 8.10-8.16 (1H, m, H-4), 
8.31-8.35 (1H, m, H-2); 13C NMR (125 MHz; CDCl3) δC 39.0 (2 × N-CH3), 120.6 (C-
Ar), 121.1 (C-Ar), 125.6 (C-Ar), 129.0 (C-2), 129.3 (C-5), 129.7 (C-4), 130.4 (C-
5’), 132.5 (C-6), 140.4 and 142.1 (C-1 and C-1’), 150.9 (C-3’). Two carbons not 
detected; LRMS (ES–) m/z 320.2 [M–H]-; HRMS calcd for C5H14NO5S [M-H]- 
320.0598, found 320.0594; HPLC 98.5% in 0.1% formic acid (aq.)/MeCN (Rt 
11.4 min); N/A in 0.1% ammonia (aq.)/MeCN. 
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3'-[(N,N-Dimethylsulfamoyl)oxy]-[1,1'-biphenyl]-4-carboxylic acid (65) 
 
Compound 65 was synthesized following general procedure E using the 
sulfamate 59 (150 mg, 0.54 mmol), 4-carboxyphenylboronic acid (90 mg, 0.54 
mmol), aq. Na2CO3 (2 M, 0.54 mL, 1.1 mmol), Pd(dppf)Cl2 · DCM (22 mg, 0.024 
mmol), and DME (1.3 mL). The reaction mixture was diluted with ethyl acetate 
and water, and filtered through Celite. The organic solvent was removed in 
vacuo, and the aqueous residue was extracted with EtOAc (50 mL). The aqueous 
layer was acidified by addition of HCl aqueous 10%, and extracted with ethyl 
acetate (3  50 mL). The combined organic layers were dried (MgSO4), filtered, 
and evaporated. Purification by MPLC (gradient elution, 0-10% MeOH/DCM) 
afforded the product as a brown solid (118 mg, 68%). Rf 0.45 (10% 
MeOH/DCM); m.p. 100-180°C (dec.); λmax (EtOH)/nm 262; νmax/cm-1 (neat) 
1147(s, SO2sy), 1183 (s, C-O), 1361 (m, SO2as), 1419, 1680 (s, C=O); 1H NMR (500 
MHz; DMSO-d6) δH 2.94 (6H, s, 2 × N-CH3), 7.39 (1H, ddd, J = 0.8, 2.5, 8.1 Hz, H-
4’), 7.61 (1H, app. t, J = 8.1 Hz, H-5’), 7.64-7.66 (1H, m, H-2’), 7.72-7.75 (1H, m, 
H-6’), 7.83 (2H, dt, J = 1.8, 8.4 Hz, H-2 and 6), 8.04 (2H, dt, J = 1.8, 8.4 Hz, H-3 and 
5), 13.0 (1H, br, -CO2H); 13C NMR (125 MHz; DMSO-d6) δC 38.4 (2 × N-CH3), 
120.2 (C-2’), 121.5 (C-4’), 125.5 (C-6’), 127.1 (C-2 and C-6), 127.7 (C-4), 130.0 
(C-3 and C-5), 130.7 (C-5’), 141.0 (C-1’), 142.7 (C-1), 150.4 (C-3’), 167.0 (-
CO2H); LRMS (ES–) m/z 320.2 [M-H]–; HRMS calcd for C5H14NO5S [M-H]– 
320.0598, found 320.0594; HPLC >99.9% in 0.1% formic acid (aq.)/MeCN (Rt 
11.4 min); N/A in 0.1% ammonia (aq.)/MeCN. 
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Methyl 3'-[(N,N-dimethylsulfamoyl)oxy]-[1,1'-biphenyl]-2-carboxylate 
(66) 
 
Compound 66 was synthesized according to general procedure E using 
sulfamate 59 (151 mg, 0.54 mmol), 2-methoxycarbonylphenylboronic acid (97 
mg, 0.54 mmol), aq. Na2CO3 (2 M, 0.54 mL, 1.1 mmol), Pd(dppf)Cl2 · DCM (22 
mg, 0.024 mmol), and DME (1.3 mL). The reaction mixture was diluted with 
water, and extracted with EtOAc (3  50 mL). The combined organic layers were 
dried (MgSO4), filtered, and evaporated in vacuo. The crude product was 
purified by MPLC (gradient elution, 0-50% EtOAc/petrol) to yield the title 
compound as a light brown oil (152 mg, 90%). Rf 0.71 (50% EtOAc/petrol); λmax 
(EtOH)/nm 238sh, 279; νmax/cm-1 (neat) 1144 (s, SO2sy), 1182 (s, C-O), 1368 (m, 
SO2as), 1452 (m, CH3 def), 1722 (s, C=O); 1H NMR (500 MHz; CDCl3) δH 2.99 (6H, 
s, 2 × N-CH3), 3.66 (3H, s, CH3), 7.23 (1H, m, H-6’), 7.20-7.25 (1H, m, H-2’), 7.30 
(1H, ddd, J = 1.1, 2.3, 8.1 Hz, H-4’), 7.36 (1H, ddd, J = 0.5, 1.2, 7.6 Hz, H-6), 7.39-
7.42 (1H, m, H-5’), 7.42-7.47 (1H, m, H-4), 7.55 (1H, td, J = 1.4, 7.6 Hz, H-5), 7.86 
(1H, ddd, J = 0.5, 1.4, 7.8 Hz, H-3); 13C NMR (125 MHz; CDCl3) δC 38.9 (2 × N-
CH3), 52.2 (-CH3), 120.6 (C-4’), 122.4 (C-2’), 126.9 (C-6’), 127.9 (C-4), 128.6 (C-
2), 129.4 (C-5’), 130.2 (C-3), 130.8 (C-6), 131.6 (C-5), 141.3 and 143.5 (C-1 and 
C-1’), 150.2 (C-3’); LRMS (ES+) m/z 336.2 [M+H]+; HRMS calcd for C16H21N2O5S 
[M+NH4]+ 353.1166, found 353.1171; HPLC 99.6% in 0.1% formic acid 
(aq.)/MeCN (Rt 12.3 min); 99.7% in 0.1% ammonia (aq.)/MeCN (Rt 12.3 min). 
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Methyl 3'-[(N,N-dimethylsulfamoyl)oxy]-[1,1'-biphenyl]-3-carboxylate 
(67) 
 
To a solution of 64 (68 mg, 0.212 mmol) in MeOH (1 mL, 4.7 mL/mmol), 
trimethylsilyl chloride (79 μL, 92 mg, 0.847 mmol) was added in one portion, 
and the reaction mixture was stirred at room temperature for 40 h. After 
complete conversion, the solution was diluted with diethyl ether, and washed 
with sat. aq. NaHCO3. The aqueous layer was extracted with Et2O, and the 
combined organic layers were washed with brine, dried (MgSO4), filtered, and 
evaporated in vacuo. Purification of the crude product by MPLC (gradient 
elution, 0-50% EtOAc/petrol) yielded the desired methyl ester (52 mg, 73%) as 
a colorless oil which solidified upon storage at room temperature giving an off-
white solid. Rf 0.36 (33% EtOAc/petrol); m.p. 99.2-99.8 °C; λmax (EtOH)/nm 
254sh; νmax/cm-1 (neat) 1147 (s, SO2sy), 1360 (s, SO2as), 1455 (w, CH3 def), 1715 
(s, C=O); 1H NMR (500 MHz; CDCl3) δH 3.02 (6H, s, 2 × N-CH3), 3.96 (3H, s, CH3), 
7.31 (1H, ddd, J = 1.1, 2.4, 7.8 Hz, H-4’), 7.51 (1H, app. t, J = 7.8 Hz, H-5’), 7.51-
7.57 (3H, m, H-Ar), 7.77 (1H, ddd, J = 1.2, 1.9, 7.8 Hz, H-4 or H-6), 7.98 (1H, m, H-
4 or H-6), 8.19 (1H, m, H-2); 13C NMR (125 MHz; CDCl3) δC 39.0 (2 × N-CH3), 52.4 
(-CO2CH3), 120.6 (C-2’ or C-6’), 121.0 (C-4’), 125.6 (C-2’ or C-6’), 128.4 (C-2), 
129.1 (C-4 or C-6), 129.2 (C-5), 130.3 (C-5’), 131.0 (C-3), 131.7 (C-4 or C-6), 
140.2 (C-1), 142.3 (C-1’), 150.9 (C-3’), 167.0 (-CO2Me); LRMS (ES+) m/z 336.3 
[M+H]+; HRMS calcd for C16H18NO5S [M+H]+ 336.0900, found 336.0908; HPLC 
99.6% in 0.1% formic acid (aq.)/MeCN (Rt 8.7 min); 99.7% in 0.1% ammonia 
(aq.)/MeCN (Rt 8.7 min). 
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Methyl 3'-[(N,N-dimethylsulfamoyl)oxy]-[1,1'-biphenyl]-4-carboxylate 
(68) 
 
The acid 65 (40 mg, 0.124 mmol) was dissolved in methanol (0.2 mL, 1.6 
mL/mmol), and a catalytic amount of conc. sulfuric acid was added (0.5 mg, 
0.26 μL, 5.1 μmol). The reaction mixture was heated at 100 °C under microwave 
irradiation for 1.5 h. A solution of sat. aq. NaHCO3 was added (0.5 mL), and the 
product was extracted with DCM (3  5 mL). The combined organic layers were 
dried with MgSO4, filtered, and the solvent was removed in vacuo. Purification 
by MPLC (gradient elution, 0-33% EtOAc/petrol) yielded the title compound as 
a colorless oil (24 mg, 57%), which solidified upon storage at room 
temperature. Rf 0.71 (50% EtOAc/petrol); m.p. 100.4-102.6 °C; λmax (EtOH)/nm 
268; νmax/cm-1 (neat) 1146 (m, SO2sy), 1179 (m, C-O), 1369 (s, SO2as), 1457 (w, 
CH3 def), 1722 (s, C=O); 1H NMR (500 MHz; CDCl3) δH 3.02 (6H, s, 2 × N-CH3), 
3.94 (3H, s, CH3), 7.29-7.35 (1H, m, H-4’), 7.45-7.52 (1H, m, H-5’), 7.52-7.56 (2H, 
m, H-2’ and H-6’), 7.65 (2H, d, J = 7.8 Hz, H-2 and H-6), 8.11 (2H, d, J = 7.8 Hz, H-
3 and H-5); 13C NMR (125 MHz; CDCl3) δC 39.0 (2 × N-CH3), 52.4 (-CO2CH3), 
120.9 (C-2’), 121.4 (C-4’), 125.7 (C-6’), 127.3 (C-2 and C-6), 129.7 (C-4), 130.4 
(C-3 and C-5), 130.5 (C-5’), 142.2 and 144.3 (C-1 and C-1’), 150.9 (C-3’), 167.0 (-
CO2Me); LRMS (ES+) m/z 336.3 [M+H]+; HRMS calcd for C16H18NO5S [M+H]+ 
336.0900, found 336.0907; HPLC 99.7% in 0.1% formic acid (aq.)/MeCN (Rt 
12.9 min); >99.9% in 0.1% ammonia (aq.)/MeCN (Rt 12.9 min). 
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3-(Pyridin-2-yl)phenyl dimethylsulfamate (78) 
 
Potassium carbonate (259 mg, 1.87 mmol), copper(II) acetate (34 mg, 0.187 
mmol), and 2-pyridyl MIDA boronate (131 mg, 0.56 mmol) were added to a 
solution of sulfamate 59 (105 mg, 0.375 mmol) in DMF (3.0 mL, 8 mL/mmol). 
After bubbling dry N2 through the mixture for 2 min, Pd(dppf)Cl2 · DCM (4.6 mg, 
0.0056 mmol), and 2-propanol (0.75 mL, 2 ml/mmol) were added, and the 
mixture was heated at 100 C for 40 min under microwave irradiation. The 
reaction mixture was diluted with aq. NaOH (1 M, 20 mL), and the product was 
extracted with Et2O (3  30 mL). The combined organic phases were dried 
(MgSO4), filtered, and the solvent was removed under high vacuum. The crude 
product was purified by MPLC (gradient elution, 0-50% EtOAc/petrol) to yield 
the title compound (51 mg, 48%) as a colorless oil giving a white solid upon 
storage at room temperature. Rf 0.53 (50% EtOAc/petrol); m.p. 57.9-59.7 °C; 
λmax (EtOH)/nm 244, 275; νmax/cm-1 (neat) 1140 (s, SO2sy), 1173 (m, C-O), 1282 
(m, ring def), 1366 (s, SO2as), 1450 (m, ring str); 1H NMR (500 MHz; CDCl3) δH 
3.01 (6H, s, 2 × N-CH3), 7.28 (1H, ddd, J = 1.1, 5.0, 7.5 Hz, H-3’), 7.36 (1H, ddd, J = 
1.0, 2.3, 7.9 Hz, H-6), 7.50 (1H, app. t, J = 7.9 Hz, H-5), 7.75 (1H, m, H-5’), 7.78 
(1H, m, H-4’), 7.92 (1H, m, H-4), 7.93 (1H, m, H-2), 8.71 (1H, m, H-6’); 13C NMR 
(125 MHz; CDCl3) δC 39.0 (2 × N-CH3), 120.5 (C-2), 121.0 (C-5’), 122.4 (C-6), 
122.9 (C-3’), 125.3 (C-4), 130.2 (C-5), 137.3 (C-4’), 141.3 (C-3), 149.7 (C-6’), 
150.9 (C-1), 155.9 (C-2’); LRMS (ES+) m/z 279.2 [M+H]+; HRMS calcd for 
C13H15N2O3S [M+H]+ 279.0798, found 279.0802; HPLC 99.6% in 0.1% formic 
acid (aq.)/MeCN (Rt 10.4 min); 98.4% in 0.1% ammonia (aq.)/MeCN (Rt 11.2 
min). 
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3-(Pyridin-3-yl)phenyl dimethylsulfamate (79) 
 
General procedure E was followed to synthesize compound 79 using the 
sulfamate 59 (150 mg, 0.54 mmol), pyridine 3-boronic acid (66 mg, 0.54 mmol), 
aq. Na2CO3 2 M (0.54 mL, 1.0 mmol), Pd(dppf)Cl2 · DCM (22 mg, 0.024 mmol), 
and DME (1.3 mL). Upon completion of the reaction, the mixture was 
partitioned between water and ethyl acetate. The aqueous layer was extracted 
with DCM (2  30 mL), and the combined organic layers were filtered through a 
Thiol MP SPE cartridge, dried (MgSO4), filtered, and evaporated. The crude 
product was purified by MPLC (gradient elution, 0-100% EtOAc/petrol) to 
afford the desired compound (139 mg, 93%) as a colorless oil that solidified 
upon storage at room temperature to give a white solid. Rf 0.24 (75% 
EtOAc/petrol); m.p. 58.4-60.0 °C; λmax (EtOH)/nm 244; νmax/cm-1 (neat) 1142 (s, 
SO2sy), 1178 (s, C-O), 1267 (m, ring def), 1360 (s, SO2as); 1H NMR (500 MHz; 
CDCl3) δH 3.02 (6H, s, 2 × N-CH3), 7.30-7.36 (1H, m, H-6), 7.42 (1H, dd, J = 4.8, 
7.9 Hz, H-5’), 7.48-7.53 (3H, m, H-2, H-4 and H-5), 7.91 (1H, ddd, J = 1.7, 2.4, 7.9 
Hz, H-4’), 8.59-8.67 (1H, m, H-6’), 8.85 (1H, br, H-2’); 13C NMR (125 MHz; CDCl3) 
δC 39.0 (2 × N-CH3), 120.6 (C-2), 121.6 (C-6), 124.0 (C-5’), 125.5 (C-4), 130.7 (C-
5), 135.2 (C-4’), 135.7 and 139.7 (C-3 and C-3’), 147.8 (C-6’), 148.6 (C-2’), 151.0 
(C-1); LRMS (ES+) m/z 279.2 [M+H]+; HRMS calcd for C13H15N2O3S [M+H]+ 
279.0798, found 279.0802; HPLC 99.9% in 0.1% formic acid (aq.)/MeCN (Rt 5.4 
min); 99.9% in 0.1% ammonia (aq.)/MeCN (Rt 7.1 min). 
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3-(Pyridin-4-yl)phenyl dimethylsulfamate (80) 
 
General procedure E was followed to synthesize compound 80 using sulfamate 
59 (153 mg, 0.55 mmol), pyridine 4-boronic acid (67 mg, 0.55 mmol), aq. 
Na2CO3 2 M (0.54 mL, 1.0 mmol), Pd(dppf)Cl2 · DCM (22 mg, 0.024 mmol), and 
DME (1.3 mL). Upon completion of the reaction, the mixture was partitioned 
between water and ethyl acetate. The aqueous layer was extracted with EtOAc 
(2  30 mL); the combined organic layers were concentrated, and filtered 
through a Thiol MP SPE cartridge. The filtered solution was dried (MgSO4), 
filtered, and evaporated. Purification by MPLC (DCM 100%) yielded the desired 
compound as a brown solid (72 mg, 49%). Rf 0.46 (10% MeOH/DCM); m.p. 55.8-
57.1 °C; λmax (EtOH)/nm 251; νmax/cm-1 (neat) 1143 (s, SO2sy), 1179 (s, C-O), 
1361 (s, SO2as), 1460 (m, ring str), 1582 and 1592 (m, ring str); 1H NMR (500 
MHz; CDCl3) δH 3.03 (6H, s, 2 × N-CH3), 7.37 (1H, ddd, J = 1.3, 2.3, 7.9 Hz, H-6), 
7.49-7.54 (3H, m, H-Ar, H-3’ and H-5’), 7.54-7.57 (2H, m, H-2 and H-4), 8.69 (2H, 
d, J = 3.7 Hz, H-2’ and H-6’); 13C NMR (125 MHz; CDCl3) δC 39.0 (2 × N-CH3), 
120.5 (C-2), 121.8 (C-3’ and C-5’), 122.3 (C-6), 125.4 (C-4), 130.7 (C-5), 140.3 
and 147.2 (C-3 and C-4’), 150.5 (C-2’ and C-6’), 151.0 (C-1); LRMS (ES+) m/z 
279.2 [M+H]+; HRMS calcd for C13H15N2O3S [M+H]+ 279.0798, found 279.0802; 
HPLC 99.4% in 0.1% formic acid (aq.)/MeCN (Rt 4.6 min); 99.5% in 0.1% 
ammonia (aq.)/MeCN (Rt 7.1 min). 
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2',3',4',5'-Tetrahydro-[1,1'-biphenyl]-3-yl dimethylsulfamate (136) 
 
Compound 136 was synthesized according to general procedure E using 
sulfamate 59 (138 mg, 0.50 mmol), 1-cyclohexen-1-yl boronic acid pinacol ester 
(103 mg, 0.50 mmol), aq. Na2CO3 (2 M, 0.50 mL, 1.1 mmol), [1,1’-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) · DCM complex (20 mg, 
0.025 mmol), and DME (1.2 mL). The reaction mixture was diluted with water 
and EtOAc. The aqueous layer was extracted with EtOAc (3  25 mL). The 
combined organic layers were dried (MgSO4), filtered, and the solvent was 
removed in vacuo. The crude product was purified by MPLC (gradient elution, 0-
25% EtOAc/petrol) to afford the desired product (69 mg, 49%) as a colorless oil 
which solidified upon storage at room temperature to give a white solid. Rf 0.85 
(50% EtOAc/petrol); m.p. 54.8-56.0 °C; λmax (EtOH)/nm 249; νmax/cm-1 (neat) 
1142 (s, SO2sy), 1178 (s, C-O), 1354 (s, SO2as), 1457 (w, CH3 def), 1602 (w, C=C), 
2938 (=C-H); 1H NMR (500 MHz; CDCl3) δH 1.66 (2H, m, -CH2-), 1.78 (2H, m, -
CH2-), 2.21 (2H, m, -CH2-), 2.38 (2H, m, -CH2-), 2.97 (6H, s, 2 × N-CH3), 6.16 (1H, 
m, -C=CH-), 7.12 (1H, dt, J = 2.2, 6.9 Hz, H-4), 7.25-7.33 (3H, m, H-5, H-2 and H-
6); 13C NMR (125 MHz; CDCl3) δC 22.2 (-CH2-), 23.1 (-CH2-), 26.0 (-CH2-), 27.5 (-
CH2-), 38.9 (2 × N-CH3), 118.4 (C-4), 119.6 (C-5), 123.3 (C-2), 126.4 (-C=CH-), 
129.4 (C-6), 135.6 (C-1) 144.9 ((-C=CH-), 150.5 (C-3); LRMS (ES+) m/z 282.3 
[M+H]+; HRMS calcd for C14H20NO3S [M+H]+ 282.1158, found 282.1162; HPLC 
99.8% in 0.1% formic acid (aq.)/MeCN (Rt 13.9 min); 99.8% in 0.1% ammonia 
(aq.)/MeCN (Rt 14.0 min). 
Sulfamoyl chloride (311)65 
 
Under an inert atmosphere, formic acid (0.55 g, 0.45 mL, 12 mmol) was added 
dropwise to neat chlorosulfonyl isocyanate (1.6 g, 1.0 mL, 12 mmol) at 0 °C with 
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gentle gas evolution. The resulting white slurry was stirred at room 
temperature for 3 h to give sulfamoyl chloride 311 as a white solid. Addition of 
anhydrous toluene (6.0 mL) yielded a solution (2 mmol/mL) of the reagent that 
was immediately used for the next step without further purification. 
3-Bromophenyl sulfamate (88)198 
 
A freshly prepared solution of sulfamoyl chloride in toluene (6.0 mL, 12 mmol) 
was added dropwise to a solution of 3-bromophenol (1.0 g, 6.0 mmol) in DMA 
(6.0 mL, 1.0 mL/mmol) at 0 °C under an inert atmosphere. The resulting 
mixture was allowed to reach room temperature and stirred overnight. After 
careful addition of water (6.0 mL), the mixture was extracted with EtOAc (3  
30 mL). The combined organic layers were washed with brine, dried (MgSO4), 
filtered and the solvent was removed in vacuo. Purification by MPLC (gradient 
elution, 0-30% EtOAc/petrol) yielded the title compound as an off-white solid 
(1.31 g, 87%). Rf 0.30 (petrol/EtOAc 7:3); m.p. 89.1-90.5 °C (lit.198 90-91 °C); 
λmax (EtOH)/nm 256sh, 267, 274sh (/dm3 mol-1 cm-1 600); νmax/cm-1 (neat) 
1164 (s, SO2sy), 1364 (s, SO2as), 1578 (m, NH2 def), 3276 (m, NH2sy), 3374 (m, 
NH2as); 1H NMR (500 MHz; CDCl3) δH 4.98 (2H, br, -NH2), 7.28-7.32 (2H, m, H-
Ar), 7.45-7.49 (1H, m, H-Ar), 7.50-7.53 (1H, m, H-Ar); 13C NMR (125 MHz; 
CDCl3) δC 121.0 (C-Ar), 125.56 (C-Ar), 130.7 (C-Ar), 131.1 (C-Ar), 150.3 (C-1). 
One quaternary carbon not detected; LRMS (ES–) m/z 250.0 and 252.0[M-H]–; 
HRMS calcd for C6H579BrNO3S [M-H]– 249.9179, found 249.9182. 
NMR data match those previously reported for this compound.198 
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[1,1'-Biphenyl]-3-yl sulfamate (89)93 
 
Compound 41 was synthesized according to general procedure E using 3-
bromophenyl sulfamate (53 mg, 0.210 mmol), phenyl boronic acid (24 mg, 0.20 
mmol), Na2CO3 (2 M aq., 0.2 mL, 0.4 mmol), [1,1’-bis(diphenylphosphino) 
ferrocene]dichloropalladium(II) DCM complex (10 mg, 0.013 mmol), and DME 
(0.5 mL). The reaction mixture was diluted with water and EtOAc. The aqueous 
layer was extracted with DCM (2  20 mL). The combined organic layers were 
dried (MgSO4), filtered, and the solvent was removed in vacuo. The crude 
product was purified by MPLC (gradient elution, 0-35% EtOAc/petrol) to afford 
the desired product (11 mg, 22%) as a white solid. Rf 0.78 (50% EtOAc/petrol); 
m.p. 88.9-93.6 °C (lit. 91-93 C)65; λmax (EtOH)/nm 248 ( /dm3 mol-1 cm-1 49 
000); νmax/cm-1 (neat) 1150 (s, SO2sy), 1364 (s, SO2as), 3311 (m, N-H), 3621 (m, 
N-H); 1H NMR (500 MHz; CDCl3) δH 5.01 (2H, s, -NH2), 7.30 (1H, ddd, J = 1.2, 2.3, 
8.1 Hz, H-Ar), 7.38 (1H, app. tt, J = 1.2, 6.5 Hz, H-Ar), 7.42-7.49 (3H, m, H-3’, H-5’ 
and H-Ar), 7.53-7.59 (4H, m, 2  H-Ar,H-2’ and H-6’); 13C NMR (125 MHz; CDCl3) 
δC 120.8 (C-Ar), 120.9 (C-Ar), 126.1 (C-Ar), 127.3 (C-2’ and C-6’), 128.2 (C-Ar), 
129.1 (C-3’ and C-5’), 130.3 (C-Ar), 139.7 and 143.6 (C-1 and C-1’), 150.6 (C-3); 
LRMS (ES–) m/z 248.2 [M-H]–; HPLC 98.6% in 0.1% formic acid (aq.)/MeCN (Rt 
11.2 min); 98.8% in 0.1% ammonia (aq.)/MeCN (Rt 5.2 min). 
NMR data match those previously reported for this compound.65 
1,1'-Sulfonylbis(2-methyl-1H-imidazole) (125)79,199 
 
A solution of sulfuryl chloride (4.2 g, 31 mmol) in DCM (20 mL, 0.65 ml/mmol) 
was added dropwise at 0 °C to a suspension of 2-methylimidazole (10.2 g, 124 
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mmol) in DCM (50 mL, 0.4 mL/mmol). The resulting pale yellow solution was 
allowed to reach room temperature, and stirred for 24 h. At 0 °C, water was 
added to the reaction mixture, and the aqueous layer was extracted with DCM. 
The combined organic layers were washed with brine, dried (MgSO4), filtered, 
and the solvent was removed in vacuo. Purification by MPLC (gradient elution, 
0-10% MeOH/DCM) yielded the title compound (4.4 g, 63%) as an off-white 
solid. Rf 0.36 (5% MeOH/DCM); m.p. 87.9-92.6 °C (lit.199 90-91 °C); λmax (EtOH) 
no maximum of absorption was detected; νmax/cm-1 (neat) 1147 (s, SO2sy), 1351 
and 1378 (m, SO2as); 1H NMR (500 MHz; CDCl3) δH 2.53 (6H, s, -CH3), 6.96 (2H, d, 
J = 1.8 Hz, C-4 or C-5), 7.39 (2H, d, J = 1.8 Hz, C-4 or C-5); 13C NMR (125 MHz; 
CDCl3) δC 15.1 (-CH3), 120.2 (C-4 or C-5), 128.7 (C-4 or C-5), 146.2 (-C-CH3). 
LRMS (ES+) m/z 227.2 [M+H]+. 
NMR data match those previously reported for this compound.199 
3-Bromophenyl 2’-methyl-1H-imidazole-1-sulfonate (126)79,93 
 
To a solution of the sulfonylbis(2-methyl-1H-imidazole) 125 (945 mg, 4.18 
mmol) in acetonitrile (18.0 mL, 4.3 mL/mmol), 3-bromophenol (361 mg, 2.09 
mmol), and cesium carbonate (748 mg, 2.30 mmol) were added in one portion 
at room temperature. The orange mixture was heated under microwave 
irradiation at 120 °C for 15 min. Upon completion of the reaction, the solvent 
was removed in vacuo, the residue was dissolved in saturated aqueous NH4Cl, 
and extracted with EtOAc (3  45 mL). The combined organic layers were 
washed with water (20 mL), brine (20 mL), dried (MgSO4), filtered, and 
evaporated. The crude product was purified by MPLC (gradient elution, 0-33% 
EtOAc/ petrol) to afford the desired compound (513 mg, 77%) as a pale yellow 
oil. Rf 0.63 (50% EtOAc/petrol); λmax (EtOH)/nm 266; νmax/cm-1 (neat) 1150 (s, 
SO2sy), 1350 and 1384 (m, SO2as); 1H NMR (500 MHz; CDCl3) δH 2.51 (3H, s,  
-CH3), 6.83 (1H, ddd, J = 0.9, 2.1, 8.3 Hz, H-4 or H-6), 6.91 (1H, d, J = 1.8 Hz, H-4’ 
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or H-5’), 7.14 (1H, d, J = 1.8 Hz, H-4’ or H-5’), 7.18 (1H, t, J = 2.1 Hz, H-2), 7.24 
(1H, t, J = 8.3 Hz, H-5), 7.51 (1H, ddd, J = 0.9, 2.1, 8.3 Hz, H-4 or H-6); 13C NMR 
(125 MHz; CDCl3) δC 15.1 (-CH3), 120.3 (C-4 or C-6), 120.5 (C-4’ or C-5’), 123.2 
(C-3), 125.4 (C-2), 128.3 (C-4’ or C-5’), 131.4 (C-5), 132.0 (C-4 or C-6), 146.9 (C-
2’), 149.2 (C-1); LRMS (ES+) m/z 317.1 and 319.1 [M+H]+; HRMS calcd for 
C10H1079BrN2O3S [M+H]+ 316.9596, found 316.9590. 
1-[(3-Bromophenoxy)sulfonyl]-2,3-dimethyl-1H-imidazol-3-ium 
tetrafluoroborate (127)79,93 
 
Trimethyloxonium tetrafluoroborate (278 mg, 1.88 mmol) was added in one 
portion to an iced cooled solution of the 2-methylimidazole sulfonate 59 (595 
mg, 1.88 mmol) in dichloromethane (8.5 mL, 4.5 mL/mmol). The suspension 
was stirred at 0 °C for 1 h, and at room temperature overnight. Addition of cold 
petrol to the reaction mixture triggered the precipitation of the desired product 
as a white solid which was filtered and used for the subsequent step without 
further purification (yield assumed quantitative). LRMS (ES+) m/z 331.1 and 
333.1 [M-BF4]+. 
bis(2,4-Dimethoxybenzyl)amine (131)79,93 
 
Under an inert atmosphere, 2,4-dimethoxybenzaldehyde (3.03 g, 18.0 mmol) 
was added in one portion to a solution of 2,4-dimethoxybenzylamine (3.00 g, 
18.0 mmol) in EtOH (9.0 mL, 0.5 mL/mmol) together with MgSO4 (a tip of a 
spatula). The mixture was stirred at 78 °C for 5 h; the reaction was monitored 
by TLC (5% MeOH/DCM + 2 drops of Et3N).  
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The resulting imine was reduced by careful addition of sodium borohydride at 
0 °C. The reaction mixture was stirred at room temperature for 2 d. The solvent 
was removed in vacuo, and the residue was partitioned between EtOAc (30 mL) 
and saturated aqueous NH4Cl (20 mL). The aqueous layer was extracted with 
EtOAc (30 mL). The combined organic layers were washed with water (30 mL) 
and brine (30 mL), dried (MgSO4), filtered, and the solvent was removed in 
vacuo. Purification by MPLC (gradient elution 0-10% MeOH/DCM) yielded the 
title compound (4.31, 75%) as a pale yellow oil which solidified upon storage at 
room temperature. Rf 0.33 (10% MeOH/DCM); λmax (EtOH)/nm 276; νmax/cm-1 
(neat) 1268 and 1286 (m, OCH3), 2831 (w, C-H), 2937 (w, C-H); 1H NMR (500 
MHz; CDCl3) δH 3.76 (4H, s, 2  CH2-), 3.79 (6H, s, 2  -OCH3), 3.82 (6H, s, 2  -
OCH3), 6.41-6.45 (4H, m, 2  H-3 and H-5), 7.20 (2H, d, J = 8.8 Hz, 2  H-6); 13C 
NMR (125 MHz; CDCl3) δC 48.1 (2  -CH2-), 55.4 (2  -OCH3), 55.5 (2  -OCH3), 
98.6 (2  C-3 or C-5), 103.9 (2  C-3 or C-5), 130.8 (2  C-6), 158.7 (2  C-2 or C-
4), 160.4 (2  C-2 or C-4); LRMS (ES+) m/z 318.3 [M+H]+. 
NMR data match those previously reported for this compound.200 
3-Bromophenyl bis(2’,4’-dimethoxybenzyl)sulfamate (115)79 
 
A solution of the 2,3-dimethylimidazolium tetrafluoroborate 127 (701 mg, 1.7 
mmol) in acetonitrile (10.0 mL) was added to a solution of the amine 131 (545 
mg, 1.7 mmol) in acetonitrile (3.5 mL). The reaction mixture was stirred for 2 d 
at room temperature, and 17 h at 60 °C. The solvent was removed in vacuo to 
yield the crude product which was purified by MPLC (gradient elution 0-20% 
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EtOAc/petrol) to yield the title compound as a colorless oil (572 mg, 55% over 
two steps). Rf 0.16 (16% EtOAc/petrol; KMnO4); λmax (EtOH)/nm 276; νmax/cm-1 
(neat) 1154 (s, SO2sy), 1190 (s, C-O), 1260 and 1299 (m, OCH3), 1371 (s, SO2as); 
1H NMR (500 MHz; CDCl3) δH 3.75 (6H, s, 2  -OMe), 3.81 (6H, s, 2  -OMe), 3.93 
(4H, s, 2  -CH2), 6.41 (2H, d, J = 2.4 Hz, H-Ar), 6.45 (2H, dd, J = 2.4, 8.3 Hz, H-Ar), 
7.04 (1H, t, J = 1.9 Hz, H-Ar), 7.09 (1H, ddd, J = 1.0, 2.4, 8.3 Hz, H-Ar), 7.16 (1H, t, 
J = 8.2 Hz, H-Ar), 7.24-7.28 (1H, m, H-Ar), 7.33 (1H, ddd, J = 1.0, 1.9, 8.0 Hz, H-
Ar); 13C NMR (125 MHz; CDCl3) δC 47.3 (2  N-CH2), 55.3 (2  OCH3), 55.6 (2  
OCH3), 98.4 (2  C-3’), 104.1 (2  C-5’), 116.68 (2  C-1’), 120.9 (C-Ar), 122.4 (C-
3), 125.5 (C-Ar), 129.6 (C-Ar), 130.6 (C-Ar), 131.3 (2  C-6’), 150.9 (C-1), 158.6 
(2  C-2’ or C-4’), 160.9 (2  C-2’ or C-4’); LRMS (ES+) m/z 574.3 and 576.3 
[M+Na]+; HRMS calcd for C24H2779BrNO7S [M+H]+ 552.0686, found 552.0680. 
1,4-Dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate (103)201 
 
KHMDS (0.5 M soln. in toluene, 33.2 mL, 16.6 mmol) was added dropwise at  
-78 °C to a solution of 1,4-cyclohexanedione monoethylene acetal (2.00 g, 12.8 
mmol) and N-phenyl-bis(trifluoromethylsulfonamide) (5.94 g, 16.6 mmol) in 
THF (128 mL, 10.0 mL/mmol), and the mixture was stirred at -78 °C for 3 h 
before cautious addition of water (50 mL). The phases were separated and the 
aquoeus layer was extracted with diethyl ether (3  100 mL). The combined 
organic layers were washed with aq. 10% Na2CO3 (100 mL), dried (MgSO4), 
filtered, and evaporated. Purification of the crude product by MPLC (gradient 
elution, 0-10% EtOAc/petrol) afforded the desired product (740 mg, 96%) as a 
light yellow oil. Rf 0.88 (Et2O 100%; 2,4-DNP); λmax (EtOH) no maximum of 
absorption was detected; νmax/cm-1 (neat) 1210 (vs, C-F), 1417 (vs, SO2str), 1692 
(w, C=C); 1H NMR (500 MHz; CDCl3) δH 1.88-1.93 (2H, m, -CH2-), 2.38-2.44 (2H, 
m, CH2-), 2.51-2.57 (2H, m, -CH2-), 3.95-4.03 (4H, m, 2  -O-CH2-), 5.55-5.68 (1H, 
m, C=C-H); 13C NMR (125 MHz; CDCl3) δC 26.5 (-CH2-), 31.2 (-CH2-), 34.3 (-CH2-), 
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64.8 (2  O-CH2-), 106.3 (O-C-O), 116.0 (C=C-H), 118.6 (-CF3, J = 320 Hz), 148.3 
(=C-OTf). 
NMR data match those previously reported for this compound.202-203 
4,4,5,5-Tetramethyl-2-(1’,4’-dioxaspiro[4’.5’]dec-7’-en-8’-yl)-1,3,2-
dioxaborolane (97)89 
 
Under an inert atmosphere, bis(pinacolato)diboron (585 mg, 2.30 mmol), 
Pd(dppf)Cl2 · DCM (47 mg, 0.0576 mmol), 1,1’-(diphenylphosphino)ferrocene 
(32 mg, 0.0576 mmol), and potassium acetate (566 mg, 5.76 mmol) were added 
to a solution of the vinyl triflate 103 (553 mg, 1.92 mmol) in 1,4-dioxane (10.0 
mL, 0.5 mL/mmol). The reaction mixture was heated at 80 °C overnight. Water 
(20 mL) was added, and the product was extracted with EtOAc (3  30 mL). The 
combined organic layers were washed with brine, dried (MgSO4), filtered, and 
evaporated. The residue was dissolved in ethyl acetate and filtered through a 
Thiol MP SPE cartridge. The crude product was purified by MPLC (gradient 
elution, 0-100% Et2O/petrol) to afford the desired boronic acid pinacol ester as 
a colorless oil (348 mg, 79%) which crystallized upon storage at room 
temperature. Rf 0.85 (Et2O 100%; 2,4-DNP); m.p. 70.6-71.7 °C (lit.204 58 °C); λmax 
(EtOH) no maximum of absorption was detected; νmax/cm-1 (neat) 1250 and 
1295 (m, O-C), 1368 and 1386 (s, B-O str.), 1415 (w, B-C str.), 1633 (m, C=C str), 
2878 (CH2as), 2924 and 2986 (w, CH2as); 1H NMR (500 MHz; CDCl3) δH 1.25 
(12H, s, 4  CH3), 1.71-1.76 (2H, m, -CH2-), 2.32-2.41 (4H, m,2  -CH2), 3.98 (4H, 
s, 2  O-CH2-), 6.47 (1H, s, C=C-H); 13C NMR (125 MHz; CDCl3) δC 25.0 (4  -CH3), 
25.9 (-CH2-), 31.2 (-CH2-), 37.2 (-CH2-), 64.5 (O-CH2-), 83.4 (2  -C(CH3)2), 108.0 
(O-C-O), 139.7 (C=C-H); LRMS (ES+) m/z 267.3 [M+H]+; HRMS calcd for 
C14H24BO4 [M+H]+ 267.1762, found 267.1755. 
NMR data match those previously reported for this compound.204 
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3-(1’,4’-Dioxaspiro[4’.5’]dec-7’-en-8’-yl)phenyl bis(2’’,4’’-
dimethoxybenzyl)sulfamate (116) 
 
The title compound was synthesized according to general procedure E using the 
3-bromosulfamate 115 (572 mg, 1.04 mmol), boronic acid pinacol ester 97 
(277 mg, 1.04 mmol), Na2CO3 (2 M aq., 1 mL, 2.0 mmol), Pd(dppf)Cl2 · DCM (42 
mg, 0.052 mmol) and DME (2.4 mL, 2.3 mL/mmol). The reaction mixture was 
diluted with water, and extracted with EtOAc (3  20 mL). The combined 
organic layers were washed with brine, dried (MgSO4), filtered and the solvent 
was removed in vacuo. The crude product was purified by MPLC (gradient 
elution,   0-50% EtOAc/petrol) to afford the title compound (552 mg, >99%) as 
a colorless oil which solidified upon storage at room temperature to give a light 
brown solid. Rf 0.35 (50% EtOAc/petrol; UV 254 nm, KMnO4 and 2,4-DNP); m.p. 
102.9-104.5 °C; λmax (EtOH) 279sh; νmax/cm-1 (neat) 1135 (m, SO2sy), 1252 and 
1298 (m, OCH3), 1353 and 1364 (m, SO2as), 1588 (m, C=C ar), 1612 (m, C=C 
aromatic str), 2946 (w, C-H and –CH2- aliphatic); 1H NMR (500 MHz; CDCl3) δH 
1.90 (2H, t, J = 6.4 Hz, -C(O-CH2-CH2-O)-CH2-CH2-), 2.44-2.49 (2H, m, -CH2-CH=), 
2.54-2.61 (2H, m, -C(O-CH2-CH2-O)-CH2-CH2-), 3.71 (6H, s, 2  -OCH3), 3.79 (6H, 
s, 2  -OCH3), 3.99-4.06 (4H, m, 2  CH2-O), 4.43 (4H, s, 2  N-CH2-), 5.92-5.97 
(1H, m, C=C-H), 6.38 (2H, d, J = 2.3 Hz, 2  H-3’), 6.43 (2H, dd, J = 2.3, 8.3 Hz, 2  
H-5’), 6.97-7.02 (2H, m, H-Ar), 7.19-7.25 (2H, m, H-Ar), 7.26-7.29 (2H, m, 2  H-
6’); 13C NMR (125 MHz; CDCl3) δC 26.7 (-C(O-Et-O)-CH2-CH2-), 31.4 (-C(O-Et-O)-
CH2-CH2-), 36.2 (-CH2-CH=C), 46.9 (2  N-CH2-), 55.2 (2  OCH3), 55.5 (2 -
OCH3), 64.6 (2  CH2-O), 98.3 (2  C-3’), 104.1 (2  C-5’), 107.7 (-O-C-O-), 116.8 
(2  C-1’), 118.8 (C-Ar), 120.3 (C-Ar), 122.8 (C=C-H), 123.2 (C-Ar), 129.2 (C-Ar), 
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131.1 (2  C-6’), 135.3 (C-Ar), 143.2 (C-3), 150.6 (C-1), 158.6 (2  C-2’ or C-4’), 
160.7 (2  C-2’ or C-4’); LRMS (ES+) m/z 634.4 [M+Na]+; HRMS calcd for 
C32H38NO9S [M+H]+ 612.2262, found 612.2261. 
4'-Oxo-2',3',4',5'-tetrahydro-[1,1'-biphenyl]-3-yl bis(2’’,4’’-
dimethoxybenzyl)sulfamate (117) 
 
To a solution of the ketal 116 (152 mg, 0.248 mmol, 1 equiv.) in acetone (4 mL, 
16 mL/mmol) and water (1 mL, 4 mL/mmol) was added p-toluenesulfonic acid 
(47 mg, 0.247 mmol, 1 equiv.) and the mixture was heated under microwave 
irradiation at 60 °C for 1 h. The solvent was removed in vacuo and the residue 
was dissolved in NaHCO3 (aq., 5% v/v). The product was extracted with EtOAc 
(3  25 mL), and the combined organic layers were dried (MgSO4), filtered, and 
evaporated. Purification by MPLC (gradient elution, 0-50% EtOAc/petrol) of the 
crude product yielded the title compound as a colorless oil (102 mg, 72%). Rf 
0.36 (petrol/EtOAc; stain UV 254 nm); λmax (EtOH)/nm 276; νmax/cm-1 (neat) 
1130 (s, SO2sy), 1157 (s, C-O), 1265 and 1291(m, O-C), 1369 (s, SO2as), 1587 (m, 
C=C ar), 1611 (s, C=C aromatic str), 1686 (m, C=O), 2838, 2937and 2957 (w, C-H 
and -CH2- aliphatic); 1H NMR (500 MHz; CDCl3) δH 2.66 (2H, t, J = 6.9 Hz, -CO-
CH2-CH2-), 2.83 (2H, m, -CO-CH2-CH2-), 3.09 (2H, m, -CH2-CH=C), 3.75 (6H, s, 2  
OCH3), 3.82 (6H, s, 2  OCH3), 4.48 (4H, s, 2  N-CH2), 6.07 (1H, m, =C-H), 6.42 
(2H, d, J = 2.4 Hz, 2  H-3’’), 6.47 (2H, dd, J = 2.4, 8.3 Hz, 2  H-5’’), 7.04 (1H, app. 
t, J = 2.0 Hz, H-Ar), 7.07 (1H, ddd, J = 1.1, 2.4, 7.9 Hz, H-Ar), 7.27 (1H, m, H-Ar), 
7.30 (1H, m, H-Ar), 7.30 (2H, t, J = 8.3 Hz, 2  H-6’’); 13C NMR (125 MHz; CDCl3) 
δC 27.8 (-CO-CH2-CH2-), 38.7 (-CO-CH2-CH2-), 40.0 (-CH2-CH=C), 46.9 (2  N-
CH2), 55.2 (2  OCH3), 55.5 (2  OCH3), 98.3 (2  C-3’’), 104.1 (2  C-5’’), 116.6 (2 
 C-1’’), 118.9 (C-Ar), 120.9 (C-Ar), 122.2 (C=C-H), 123.2 (C-Ar), 129.6 (C-Ar), 
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131.1 (2  C-6’), 136.8 (C-1’), 142.4 (C-3), 150.7 (C-1), 158.6 (2  C-2’ or C-4’), 
160.7 (2  C-2’ or C-4’), 209.7 (C=O); LRMS (ES+) m/z 590.4 [M+Na]+. 
3-(1’,4’-Dioxaspiro[4.5]decan-8-yl)phenyl bis(2’’,4’’-
dimethoxybenzyl)sulfamate (132) 
 
A solution of 116 (1.01 g, 1.65 mmol) in EtOH/THF 4:1 (66 mL, 40 mL/mmol) 
was hydrogenated over 10% Pd/C in a flow reactor (1.0 mL/min) for 5.5 h with 
recycling of the reaction mixture. Solvent was removed in vacuo to obtain 
compound 132. The title compound (colorless oil; 0.97 g, 96%) was used in the 
following step without further purification. Rf 0.44 (50% EtOAc/petrol; 254 nm, 
KMnO4, DNP); λmax (EtOH)/nm 277, 283sh; νmax/cm-1 (neat) 1130 (s, SO2sy), 
1158 (s, C-O), 1173 (s, C-O-C-O-C vib), 1267 and 1292 (m, O-C), 1374 (m, SO2as), 
1612 (s, C=C aromatic str); 1H NMR (500 MHz; CDCl3) δH 1.62-1.68 (4H, m, 
cyclohexyl Hax), 1.78-1.90 (4H, m, Heq), 2.44-2.55 (1H, m, -CH-Ar), 3.71 (6H, s, 2 
 OCH3), 3.79 (6H, s, 2  OCH3), 3.98 (4H, s, -O-CH2-CH2-O-), 4.43 (4H, s, 2  N-
CH2-), 6.39 (2H, d, J = 2.4 Hz, 2  H-3’’), 6.44 (2H, dd, J = 2.4, 8.5 Hz, 2  H-5’’), 
6.82-6.87 (1H, m, H-Ar), 6.93-7.00 (1H, m, H-Ar), 7.06-7.13 (1H, m, H-Ar), 7.22 
(1H, app. t, J = 8.0 Hz, H-5), 7.27 (2H, t, J = 8.5 Hz, 2  H-6’’); 13C NMR (125 MHz; 
CDCl3) δC 31.5 (2  CH2), 35.3 (2  CH2), 43.3 (CH-Ar), 46.9 (2  N-CH2-), 55.2 (2 
 -OCH3), 55.5 (2  -OCH3), 64.4 (-O-CH2-CH2-O-), 98.4 (2  C-3’’), 104.1 (2  C-
5’’), 108.5 (C-4’), 116.8 (2  C-1’’), 119.8 (C-Ar), 120.6 (C-Ar), 125.1 (C-Ar), 
129.6 (C-Ar), 131.1 (2  C-6’’), 148.5 (C-Ar), 150.6 (C-1), 158.6 (2  C-2’’ or C-
4’’), 160.7 (2  C-2’’ or C-4’’); LRMS (ES+) m/z 636.6 [M+Na]+; HRMS calcd for 
C32H40NO9S [M+H]+ 614.2418, found 614.2412. 
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3-(4’-Oxocyclohexyl)phenyl bis(2’’,4’’-dimethoxybenzyl)sulfamate (118) 
 
The ketone 118 was prepared according to general procedure F using the ketal 
132 (0.87 g, 1.42 mmol), a mixture of THF (10 mL), water (30 mL) and acetic 
acid (60 mL). Purification by MPLC (gradient elution, 0-10% MeOH/DCM) 
yielded the title compound (0.70 g, 87%) as a pale yellow oil which solidified 
upon storage at RT to give a white solid. Rf 0.48 (50% EtOAc/petrol); m.p. 
125.2-126.5 °C; λmax (EtOH)/nm 278; νmax/cm-1 (neat) 1125 (s, SO2sy), 1157 (s, 
C-O), 1371 (s, SO2as), 1710 (m, C=O), 2939 (w, C-H and -CH2- aliphatic); 1H NMR 
(500 MHz; CDCl3) δH 1.72–1.88 (2H, m, 2  CHeqHax-CHAr), 2.09–2.20 (2H, m, 2  
CHeqHax-CHAr), 2.42–2.55 (4H, m, 2  CH2-CO), 2.95 (1H, tt, J = 3.2, 12.1 Hz, CH-
Ar), 3.72 (6H, s, 2  -OCH3), 3.80 (6H, s, 2  -OCH3), 4.42 (4H, s, 2  N-CH2-), 6.40 
(2H, d, J = 2.4 Hz, 2  H-3’’), 6.45 (2H, dd, J = 2.4, 8.5 Hz, 2  H-5’’), 6.77 (1H, t, J = 
1.9 Hz, H-Ar), 6.99–7.03 (1H, m, H-Ar), 7.07–7.12 (1H, m, H-Ar), 7.24 (1H, s, H-
Ar), 7.29 (2H, t, J = 8.5 Hz, 2  H-6’’); 13C NMR (125 MHz; CDCl3) δC 33.8 (2  
CH2-CHAr), 41.3 (2  CH2-CO), 42.4 (CH-Ar), 46.9 (2  N-CH2), 55.2 (2  OCH3), 
55.4 (2  OCH3), 98.2 (2  C-3’’), 104.1 (2  C-5’’), 116.5 (2  C-1’’), 120.2 (C-Ar), 
120.4 (C-Ar), 125.0 (C-Ar), 129.7 (C-Ar), 131.0 (2  C-6’’), 146.6 (C-Ar), 150.7 
(C-1), 158.5 (2  C-2’’ or C-4’’), 160.7 (2  C-2’’ or C-4’’), 210.7 (C=O); LRMS 
(ES+) m/z 592.5 [M+Na]+; HRMS calcd for C30H39N2O8S [M+NH4]+ 587.2422, 
found 587.2391. 
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3-(cis-4’-Hydroxycyclohexyl)phenyl bis(2’’,4’’-dimethoxybenzyl)sulfamate 
(119) 
 
A solution of lithium tri-sec-butylborohydride (1.0 M in THF, 0.73 mL, 0.73 
mmol) was added dropwise to a solution of 119 (345 mg, 0.61 mmol) in THF 
(10 mL, 16 mL/mmol) at -78 °C. The solution was stirred at -78 °C for 1 h. The 
unreacted L-Selectride was quenched by addition of NH4Cl (sat. aq., 2 mL) at 
0 °C. The mixture was diluted with water (10 mL) and extracted with ethyl 
acetate (3  25 mL). The combined organic layers were washed with brine, 
dried (MgSO4), filtered, and the solvent was removed in vacuo. Purification by 
MPLC (gradient elution, 0-75% EtOAc/petrol) yielded the title compound (240 
mg, 69%) as a pale yellow oil (formation of the trans-diastereoisomer 118 was 
also observed even though the compound was not isolated). Rf 0.26 (50% 
EtOAc/petrol; KMnO4, DNP); λmax (EtOH)/nm 278; νmax/cm-1 (neat) 1127 (s, 
SO2sy), 1158 (s, C-O), 1267 and 1291 (m, O-C), 1369 (s, SO2as), 1588 (m, C=C ar), 
1611 (s, C=C str), 2932 (w, C-H and -CH2- aliphatic); 1H NMR (500 MHz; CDCl3) 
δH 1.52 (1H, br, O-H), 1.58–1.64 (2H, m, 2  CHeqHax-CHAr), 1.64-1.71 (2H, m, 2  
CHeqHax-CHOH), 1.72–1.84 (2H, m, 2  CHeqHax-CHAr), 1.84–1.94 (2H, m, 2  
CHeqHax -CHOH), 2.41-2.52 (1H, m CH-Ar), 3.71 (6H, s, 2  OCH3), 3.80 (6H, s, 2  
OCH3), 4.09-4.14 (1H, m, CH-OH), 4.43 (4H, s, 2  N-CH2-), 6.41 (2H, d, J = 2.4 Hz, 
2  H-3’’), 6.45 (2 H, dd, J = 2.4, 8.4 Hz, 2  H-5’’), 6.78 (1H, t, J = 2.0 Hz, H-Ar), 
6.98 (1H, ddd, J = 1.1, 2.4, 8.1 Hz, H-Ar), 7.04–7.12 (1H, m, H-Ar), 7.22 (1H, t, J = 
7.9 Hz, H-Ar), 7.28 (2H, d, J = 8.4 Hz, 2  H-6’’); 13C NMR (125 MHz; CDCl3) δC 
27.6 (2  CH2-CHAr), 33.1 (2  CH2-CHOH), 43.7 (CH-Ar), 46.8 (2  N-CH2), 55.2 
(2  OCH3), 55.5 (2  OCH3), 65.6 (-CH-OH), 98.3 (2  C-3’’), 104.1 (2  C-5’’), 
116.8 (2  C-1’’), 119.7 (C-Ar), 120.4 (C-Ar), 125.1 (C-Ar), 129.4 (C-Ar), 131.1 (2 
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 C-6’’), 149.3 (C-Ar), 150.7 (C-Ar), 158.6 (2  C-2’’ or C-4’’), 160.6 (2  C-2’’ or 
C-4’’); LRMS (ES+) m/z 572.5 [M+H]+; HRMS calcd for C30H38NO8S [M+H]+ 
572.2313, found 572.2305. 
3-(cis-4’-Hydroxycyclohexyl)phenyl sulfamate (110) 
 
Compound 110 was synthesized according to general procedure G using the 
alcohol 119 (261 mg, 0.457 mmol), DCM (6.4 mL), and TFA (0.7 mL). Complete 
conversion was reached after 1 h. The pure product (pale brown solid, 65 mg, 
53%) was obtained by MPLC (gradient elution, 0-50% EtOAc/petrol). Rf 0.23 
(50% EtOAc/petrol; KMnO4); m.p. 119.4-120.8 °C; λmax (EtOH)/nm 261, 280sh; 
νmax/cm-1 (neat) 1176 (s, SO2sy), 1366 (s, SO2as), 1582 (m), 2952 (m), 3302 (m), 
3519 (m); 1H NMR (500 MHz; CD3OD) δH 1.55 – 1.73 (4H, m, CHax), 1.81 – 1.98 
(4H, m, CHeq), 2.55-2.64 (1H, m, CH-Ar), 3.99 – 4.07 (1H, m, H-Ar), 7.12 (1H, ddd, 
J = 1.1, 2.4, 8.1 Hz, H-Ar), 7.20 (2H, m, H-Ar), 7.32 (1H, t, J = 8.1 Hz, H-5); 13C 
NMR (125 MHz; CD3OD) δC 28.8 (2  CH2-CHAr), 33.6 (2  CH2-CHOH), 44.9 (CH-
Ar), 66.2 (-CH-OH), 120.7 (C-Ar), 121.8 (C-Ar), 126.3 (C-Ar), 130.4 (C-5), 151.0 
(C-Ar q), 152.1 (C-Ar q); LRMS (ES–) m/z 270.3 [M-H]–; HRMS calcd for 
C12H16NO4S [M-H]– 270.0806, found 270.0796; HPLC 96.6% in water/MeCN (Rt 
6.1 min); 98.0% in 0.1% formic acid (aq.)/MeCN (Rt 6.1 min); 98.0% in 0.1% 
ammonia (aq.)/MeCN (Rt 3.8 min). 
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3-(trans-4’-Hydroxycyclohexyl)phenyl bis(2’’,4’’-
dimethoxybenzyl)sulfamate (120) 
 
NaBH4 (46 mg, 1.2 mmol) was added to a solution of 118 (345 mg, 0.61 mmol) 
in EtOH/THF 3:1 (28 mL), at -78 °C. The reaction mixture was stirred at -78 °C 
for 1.5 h and it was poured into iced saturated NH4Cl (aq., 50 mL) to quench the 
unreacted sodium borohydride. The product was extracted with EtOAc (3  50 
mL) and the combined organic layers were washed with brine, dried (MgSO4), 
filtered and evaporated. Purification by MPLC (gradient elution, 0-75% 
EtOAc/petrol) yielded the desired compound (270 mg, 78%) as an oil which 
solidified to give a white amorphous solid (19 mg, 5.5% yield of the cis-
diastereoisomer 119 were also obtained as an oil). Rf 0.15 (50% EtOAc/petrol); 
λmax (EtOH)/nm 278; νmax/cm-1 (neat) 1127 (s, SO2sy), 1157 (s, C-O), 1370 (s, 
SO2as), 1586 (m, C=C ar), 1612 (s, C=C str), 2558 and 2931 (w, C-H and -CH2- 
aliphatic); 1H NMR (500 MHz; CDCl3) δH 1.34–1.48 (4H, m, CH, 4  CHeqHax), 
1.81–1.93 (2H, m, 2  CHeqHax), 2.04-2.13 (2H, m, 2  CHeqHax), 2.38-2.48 (1H, m, 
CH-Ar), 3.63–3.70 (1H, m, CHOH), 3.72 (6H, s, 2  OCH3), 3.80 (6H, s, 2  OCH3), 
4.42 (4H, s, 2  N-CH2), 6.40 (2H, d, J = 2.4 Hz, 2  H-3’’), 6.45 (2H, dd, J = 2.4, 8.4 
Hz, 2  H-5’’), 6.74-6.79 (1H, m, H-Ar), 6.97 (1H, ddd, J = 1.0, 2.4, 8.0 Hz, H-Ar), 
6.95–7.00 (1H, m, H-Ar), 7.15 (1H, t, J = 8.0 Hz, H-5), 7.20 (1 H, d, J = 8.4 Hz, 2  
H-6’’); 13C NMR (125 MHz; CDCl3) δC 32.2 (2  CH2-CHAr), 35.8 (2  CH2-CHOH), 
43.1 (CH-Ar), 46.6 (2  N-CH2-), 55.1 (2  -OCH3), 55.4 (2  -OCH3), 70.4 (-CH-
OH), 98.2 (2  C-3’’), 104.0 (2  C-5’’), 116.6 (2  C-1’’), 119.8 (C-Ar), 120.2 (C-
Ar), 125.0 (C-Ar), 129.4 (C-Ar), 131.0 (2  C-6’’), 148.4 (C-Ar), 150.5 (C-Ar), 
158.5 (2  C-2’’ or C-4’’), 160.6 (2  C-2’’ or C-4’’); LRMS (ES+) m/z 594.6 
[M+Na]+; HRMS calcd for C30H38NO8S [M+H]+ 572.2313, found 572.2301. 
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3-(trans-4’-Hydroxycyclohexyl)phenyl sulfamate (111) 
 
Compound 111 was obtained according to general procedure G using the 
alcohol 120 (270 mg, 0.47 mmol), DCM (6.4 mL), and TFA (0.7 mL). The 
reaction mixture was stirred overnight at RT. The crude product was purified 
by MPLC (gradient elution, 0-50% EtOAc/petrol) to give the title compound (59 
mg, 46%) as an oil which solidified to give an off-white solid. Rf 0.16 (50% 
EtOAc/petrol; KMnO4); m.p. 136.4-136.7 °C; λmax (EtOH)/nm 262; νmax/cm-1 
(neat) 1186 (s, SO2sy), 1360 (s, SO2as), 1585 (m, NH2 def), 3303 (m, N-H); 1H 
NMR (500 MHz; CD3OD) δH 1.35–1.48 (2H, m, CHHax-CHOH), 1.49–1.64 (2H, m, 
CHHax-CHAr), 1.83–1.97 (2H, m, CHHeq-CHAr), 1.98–2.12 (2H, m, CHHeq-CHOH), 
2.54 (1H, tt, J = 3.4, 12.0 Hz, CH-Ar), 3.60 (1H, tt, J = 4.3, 11.0 Hz, CH-OH), 7.12 
(1H, m, H-Ar), 7.16–7.20 (2H, m, H-Ar), 7.29–7.34 (1H, m, H-5). 13C NMR (125 
MHz; CD3OD) δC 33.5 (2  CH2-CHAr), 36.5 (2  CH2-CHOH), 44.7 (CH-Ar), 71.02 
(-CH-OH), 120.8 (C-Ar), 121.8 (C-Ar), 126.2 (C-Ar), 130.5 (C-5), 150.2 (C-Ar q), 
152.1 (C-Ar q); LRMS (ES–) m/z 270.2 [M-H]-; HRMS calcd for C12H16NO4S [M-H]- 
270.0806, found 270.0796; HPLC 97.6% in water/MeCN (Rt 5.8 min); 98.0% in 
0.1% formic acid (aq.)/MeCN (Rt 5.8 min); 98.7% in 0.1% ammonia (aq.)/MeCN 
(Rt 3.4 min). 
3-(1’,4’-Dioxaspiro[4’.5’]dec-7’-en-8’-yl)phenol (106) 
 
Procedure 1: compound 106 was synthesized following general procedure E 
using the triflate 103 (219 mg, 0.76 mmol), the boronic ester 114 (167 mg, 0.76 
mmol), sodium carbonate (2 M aq., 0.76 mL, 1.52 mmol), [Pd(dppf)Cl2] (31 mg, 
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0.038 mmol) and DME (1.8 mL, 2.4 mL/mmol). Complete conversion was 
reached after 15 min. The crude product was purified by MPLC (gradient 
elution, 0-40% EtOAc/petrol) to yield the title compound (113 mg, 64%) as a 
yellow oil. Procedure 2: compound 106 was synthesized according to general 
procedure E using 3-bromophenol (250 mg, 1.44 mmol), the boronic ester 97 
(383 mg, 1.44 mmol), sodium carbonate (2 M aq., 1.44 mL, 2.88 mmol), 
[Pd(dppf)Cl2] (59 mg, 0.072 mmol) and DME (3.5 mL, 2.4 mL/mmol). The 
reaction mixture was heated under microwave irradiation for 45 min. The 
crude product was purified by MPLC (gradient elution, 0-40% EtOAc/petrol) to 
yield the title compound (95 mg, 28%) as a yellow oil. Rf 0.46 (40% 
EtOAc/petrol); λmax (EtOH)/nm 246, 288; νmax/cm-1 (neat) 1282 (s, O-C), 1580 
(s, C=C), 2888 and 2924 (m, C-H and -CH2- aliphatic), 3339 (br, O-H); 1H NMR 
(500 MHz; CDCl3) δH 1.88–1.96 (2H, m, -CH2-C-Ar), 2.41–2.50 (2H, m, -CH2-
CH=C), 2.58–2.69 (2H, m, -C(O-CH2CH2-O)-CH2-CH2-), 4.03 (4H, s, O-CH2-CH2-O), 
5.95–5.99 (1H, m, CH=CAr), 6.67–6.72 (1H, m, H-Ar), 6.83–6.86 (1H, m, H-2), 
6.94–6.99 (1H, m, H-Ar), 7.16 (1 H, t, J = 7.9 Hz, H-5); 13C NMR (125 MHz; CDCl3) 
δC 26.9 (-C(O-CH2CH2-O)-CH2-CH2-), 31.5 (-CH2-C-Ar), 36.3 (-CH2-CH=C), 64.6 
(O-CH2-CH2-O), 107.9 (O-C-O), 112.4 (C-2), 113.9 (C-Ar), 118.0 (C-Ar), 122.0 
(CH=C-Ar), 129.5 (C-5), 136.1 (CH=C-Ar), 143.4 (C-Ar q), 155.6 (C-Ar q); LRMS 
(ES+) m/z 233.3 [M+H]+. 
3-(1’,4’-Dioxaspiro[4’.5’]decan-8’-yl)phenol (107) 
 
A solution of 106 (387 mg, 1.65 mmol) in ethanol (56 mL, 34 mL/mmol) was 
passed over a 10% Pd/C catalyst cartridge embedded in a Thales H-cube. Flow 
rate, H2 pressure, and temperature were set according to the manufacture 
instructions (full H2 mode, 40 °C, 2 h 45 min). Upon completion of the reaction, 
the solvent was removed in vacuo. The product (white solid; 371 mg, 96%) was 
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used in the next step without further purification. Rf 0.30 (25% EtOAc/petrol); 
m.p. 97.8-98.9 °C; λmax (EtOH)/nm 273; νmax/cm-1 (neat) 1280 (s, O-C), 2932 (m, 
C-H and -CH2- aliphatic), 3295 (m, O-H); 1H NMR (500 MHz; CDCl3) δH 1.62–1.90 
(8H, m, 4  CH2), 2.51 (1H, tt, J = 3.4, 11.9 Hz, CH-Ar), 3.98 (4H, s, O-CH2-CH2-O), 
6.66 (1H, ddd, J = 1.0, 2.5, 7.9 Hz, H-6), 6.69–6.74 (1H, m, H-2), 6.77–6.86 (1H, m, 
H-4), 7.15 (1H, t, J = 7.9 Hz, H-5); 13C NMR (125 MHz; CDCl3) δC 31.6 (2  CH2), 
35.2 (2  CH2), 43.3 (CH-Ar), 64.4 (-O-CH2-CH2-O-), 64.5 (-O-CH2-CH2-O-), 108.7 
(O-C-O), 113.1 (C-Ar), 113.9 (C-2), 119.6 (C-Ar), 129.6 (C-5), 148.8 (C-Ar q), 
155.7 (C-Ar q); LRMS (ES+) m/z 235.3 [M+H]+; HRMS calcd for C14H17O3 [M-H]- 
233.1173, found 233.1173. 
Cyclohex-1-en-1-yl trifluoromethanesulfonate (105) 
 
Compound 105 was synthesized according to general procedure H using 
cyclohexanone (250 mg, 2.55 mmol), KHMDS 0.5 M in toluene (6.64 mL, 3.32 
mmol), N-phenylbis(trifluoromethanesulfonamide) (1.18 g, 3.32 mmol) and 
THF (25.5 mL, 10 mL/mmol). Purification by MPLC (gradient elution, petrol 0-
2% EtOAc/petrol) afforded the title compound (380 mg, 65%) as a colorless oil. 
Rf 0.60 (5% EtOAc/petrol; UV 254 nm, KMnO4); λmax (EtOH)/nm 263; νmax/cm-1 
(neat) 1199 (vs, C-F), 1413 (vs, SO2str), 1689 (w, C=C); 1H NMR (500 MHz; 
CDCl3) δH 1.56–1.64 (2H, m, =CHCH2-CH2), 1.74–1.81 (2H, m, CH2CH2C-
OSO2CF3), 2.13–2.22 (2H, m, =CH-CH2), 2.27–2.36 (2H, m, CH2C-OSO2CF3), 5.75 
(1H, tt, J = 1.6, 4.1 Hz, C=CHCH2-); 13C NMR (125 MHz; CDCl3) δC 21.1 (C=CH-
CH2-CH2), 22.8 (CH2CH2C-OSO2CF3), 24.0 (C=CH-CH2), 27.7 (CH2C-OSO2CF3), 
118.6 (CH2C=CH), 118.7 (q, J = 320 Hz, CF3), 149.5 (CH2C=CH); 19F NMR (470 
MHz; CDCl3) δF -74.1; HRMS calcd for C7H10O4F3S [M+OH]+ 247.0246, found 
247.0244. 
NMR data match those previously reported for this compound.203 
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3-(4’,4’,5’,5’-Tetramethyl-1’,3’,2’-dioxaborolan-2’-yl)phenol (114) 
 
Compound 114 was obtained following general procedure I using 3-
bromophenol (500 mg, 2.89 mmol), B2pin2 (881 mg, 3.47 mmol), [Pd(dppf)Cl2] 
(71 mg, 0.0867 mmol), potassium acetate (852 mg, 8.67 mmol) and 1,4-dioxane 
(15 mL). The crude product was purified by MPLC (gradient elution, 0-25% 
EtOAc/petrol) to afford the title compound as a pale yellow oil, which solidified 
upon storage at RT (580 mg, 81%). Rf 0.45 (25% EtOAc/petrol; KMnO4); m.p. 
77.5-79.3 °C; λmax (EtOH)/nm 249; νmax/cm-1 (neat) 2979, 3387 (m, OH); 1H 
NMR (500 MHz; CDCl3) δH 1.27 (12H, s, 4  CH3), 6.88 (1H, ddd, J = 1.1, 2.9, 8.0 
Hz, H-6), 7.15 – 7.18 (1H, m, H-2), 7.18 – 7.22 (1H, m, H-5), 7.28 – 7.33 (1H, m, 
H-4); 13C NMR (125 MHz; CDCl3) δC 25.0 (4  CH3), 84.1 (2  C-(CH3)2), 118.6 (C-
6), 121.2 (C-2), 127.2 (C-4), 129.4 (C-5), 155.2 (C-1). One quaternary carbon not 
detected; LRMS (ES–) m/z 219.3 [M-H]–; HRMS calcd for C12H16O3B [M-H]– 
219.1198, found 219.1190. 
NMR data match those previously reported for this compound.205 
2-(Cyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (101) 
 
Compound 101 was synthesized according to general procedure I using the 
triflate 105 (1.52 g, 6.60 mmol), (Bpin)2 (2.01 g, 7.92 mmol), [Pd(dppf)Cl2] (162 
mg, 0.198 mmol), potassium acetate (1.95 g, 19.8 mmol) and 1,4-dioxane (34 
mL). The crude product was purified by MPLC (gradient elution, 0-3% 
EtOAc/petrol) to afford the title compound as a colorless oil (981 mg, 71%). Rf 
0.68 (20% EtOAc/petrol; UV 254 nm, KMnO4); λmax (EtOH)/nm no max of 
absorption; νmax/cm-1 (neat) 1382 (s, B-O str.), 1447 (s, B-C str.), 1633 (m, C=C 
str), 2929 and 2977 (w, CH2as); 1H NMR (500 MHz; CDCl3) δH 1.25 (12H, s, 4 
CH3), 1.52 – 1.66 (4H, m, 2  CH2), 2.01 – 2.16 (4H, m, 2  CH2), 6.52 – 6.61 (1H, 
 
 
230 
 
m, C=CHCH2-); 13C NMR (125 MHz; CDCl3) δC 22.3 (CH2), 22.7 (CH2), 24.9 (4  
CH3), 26.2 (CH2), 26.7 (CH2), 83.1 (2  C-(CH3)2), 143.1 (CH2C=CH); LRMS (ES+) 
m/z 209.4 [M+H]+; HRMS calcd for C12H2010BO2 [M-H]– 206.1587, found 
206.1587. 
NMR data match those previously reported for this compound.206 
1-(Benzyloxy)-3-bromobenzene (112) 
 
Potassium carbonate (799 mg, 5.78 mmol) and benzyl bromide (544 mg, 3.18 
mmol) were added to a solution of 3-bromophenol (500 mg, 2.89 mmol) in 
acetone and the mixture was stirred at 57 °C for 3 h. The solvent was 
evaporated and the residue was dissolved in DCM (5 mL) and water (5 mL). The 
layers were separated and the aqueous phase was extracted with DCM (2  7.5 
mL). The combined organic layers were dried (MgSO4), filtered and evaporated 
in vacuo. Purification by MPLC (gradient elution, 0-1% EtOAc/petrol) yielded 
the title compound (680 mg, 89%) as an oil which solidified to give a white 
solid. Rf 0.50 (5% EtOAc/petrol); m.p. 61.4-62.6 °C (lit.207 61-62 °C); λmax 
(EtOH)/nm 249, 279; νmax/cm-1 (neat) 1237 (s, C-O-Cas), 2939 (aliphatic 
stretch), 3034, 3062, and 3103 (aromatic stretch); 1H NMR (500 MHz; CDCl3) δH 
5.04 (2H, s, CH2), 6.88–6.93 (1H, m H-Ar), 7.07–7.17 (3H, m, H-Ar), 7.31–7.48 
(5H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 70.4 (CH2), 114.0 (C-Ar), 118.3 (C-
Ar), 123.0 (C-Ar q), 124.2 (C-Ar), 127.6 (C-Ar), 128.3 (C-Ar), 128.8 (C-Ar), 130.7 
(C-Ar), 136.5 (C-Ar q), 159.7 (C-Ar q). 
NMR data match those previously reported for this compound.207 
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8-[3’-(Benzyloxy)phenyl]-1,4-dioxaspiro[4.5]dec-7-ene (113) 
 
Compound 113 was synthesized according to general procedure E using 
boronic ester 97 (202 mg, 0.760 mmol), bromide 112 (200 mg, 0.760 mmol), 
Na2CO3 (2 M aq., 0.76 mL, 1.52 mmol), [Pd(dppf)Cl2] (31 mg, 0.0380 mmol) and 
DME (1.8 mL). Purification by MPLC (gradient elution, 0-10% EtOAc/petrol) 
yielded the desired compound (183 mg, 75%) as a colorless oil. Rf 0.27 (10% 
EtOAc/petrol); λmax (EtOH)/nm 246, 285; νmax/cm-1 (neat) 1115, 1188 (m, C-O-
C-O-C vib), 1267 and 1285 (m, O-C), 1576 (m, C=C ar), 1597, 1603 (m, C=C str), 
2879, 2925 and 2947 (w, C-H and –CH2- aliphatic); 1H NMR (500 MHz; CDCl3) δH 
1.77–1.90 (2H, m, C(O-CH2-CH2-O)-CH2-CH2-), 2.33–2.43 (2H, m, -CH2-CH=C), 
2.58 (2H, tq, J = 6.3, 2.0 Hz, -C(O-Et-O)-CH2-CH2), 3.95 (4H, s, O-CH2-CH2-O), 4.99 
(2H, s, CH2-Ph), 5.89–5.93 (1H, m, C=C-H), 6.78 (1H, ddd, J = 1.0, 2.5, 8.2 Hz, H-
Ar), 6.90–6.97 (2H, m, H-Ar), 7.14 (1H, app. t, J = 7.9 Hz, H-5’), 7.22–7.29 (1H, m, 
H-Ar), 7.29–7.34 (2H, m, H-Ar), 7.34–7.39 (2H, m, H-Ar); 13C NMR (125 MHz; 
CDCl3) δC 27.0 (-C(O-Et-O)-CH2-CH2-), 31.5 (-C(O-Et-O)-CH2-CH2-), 36.3 (-CH2-
CH=C), 64.6 (O-CH2-CH2-O), 70.1 (CH2-Ph), 107.9 (-O-C-O-), 112.3 (C-Ar), 113.3 
(C-Ar), 118.2 (C-Ar), 122.0 (C=C-H), 127.6 (2  C-Ar), 128.1 (C-Ar), 128.7 (2  C-
Ar), 129.3 (C-5’), 136.3 (C q), 137.2 (C q), 143.2 (C-1’), 158.9 (C-Ar q); LRMS 
(ES+) m/z 323.5 [M+H]+; HRMS calcd for C21H23O3 [M+H]+ 323.1642, found 
323.1645. 
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2',3',4',5'-tetrahydro-[1,1'-biphenyl]-3-yl bis(2’’,4’’-
dimethoxybenzyl)sulfamate (121) 
 
Compound 121 was synthesized according to general procedure E using 
boronic ester 101 (574 mg, 2.76 mmol), bromide 115 (1.52 g, 2.76 mmol), 
Na2CO3 (2 M aq., 2.76 mL, 5.52 mmol), [Pd(dppf)Cl2] (113 mg, 0.138 mmol) and 
DME (6.6 mL). Complete conversion was reached after 75 min. Purification by 
MPLC (gradient elution, 0-20% EtOAc/petrol) yielded the desired compound 
(1.47 g, 96%) as a pale yellow oil. Rf 0.20 (10% EtOAc/petrol); λmax (EtOH)/nm 
no maximum absorption observed; νmax/cm-1 (neat) 1133 (m, SO2sy), 1157 (m, 
C-O), 1369 (m, SO2as), 1588 (m, C=C ar), 2934 (w, C-H and –CH2- aliphatic); 1H 
NMR (500 MHz; CDCl3) δH 1.61–1.70 (2H, m, =CHCH2-CH2), 1.72–1.82 (2H, m, 
CH2CH2C-Ar), 2.16–2.24 (2H, m, =CH-CH2), 2.26–2.35 (2H, m, CH2C-Ar), 3.72 
(6H, s, 2  OCH3), 3.80 (6H, s, 2  OCH3), 4.45 (4H, s, 2  N-CH2-), 6.07 (1H, tt, J = 
1.8, 3.9 Hz, =CHCH2-), 6.38 (2H, d, J = 2.4 Hz, 2  H-3’’), 6.44 (2H, dd, J = 2.4, 8.4 
Hz, 2  H-5’’), 6.96–7.02 (2H, m, H-Ar), 7.20–7.24 (2H, m, H-Ar), 7.25–7.31 (2H, 
m, 2  H-6’’); 13C NMR (125 MHz; CDCl3) δC 22.2 (C=CHCH2-CH2), 23.1 (CH2CH2C-
Ar), 26.0 (C=CH-CH2), 27.4 (CH2C-Ar), 46.9 (2  N-CH2), 55.2 (2  OCH3), 55.5 (2 
 OCH3), 98.3 (2  C-3’’), 104.1 (2  C-5’’), 116.8 (2  C-1’’), 118.6 (C-Ar), 120.0 
(C-Ar), 122.9 (C-Ar), 126.0 (C=C-H), 129.2 (C-Ar), 131.1 (2  C-6’’), 135.7 (C q), 
144.5 (C q), 150.6 (C-3 ), 158.6 (2  C-2’’ or C-4’’), 160.7 (2  C-2’’ or C-4’’); 
LRMS (ES+) m/z 576.5 [M+Na]+; HRMS calcd for C30H36NO7S [M+H]+ 554.2207, 
found 554.2198. 
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4-(3’-Hydroxyphenyl)cyclohexanone (109) 
 
Compound 109 was prepared according to general procedure F using ketal 107 
(371 mg, 1.58 mmol), THF/H2O 1:3 (44 mL, 28 mL/mmol) and acetic acid (68 
mL, 42 mL/mmol). The crude product was purified by MPLC (gradient elution, 
0-40% EtOAc/petrol) to yield the title compound as a white solid (230 mg, 
77%). Rf 0.36 (33% EtOAc/petrol; UV 254 nm, KMnO4); m.p. 132-134 C; λmax 
(EtOH)/nm 274, 380; νmax/cm-1(neat) 1689 (vs, C=O), 3386 (s, O-H); 1H NMR 
(500 MHz; CDCl3) δH 1.83–1.99 (2H, m, 2  CHeqHax), 2.15–2.27 (2H, m, 2  
CHeqHax), 2.44–2.57 (4H, m, 2  CH2-C=O), 2.97 (1H, tt, J = 3.4, 12.1,), 6.07 (1H, 
br, OH), 6.69–6.76 (2H, m, H-2’ and H-4’), 6.77–6.82 (1H, m, H-6’), 7.15–7.21 
(1H, m, H-5’); 13C NMR (125 MHz; CDCl3) δC 34.0 (C-3 and C-5), 41.4 (C-2 and C-
6), 42.7 (C-4), 113.7 and 113.8 (C-2’ and C-4’), 119.1 (C-6’), 129.9 (C-5’), 146.7 
(C-1’), 156.2 (C-3’), 212.7 (CO); LRMS (ES–) m/z 189.2 [M-H]–; HRMS calcd for 
C12H14O2Na [M+Na]+ 213.0886, found 213.0887. 
2',3',4',5'-Tetrahydro-[1,1'-biphenyl]-3-yl sulfamate (135) 
 
Sulfamate 135 was prepared according to general procedure G using protected 
sulfamate 121 (256 mg, 0.462 mmol), DCM (5.4 mL) and TFA (0.6 mL.) 
Purification by MPLC (gradient elution, 0-40% EtOAc/petrol) yielded the 
desired compound as a white solid (87 mg; 74%). Rf 0.52 (50% EtOAc/petrol); 
m.p. 99.6-100.7 °C; λmax (EtOH)/nm 248; νmax/cm-1 (neat) 1146 and 1178 (s, 
SO2sy), 1351 (s, SO2as), 1605 (m, C=C), 2933 (m, C-H and –CH2- aliphatic), 3263 
and 3365 (m, N-H str.); 1H NMR (500 MHz; CDCl3) δH 1.59–1.71 (2H, m, 
C=CHCH2-CH2), 1.71–1.82 (2H, m, CH2CH2C-Ar), 2.13–2.28 (2H, m, C=CH-CH2), 
2.34–2.30 (2H, tt, J = 2.5, 6.2 Hz, CH2C-Ar), 5.05 (2H, s, NH2), 6.14–6.18 (1H, m, 
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C=CHCH2-), 7.13–7.19 (1H, m, H-Ar), 7.30–7.35 (3H, m, H-Ar); 13C NMR (125 
MHz; CDCl3) δC 22.1 (C=CHCH2-CH2), 23.0 (CH2CH2C-Ar), 26.0 (C=CH-CH2), 27.4 
(CH2C-Ar), 118.6 (C-Ar), 119.9 (C-Ar), 123.9 (C-Ar), 126.7 (C=C-H), 129.6 (C-Ar), 
135.4 (C q), 145.0 (C q), 150.3 (C-3); LRMS (ES–) m/z 252.2 [M-H]–; HRMS calcd 
for C12H14O3NS [M-H]– 252.0700, found 252.0689; HPLC 99.0% in water/MeCN 
(Rt 8.2 min); 99.3% in 0.1% formic acid (aq.)/MeCN (Rt 8.2 min); 99.2% in 0.1% 
ammonia (aq.)/MeCN (Rt 6.2 min). 
3-(2’-Hydroxycyclohexyl)phenyl bis(2’’,4’’-dimethoxybenzyl)sulfamate 
(122) and 3-(1’-hydroxycyclohexyl)phenyl bis(2’’,4’’-
dimethoxybenzyl)sulfamate (137) 
   
To a solution of alkene 121 (1.01 g, 1.82 mmol) in THF (1.02 mL, 0.56 
mL/mmol), BH3 · THF complex (1.0 M, 1.82 mL, 1.82 mmol) was added 
dropwise at 0 °C and the mixture was stirred for 1 h at 0 °C and 3 h at RT. NaOH 
(3 M aq., 0.38 mL, 1.15 mmol) and H2O2 (aq. 30% w/v, 0.33 mL, 2.84 mmol) 
were added and the mixture was stirred overnight at RT. Water (30 mL) was 
added and the product was extracted with EtOAc (3  30 mL). The combined 
organic layers were washed with  Na2S2O3 (sat. aq.), brine, dried (MgSO4), 
filtered and evaporated. Purification by MPLC (gradient elution, 0-40% 
EtOAc/petrol) yielded the desired compound 122 (570 mg, 55%) and the side 
product 137 (170 mg, 16%) as colorless oils. 
122 
Rf 0.44 (50% EtOAc/petrol; UV 254 nm, KMnO4); λmax (EtOH)/nm 277; νmax/cm-
1 (neat) 1128 (s, SO2sy), 1157 (s, C-O), 1375 (m, SO2as), 1587 (m, C=C ar), 2933 
(w, C-H and –CH2- aliphatic); 1H NMR (500 MHz; CDCl3) δH 1.20–1.40 (4H, m, 
CHaxHeq), 1.60–1.74 (2H, m, CHaxHeq), 1.74–1.83 (1H, m, CHaxHeq), 1.98–2.05 (1H, 
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m, CHaxHeq), 2.24–2.35 (1H, m, CH-Ar), 3.43 (1H, app. td, J = 4.2, 10.1 Hz, CHOH), 
3.64 (6H, s, 2  -OCH3), 3.72 (6H, s, 2  -OCH3), 4.33 (4H, s, 2  N-CH2-), 6.33 (2H, 
d, J = 2.4 Hz, 2  H-3’’), 6.38 (2H, dd, J = 2.4, 8.4 Hz, 2  H-5’’), 6.65 (1H, app. t, J = 
2.0 Hz, H-2), 6.97 (1H, ddd, J = 1.0, 2.3, 8.1 Hz, H-Ar), 7.00–7.05 (1H, m, H-Ar), 
7.18 (1H, app. t, J = 8.1 Hz, H-5), 7.22 (2H, d, J = 8.1 Hz, 2  H-6’’); 13C NMR (125 
MHz; CDCl3) δC 25.0 (C-4’), 26.1 (C-5’), 33.3 (C-6’), 34.7 (C-3’), 46.7 (2  N-CH2-), 
53.0 (C-1’), 55.2 (2  -OCH3), 55.5 (2  -OCH3), 74.1 (C-2’), 98.3 (2  C-3’’), 104.1 
(2  C-5’’), 116.6 (2  C-1’’), 120.7 (C-Ar), 120.9 (C-2), 126.6 (C-Ar), 129.8 (C-5), 
131.0 (C-6’’), 145.5 (C-3), 150.9 (C-1), 158.5 (2  C-2’’ or C-4’’), 160.7 (2  C-2’’ 
or C-4’’); LRMS (ES+) m/z 594.6 [M+Na]+; HRMS calcd for C30H41O8N2S [M+NH4]+ 
589.2578, found 589.2553. 
137 
Rf 0.56 (50% EtOAc/petrol; UV 254 nm, KMnO4); λmax (EtOH)/nm 278; νmax/cm-1 
(neat) 1128 (s, SO2sy), 1157 (s, C-O), 1372 (m, SO2as), 1588 (m, C=C ar), 2934 (w, 
C-H and –CH2- aliphatic); 1H NMR (500 MHz; CDCl3) δH 1.23–1.37 (1H, m, 
cyclohexyl CH), 1.54 –1.83 (9H, m, 9  cyclohexyl CH), 3.71 (6H, s, 2  OCH3), 
3.80 (6H, s, 2  -OCH3), 4.43 (4H, s, 2  N-CH2-), 6.39 (2H, d, J = 2.4 Hz, 2  H-3’’), 
6.44 (2H, dd, J = 2.4, 8.3 Hz, 2  H-5’’), 7.01–7.08 (2H, m, H-Ar), 7.23–7.32 (3H, 
m, H-Ar and 2  H-6’’), 7.33–7.42 (1H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 
22.2 (2  CH2), 25.5 (CH2), 38.8 (2  CH2), 46.8 (2  N-CH2), 55.2 (2  OCH3), 55.5 
(2  OCH3), 73.0 (C-1’), 98.3 (2  C-3’’), 104.1 (2  C-5’’), 116.7 (2  C-1’’), 118.5 
(C-Ar), 120.4 (C-Ar), 122.7 (C-Ar), 129.4 (C-Ar), 131.0 (2  C-6’’), 150.6 (C-1), 
151.7 (C-3), 158.6 (2  C-2’’ or C-4’’), 160.7 (2  C-2’’ or C-4’’); LRMS (ES+) m/z 
594.6 [M+Na]+; HRMS calcd for C30H41O8N2S [M+NH4]+ 589.2578, found 
589.2569. 
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3-(trans-2’-Hydroxycyclohexyl)phenyl sulfamate (123) 
 
Compound 123 was obtained according to general procedure G using protected 
sulfamate 122 (570 mg, 1.00 mmol) and 10% TFA/DCM (10 mL). Purification 
by MPLC (gradient elution, 0-50% EtOAc/petrol) yielded the desired racemic 
compound (94 mg, 35%) as an oil. Rf 0.26 (50% EtOAc/petrol; UV 254 nm, 
KMnO4); λmax (EtOH)/nm 261; νmax/cm-1 (neat) 1135 (m, SO2sy), 1182 (s, C-O), 
1372 (m, SO2as), 2930 (w, C-H and –CH2- aliphatic), 3358 (br, O-H); 1H NMR 
(500 MHz; CDCl3) δH 1.30–1.69 (5H, m, 5  cyclohexyl CH), 1.77–1.87 (1H, m, 
cyclohexyl CH), 1.89-2.02 (2H, m, 2  cyclohexyl CH), 2.13-2.20 (1H, m, CH-Ar), 
2.71 (1H, ddd, J = 12.6, 10.8, 3.8 Hz, CH-OH), 5.07 (1H, td, J = 4.5, 10.8 Hz, OH), 
6.63–6.72 (2H, m, H-Ar), 6.75 (1H, dt, J = 7.7, 1.3 Hz, H-Ar), 7.11-7.17 (1H, m, H-
Ar); 13C NMR (125 MHz; CDCl3) δC 24.7 (CH2), 25.5 (CH2), 31.8 (CH2), 33.1 (CH2), 
49.3 (CH-Ar), 81.0 (CH-OH), 114.1 (C-Ar), 114.5 (C-Ar), 120.0 (C-Ar), 129.8 (C-
Ar), 143.4 (C-3), 155.8 (C-1); LRMS (ES–) m/z 270.2 [M-H]–; HRMS calcd for 
C12H21O7N2S [M+NH4]+ 289.1217, found 289.1220; HPLC 97.0% in water/MeCN 
(Rt 6.3 min); 99.2% in 0.1% formic acid (aq.)/MeCN (Rt 6.5 min); 97.5% in 0.1% 
ammonia (aq.)/MeCN (Rt 3.8 min). 
Sodium trans-2-[3-(sulfamoyloxy)phenyl]cyclohexyl sulfate (93) 
 
Sulfate 93 was obtained following general procedure D (method 2) using 
alcohol 123 (45 mg, 0.166 mmol), sulfur trioxide pyridine complex (53 mg, 
0.332 mmol) and DMF (0.45 mL). Purification by MPLC yielded the desired 
compound (20 mg, 32%) as a white solid. Rf 0.27 (10% MeOH/EtOAc; KMnO4); 
m.p. 205-218 (dec.); λmax (EtOH)/nm 260; νmax/cm-1 (neat) 1198 (vs, SO2sy), 
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1382 (m, SO2as), 2926 (w, CH and CH2 aliphatic), 3254 and 3346 (w, N-H); 1H 
NMR (500 MHz; DMSO-d6) δH 1.21 – 1.44 (4H, m, 4  cyclohexyl CH), 1.60-1.69 
(1H, m, cyclohexyl CH), 1.70–1.86 (2H, m, 2  cyclohexyl CH), 2.52 (1H, m, 
cyclohexyl CH), 2.55–2.62 (1H, m, CH-Ar), 4.19–4.28 (1H, m, CH-OSO3Na), 6.98–
7.05 (1H, m, H-Ar), 7.19 (1H, app. d, J = 7.8 Hz), 7.22–7.26 (1H, m), 7.30 (1H, 
app. t, J = 7.8 Hz), 7.71 (2H, br, NH2) ppm. One proton signal is covered by the 
DMSO signal (confirmed by COSY and HSQC); 13C NMR (125 MHz; DMSO-d6) δC 
24.4 (CH2), 25.6 (CH2), 32.9 (CH2), 35.0 (CH2), 49.6 (CH-Ar), 77.4 (CH-OSO3Na), 
119.6 (C-Ar), 120.9 (C-Ar), 126.3 (C-Ar), 129.0 (C-Ar), 146.4 (C-Ar), 149.9 (C-3’); 
LRMS (ES–) m/z 350.2 [M-Na]–; HRMS calcd for C12H16O7NS2 [M-Na]– 350.0374, 
found 350.0367; HPLC 97.0% in water/MeCN (Rt 4.2 min); 96.5% in 0.1% 
formic acid (aq.)/MeCN (Rt 7.7 min); 92.5% in 0.1% ammonia (aq.)/MeCN (Rt 
3.4 min). 
Sodium cis-4-[3’-(sulfamoyloxy)phenyl]cyclohexyl sulfate (91) 
 
Sulfate 91 was obtained following general procedure D (method 2) using 
alcohol 110 (85 mg, 0.313 mmol), sulfur trioxide pyridine complex (200 mg, 
1.25 mmol), and DMF (0.85 mL). Purification by MPLC yielded the desired 
compound (114 mg, 98%) as a white solid. Rf 0.10 (10% MeOH/EtOAc; KMnO4); 
m.p. 144.6-146.0 °C; λmax (EtOH)/nm 261; νmax/cm-1 (neat) 1195 (vs, SO2sy), 
1380 (m, SO2as), 2861 and 2943 (w, C-H and –CH2- aliphatic), 3108 and 3254 (w, 
N-H); 1H NMR (500 MHz; DMSO-d6) δH 1.43–1.62 (4H, m, CHax), 1.70 (2H, m, 2  
CHeq), 2.03 (2H, m, 2  CHeq), 2.53–2.62 (1H, m, CH-Ar), 4.35-4.40 (1H, m, CH-
OSO3Na), 7.07–7.11 (1H, dd, J = 2.0, 7.9 Hz, H-Ar), 7.12 (1H, app. t, J = 2.0, H-2’), 
7.19 (1H, app. d, J = 7.9, H-Ar), 7.37 (1H, app. t, J = 7.9, H-5’), 7.94 (2H, s, NH2); 
13C NMR (125 MHz; DMSO-d6) δC 27.9 (2  CH2), 30.5 (2  CH2), 42.4 (CH-Ar), 
69.8 (CH-OSO3Na), 119.6 (C-Ar), 120.4 (C-Ar), 124.9 (C-Ar), 129.5 (C-Ar), 149.5 
(C-Ar q), 150.2 (C-Ar q); LRMS (ES–) m/z 350.2 [M-Na]–; HRMS calcd for 
C12H16O7NS2 [M-Na]– 350.0374, found 350.0368; HPLC 97.0% in water/MeCN 
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(Rt 3.6 min); 97.9% in 0.1% formic acid (aq.)/MeCN (Rt 7.0 min); N/A in 0.1% 
ammonia (aq.)/MeCN. 
Sodium trans-4-[3’-(sulfamoyloxy)phenyl]cyclohexyl sulfate (92) 
 
Compound 92 was obtained following general procedure D (method 2) using 
alcohol 111 (114 mg, 0.420 mmol), sulfur trioxide pyridine complex (134 mg, 
0.840 mmol), and DMF (1.13 mL). Purification by MPLC yielded the desired 
compound (132 mg, 84%) as a colorless oil. Rf 0.10 (10% MeOH/EtOAc; 
KMnO4); λmax (EtOH)/nm 260; νmax/cm-1 (neat) 1183 (vs, SO2sy), 1373 (s, SO2as), 
2864 and 2938 (w, C-H and –CH2- aliphatic), 3089 and 3263 (w, N-H); 1H NMR 
(500 MHz; DMSO-d6) δH 1.29 – 1.40 (2H, m, CHax), 1.41–1.56 (2H, m, CHax), 1.74–
1.85 (2H, m, CHeq), 2.07–2.18 (2H, m, CHax), 3.99–4.11 (1H, m, CH-OSO3Na), 7.09 
(1H, dd, J = 1.9, 8.0 Hz, H-Ar), 7.14 (1H, app. t, J = 1.9 Hz, H-2’), 7.21 (1H, d, J = 
8.0 Hz, H-Ar), 7.35 (1H, t, J = 8.0 Hz, H-5’), 7.91 (2H, br, NH2). One proton signal 
(CH-Ar) is covered by the DMSO signal (confirmed by COSY and HSQC); 13C NMR 
(125 MHz; DMSO-d6) δC 32.0 (CH2), 33.0 (CH2), 42.4 (CH2), 74.2 (CH2), 119.6 (C-
Ar), 120.5 (C-Ar), 124.8 (C-Ar), 129.4 (C-Ar), 148.7 (C-Ar q), 150.2 (C-Ar q); 
LRMS (ES–) m/z 350.2 [M - Na]–; HRMS calcd for C12H16O7NS2 [M-Na]– 350.0374, 
found 350.0367; HPLC 95.7% in water/MeCN (Rt 3.5 min); 97.0% in 0.1% 
formic acid (aq.)/MeCN (Rt 7.0 min); N/A in 0.1% ammonia (aq.)/MeCN. 
 MDMX project experimental procedures  9.3
9.3.1 MDMX and MDM2 biological assay protocols 
ELISA 
Biological testing of compounds was undertaken by Dr Yan Zhao at the 
Northern Institute for Cancer Research using an ELISA assay (details taken from 
Hardcastle et al.).208 The 96-well black and white high binding luminometry 
isoplates (Wallac, Cat N0 140-155) were coated by overnight incubation at 
35 °C with 200 μL per well of 5 μg mL-1 streptavidin (Chemicon International) 
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in coating buffer (0.1 M Na2HPO4·2 H2O; 0.1 M citric acid; pH 5.0). The plates 
were washed five times in 1 dissociation enhanced lanthanide fluorescence 
immunoassay (DELFIA) buffer (Wallac) and then incubated for 3 h at room 
temperature with saturation buffer (0.3 M D-sorbitol; 50 mM Tris; 150 mM 
NaCl; 0.1% BSA; 0.05% sodium azide; pH 7.0) to block nonspecific protein 
binding sites on the plate. After removal of the buffer from the plates, they were 
allowed to dry in a sterile laminar air flow hood at room temperature before 
incubation for 1 h at 4 °C with 200 μL per well of 100 μg/mL-1 biotinylated IP3 
peptide (b-IP3: Ac-Met-Pro-Arg-Phe19-Met-Asp-Tyr-Trp-Glu-Gly-Leu26-Asn-
NH2) dissolved in 0.05% DMSO-PBS, pH 7.4 buffer. After washing the wells 
three times with PBS, the plates were ready to use for MDM2 binding. 
For initial testing, the compounds and controls were plated out in triplicate 
into clear 96-well plates (Nunc) in 10 μL aliquots to give final concentrations of  
500 μM, 100 μM and 20 μM in the assay. Control samples consisted of 5% DMSO 
carrier alone as a negative control and 100 nM active peptide (AP-B: Ac-Phe19-
Met-Aib-Pmp-6-Cl-Trp-Glu-Ac3-Leu26-NH2)163 as a positive control peptide 
antagonist of the MDM2:p53 interaction (IC50 = 5 nM). Compounds and controls 
aliquoted in 96-well plates were preincubated at 20° C for 20 min with 190 μL 
aliquots of optimized concentrations of in vitro translated MDM2, before 
transfer of the MDM2-compound mixture to the b-IP3 streptavidin plates, and 
incubation at 4 °C for 90 min. After washing three times with PBS to remove 
unbound MDM2, each well was incubated at 20 °C for 1 h with a TBS-Tween (50 
mM Tris pH 7.5; 150 mM NaCl; 0.05% Tween 20 non-ionic detergent) buffered 
solution of primary mouse monoclonal anti-MDM2 antibody (Ab-5, Calbiochem, 
used at a 1/200 dilution), washed three times with TBS-Tween before 
incubation for 45 min at 20 °C with a goat-anti-mouse horseradish peroxidase 
(HRP) conjugated secondary antibody (Dako, used at 1/2000). The unbound 
secondary antibody was removed by washing three times with TBS-Tween. The 
bound HRP activity was measured by enhanced chemiluminescence (ECL, 
Amersham Biosciences) using the oxidation of the diacylhydrazide substrate, 
luminol, to generate a quantifiable light signal. The luminol substrate together 
with enhancer was automatically injected into each well and the relative 
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luminescence units (RLU) measured over 30 s using a Berthold MicroLumat-
Plus LB 96 V microplate luminometer. The percentage MDM2 inhibition at a 
given concentration was calculated as the (RLU detected in the compound 
treated sample ÷ RLU of DMSO controls)  100. The IC50 was calculated using a 
plot of % MDM2 inhibition vs concentration and is the average of three 
independent experiments. 
The same procedure was used for measuring MDMX inhibition. Unless 
otherwise stated, only one measurement was performed. 
9.3.2 General synthetic procedures 
General procedure J: N-aroylhydrazone formation158 
Under an inert atmosphere, the benzaldehyde (1.0 equiv.) was dissolved in 
acetic acid (4.2 mL/mmol), and the appropriate hydrazide (1.1 equiv.) was 
added in one portion at RT. Upon completion of the reaction, the solution was 
cautiously poured into ice water. The white slurry was filtered, washed with a 
little cold water and triturated with petrol. The solid was dried overnight at 
40 °C over P2O5. The product was used directly without further purification. 
General procedure K: Pb(OAc)4-mediated benzoylbenzaldehyde 
formation158 
At RT, lead tetraacetate (1.2 equiv.) was added in small portions to a solution 
of the hydrazone (1.0 equiv.) in THF (7.7 mL/mmol) and the mixture was 
stirred for 3 h. Upon completion of the reaction, the mixture was diluted with 
ethyl acetate, filtered through Celite, washed with sat. aq. NaHCO3 and brine, 
dried, filtered and evaporated in vacuo. The crude product was purified by 
MPLC. 
General procedure L: Pinnick oxidation 
NaClO2 (1.3 equiv. in water, 1.4 mL/mmol) and sulfamic acid (1.3 equiv. in 
water, 1.4 mL/mmol) were added to a solution of the benzaldehyde in 
acetonitrile in one portion and the yellow solution was stirred at RT for 2 h. The 
solvent was removed in vacuo, and the residue was dissolved in ethyl acetate 
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and washed with water and brine. The organic layer was dried, filtered and 
evaporated. Unless otherwise stated, further purification was not required. 
General procedure M: isoindolinone formation 
To a solution of the benzoylbenzoic acid (1.0 equiv.) in THF (1.2 mL/mmol), 
thionyl chloride (2.0 equiv.) was added followed by a catalytic amount of DMF 
(1-3 drops); the solution was stirred at RT for 4 h, and evaporated. The residue 
was redissolved in THF (1.2 mL/mmol), and the appropriate amine (1.1 equiv.) 
and DIPEA (1.1 equiv.) were added dropwise. The resulting solution was stirred 
at RT overnight. Ethyl acetate was added to the mixture and the layers were 
separated. The aqueous layer was extracted with EtOAc and the combined 
organic layers were dried (MgSO4), filtered and the solvent was removed in 
vacuo. The crude product was purified by MPLC. 
General procedure N: side chain addition 
Under an inert atmosphere, the isoindolinone (1.0 equiv.) was dissolved in 
1,2-dichloroethane. InBr3 (0.20 equiv.) and 1,1-
bis(hydroxymethyl)cyclopropane (5.0 equiv.) were added in one portion and 
the reaction mixture was stirred at 85 °C. Upon completion of the reaction, the 
solvent was removed in vacuo. The residue was dissolved in Et2O (20 mL) and 
the resulting solution was washed with water (3  30 mL). The aqueous layer 
was back-extracted with Et2O (2  30 mL). The combined organic layers were 
washed with brine, dried (MgSO4), filtered and evaporated. Unless otherwise 
stated, the crude product was purified by MPLC. 
General procedure O: Suzuki coupling of 7-bromoisoindolinones 
Under an inert atmosphere, the appropriate boronic acid (1.3 equiv.) and 
Na2CO3 (aq. 2M, 3.0 equiv.) were added to a solution of the 7- 
bromoisoindolinone (1.0 equiv.) in acetonitrile (1.2 mL/mmol) and the mixture 
was degassed for 3-5 min before adding tetrakis(triphenylphosphine)palladium 
(0.10 equiv.). After further degassing, the reaction mixture was heated at 85 °C. 
Upon completion of the reaction, the mixture was diluted with EtOAc (10 mL) 
and water (10 mL); the layers were separated and the aqueous phase was 
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extracted with EtOAc (3  15 mL). The combined organic layers were washed 
with brine, dried (MgSO4), filtered and evaporated. The residue was dissolved in 
MeOH and filtered though a Thiol MP SPE cartridge. The crude product was 
purified by MPLC. 
General procedure P: TBAF deprotection 
At 0 °C and under an inert atomosphere, TBAF (1 M in THF, 1.1 equiv.) was 
added dropwise to a solution of the silylated compound (1.0 equiv.) in THF (60 
mL/mmol). The yellow solution was allowed to warm up to RT and stirred for 3 
h. Upon completion of the reaction, the solvent was removed in vacuo and the 
crude product was purified by MPLC. 
General procedure Q: phthalimide formation 
At 0 °C, the amine (1.0 equiv.) was added to a solution of the anhydride (1.0 
equiv.) in THF (0.5 mL/mmol). The suspension was refluxed until 
disappearance of the starting material. The solvent was removed in vacuo and 
the residue was taken up in EtOAc, washed with water (3  10 mL) and brine 
(10 mL). The organic layer was dried (MgSO4), filtered and concentrated in 
vacuo. The crude product was purified by MPLC. 
General procedure R: addition of a Grignard to a phthalimide 
Under an inert atmosphere, phenylmagnesium bromide (3.0 equiv.) was 
added dropwise to a cooled solution (-78 °C) of the imide (1.0 equiv.) in THF 
(2.0 mL/mmol). The deep red reaction mixture was stirred for 1 h at 0 °C and 1 
h at RT. Upon completion of the reaction, the mixture was quenched with NH4Cl 
(sat. aq., 5 mL) and the product was extracted with EtOAc (3  15 mL). The 
combined organic layers were washed with brine (20 mL), dried (MgSO4), 
filtered and evaporated. The crude product was purified by MPLC. 
General procedure S: oxidation of a primary alcohol 
The alcohol (1.0 equiv.) was dissolved in a mixture of EtOAc (1.43 mL/mmol), 
acetonitrile (1.43 mL/mmol) and water (2.5 mL/mmol). NaIO4 (4.1 equiv.) was 
added at RT in one portion followed by RuCl3 · H2O. The mixture was stirred at 
RT for 20 min, diluted with EtOAc (1.2 mL) and filtered through a Celite 
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cartridge. The filtrate was washed with H2O (2 mL) and the aqueous layer was 
back-extracted with EtOAc (2  2 mL). The combined organic layers were 
washed with brine (4 mL), dried (MgSO4) and the solvent was removed in 
vacuo. The product was purified by MPLC as described for each compound. 
9.3.3 MDMX project - Synthesized compounds 
(E)-4-Chloro-N'-(3’-chloro-2’-hydroxybenzylidene)benzohydrazide (178) 
 
Compound 178 was synthesized according to general procedure J using 3-
chloro-2-hydroxybenzaldehyde (1.00 g, 6.39 mmol), 4-chlorobenzydrazide 
(1.09 g, 6.39 mmol) and acetic acid (27 mL). The crude product (off-white solid; 
1.70 g, 86%) was used for the next step without further purification. Rf 0.58 
(10% MeOH/DCM); m.p. 217.0-217.4 °C; λmax (EtOH)/nm 292, 304, 330; 
νmax/cm-1 (neat) 1665 (s, C=O), 3074 (m, C-H str, aromatic), 3205 (m, N-H), 
3348 (w, C=O, overtone), 3543 (m, O-H); 1H NMR (500 MHz; DMSO-d6) δH 6.98 
(1H, app. t, J = 7.8 Hz, H-5’), 7.47-7.54 (2H, m, H-4’ and H-6’), 7.63–7.68 (2H, m, 
H-3 and H-5), 7.94 – 8.01 (2H, m, H-2 and H-6), 8.61 (1H, s, CH=N), 12.36 and 
12.45 (2  1H, br s, O-H and N-H); 13C NMR (125 MHz; DMSO-d6) δC 119.6 (C-1’ 
or C-3’), 120.1 (C-5’), 120.4 (C-1’ or C-3’), 128.8 (C-3 and C-5), 129.6 (C-4’ or C-
6’), 129.7 (C-2 and C-6), 131.1 (C-4), 131.4 (C-4’ or C-6’), 137.1 (C-1), 148.9 
(CH=N), 153.3 (C-2’), 161.9 (C=O); LRMS (ES+) m/z 309.3 [M+H]+; HRMS calcd 
for C14H11O2N235Cl2 [M+H]+ 309.0192, found 309.0191. 
(E)-N'-(3’-Chloro-2’-hydroxybenzylidene)benzohydrazide (181) 
 
Compound 181 was synthesized according to general procedure J using 3-
chloro-2-hydroxybenzaldehyde (1.00 g, 6.39 mmol), benzohydrazide (0.87 g, 
6.39 mmol) and acetic acid (27 mL). The crude product (off-white solid; 1.67 g, 
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95%) was used for the next step without further purification. Rf 0.54 (10% 
MeOH/DCM);m.p. 190.5-191.1 °C; λmax (EtOH)/nm 291, 302, 329; νmax/cm-1 
(neat) 1643 (s, C=O), 3197 (m, C-H str, aromatic), 3195 (m, N-H); 1H NMR (500 
MHz; DMSO-d6) δH 6.97 (1H, t, J = 7.7 Hz, H-5’), 7.49 (2H, app. d, J = 7.7 Hz, H-4’ 
and H-6’), 7.53-7.60 (2H, m, H-3 and H-5), 7.60-7.67 (1H, m, H-4), 7.92-8.00 (2 
H, m, H-2 and H-6), 8.62 (1H, s, CH=N), 12.39 and 12.44 (2  1H, br s, O-H and N-
H); 13C NMR (125 MHz; DMSO-d6) δC 119.6 (C-1’ or C-3’), 120.0 (C-5’), 120.3 (C-
1’ or C-3’), 127.7 (C-2 and C-6), 128.6 (C-3 and C-5), 129.5 (C-4’ or C-6’), 131.3 
(C-4’ or C-6’), 132.3 (C-4), 132.4 (C-1), 148.6 (CH=N), 153.3 (C-2’), 162.9 (C=O); 
LRMS (ES–) m/z 273.2 [M-H]–; HRMS calcd for C14H10O2N235Cl [M-H]– 273.0436, 
found 273.0435. 
(E)-4-Chloro-N'-(2’-hydroxybenzylidene)benzohydrazide (184) 
 
Compound 184 was synthesized according to general procedure J using 
salicylaldehyde (4.92 g, 40.3 mmol), 4-chlorobenzydrazide (6.87 g, 40.3 mmol) 
and acetic acid (169 mL). The crude product (off-white solid; 10.77 g, 97%) was 
used in the following step without further purification. Rf 0.60 (10% 
MeOH/DCM); m.p. 220.1-220.3 °C; λmax (EtOH)/nm 287, 398, 330; νmax/cm-1 
(neat) 1641 (s, C=O), 3068 (m, C-H str, aromatic), 3212 (m, N-H); 1H NMR (500 
MHz; DMSO-d6) δH 6.90-6.97 (2H, m, H-4’ and H-6’), 7.28–7.34 (1H, m, H-5’), 
7.57 (1H, dd, J = 1.7, 7.6, H-3’), 7.60–7.67 (2H, m, H-3 and H-5), 7.93–8.01 (2H, 
m, H-2 and H-6), 8.64 (1H, s, CH=N), 11.22 and 12.17 (2  1H, br s, O-H and N-
H); 13C NMR (125 MHz; DMSO-d6) δC 116.4 (C-4), 118.7 (C-1’), 119.3 (C-6’), 
128.6 (C-3 and C-5), 129.4 (C-3’), 129.5 (C-2 and C-6), 131.5 (C-5’), 131.5 (C-4), 
136.8 (C-1), 148.4 (CH=N), 157.4 (C-2’), 161.7 (C=O); LRMS (ES–) m/z 273.2 [M-
H]–; HRMS calcd for C14H10O2N235Cl [M-H]– 273.0436, found 273.0425. 
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(E)-N'-(2’-Hydroxybenzylidene)benzohydrazide (187) 
 
Compound 187 was synthesized according to general procedure J using 
salicylaldehyde (5.00 g, 40.9 mmol), benzhydrazide (5.57 g, 40.9 mmol) and 
acetic acid (172 mL). The crude product (off-white solid; 1.70 g, 86%) was used 
for the next step without further purification. Rf 0.54 (10% MeOH/DCM); m.p. 
171.2-171.5°C; λmax (EtOH)/nm 286, 297, 328; νmax/cm-1 (neat) 1671 (s, C=O), 
3057 (w, C-H str, aromatic), 3264 (m, N-H); 1H NMR (500 MHz; DMSO-d6) δH 
6.89–6.98 (2H, m, H-4’ and H-6’), 7.27–7.34 (1H, m, H-5’), 7.52–7.58 (3H, m, H-3, 
H-3, and H-5), 7.59–7.64 (1H, m, H-4), 7.91–7.98 (2H, m, H-2 and H-6), 8.65 (1H, 
s, CH=N), 11.30 and 12.13 (2  1H, br s, O-H and N-H); 13C NMR (125 MHz; 
DMSO-d6) δC 116.4 (C-4’), 118.7 (C-1’), 119.4 (C-6’), 127.7 (C-2 and C-6), 128.6 
(C-3 and C-5), 129.5 (C-3’), 131.4 (C-5’), 132.0 (C-4), 132.8 (C-1), 148.3 (CH=N), 
157.5 (C-2’), 162.8 (C=O); LRMS (ES+) m/z 241.3 [M+H]+; (ES–) m/z 239.3 [M-
H]–; HRMS calcd for C14H11O2N2 [M-H]– 239.0826, found 239.0817. 
3-Chloro-2-(4’-chlorobenzoyl)benzaldehyde (179) 
 
Compound 179 was synthesized according to general procedure K using 
benzohydrazide 178 (1.5 g, 4385 mmol), lead tetraacetate (2.58 g, 5.82 mmol) 
and THF (37 mL). The crude product was purified by MPLC (gradient elution, 0-
25% EtOAc/petrol) to yield the title compound (1.29 g, 95%) as an orange oil 
which solidified upon storage at RT to give an orange solid. Rf 0.27 (20% 
EtOAc/petrol); m.p. 99.8-100.9 °C; λmax (EtOH)/nm 257; νmax/cm-1 (neat) 1669 
(s, C=O ketone), 1695 (s, C=O aldehyde); 1H NMR (500 MHz; CDCl3) δH 7.40–7.47 
(2H, m, H-3’ and H-5’), 7.64 (1H, app. t, J = 7.8 Hz, H-5), 7.69–7.74 (3H, m, H-4, 
H-2’ and H-6’), 7.90 (1H, dd, J = 7.8, 1.2 Hz, H-6), 9.88 (1H, s, CHO); 13C NMR 
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(125 MHz; CDCl3) δC 129.3 (C-3’ and C-5’), 130.4 (C-2’ and C-6’), 130.5 (C-6), 
130.8 (C-5), 132.4 (C-4’), 134.7 (C-3), 135.3 (C-4), 135.9 (C-1), 139.2 (C-2), 
140.5 (C-1’), 189.4 (CHO), 193.1 (C=O); LRMS (ES+) m/z 279.2 [M+H]+; HRMS 
calcd for C14H935Cl2O2 [M+H]+ 278.9974, found 278.9977. 
2-Benzoyl-3-chlorobenzaldehyde (182) 
 
Compound 182 was synthesized according to general procedure K using 
benzohydrazide 181 (1.50 g, 5.46 mmol), lead tetraacetate (2.91 g, 6.55 mmol) 
and THF (42 mL). The crude product was purified by MPLC (gradient elution, 0-
30% EtOAc/petrol) to yield the title compound (1.20 g, 90%) in form of yellow 
crystals. Rf 0.20 (20% EtOAc/petrol); m.p. 121.0-122.9 °C; λmax (EtOH)/nm 248; 
νmax/cm-1 (neat) 1666 (s, C=O ketone), 1697 (s, C=O aldehyde); 1H NMR (500 
MHz; DMSO-d6) δH 7.48–7.56 (2H, m, H-2’and H-6’), 7.62–7.70 (3H, m, H-3’, H-4’, 
and H-5’), 7.84 (1H, app. t, J = 7.9 Hz, H-5), 7.95 (1H, dd, J = 7.9, 1.1 Hz, H-4), 
8.15 (1H, dd, J = 7.9, 1.1 Hz, H-6), 9.91 (1H, s, CHO); 13C NMR (125 MHz; DMSO-
d6) δC 128.5 (C-3’ and C-5’), 129.0 (C-2’ and C-6’), 130.8 (C-3), 131.6 (C-5), 133.0 
(C-6), 133.9 (C-4’), 135.2 (C-4), 135.7 (C-1’), 135.8 (C-1), 137.7 (C-2), 191.6 
(CHO), 193.9 (C=O); LRMS (ES+) m/z 245.2 [M+H]+; HRMS calcd for C14H1035ClO2 
[M+H]+ 245.0364, found 245.0365. 
2-(4’-Chlorobenzoyl)benzaldehyde (185) 
 
Compound 185 was synthesized according to general procedure K using 
benzohydrazide 184 (5.39 g, 19.6 mmol), lead tetraacetate (10.4 g, 23.5 mmol) 
and THF (150mL). The crude product was purified by medium pressure liquid 
chromatography (gradient elution, 0-20% EtOAc/petrol) to yield the desired 
aldehyde (4.48 g, 93%) as an orange solid. Rf 0.29 (20% EtOAc/petrol);  
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m.p. 102.8-107-1 °C; λmax (EtOH)/nm 258; νmax/cm-1 (neat) 1664 (s, C=O 
ketone), 1689 (m, C=O aldehyde); 1H NMR (500 MHz; CDCl3) δH 7.41–7.45 (2H, 
m, H-3’ and H-5’), 7.46–7.51 (1H, m, H-Ar), 7.67–7.78 (4H, m, 2  H-Ar, H-2’ and 
H-6’), 7.97–8.06 (1H, m, H-Ar), 10.01 (1H, s, CHO); 13C NMR (125 MHz; CDCl3) δC 
128.8 (C-Ar), 129.1 (C-3’ and C-5’), 130.9 (C-Ar), 130.9 (C-Ar), 131.3 (C-2’ and C-
6’), 133.7 (C-Ar), 135.4 (C-Ar), 135.5 (C-Ar), 140.3 (C-Ar), 140.8 (C-Ar), 190.7 
(CHO), 195.5 (C=O); LRMS (ES+) m/z 245.2 [M+H]+; HRMS calcd for C14H1035ClO2 
[M+H]+ 245.0364, found 245.0365. 
2-Benzoylbenzaldehyde (188) 
 
Compound 188 was synthesized according to general procedure K using 
benzohydrizide 187 (4.50 g, 18.7 mmol), lead tetraacetate (9.93 g, 22.4 mmol), 
and THF (145 mL). The crude product was purified by MPLC (gradient elution, 
petrol to petrol/EtOAc 4:1) to yield the title compound (3.58 g, 90%) as an 
orange solid. Rf 0.39 (20% EtOAc/petrol); m.p. 65.4-65.9 °C; λmax (EtOH)/nm 
251; νmax/cm-1 (neat) 1664 (s, C=O ketone), 1682 (m, C=O aldehyde); 1H NMR 
(500 MHz; CDCl3) δH 7.44–7.50 (2H, m, H-2’, and H-6’), 7.50–7.54 (1H, m, H-Ar), 
7.58–7.65 (1H, m, H-4’), 7.65–7.73 (2H, m, H-3’ and H-5’), 7.77–7.83 (2H, m, 2  
H-Ar), 8.00–8.07 (1H, m, H-Ar), 10.03 (1H, s, CHO); 13C NMR (125 MHz; CDCl3) 
δC 128.8 (C-2’ and C-6’), 129.0 (C-Ar), 130.1 (C-3’ and C-5’), 130.2 (C-Ar), 130.8 
(C-Ar), 133.5 (C-Ar), 133.8 (C-4’), 135.6 (C-Ar), 137.2 (C-Ar), 141.6 (C-Ar), 190.7 
(CHO), 196.6 (C=O); LRMS (ES+) m/z 211.3 [M+H]+; HRMS calcd for C14H11O2 
[M+H]+ 211.0754, found 211.0755. 
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3-Chloro-2-(4’-chlorobenzoyl)benzoic acid (180) 
 
Compound 180 was obtained following general procedure L using 179 (1.15 g, 
4.12 mmol), sodium chlorite (485 mg, 5.36 mmol), sulfamic acid (520 mg, 5.36 
mmol), acetonitrile (52 mL) and water (2  7.5 mL). The crude product (yellow 
solid; 1.15 g, 95%) was used in the following step without further purification. 
Rf 0.17 (10% MeOH/DCM); m.p. 179.7-180.0 °C; λmax (EtOH)/nm 257; νmax/cm-1 
(neat) 1678 (s, C=O), 2543, 2661, and 2833 (m br, O-H, hydrogen bonded); 1H 
NMR (500 MHz; CDCl3) δH 7.37–7.45 (2H, m, H-3’ and H-5’), 7.52 (1H, t, J = 8.0 
Hz, H-5), 7.62–7.72 (3H, m, H-4, H-2’ and H-6’), 8.02–8.09 (1H, m, H-6); 13C NMR 
(125 MHz; CDCl3) δC 129.2 (C-Ar), 129.2 (C-3’ and C-5’), 129.9 (C-6), 130.4 (C-5, 
C-2’ and C-6’), 132.1 (C-Ar), 135.0 (C-Ar), 135.2 (C-4), 140.1 (C-1’), 140.8 (C-2), 
169.3 (CO2H), 193.2 (C=O); LRMS (ES–) m/z 293.2 [M-H]–;HRMS calcd for 
C14H7O335Cl2 [M-H]– 292.9778, found 292.9763. 
2-Benzoyl-3-chlorobenzoic acid (183) 
 
Compound 183 was synthesized according to general procedure L using the 
aldehyde 182 (1.19 g, 4.86 mmol), sodium chlorite (572 mg, 6.32 mmol), 
sulfamic acid (614 mg, 6.32 mmol), acetonitrile (60 mL) and water (2  6.8 mL). 
The crude product (yellow solid; 1.22 g, 96%) was used in the following step 
without further purification. Rf 0.16 (10% MeOH/DCM); m.p. 231.7-232.3 °C; 
λmax (EtOH)/nm 245; νmax/cm-1 (neat) 1675 (s, C=O), 2548, 2661, and 2815 (m 
br, O-H, hydrogen bonded); 1H NMR (500 MHz; DMSO-d6) δH 7.52 (2H, m, H-2’ 
and H-6’), 7.60–7.72 (4H, m, H-5, H-3’, H-4’, and H-5’), 7.82–7.91 (1H, m, H-4), 
8.04 (1H, d, J = 7.9 Hz, H-6), 13.54 (1H, s, CO2H); 13C NMR (125 MHz; DMSO-d6) 
δC 128.5 (C-3’ and C-5’), 128.9 (C-2’ and C-6’), 129.2 (C-6), 130.3 (C-Ar), 130.9 
(C-5), 131.3 (C-Ar), 133.5 (C-4’) , 133.9 (C-4), 136.3 (C-Ar), 139.8 (C-Ar), 165.6 
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(CO2H), 193.7 (C=O); LRMS (ES–) m/z 259.2 [M-H]–; HRMS calcd for C14H8O335Cl 
[M-H]– 259.0167, found 259.0169. 
2-(4’-Chlorobenzoyl)benzoic acid (186) 
 
Compound 186 was synthesized according to general procedure L using the 
aldehyde 185 (4.40 g, 18.0 mmol), sodium chlorite (2.12 g, 23.4 mmol), sulfamic 
acid (2.27 g, 23.4 mmol), MeCN (225 mL) and water (2  25 mL). 
Recrystallization from petrol/ethyl acetate yielded the title compound as a 
white solid (2.69 g, 57%). Rf 0.31 (10% MeOH/DCM); m.p. 151.5-152.1 °C; λmax 
(EtOH)/nm 256; νmax/cm-1 (neat) 1670 (s, C=O), 2549, 2672, and 2835 (m br, O-
H, hydrogen bonded); 1H NMR (500 MHz; DMSO-d6) δH 7.39–7.48 (1H, m, H-Ar), 
7.54–7.59 (2H, m, H-3’ and H-5’), 7.59–7.64 (2H, m, H-Ar), 7.67 (1H, td, J = 7.6, 
1.3 Hz, H-Ar), 7.74 (1H, td, J = 7.6, 1.3 Hz, H-Ar), 7.97–8.03 (1H, m, H-Ar), 13.25 
(1H, s, CO2H); 13C NMR (125 MHz; DMSO-d6) δC 127.4 (C-Ar), 128.9 (C-3’ and C-
5’), 129.8 (C-Ar), 129.9 (C-Ar), 130.0 (C-Ar), 130.6 (C-2’ and C-6’), 132.6 (C-Ar), 
135.8 (C-Ar), 138.0 (C-Ar), 141.0 (C-Ar), 166.8 (CO2H), 195.4 (C=O); LRMS (ES–) 
m/z 259.2 [M-H]–; HRMS calcd for C14H8O335Cl [M-H]– 259.0167, found 
259.0159. 
2-Benzoylbenzoic acid (189) 
 
Compound 189 was obtained following general procedure L using aldehyde 
188 (3.55 g, 16.9 mmol), sodium chlorite (1.99 g, 22.0 mmol), sulfamic acid 
(2.14 g, 22.0 mmol), MeCN (211 mL), and water (2  24 mL). The crude product 
(off-white solid; 3.65 g, 95%) was used for the following step without further 
purification. Rf 0.22 (10% MeOH/DCM); m.p. 117.7-119.7 °C; λmax (EtOH)/nm 
244; νmax/cm-1 (neat) 1675 (s, C=O), 2555, 2661, and 2825 (m br, O-H, hydrogen 
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bonded); 1H NMR (500 MHz; DMSO-d6) δH 7.38–7.46 (1H, m, H-3), 7.46–7.57 
(2H, m, H-3’ and H-5’), 7.58–7.65 (2H, m, H-2’ and H-6’), 7.67 (1H, td, J = 7.5, 1.3 
Hz, H-Ar), 7.74 (1H, td, J = 7.5, 1.3, H-Ar), 7.94–8.07 (1H, m, H-6), 13.18 (1 H, s, 
CO2H); 13C NMR (125 MHz; DMSO-d6) δC 127.4 (C-3), 128.7 (C-3’ and C-5’), 128.9 
(C-2’ and C-6’), 129.8 (C-6), 129.8 (C-Ar), 132.4 (C-Ar), 133.1 (C-Ar), 136.9 (C-
Ar), 141.4 (C-Ar), 166.8 (CO2H), 196.4 (C=O). One quaternary carbon not 
detected; LRMS (ES–) m/z 225.2 [M-H]–; HRMS calcd for C14H9O3 [M-H]– 
225.0557, found 225.0549. 
 (3R,1’R)-4-Chloro-3-(4’’’-chlorophenyl)-3-hydroxy-2-(1’-
phenylethyl)isoindolin-1-one (190) and (3S,1’R)-4-chloro-3-(4’’’-
chlorophenyl)-3-hydroxy-2-(1’-phenylethyl)isoindolin-1-one (192) 
   
To a solution of the benzoylbenzoic acid 180 (550 mg, 1.86 mmol) in THF (2.2 
mL, 1.2 mmol/mL), thionyl chloride (0.27 mL, 443 mg, 3.72 mmol) and a 
catalytic amount of DMF (1 drop) were added at room temperature. The 
solution was stirred for 2 h before removal of solvent and excess SOCl2 in vacuo. 
THF (2.2 mL, 1.2 mmol/mL) was added to the residue, followed by (R)-(+)-
methylbenzylamine (0.26 mL, 248 mg, 2.05 mmol) and diisopropylamine (0.36 
mL, 260 mg, 2.57 mmol), and the reaction mixture was stirred overnight. Water 
(10 mL) and EtOAc (10 mL) were added, and the two layers were separated. 
The aqueous layer was extracted with EtOAc (20 mL). The combined organic 
layers were washed with brine, dried (MgSO4), filtered and the solvent was 
removed in vacuo. The crude product was purified by MPLC (gradient elution, 0-
25% EtOAc/petrol) to yield isoindolinones 190 (151 mg, 20%) and 192 (171 
mg, 23%) as colorless oils which crystallized upon storage at RT. A mixture of 
the two diasteroisomers was also recovered (79 mg, 54% overall yield). 
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190 
Rf 0.60 (33% EtOAc/petrol); m.p. 164.7-166.6 °C; [𝛼]D
29 +161° (c 0.511, EtOAc); 
λmax (EtOH)/nm 258; νmax/cm-1 (neat) 1588 (s, C-N amide), 1679 (s, C=O), 3244 
(br, O-H); 1H NMR (500 MHz; DMSO-d6) δH 1.42 (3H, d, J = 7.2 Hz, CHCH3), 4.40 
(1H, q, J = 7.2 Hz, CHCH3), 7.17-7.23 (1H, m, H-4’), 7.24-7.30 (2H, m, H-Ar), 7.37-
7.49 (6H, br m, H-Ar), 7.52 (1H, s, OH), 7.56-7.62 (2H, m, H-Ar), 7.65-7.70 (1H, 
m, H-Ar); 13C NMR (125 MHz; DMSO-d6) δC 17.7 (CHCH3), 50.3 (CHCH3), 90.3 (C-
3), 121.2 (C-Ar), 126.5 (C-Ar), 127.3 (C-Ar), 127.7 (2  C-Ar), 128.2 (2  C-Ar), 
128.5 (C-Ar), 128.7 (2  C-Ar), 129.5 (C-Ar), 131.7 (C-Ar), 133.8 (C-Ar), 134.2 
(C-Ar), 135.5 (C-Ar), 142.2 (C-Ar), 143.4 (C-Ar), 165.8 (C-1); LRMS (ES–) m/z 
[M-H]– 396.2; HRMS calcd for C22H1635Cl2NO2 [M-H]– 396.0564, found 396.0547; 
HPLC 96.9% in 0.1% formic acid (aq)/MeCN (Rt 9.7 min); 99.1% in 0.1% 
ammonia (aq)/MeCN (Rt 9.6 min); 97.5% in water/MeCN (Rt 9.8 min). 
192 
Rf 0.51 (33% EtOAc/petrol); m.p. 201.5-204.5 °C; [𝛼]D
29 +58° (c 0.542, EtOAc); 
λmax (EtOH)/nm 257; νmax/cm-1 (neat) 1589 (s, C-N amide), 1670 (s, C=O), 3127 
(br, O-H); 1H NMR (500 MHz; DMSO-d6) δH 1.79 (3H, d, J = 7.0 Hz, CHCH3), 4.48 
(1H, q, J = 7.0 Hz, CHCH3), 6.94-6.99 (2H, m, H-Ar), 7.01-7.09 (3H, m, H-Ar), 
7.16-7.25 (4H, br, H-Ar), 7.49 (1H, s, OH), 7.57-7.62 (2H, m, H-Ar), 7.67-7.73 
(1H, m, H-Ar); 13C NMR (125 MHz; DMSO-d6) δC 19.7 (CHCH3), 51.0 (CHCH3), 
90.1 (C-3), 121.3 (C-Ar), 126.4 (C-Ar), 127.1 (2  C-Ar), 127.5 (2  C-Ar), 127.8 
(2  C-Ar), 128.4 (C-Ar), 128.6 (2  C-Ar), 131.7 (C-Ar), 132.6 (C-Ar), 133.3 (C-
Ar), 134.5 (C-Ar), 136.8 (C-Ar), 141.9 (C-Ar), 143.9 (C-Ar), 164.9 (C-1); LRMS 
(ES–) m/z [M-H]– 396.2; HRMS calcd for C22H1635Cl2NO2 [M-H]– 369.0564, found 
396.0546; HPLC 94.1% in 0.1% formic acid (aq)/MeCN (Rt 9.5 min); 99.4% in 
0.1% ammonia (aq)/MeCN (Rt 9.6 min); 96.2% in water/ MeCN (Rt 9.5 min). 
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(3S,1’S)-4-Chloro-3-(4’’’-chlorophenyl)-3-hydroxy-2-(1’-
phenylethyl)isoindolin-1-one (194) and (3R,1’S)-4-chloro-3-(4’’’-
chlorophenyl)-3-hydroxy-2-(1’-phenylethyl)isoindolin-1-one (196) 
   
Isoindolinones 194 and 196 were synthesized according to general  
procedure M using benzylbenzoic acid 180 (550 mg, 1.86 mmol), thionyl 
chloride (0.27 mL, 443 mg, 3.72 mmol), catalytic DMF (3 drops), THF (2  2.2 
mL), (S)-(-)-methylbenzylamine (0.26 mL, 248 mg, 2.05 mmol) and DIPEA (0.36 
mL, 265 mg, 2.05 mmol). The crude product was purified by MPLC (gradient 
elution, 0-75% EtOAc/petrol) to yield the desired compounds 194 (298 mg, 
40%) and 196 (219 mg, 30%) as off-white solids. 
194 
Rf 0.60 (33% EtOAc/petrol); m.p. 164.5-168.1 C; [𝛼]D
29 -168° (c 0.513, EtOAc); 
λmax (EtOH)/nm 259; νmax/cm-1(neat) 1587 (m, C-N amide), 1674 (vs, C=O), 
3257 (br, O-H); 1H NMR (500 MHz; DMSO-d6) δH 1.42 (3H, d, J = 7.1 Hz, CHCH3), 
4.39 (1H, q, J = 7.1 Hz, CHCH3), 7.16–7.22 (1H, m, H-4’), 7.22–7.29 (2H, m, H-Ar), 
7.33–7.49 (6H, m, H-Ar), 7.51 (1H, s, OH), 7.56–7.61 (2H, m, H-Ar), 7.64–7.69 
(1H, m, H-Ar); 13C NMR (125 MHz; DMSO-d6) δC 17.7 (CHCH3), 50.3 (CHCH3), 
90.3 (C-3), 121.2 (C-Ar), 126.5 (C-Ar), 127.3 (2  C-Ar), 127.7 (2  C-Ar), 128.1 
(2  C-Ar), 128.5 (C-Ar), 128.7 (2  C-Ar), 131.6 (C-Ar), 132.8 (C-Ar), 133.3 (C-
Ar), 134.2 (C-Ar), 137.1 (C-Ar), 141.7 (C-Ar), 143.8 (C-Ar), 164.4 (C-1); LRMS 
(ES–) m/z [M-H]– 396.2; HRMS calcd for C22H1635Cl2NO2 [M-H]– 396.0562, found 
396.0564. 
 
196 
Rf 0.51 (33% EtOAc/petrol); m.p. 202.7-203.9 °C; [𝛼]D
29 -62° (c 0.568, EtOAc); 
λmax (EtOH)/nm 257; νmax/cm-1 (neat) 1589 (s, C-N amide), 1671 (s, C=O), 3155 
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(br, O-H); 1H NMR (500 MHz; DMSO-d6) δH 1.77 (3H, d, J = 7.0 Hz, CHCH3), 4.48 
(1H, q, J = 7.0 Hz, CHCH3), 6.94-6.99 (2H, m, H-Ar), 7.02-7.09 (3H, m, H-Ar), 
7.13-7.28 (4H, m, H-Ar), 7.49 (1H, s, OH), 7.57-7.62 (2H, m, H-Ar), 7.66-7.73 (1H, 
m, H-Ar); 13C NMR (125 MHz; DMSO-d6) δC 19.8 (CHCH3), 51.0 (CHCH3), 90.1 (C-
3), 121.3 (C-Ar), 126.4 (C-Ar), 127.1 (2  C-Ar), 127.5 (2  C-Ar), 127.8 (2  C-
Ar), 128.4 (C-Ar), 128.6 (2  C-Ar), 131.7 (C-Ar), 132.6 (C-Ar), 133.3 (C-Ar), 
134.5 (C-Ar), 136.8 (C-Ar), 141.9 (C-Ar), 143.9 (C-Ar), 164.9 (C-1); LRMS (ES–) 
m/z [M-H]– 396.2; HRMS calcd for C22H1635Cl2NO2 [M-H]– 396.0564, found 
396.0564; HPLC 96.5% in 0.1% formic acid (aq)/MeCN (Rt 9.5 min); 99.6% in 
0.1% ammonia (aq)/MeCN (Rt 9.6 min); 95.3% in water/ MeCN (Rt 9.5 min). 
(3R,1’R)-3-Hydroxy-3-phenyl-2-(1’-phenylethyl)isoindolin-1-one (209) 
and (3R,1’R)-3-Hydroxy-3-phenyl-2-(1’-phenylethyl)isoindolin-1-one 
(211) 
   
Compounds 209 and 211 were synthesized according to general  
procedure M using benzoylbenzoic acid 189 (1.00 g, 4.42 mmol), thionyl 
chloride (1.72 mL, 1.05 g, 8.84 mmol), catalytic DMF (3 drops), THF (2  5.3 
mL), (R)-(+)-methylbenzylamine (0.62 mL, 589 mg, 4.86 mmol) and DIPEA 
(0.85 mL, 628 mg, 4.86 mmol). The crude product was purified by MPLC 
(gradient elution, 0-24% EtOAc/petrol) to yield the desired compounds 209 
(239 mg, 16%) and 211 (158 mg, 11%) as white solids. The total yield of the 
two diasteroisomers was 1.18 g (81%). 
209 
Rf 0.68 (50% EtOAc/petrol); m.p. 129.8-131.7°C; [𝛼]D
30 +179° (c 0.488, EtOAc); 
λmax (EtOH)/nm 252; νmax/cm-1 (neat) 1670 (s, C=O), 3220 (br, O-H); 1H NMR 
(500 MHz; DMSO-d6) δH 1.46 (3H, d, J = 7.1 Hz, CHCH3), 4.40 (1H, q, J = 7.1 Hz, 
CHCH3), 7.15-7.22 (2H, m, H-Ar), 7.22-7.28 (3H, m, H-Ar), 7.29-7.43 (5H, m, H-
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Ar and OH), 7.44-7.58 (4H, m, H-Ar), 7.64-7.72 (1H, m, H-Ar); 13C NMR (125 
MHz; DMSO-d6) δC 17.8 (CHCH3), 50.6 (CHCH3), 91.1 (C-3), 122.2 (C-Ar), 122.9 
(C-Ar), 126.3 (2  C-Ar), 126.4 (C-Ar), 127.4 (2  C-Ar), 127.7 (2  C-Ar), 128.1 
(C-Ar), 128.3 (2  C-Ar), 129.2 (C-Ar), 131.4 (C-Ar), 132.4 (C-Ar), 140.1 (C-Ar), 
142.3 (C-Ar), 149.0 (C-Ar), 166.0 (C-1); LRMS (ES–) m/z [M-H]– 328.3; HRMS 
calcd for C22H20NO2 [M+H]+ 330.1489, found 330.1491; HPLC 95.2% in 0.1% 
formic acid (aq)/MeCN (Rt 8.7 min); 98.4% in 0.1% ammonia (aq)/MeCN (Rt 8.5 
min); 93.7% in water/ MeCN (Rt 8.7 min). 
211 
Rf 0.63 (50% EtOAc/petrol); m.p. 172.1-174.4 °C; [𝛼]D
30 -34° (c 0.536, EtOAc); 
λmax (EtOH)/nm 252; νmax/cm-1 (neat) 1668 (s, C=O), 3211 (br, O-H); 1H NMR 
(500 MHz; DMSO-d6) δH 1.75 (3H, d, J = 7.2 Hz, CHCH3), 4.52 (1H, q, J = 7.2 Hz, 
CHCH3), 6.98-7.08 (5H, m, H-Ar), 7.14-7.23 (6H, m, H-Ar), 7.24 (1H, s, OH), 7.49-
7.58 (2H, m, H-Ar), 7.67-7.72 (1H, m, H-Ar); 13C NMR (125 MHz; DMSO-d6) δC 
19.7 (CHCH3), 51.1 (CHCH3), 90.9 (C-3), 122.2 (C-Ar), 122.8 (C-Ar), 126.3 (C-Ar), 
126.4 (2  C-Ar), 127.3 (2  C-Ar), 127.5 (2  C-Ar), 127.9 (2  C-Ar), 127.9 (C-
Ar), 129.3 (C-Ar), 131.5 (C-Ar), 132.4 (C-Ar), 139.7 (C-Ar), 142.2 (C-Ar), 149.2 
(C-Ar), 166.4 (C-1); LRMS (ES–) m/z [M-H]– 328.3; HRMS calcd for C22H20NO2 
[M+H]+ 330.1489, found 330.1493; HPLC 95.2% in 0.1% formic acid (aq)/MeCN 
(Rt 8.5 min); 99.6% in 0.1% ammonia (aq)/MeCN (Rt 8.5 min); 94.5% in water/ 
MeCN (Rt 8.5 min). 
(3S,1’S)-3-Hydroxy-3-phenyl-2-(1’-phenylethyl)isoindolin-1-one (213) 
and (3R,1’S)-3-hydroxy-3-phenyl-2-(1’-phenylethyl)isoindolin-1-one 
(215) 
   
Compounds 213 and 215 were synthesized according to general  
procedure M using benzoylbenzoic acid 189 (1.00 g, 4.42 mmol), thionyl 
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chloride (1.72 mL, 1.05 g, 8.84 mmol), catalytic DMF (3 drops), THF (2  5.3 
mL), (S)-(-)-methylbenzylamine (0.62 mL, 589 mg, 4.86 mmol) and DIPEA (0.85 
mL, 628 mg, 4.86 mmol). The crude product was purified by MPLC (gradient 
elution, 3-20% EtOAc/petrol) to yield the desired compounds 213 (0.49 g, 
34%) and 215 (0.53 g, 36%) as white solids. The total yield of the two 
diasteroisomers was 1.26 g (87%). 
213 
Rf 0.68 (50% EtOAc/petrol); m.p. 129.8-131.7°C; [𝛼]D
30 -184° (c 0.424, EtOAc); 
λmax (EtOH)/nm 252; νmax/cm-1 (neat) 1665 (s, C=O), 3224 (br, O-H); 1H NMR 
(500 MHz; DMSO-d6) δH 1.47 (3H, d, J = 7.1Hz, CHCH3), 4.41 (1H, q, J = 7.1 Hz, 
CHCH3), 7.15-7.22 (2H, m, H-Ar), 7.22-7.29 (3H, m, H-Ar), 7.30-7.42 (5H, m, H-
Ar and OH), 7.46-7.58 (4H, m, H-Ar), 7.66-7.70 (1H, m, H-Ar); 13C NMR (125 
MHz; DMSO-d6) δC 17.8 (CHCH3), 50.5 (CHCH3), 91.1 (C-3), 122.2 (C-Ar), 122.8 
(C-Ar), 126.2 (2  C-Ar), 126.4 (C-Ar), 127.3 (2  C-Ar), 127.6 (2  C-Ar), 128.0 
(C-Ar), 128.3 (2  C-Ar), 129.2 (C-Ar), 131.3 (C-Ar), 132.4 (C-Ar), 140.1 (C-Ar), 
142.3 (C-Ar), 149.0 (C-Ar), 166.0 (C-1); LRMS (ES–) m/z 328.3 [M-H]–; HRMS 
calcd for C22H20NO2 [M+H]+ 330.1489, found 330.1491; HPLC 95.3% in 0.1% 
formic acid (aq)/MeCN (Rt 8.6 min); 98.0% in 0.1% ammonia (aq)/MeCN (Rt 8.5 
min); 94.8% in water/ MeCN (Rt 8.7 min). 
215 
Rf 0.63 (50% EtOAc/petrol); m.p. 170.8-173.2 C; [𝛼]D
30 +51° (c 0.593, EtOAc); 
λmax (EtOH)/nm 252; νmax/cm-1 (neat) 1669 (s, C=O), 3216 (br, O-H); 1H NMR 
(500 MHz; DMSO-d6) δH 1.76 (3H, d, J = 7.2 Hz, CHCH3), 4.53 (1H, q, J = 7.2 Hz, 
CHCH3), 6.99–7.09 (5H, m, H-Ar), 7.15–7.24 (6H, m, H-Ar), 7.25 (1H, s, OH), 
7.51–7.59 (2H, m, H-Ar), 7.67–7.73 (1H, m, H-Ar); 13C NMR (125 MHz; DMSO-d6) 
δC 19.7 (CHCH3), 51.0 (CHCH3), 90.9 (C-3), 122.2 (C-Ar), 122.8 (C-Ar), 126.3 (C-
Ar), 126.3 (2  C-Ar), 127.3 (2  C-Ar), 127.4 (2  C-Ar), 127.9 (2  C-Ar), 127.9 
(C-Ar), 129.2 (C-Ar), 131.5 (C-Ar), 132.4 (C-Ar), 139.7 (C-Ar), 142.2 (C-Ar), 
149.2 (C-Ar), 166.4 (C-1); LRMS (ES–) m/z 328.3 [M-H]–; HRMS calcd for 
C22H20NO2 [M+H]+ 330.1489, found 330.1493. 
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(1’R)-4-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-hydroxy-3-
phenylisoindolin-1-one (198) 
 
Compound 198 was synthesized according to general procedure M using acid 
183 (600 mg, 2.30 mmol), thionyl chloride (0.33 mL, 547 mg, 4.60 mmol), 
catalytic DMF (3 drops), (R)-4-chloro-α-methylbenzylamine (0.35 mL, 394 mg, 
2.53 mmol), DIPEA (0.44 mL, 327 mg, 2.53 mmol) and THF (2  2.8 mL). The 
product was obtained as a mixture of diastereoisomers (cream-colored solid; 
0.81 g, 88%) after purification by MPLC (gradient elution, 3-30% EtOAc/petrol). 
Rf(1) 0.55; Rf(2) 0.40 (25% EtOAc/petrol); no clear m.p. detected; λmax (EtOH)/nm 
259; νmax/cm-1 (neat) 1660 and 1673 (vs, C=O), 3212 (br, O-H); 1H NMR (500 
MHz; DMSO-d6) δH 1.36 (3H, d, J = 7.1 Hz, -CH3), 1.75 (3H, d, J = 7.1 Hz, CH3), 4.38 
(1H, q, J = 7.1 Hz, CHCH3), 4.50 (1H, q, J = 7.0 Hz, CHCH3), 6.88 – 6.97 (2H, m, H-
Ar), 7.03 – 7.15 (2H, m, H-Ar), 7.23 (5H, br, J = 14.5 Hz, H-Ar), 7.29 – 7.48 (8H, 
m, H-Ar), 7.48 – 7.54 (2H, m, H-Ar), 7.54 – 7.63 (3H, m, H-Ar), 7.67 (1H, dd, J = 
5.3, 3.0 Hz, H-Ar), 7.70 (1H, dd, J = 5.2, 3.2 Hz, H-Ar); 13C NMR (125 MHz; DMSO-
d6) δC 17.3 (CHCH3), 19.4 (CHCH3), 49.6 (CHCH3), 50.1 (CHCH3), 90.5 (C-3), 90.7 
(C-3), 121.1 (C-Ar), 121.1 (C-Ar), 126.5 (C-Ar), 126.6 (C-Ar), 127.3 (C-Ar), 127.6 
(C-Ar), 127.8 (C-Ar), 128.1 (C-Ar), 128.1 (C-Ar), 128.2 (C-Ar), 128.5 (C-Ar), 
128.6 (C-Ar), 129.1 (C-Ar), 129.3 (C-Ar), 130.9 (C-Ar), 131.2 (C-Ar), 131.5 (C-
Ar), 131.5 (C-Ar), 133.3 (C-Ar), 134.2 (C-Ar), 134.4 (C-Ar), 137.6 (C-Ar), 137.8 
(C-Ar), 140.7 (C-Ar), 140.8 (C-Ar), 144.2 (C-Ar), 144.3 (C-Ar), 164.4 (C-Ar), 
164.8 (C-Ar); LRMS (ES+) m/z 420.2 [M+Na]+; HRMS calcd for C22H1835Cl2NO2 
[M+H]+ 398.0709, found 398.0712. 
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(1’R)-3-(4-Chlorophenyl)-2-[1’-(4’’’-chlorophenyl)ethyl]-3-
hydroxyisoindolin-1-one (203) 
 
Compound 203 was synthesized according to general procedure M using acid 
186 (600 mg, 2.30 mmol), thionyl chloride (0.33 mL, 547 mg, 4.60 mmol), 
catalytic DMF (3 drops), (R)-4-chloro-α-methylbenzylamine (0.35 mL, 394 mg, 
2.53 mmol), DIPEA (0.44 mL, 327 mg, 2.53 mmol) and THF (2  2.8 mL). The 
product was obtained as a mixture of diastereoisomers (white solid; 0.88 g, 
96%) after purification by MPLC (gradient elution, 3-50% EtOAc/petrol). Rf(1) 
0.51; Rf(2) 0.32 (25% EtOAc/petrol); no clear m.p. detected; λmax (EtOH)/nm 
252sh; νmax/cm-1 (neat) 1672 (vs, C=O), 3265 (br, O-H); 1H NMR (500 MHz; 
DMSO-d6) δH 1.48 (3H, d, J = 7.1 Hz, CH3), 1.74 (3H, d, J = 7.2 Hz, CH3), 4.44 (1H, 
q, J = 7.1 Hz, CHCH3), 4.54 (1H, q, J = 7.1 Hz, CHCH3), 7.08 – 7.13 (2H, m, H-Ar), 
7.13 – 7.18 (2H, m, H-Ar), 7.18 – 7.27 (5H, m, H-Ar), 7.28 – 7.34 (2H, m, H-Ar), 
7.35 – 7.45 (5H, m, H-Ar), 7.46 – 7.51 (2H, m, H-Ar), 7.51 – 7.61 (4H, m, H-Ar), 
7.66 – 7.70 (1H, m, H-Ar), 7.70 – 7.75 (1H, m, H-Ar); 13C NMR (125 MHz; DMSO-
d6) δC 17.8 (CHCH3), 19.9 (CHCH3), 49.9 (CHCH3), 50.6 (CHCH3), 90.4 (C-3), 90.6 
(C-3), 122.3 (C-Ar), 122.4 (C-Ar), 122.8 (C-Ar), 122.8 (C-Ar), 127.5 (C-Ar), 127.5 
(C-Ar), 127.9 (C-Ar), 128.3 (C-Ar), 128.3 (C-Ar), 129.1 (C-Ar), 129. (C-Ar)3, 
129.4 (C-Ar), 129.5 (C-Ar), 131.0 (C-Ar), 131.0 (C-Ar), 131.1 (C-Ar), 131.2 (C-
Ar), 132.6 (C-Ar), 132.7 (C-Ar), 132.7 (C-Ar), 132.8 (C-Ar), 138.7 (C-Ar), 139.1 
(C-Ar), 141.0 (C-Ar), 141.4 (C-Ar), 148.6 (C-Ar), 148.7 (C-Ar), 166.0 (C-Ar), 
166.5 (C-Ar); LRMS (ES+) m/z 420.2 [M+Na]+; HRMS calcd for C22H1635Cl2NO2 
[M-H]- 396.0564, found 396.0564. 
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(1’S)-4-Chloro-2-[1’-(4’’’-chlorophenyl)ethyl]-3-hydroxy-3-
phenylisoindolin-1-one (200) 
 
Compound 200 was synthesized according to general procedure M using acid 
183 (538 mg, 2.06 mmol), thionyl chloride (0.30 mL, 490 mg, 4.12 mmol), 
catalytic DMF (3 drops), (S)-4-chloro-α-methylbenzylamine (0.32 mL, 353 mg, 
2.27 mmol), DIPEA (0.40 mL, 293 mg, 2.27 mmol) and THF (2  2.5 mL). The 
product was obtained as a mixture of diastereoisomers (off-white solid; 0.77 g, 
94%) after purification by MPLC (gradient elution, petrol 0-25% EtOAc/petrol). 
Rf(1) 0.52; Rf(2) 0.35 (25% EtOAc/petrol); no clear m.p. detected; λmax (EtOH)/nm 
259; νmax/cm-1 (neat) 1660 and 1673 (vs, C=O), 3215 (O-H); 1H NMR (500 MHz; 
DMSO-d6) δH 1.36 (3H, d, J = 7.1 Hz, -CH3), 1.75 (3H, d, J = 7.2 Hz, CH3), 4.38 (1H, 
q, J = 7.1 Hz, CHCH3), 4.50 (1H, q, J = 7.0 Hz, CHCH3), 6.88 – 6.97 (2H, m, H-Ar), 
7.03 – 7.15 (2H, m, H-Ar), 7.23 (5H, br, J = 14.5 Hz, H-Ar), 7.29 – 7.48 (8H, m, H-
Ar), 7.48 – 7.54 (2H, m, H-Ar), 7.54 – 7.63 (3H, m, H-Ar), 7.67 (1H, dd, J = 5.3, 3.0 
Hz, H-Ar), 7.70 (1H, dd, J = 5.2, 3.2 Hz, H-Ar); 13C NMR (125 MHz; DMSO-d6) δC 
17.3 (CHCH3), 19.4 (CHCH3), 49.6 (CHCH3), 50.1 (CHCH3), 90.5 (C-3), 90.7 (C-3), 
121.1 (C-Ar), 121.1 (C-Ar), 126.5 (C-Ar), 126.6 (C-Ar), 127.3 (C-Ar), 127.6 (C-
Ar), 127.8 (C-Ar), 128.1 (C-Ar), 128.1 (C-Ar), 128.2 (C-Ar), 128.5 (C-Ar), 128.6 
(C-Ar), 129.1 (C-Ar), 129.3 (C-Ar), 130.9 (C-Ar), 131.2 (C-Ar), 131.5 (C-Ar), 
131.5 (C-Ar), 133.3 (C-Ar), 134.2 (C-Ar), 134.4 (C-Ar), 137.6 (C-Ar), 137.8 (C-
Ar), 140.7 (C-Ar), 140.8 (C-Ar), 144.2 (C-Ar), 144.3 (C-Ar), 164.4 (C-Ar), 164.8 
(C-Ar); LRMS (ES+) m/z 420.1 [M+Na]+; HRMS calcd for C22H1835Cl2NO2 [M+H]+ 
398.0709, found 398.0714 
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(1’S)-3-(4’’-Chlorophenyl)-2-[1’-(4’’’-chlorophenyl)ethyl]-3-
hydroxyisoindolin-1-one (206) 
 
Compound 206 was synthesized according to general procedure M using acid 
186 (600 mg, 2.30 mmol), thionyl chloride (0.33 mL, 547 mg, 4.60 mmol), 
catalytic DMF (3 drops), (S)-4-chloro-α-methylbenzylamine (0.35 mL, 394 mg, 
2.53 mmol), DIPEA (0.44 mL, 327 mg, 2.53 mmol) and THF (2  2.8 mL). The 
product was obtained as a mixture of diastereoisomers (white solid; 0.86 g, 
94%) after purification by MPLC (gradient elution, 0-20% EtOAc/petrol). Rf(1) 
0.52; Rf(2) 0.35 (25% EtOAc/petrol); no clear m.p. detected; λmax (EtOH)/nm 
252sh; νmax/cm-1 (neat) 1673 (vs, C=O), 3265 (br, O-H); 1H NMR (500 MHz; 
DMSO-d6) δH 1.48 (3H, d, J = 7.1 Hz, CH3), 1.74 (3H, d, J = 7.2 Hz, CH3), 4.44 (1H, 
q, J = 7.1 Hz, CHCH3), 4.54 (1H, q, J = 7.1 Hz, CHCH3), 7.08 – 7.13 (2H, m, H-Ar), 
7.13 – 7.18 (2H, m, H-Ar), 7.18 – 7.27 (5H, m, H-Ar), 7.28 – 7.34 (2H, m, H-Ar), 
7.35 – 7.45 (5H, m, H-Ar), 7.46 – 7.51 (2H, m, H-Ar), 7.51 – 7.61 (4H, m, H-Ar), 
7.66 – 7.70 (1H, m, H-Ar), 7.70 – 7.75 (1H, m, H-Ar); 13C NMR (126 MHz, DMSO-
d6) δC 17.8 (CHCH3), 19.9 (CHCH3), 49.9 (CHCH3), 50.6 (CHCH3), 90.4 (C-3), 90.6 
(C-3), 122.3 (C-Ar), 122.4 (C-Ar), 122.8 (C-Ar), 122.8 (C-Ar), 127.5 (C-Ar), 127.5 
(C-Ar), 127.9 (C-Ar), 128.3 (C-Ar), 128.3 (C-Ar), 128.3 (C-Ar), 129.1 (C-Ar), 
129.3 (C-Ar), 129.4 (C-Ar), 129.5 (C-Ar), 131.0 (C-Ar), 131.0 (C-Ar), 131.1 (C-
Ar), 131.2 (C-Ar), 132.6 (C-Ar), 132.7 (C-Ar), 132.7 (C-Ar), 132.8 (C-Ar), 138.7 
(C-Ar), 139.1 (C-Ar), 141.0 (C-Ar), 141.4 (C-Ar), 148.6 (C-Ar), 148.7 (C-Ar), 
166.0 (C-Ar), 166.5 (C-Ar); LRMS (ES+) m/z 420.1 [M+Na]+; HRMS calcd for 
C22H1635Cl2NO2 [M-H]- 396.0564, found 396.0563. 
 
 
260 
 
(3R,1’R)-3-{[1’’’’-(Hydroxymethyl)cyclopropyl]methoxy}-3-phenyl-2- 
(1’-phenylethyl)isoindolin-1-one (210) and (3S,1’R)-3- 
{[1’’’’-(hydroxymethyl)cyclopropyl]methoxy}-3-phenyl-2-(1’-
phenylethyl)isoindolin-1-one (212) 
   
Alcohols 210 and 212 were obtained following general procedure N using 
isoindolinone 209 and 211 (341 mg, 1.03 mmol), indium tribromide  
(73 mg, 0.206 mmol), 1,1-bis(hydroxymethyl)cyclopropane (0.49 mL, 526 mg, 
5.15 mmol), and DCE (10 mL, 10 mL/mmol). Purification by MPLC (gradient 
elution, 0-4% MeOH/DCM) yielded the pure diastereoisomers as white 
amorphous solids (210: 104 mg, 24%; 212: 96 mg, 23%). 
210 
Rf 0.49 (4% MeOH/DCM); no clear m.p. detected; [𝛼]D
30 +89° (c 0.425, EtOAc); 
λmax (EtOH)/nm 252; νmax/cm-1 (neat) 1682 and 1697 (s, C=O), 2874, 2933 and 
3059 (w, C-H and –CH2- aliphatic), 3400 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 
-0.12 – 0.05 (2H, m, cyclopropyl), 0.22 – 0.35 (2H, m, cyclopropyl), 1.48 – 1.56 
(1H, ABXdd, JAX = 5.4 Hz, JBX = 6.4 Hz, O-H), 1.71 (3H, d, J = 7.3 Hz, CHCH3), 2.53 
(1H, d, JAB = 9.4 Hz, CHAHBO-), 2.68 (1H, d, JAB = 9.4 Hz, CHAHBO-), 3.23 and 3.31 
(2H, ABX dq, JAX = 5.4 Hz, JBX = 6.4 Hz, JAB = 11.3 Hz, CH2OH), 4.22 (1H, q, J = 7.3 
Hz, CHCH3), 7.04 – 7.10 (1H, m, H-Ar), 7.21 – 7.26 (1H, m, H-Ar), 7.28 – 7.33 (2H, 
m, H-Ar), 7.33 – 7.41 (3H, m, H-Ar), 7.41 – 7.53 (4H, m, H-Ar), 7.59 – 7.66 (2H, 
m, H-Ar), 7.84 – 7.91 (1H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 8.6 (CH2 
cyclopropyl), 8.7 (CH2 cyclopropyl), 20.6 (CHCH3), 22.2 (C q. cyclopropyl), 54.5 
(CHCH3), 68.1 (CH2O-), 68.4 (CH2OH), 96.8 (C-3), 122.9 (C-Ar), 123.4 (C-Ar), 
126.6 (2  C-Ar), 127.4 (C-Ar), 128.1 (2  C-Ar), 128.6 (2  C-Ar), 128.8 (2  C-
Ar), 129.8 (C-Ar), 132.8 (C-Ar), 132.8 (C-Ar), 139.2 (C-Ar q), 143.8 (C-Ar q), 
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145.3 (C-Ar q), 168.6 (C-1); LRMS (ES+) m/z 436.4 [M+Na]+; HRMS calcd for 
C27H28NO3 [M+H]+ 414.2064, found 414.2066; HPLC 99.4% in 0.1% formic acid 
(aq)/MeCN (Rt 8.9 min); 99.7% in 0.1% ammonia (aq)/MeCN (Rt 8.9 min); 
99.3% in isocratic 0.1% formic acid (aq)/MeCN (Rt 15.4 min). 
212 
Rf 0.41 (4% MeOH/DCM); m.p. 124.7-126.0 °C; [𝛼]D
30 -61° (c 0.459, EtOAc); λmax 
(EtOH)/nm 253; νmax/cm-1 (neat) 1680 and 1697 (s, C=O), 2874 and 2926 (w, C-
H and –CH2- aliphatic), 3391 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 0.32 – 0.44 
(1H, m, cyclopropyl), 0.46 – 0.65 (3H, m, cyclopropyl), 1.85 (1H, ABX app. t, JAX = 
JBX = 5.7 Hz, OH), 1.90 (3H, d, J = 7.3 Hz, CHCH3), 2.96 (1H, d, JAB = 9.5 Hz, 
CHAHBO-), 3.28 (1H, d, JAB = 9.5 Hz, CHAHBO-), 3.56 – 3.70 (2H, ABX m, JAX = JBX = 
5.7 Hz, JAB = 11.4 Hz, CH2OH), 4.47 (1H, q, J = 7.3 Hz, CHCH3), 6.97 – 7.08 (7H, m, 
H-Ar), 7.08 – 7.17 (4H, m, H-Ar), 7.44 – 7.53 (2H, m, H-Ar), 7.81 – 7.91 (1H, m, 
H-Ar); 13C NMR (125 MHz; CDCl3) δC 9.0 (CH2 cyclopropyl), 9.0 (CH2 
cyclopropyl), 20.2 (CHCH3), 22.7 (C q. cyclopropyl), 53.0 (CHCH3), 68.1 (CH2O-), 
68.5 (CH2OH), 95.5 (C-3), 123.1 (C-Ar), 123.4 (C-Ar), 126.8 (C-Ar), 127.0 (C-Ar), 
127.8 (C-Ar), 128.0 (C-Ar), 128.4 (C-Ar), 129.9 (C-Ar), 132.7 (C-Ar), 132.9 (C-
Ar), 138.3 (C-Ar q), 142.7 (C-Ar q), 145.2 (C-Ar q), 168.3 (C-1); LRMS (ES+) m/z 
436.4 [M+Na]+; HRMS calcd for C27H28NO3 [M+H]+ 414.2064, found 414.2067; 
HPLC 97.5% in 0.1% formic acid (aq)/MeCN (Rt 8.8 min); 97.3% in 0.1% 
ammonia (aq)/MeCN (Rt 8.7 min); 95.9% in isocratic 0.1% formic acid 
(aq)/MeCN (Rt 14.8 min). 
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(3S,1’S)-3-{[1-(Hydroxymethyl)cyclopropyl]methoxy}-3-phenyl-2-(1-
phenylethyl)isoindolin-1-one (214) and (3R,1’S)-3-{[1-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenyl-2-(1-
phenylethyl)isoindolin-1-one (216) 
   
Alcohols 214 and 216 were synthesized following general procedure N using 
isoindolinones 213 and 215 (255 mg, 0.774 mmol), indium tribromide (55 mg, 
0.155 mmol), 1,1-bis(hydroxymethyl)cyclopropane (0.37 mL, 396 mg, 3.87 
mmol) and DCE (8 mL, 10 mL/mmol). Purification by MPLC (gradient elution, 0-
4% MeOH/DCM) yielded the two pure diastereoisomers as a colorless oil which 
solidified upon storage at RT (214 65 mg, 20%) and a amorphous solid (216 29 
mg, 9%). 
214 
Rf 0.49 (4% MeOH/DCM); no clear m.p. detected; [𝛼]D
30 -89° (c 0.443, EtOAc); 
λmax (EtOH)/nm 252; νmax/cm-1 (neat) 1682 and 1697 (s, C=O), 2876, 2933 and 
3060 (s, C=O), 3400 (br, O-H); 1H NMR (500 MHz; CDCl3) δH -0.11 – 0.04 (2H, m, 
cyclopropyl), 0.25 – 0.33 (2H, m, cyclopropyl), 1.48 – 1.56 (1H, ABXdd, JAX = 5.4 
Hz, JBX = 6.4 Hz, O-H), 1.71 (3H, d, J = 7.3 Hz, CHCH3), 2.53 (1H, d, JAB = 9.4 Hz, 
CHAHBO-), 2.68 (1H, d, JAB = 9.4 Hz, CHAHBO-), 3.23, 3.31 (2H, ABXdq, JAX = 5.4 Hz, 
JBX = 6.4 Hz, JAB = 11.3 Hz, CH2OH), 4.22 (1H, q, J = 7.3 Hz, CHCH3), 7.04 – 7.10 
(1H, m, H-Ar), 7.20 – 7.25 (1H, m, H-Ar), 7.28 – 7.33 (2H, m, H-Ar), 7.33 – 7.41 
(3H, m, H-Ar), 7.41 – 7.53 (4H, m, H-Ar), 7.60 – 7.67 (2H, m, H-Ar), 7.84 – 7.91 
(1H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 8.6 (CH2 cyclopropyl), 8.7 (CH2 
cyclopropyl), 20.6 (CHCH3), 22.2 (C q. cyclopropyl), 54.5 (CHCH3), 68.1 (CH2O-), 
68.4 (CH2OH), 96.8 (C-3), 122.9 (C-Ar), 123.4 (C-Ar), 126.6 (2  C-Ar), 127.5 (C-
Ar), 128.1 (2  C-Ar), 128.6 (2  C-Ar), 128.8 (2  C-Ar), 129.8 (C-Ar), 132.8 (C-
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Ar), 132.8 (C-Ar), 139.2 (C-Ar q), 143.8 (C-Ar q), 145.3 (C-Ar q), 168.6 (C-1); 
LRMS (ES+) m/z 436.4 [M+Na]+; HRMS calcd for C27H28NO3 [M+H]+ 414.2064, 
found 414.2065; HPLC 98.6% in 0.1% formic acid (aq)/MeCN (Rt 8.9 min); 
98.0% in 0.1% ammonia (aq)/MeCN (Rt 8.9 min); 98.6% in isocratic 0.1% 
formic acid (aq)/MeCN (Rt 7.1 min). 
216 
Rf 0.41 (4% MeOH/DCM); no clear m.p. detected; [𝛼]D
30 +62° (c 0.502, EtOAc); 
λmax (EtOH)/nm 253; νmax/cm-1 (neat) 1678 and 1697 (s, C=O), 2874 and 2932 
(s, C=O), 3403 (br,O-H); 1H NMR (500 MHz; CDCl3) δH 0.32 – 0.44 (1H, m, 
cyclopropyl), 0.46 – 0.64 (3H, m, cyclopropyl), 1.85 (1H, ABX app. t, JAX = JBX = 
5.7 Hz, OH), 1.90 (3H, d, J = 7.3 Hz, CHCH3), 2.96 (1H, d, JAB = 9.5 Hz, CHAHBO-), 
3.28 (1H, d, JAB = 9.5 Hz, CHAHBO-), 3.56 – 3.70 (2H, ABXm, JAX = JBX = 5.7 Hz, JAB = 
11.4 Hz, CH2OH), 4.47 (1H, q, J = 7.3 Hz, CHCH3), 6.97 – 7.07 (7H, m, H-Ar), 7.07 
– 7.17 (4H, m, H-Ar), 7.44 – 7.54 (2H, m, H-Ar), 7.81 – 7.91 (1H, m, H-Ar); 13C 
NMR (125 MHz; CDCl3) δC 9.0 (CH2 cyclopropyl), 9.0 (CH2 cyclopropyl), 20.2 
(CHCH3), 22.7 (C q. cyclopropyl), 53.0 (CHCH3), 68.1 (CH2O-), 68.5 (CH2OH), 
95.5 (C-3), 123.1 (C-Ar), 123.4 (C-Ar), 126.8 (C-Ar), 127.0 (C-Ar), 127.8 (C-Ar), 
128.0 (C-Ar), 128.4 (C-Ar), 129.9 (C-Ar), 132.7 (C-Ar), 132.9 (C-Ar), 138.3 (C-Ar 
q), 142.7 (C-Ar q), 145.2 (C-Ar q), 168.3 (C-1); LRMS (ES+) m/z 436.4 [M+Na]+; 
HRMS calcd for C27H28NO3 [M+H]+ 414.2064, found 414.2067; HPLC 96.6% in 
0.1% formic acid (aq)/MeCN (Rt 8.9 min); 97.1% in 0.1% ammonia (aq)/MeCN 
(Rt 8.9 min); 98.5% in isocratic 0.1% formic acid (aq)/MeCN (Rt 6.8 min). 
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(3R,1’R)-4-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenylisoindolin-1-one (159) 
and (3S,1’R)-4-chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenylisoindolin-1-one (199) 
    
Compounds 159 and 199 were synthesized according to general procedure N 
using isoindolinone 198 as a mixture of (3R,1’R) and (3S,1’R) diastereoisomers 
(0.77 g, 1.9 mmol), InBr3 (0.14 g, 0.38 mmol), 1,1-
bis(hydroxymethyl)cyclopropane (0.91 mL, 0.97 g, 9.5 mmol) and DCE (19 mL). 
Purification of the crude product by MPLC (gradient elution, 0-22% EtOAc 
petrol) afforded the desired compounds 159 (0.33 g, 36%) and 199 (0.40 g, 
44%), as white solids. 
159 
Rf 0.25 (25% EtOAc/petrol); m.p. 66-69 °C; [𝛼]D
𝑅𝑇 +118° (c 0.764, EtOAc); λmax 
(EtOH)/nm 259; νmax/cm-1 (neat) 1699 (s, C=O), 3439 (br, O-H); 1H NMR (500 
MHz; CDCl3) δH -0.07-0.04 (1H, m, cyclopropyl), 0.14-0.25 (1H, m, cyclopropyl), 
0.32-0.44 (2H, m, cyclopropyl), 1.58 (3H, d, J = 7.2 Hz, CHCH3), 1.76 (1H, ABX br, 
OH), 1.69 (1H, d, JAB = 9.2 Hz, CHAHBO-), 2.89 (1H, d, JAB = 9.2 Hz, CHAHBO-), 3.27-
3.37 and 3.40-3.50 (2H, ABX m, CH2OH), 4.24 (1H, q, J = 7.2 Hz, CH-CH3), 7.27-
7.32 (2H, m, H-Ar), 7.35-7.43 (4H, br, H-Ar), 7.43-7.47 (1H, dd, J = 0.9, 7.8, H-Ar), 
7.51 (1H, app. t, J = 7.8 Hz, H-6), 7.57 (2H, m, H-Ar), 7.83 (1H, dd, J = 0.9, 7.8 Hz, 
H-Ar); 13C NMR (125 MHz; CDCl3) δC 8.6 (CH2 cyclopropyl), 8.7 (CH2 
cyclopropyl), 20.1 (CHCH3), 22.1 (C q cyclopropyl), 53.4 (CHCH3), 68.4 (CH2OH), 
68.7 (CH2O-), 96.4 (C-3), 122.0 (C-Ar), 127.1 (2  C-Ar), 128.5 (2  C-Ar), 128.7 
(2  C-Ar), 129.0 (C-Ar), 129.5 (2  C-Ar), 129.6 (C-Ar q), 131.7 (C-Ar), 133.3 (C-
Ar q), 133.8 (C-Ar), 135.2 (C-Ar q), 136.7 (C-Ar q), 140.8 (C-Ar q), 141.6 (C-Ar 
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q), 167.0 (C-1); LRMS (ES+) m/z 504.4 [M+Na]+; HRMS calcd for C27H2635Cl2NO3 
[M+H]+ 482.1284, found 482.1285; HPLC 99.7% in 0.1% formic acid 
(aq.)/MeCN (Rt 9.7 min); 99.2% in 0.1% ammonia (aq.)/MeCN (Rt 9.7 min). 
199 
Rf 0.14 (25% EtOAc/petrol); m.p. 66-69 °C; [𝛼]D
𝑅𝑇 +35° (c 0.747, EtOAc); λmax 
(EtOH)/nm 260sh; νmax/cm-1 (neat) 1693 (s, C=O), 3456 (w, O-H); 1H NMR (500 
MHz; CDCl3) δH 0.51-0.71 (4H, m, 2  CH2 cyclopropyl), 1.92 (3H, d, J= 7.3 Hz, 
CH3), 1.95 (1H, ABX app. t, JAX = JBX = 5.6 Hz, OH), 3.05 (1H, d, JAB = 9.4 Hz, 
CHAHBO-), 3.36 (1H, d, JAB = 9.4 Hz, CHAHBO-), 3.73 (2H, ABX dq, J = 5.6, 11.4 Hz, 
CH2OH), 4.39 (1H, q, J = 7.3 Hz , CHCH3), 6.90 (2H, m, H-Ar), 6.97 (2H, m, H-Ar), 
7.02-7.29 (4H, br, H-Ar), 7.22 (1H, m, H-Ar), 7.44 (1H, dd, J = 1.0, 7.9 Hz, H-Ar), 
7.50 (1H, m, H-Ar), 7.80 (1H, dd, J = 1.0, 7.4 Hz, H-Ar); 13C NMR (125 MHz; 
CDCl3) δC 8.9 (CH2 cyclopropyl), 9.1 (CH2 cyclopropyl), 19.8 (CHCH3), 22.7 (C q, 
cyclopropyl), 52.1 (CHCH3), 68.3 (CH2OH), 68.5 (CH2O-), 95.2 (C-3), 121.9 (C-
Ar), 127.1 (2  C-Ar), 127.9 (2  C-Ar), 128.1 (2  C-Ar), 128.6 (C-Ar), 129.4 (2  
C-Ar), 129.8 (C-Ar q), 131.7 (C-Ar), 132.7 (C-Ar q), 133.6 (C-Ar), 135.4 (C-Ar q), 
136.4 (C-Ar q), 140.6 (C-Ar q), 140.6 (C-Ar q), 166.5 (C-1); LRMS (ES+) m/z 
482.4 [M+H]+; HRMS calcd for C27H2635Cl2NO3 [M+H]+ 482.1284, found 
482.1284; HPLC 98.8% in 0.1% formic acid (aq.)/MeCN (Rt 9.8 min); 98.4% in 
0.1% ammonia (aq.)/MeCN (Rt 9.8 min). 
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(3S,1’S)-4-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenylisoindolin-1-one (201) 
and (3R,1’S)-4-chloro-2-[1’-(4’'-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenylisoindolin-1-one (202) 
    
Compounds 201 and 202 were synthesized according to general procedure N 
using isoindolinone 200 as a mixture of (3S,1’S) and (3R,1’S) diastereoisomers 
(0.70 g, 1.76 mmol), InBr3 (0.12 g, 0.35 mmol), 1,1-
bis(hydroxymethyl)cyclopropane (0.84 mL, 0.90 g, 8.8 mmol) and DCE (18 mL). 
Purification of the crude product by MPLC (gradient elution, 0-20% 
EtOAc/petrol) afforded the desired compounds 201 (0.36 g, 43%) and 202 
(0.42 g, 50%), as colorless oils. 
201 
Rf 0.25 (25% EtOAc/petrol); [𝛼]D
𝑅𝑇 -115° (c 0.745, EtOAc); λmax (EtOH)/nm 259; 
νmax/cm-1 (neat) 1699 (s, C=O), 3437 (br, O-H); 1H NMR (500 MHz; CDCl3) δH -
0.07-0.04 (1H, m, cyclopropyl), 0.14-0.25 (1H, m, cyclopropyl), 0.32-0.44 (2H, 
m, cyclopropyl), 1.58 (3H, d, J = 7.2 Hz, -CH3), 1.76 (1H, ABXbr, OH), 1.69 and 
2.89 (2H, ABq, JAB = 9.2 Hz, CH2O-), 3.27-3.37 and 3.40-3.50 (2H, ABXm, CH2OH), 
4.24 (1H, q, J = 7.2 Hz, CH-CH3), 7.27-7.32 (3H, m, H-Ar), 7.35-7.43 (4H, br, H-
Ar), 7.43-7.47 (1H, dd, J = 0.9, 8.0, H-Ar), 7.48-7.53 (1H, m, H-Ar), 7.57 (2H, m, 
H-Ar), 7.83 (1H, dd, J = 0.9, 7.5 Hz, H-Ar); 13C NMR (125 MHz; CDCl3) δC 8.6 (CH2 
cyclopropyl), 8.7 (CH2 cyclopropyl), 20.1 (CH3), 22.1 (C q cyclopropyl), 53.4 
(CHCH3), 68.4 (CH2OH), 68.7 (CH2O-), 96.4 (C-3), 122.0 (C-Ar), 127.1 (2  C-Ar), 
128.5 (2  C-Ar), 128.7 (2  C-Ar), 129.0 (C-Ar), 129.5 (2  C-Ar), 129.6 (C-Ar q), 
131.7 (C-Ar), 133.3 (C-Ar q), 133.8 (C-Ar), 135.2 (C-Ar q), 136.7 (C-Ar q), 140.8 
(C-Ar q), 141.6 (C-Ar q), 167.0 (C-1); LRMS (ES+) m/z 504.4 [M+Na]+; HRMS 
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calcd for C27H2635Cl2NO3 [M+H]+ 482.1284, found 482.1284; HPLC 97.7% in 
0.1% formic acid (aq.)/MeCN (Rt 9.7 min); 97.6% in 0.1% ammonia (aq.)/MeCN 
(Rt 9.7 min). 
202 
Rf 0.14 (25% EtOAc/petrol); [𝛼]D
𝑅𝑇 -35° (c 0.878, EtOAc); λmax (EtOH)/nm 260sh; 
νmax/cm-1 (neat) 1686 (s, C=O), 3416 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 
0.51-0.71 (4H, m, 2  CH2 cyclopropyl), 1.92 (3H, d, J= 7.3, CH3), 1.95 (1H, ABX 
app. t, JAX = JBX = 5.6 Hz, OH), 3.05 (1H, d, JAB = 9.4 Hz, CHAHBO-), 3.36 (1H, d, JAB = 
9.4 Hz, CHAHBO-), 3.73 (2H, ABX dq, J = 5.6, 11.4 Hz, CH2OH), 4.39 (1H, q, J = 7.3 
Hz , CHCH3), 6.90 (2H, m, H-Ar), 6.97 (2H, m, H-Ar), 7.02-7.29 (4H, br, H-Ar), 
7.22 (1H, m, H-Ar), 7.44 (1H, dd, J = 1.0, 7.9 Hz, H-Ar), 7.50 (1H, m, H-Ar), 7.80 
(1H, dd, J = 1.0, 7.4 Hz, H-Ar); 13C NMR (125 MHz; CDCl3) δC 8.9 (CH2 
cyclopropyl), 9.1 (CH2 cyclopropyl), 19.8 (CHCH3), 22.7 (C q, cyclopropyl), 52.1 
(CHCH3), 68.3 (CH2OH), 68.5 (CH2O-), 95.2 (C-3), 121.9 (C-Ar), 127.1 (2  C-Ar), 
127.9 (2  C-Ar), 128.1 (2  C-Ar), 128.6 (C-Ar), 129.4 (2  C-Ar), 129.8 (C-Ar q), 
131.7 (C-Ar), 132.7 (C-Ar q), 133.6 (C-Ar), 135.4 (C-Ar q), 136.4 (C-Ar q), 140.6 
(C-Ar q), 140.6 (C-Ar q), 166.5 (C-1); LRMS (ES+) m/z 482.4 [M+H]+; HRMS calcd 
for C27H2635Cl2NO3 [M+H]+ 482.1284, found 482.1285; HPLC 95.4% in 0.1% 
formic acid (aq.)/MeCN (Rt 9.8 min); 95.6% in 0.1% ammonia (aq.)/MeCN (Rt 
9.8 min). 
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(3R,1’R)-3-(4’’’-Chlorophenyl)-2-[1’-(4’’-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}isoindolin-1-one (204) and 
(3S,1’R)-3-(4’’’-chlorophenyl)-2-[1’-(4’’-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}isoindolin-1-one (205) 
   
Compounds 204 and 205 were synthesized according to general procedure N 
using isoindolinone 203 as a mixture of (3R,1’R) and (3S,1’S) diastereoisomers 
(0.84 g, 2.1 mmol), InBr3 (0.15 g, 0.42 mmol), 1,1-bis(hydroxy-
methyl)cyclopropane (1.00 mL, 1.07 g, 10.5 mmol) and DCE (21 mL). 
Purification of the crude product by MPLC (gradient elution, 3-22% 
EtOAc/petrol) afforded the desired compounds 204 (0.40 g, 40%) and 205 
(0.38 g, 38%), as white solids. 
204 
Rf 0.17 (25% EtOAc/petrol); m.p. 69-70 °C; [𝛼]D
30 +105° (c 0.502, EtOAc); λmax 
(EtOH)/nm 258sh; νmax/cm-1 (neat) 1684 and 1698 (s, C=O), 3441 (br, O-H); 1H 
NMR (500 MHz; CDCl3) δH 0.00 (2H, m, cyclopropyl), 0.32 (2H, m, cyclopropyl), 
1.46 (1H, ABX app. t, JAX = JBX = 5.0 Hz, OH), 1.64 (3H, d, J = 7.3 Hz, CH3), 2.52 
(1H, d, JAB = 9.5 Hz, CHAHBO-), 2.71 (1H, d, JAB = 9.5 Hz, CHAHBO-), 3.22 and 3.41 
(2H, ABX dq, JAX = JBX = 5.0, JAB = 11.3 Hz, CH2OH), 4.21 (1H, q, J = 7.3 Hz, CH-
CH3), 7.01-7.07 (1H, m, H-Ar), 7.20-7.27 (3H, m, H-Ar), 7.28-7.39 (3H, m, H-Ar), 
7.44-7.51 (2H, m, H-Ar), 7.51-7.56 (2H, m, H-Ar), 7.81-7.86 (1H, m, H-Ar); 13C 
NMR (125 MHz; CDCl3) δC 8.7 (CH2 cyclopropyl), 8.8 (CH2 cyclopropyl), 20.1 
(CH3), 22.2 (C q cyclopropyl), 53.5 (CHCH3), 68.1 (CH2O-), 68.2 (CH2OH), 96.2 
(C-3), 122.9 (C-Ar), 123.6 (C-Ar), 128.1 (2  C-Ar), 128.7 (2  C-Ar), 129.0 (2  
C-Ar), 129.6 (2  C-Ar), 130.6 (C-Ar), 132.5 (C-Ar q), 133.1 (C-Ar), 133.3 (C-Ar 
q), 134.8 (C-Ar q), 137.6 (C-Ar q), 141.7 (C-Ar q), 144.9 (C-Ar q), 168.4 (C-1); 
LRMS (ES+) m/z 482.4 [M+H]+; HRMS calcd for C27H2635Cl2NO3 [M+H]+ 
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482.1284, found 482.1283; HPLC 99.0% in 0.1% formic acid (aq.)/MeCN (Rt 
10.0 min); 98.7% in 0.1% ammonia (aq.)/MeCN (Rt 9.9 min). 
205 
Rf 0.09 (25% EtOAc/petrol); m.p. 139-140 °C; [𝛼]D
30 +21° (c 0.210, EtOAc); λmax 
(EtOH)/nm 258sh; νmax/cm-1 (neat) 1680 (s, C=O), 3395 (br, O-H); 1H NMR (500 
MHz; CDCl3) δH 0.34-0.41 (1H, m, cyclopropyl), 0.45-0.50 (1H, m, cyclopropyl), 
0.50-0.60 (2H, m, cyclopropyl), 1.65 (1H, ABX app.t, JAX = JBX = 5.0 Hz, OH), 1.89 
(3H, d, J = 7.3 Hz, CH3), 2.90 (1H, d, JAB = 9.5 Hz, CHAHBO-), 3.27 (1H, d, JAB = 9.5 
Hz, CHAHBO-), 3.62 (2H, ABX app. d, JAX = JBX = JAB= 5.0 Hz, CH2OH), 4.33 (1H, q, J 
= 7.3 Hz, CH-CH3), 6.95-7.09 (9H, m, H-Ar), 7.44-7.52 (2H, m, H-Ar), 7.79-7.85 
(1H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 8.9 (CH2 cyclopropyl), 9.0 (CH2 
cyclopropyl), 20.2 (CH3), 22.7 (C q cyclopropyl), 52.5 (CHCH3), 67.8 (CH2O-), 
68.1 (CH2OH), 95.0 (C-3), 123.0 (C-Ar), 123.5 (C-Ar), 128.1 (2  C-Ar), 128.2 (2  
C-Ar), 128.4 (2  C-Ar), 129.4 (2  C-Ar), 130.2 (C-Ar), 132.7 (C-Ar q), 132.8 (C-
Ar q), 132.9 (C-Ar), 134.6 (C-Ar q), 137.0 (C-Ar q), 141.3 (C-Ar q), 144.6 (C-Ar 
q), 168.1 (C-1); LRMS (ES+) m/z 482.4 [M+H]+; HRMS calcd for C27H2635Cl2NO3 
[M+H]+ 482.1284, found 482.1284; HPLC 99.8% in 0.1% formic acid 
(aq.)/MeCN (Rt 9.9 min); 99.7% in 0.1% ammonia (aq.)/MeCN (Rt 9.9 min). 
(3S,1’S)-3-(4’’’-Chlorophenyl)-2-[1-(4-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}isoindolin-1-one (207) and 
(3R,1’S)-3-(4’’’-chlorophenyl)-2-[1-(4-chlorophenyl)ethyl]-3-{[1-
(hydroxymethyl)cyclopropyl]methoxy}isoindolin-1-one (208) 
    
Compounds 207 and 208 were synthesized according to general procedure N 
using isoindolinone 206 as a mixture of (3S,1’S) and (3R,1’S) diastereoisomers 
(0.79 g, 1.98 mmol), InBr3 (0.14 g, 0.40 mmol), 1,1-bis(hydroxy-
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methyl)cyclopropane (0.95 mL, 1.01 g, 9.9 mmol) and DCE (20 mL). The 
reaction mixture was heated at 80 °C for 3.5 days. Purification of the crude 
product by MPLC (gradient elution, 3-22% EtOAc/petrol) afforded the desired 
compounds 207 (0.37 g, 39%) and 208 (0.36 g, 38%), as white solids. 
207 
Rf 0.17 (25% EtOAc/petrol); m.p. 69-70 °C; [𝛼]D
30 -105° (c 0.477, EtOAc); λmax 
(EtOH)/nm 258sh; νmax/cm-1 (neat) 1684 and 1698 (s, C=O), 3441 (br, O-H); 1H 
NMR (500 MHz; CDCl3) δH 0.00 (2H, m, cyclopropyl), 0.32 (2H, m, cyclopropyl), 
1.46 (1H, ABX app. t, JAX = JBX = 5.7 Hz, OH), 1.64 (3H, d, J = 7.3 Hz, CH3), 2.52 
(1H, d, JAB = 9.5 Hz, CHAHBO-), 2.71 (1H, d, JAB = 9.5 Hz, CHAHBO-), 3.22 and 3.41 
(2H, ABX dq, JAX = JBX= 6.2, JAB = 11.3 Hz, CH2OH), 4.21 (1H, q, J = 7.3 Hz, CH-CH3), 
7.01-7.07 (1H, m, H-Ar), 7.20-7.27 (3H, m, H-Ar), 7.28-7.39 (3H, m, H-Ar), 7.44-
7.51 (2H, m, H-Ar), 7.51-7.56 (2H, m, H-Ar), 7.81-7.86 (1H, m, H-Ar); 13C NMR 
(125 MHz; CDCl3) δC 8.7 (CH2 cyclopropyl), 8.8 (CH2 cyclopropyl), 20.1 (CH3), 
22.2 (C q cyclopropyl), 53.5 (CHCH3), 68.1 (CH2O-), 68.2 (CH2OH), 96.2 (C-3), 
122.9 (C-Ar), 123.6 (C-Ar), 128.1 (2  C-Ar), 128.7 (2  C-Ar), 129.0 (2  C-Ar), 
129.6 (2  C-Ar), 130.2 (C-Ar), 132.5 (C-Ar q), 133.1 (C-Ar), 133.3 (C-Ar q), 
134.8 (C-Ar q), 137.6 (C-Ar q), 141.7 (C-Ar q), 144.9 (C-Ar q), 168.4 (C-1); LRMS 
(ES+) m/z 482.4 [M+H]+; HRMS calcd for C27H2635Cl2NO3 [M+H]+ 482.1284, 
found 482.1282; HPLC 97.2% in 0.1% formic acid (aq.)/MeCN (Rt 10.0 min); 
96.9% in 0.1% ammonia (aq.)/MeCN (Rt 10.0 min). 
208 
Rf 0.09 (25% EtOAc/petrol); m.p. 134-135 °C; [𝛼]D
30 -22° (c 0.200, EtOAc); λmax 
(EtOH)/nm 256sh; νmax/cm-1 (neat) 1681 (s, C=O), 3441 (br, O-H); 1H NMR (500 
MHz; CDCl3) δH 0.34-0.41 (1H, m, cyclopropyl), 0.45-0.50 (1H, m, cyclopropyl), 
0.50-0.60 (2H, m, cyclopropyl), 1.65 (1H, ABX app.t, JAX = JBX = 5.0 Hz, OH), 1.89 
(3H, d, J = 7.3 Hz, CH3), 2.90 (1H, d, JAB = 9.5 Hz, CHAHBO-), 3.27 (1H, d, JAB = 9.5 
Hz, CHAHBO-), 3.61 (2H, ABX app. d, JAX = JBX = JAB= 5.0 Hz, CH2OH), 4.33 (1H, q, J 
= 7.3 Hz, CH-CH3), 6.95-7.09 (9H, m, H-Ar), 7.44-7.52 (2H, m, H-Ar), 7.79-7.85 
(1H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 8.9 (CH2 cyclopropyl), 9.0 (CH2 
cyclopropyl), 20.2 (CH3), 22.7 (C q cyclopropyl), 52.5 (CHCH3), 67.8 (CH2O-), 
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68.1 (CH2OH), 95.0 (C-3), 123.0 (C-Ar), 123.5 (C-Ar), 128.1 (2  C-Ar), 128.2 (2  
C-Ar), 128.4 (2  C-Ar), 129.4 (2  C-Ar), 130.2 (C-Ar), 132.7 (C-Ar q), 132.8 (C-
Ar q), 132.9 (C-Ar), 134.6 (C-Ar q), 137.0 (C-Ar q), 141.2 (C-Ar q), 144.6 (C-Ar 
q), 168.1 (C-1); LRMS (ES+) m/z 482.4 [M+H]+; HRMS calcd for C27H2635Cl2NO3 
[M+H]+ 482.1284, found 482.1283; HPLC 99.4% in 0.1% formic acid 
(aq.)/MeCN (Rt 9.9 min); 99.3% in 0.1% ammonia (aq.)/MeCN (Rt 9.9 min). 
(3R,1’R)-4-chloro-3-(4’’’-chlorophenyl)-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-2-(1’-phenylethyl)isoindolin-1-
one (191) and (3S,1’R)-4-chloro-3-(4’’’-chlorophenyl)-3-{[1’-
(hydroxymethyl)cyclopropyl]methoxy}-2-(1’-phenylethyl)isoindolin-1-
one (193) 
   
Compounds 191 and 193 were obtained following general procedure N using 
isoindolinone 312 as a mixture of (3R,1’R) and (3S,1’R) diastereoisomers (456 
mg, 1.14 mmol), InBr3 (81 mg, 0.228 mmol), 1,1-
bis(hydroxymethyl)cyclopropane (0.55 mL, 582 mg, 5.70 mmol) and DCE (11 
mL). Purification of the crude product by MPLC (gradient elution, 3-18% 
EtOAc/petrol) afforded the desired compounds 191 (116 mg, 24%) and 193 
(111 mg, 23%), as white amorphous solids. 
191 
Rf 0.20 (25% EtOAc/petrol); no clear m.p. detected; [𝛼]D
30 +86° (c 0.600, EtOAc); 
λmax (EtOH)/nm 258sh; νmax/cm-1 (neat) 1701 (s, CO=), 2873, 2922 and 2981 
(w, C-H and –CH2- aliphatic), 3400 (br, O-H); 1H NMR (500 MHz; CDCl3) δH -0.16 
– -0.06 (1H, m, cyclopropyl), 0.08 – 0.17 (1H, m, cyclopropyl), 0.24 – 0.36 (2H, 
m, cyclopropyl), 1.43 (1H, ABX dd, JAX = 5.4 Hz, JBX = 6.9 Hz, OH), 1.63 (3H, d, J = 
7.3 Hz, CH3), 2.68 (1H, d, JAB = 9.1 Hz, CHAHBO-), 2.79 (1H, d, JAB = 9.1 Hz, 
 
 
272 
 
CHAHBO-), 3.21 – 3.38 (2H, ABX dq, JAX = 5.4 Hz, JBX = 6.9 Hz, JAB = 11.5 Hz, 
CH2OH), 4.19 (1H, q, J = 7.3 Hz, CHCH3), 7.22 – 7.24 (1H, m, H-Ar), 7.26 – 7.40 
(6H, m, H-Ar), 7.43 (1H, dd, J = 1.0, 7.7 Hz, H-Ar), 7.49 (1H, app. t, J = 7.7 Hz, H-
6), 7.54 – 7.61 (2H, m, H-Ar), 7.83 (1H, dd, J = 1.0, 7.7 Hz, H-Ar); 13C NMR (125 
MHz; CDCl3) δC 8.5 (CH2 cyclopropyl), 8.6 (CH2 cyclopropyl), 20.7 (CH3), 22.1 (C 
q cyclopropyl), 54.3 (CHCH3), 68.1 (CH2OH), 68.3 (CH2O-), 96.1 (C-3), 122.2 (C-
Ar), 127.6 (2  C-Ar), 127.8 (2  C-Ar), 128.7 (2  C-Ar), 129.5 (2  C-Ar), 131.9 
(C-Ar), 133.7 (C-Ar), 134.9 (C-Ar q), 135.3 (C-Ar q), 135.7 (C-Ar q), 140.5 (C-Ar 
q), 143.3 (C-Ar q), 167.0 (C-1). Two quaternary carbons not detected; LRMS 
(ES+) m/z 504.4 [M+Na]+; HRMS calcd for C27H2635Cl2NO3 [M+H]+ 482.1284, 
found 482.1284; HPLC 99.9% in 0.1% formic acid (aq)/MeCN (Rt 9.9 min); 
99.9% in 0.1% ammonia (aq)/MeCN (Rt 9.9 min); 99.7% in isocratic 0.1% 
formic acid (aq)/MeCN (Rt 14.0 min). 
193 
Rf 0.14 (25% EtOAc/petrol); no clear m.p. detected; [𝛼]D
30 +10° (c 0.459, EtOAc); 
λmax (EtOH)/nm 258sh; νmax/cm-1 (neat) 1686 (s, C=O), 2874 and 2930 (w, C-H 
and –CH2- aliphatic), 3400 br, O-H); 1H NMR (500 MHz; CDCl3) δH 0.49 – 0.68 
(4H, m, cyclopropyl), 1.82 (1H, ABX app. t, JAX = JBX = 5.9 Hz, OH), 1.93 (3H, d, J = 
7.3 Hz), 3.01 (1H, d, JAB = 9.0 Hz, CHAHBO-), 3.32 (1H, d, JAB = 9.0 Hz, CHAHBO-), 
3.65 – 3.76 (2H, ABX dq, JAX = JBX = 5.9 Hz, JAB = 11.5 Hz, CH2OH), 4.36 (1H, q, J = 
7.3 Hz, CHCH3), 6.88 – 7.15 (9H, m, H-Ar), 7.41 (1H, dd, J= 1.0, 7.7 Hz, H-Ar), 7.47 
(1H, app. t, J = 7.7 Hz, H-6), 7.79 (1H, dd, J = 1.0, 7.7 Hz, H-Ar); 13C NMR (125 
MHz; CDCl3) δC 8.9 (CH2 cyclopropyl), 9.1 (CH2 cyclopropyl), 20.2 (CH3), 22.7 (C 
q cyclopropyl), 53.2 (CHCH3), 68.1 (CH2OH), 68.4 (CH2O-), 94.7 (C-3), 122.1 (C-
Ar), 127.0 (C-Ar), 127.8 (2  C-Ar), 128.0 (2  C-Ar), 128.0 (2  C-Ar), 128.7 (2  
C-Ar), 129.6 (C-Ar q), 131.8 (C-6), 133.6 (C-Ar), 134.4 (C-Ar q), 135.6 (C-Ar q), 
135.4 (C-Ar q), 140.3 (C-Ar q), 142.5 (C-Ar q), 166.6 (C-1); LRMS (ES+) m/z 
482.4 [M+H]+; HRMS calcd for C27H2635Cl2NO3 [M+H]+ 482.1284, found 
482.1286; HPLC 98.5% in 0.1% formic acid (aq)/MeCN (Rt 9.8 min); 98.6% in 
0.1% ammonia (aq)/MeCN (Rt 9.8 min); 98.6% in isocratic 0.1% formic acid 
(aq)/MeCN (Rt 12.7 min). 
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(3S,1’S)-4-chloro-3-(4’’’-chlorophenyl)-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-2-(1-phenylethyl)isoindolin-1-
one (195) and (3R,1’S)-4-chloro-3-(4’’’-chlorophenyl)-3-{[1-
(hydroxymethyl)cyclopropyl]methoxy}-2-(1-phenylethyl)isoindolin-1-
one (197) 
   
Compounds 195 and 197 were obtained following general procedure N using 
isoindolinone 313 as a mixture of (3S,1’S) and (3R,1’S) diasteroisomers (456 
mg, 1.14 mmol), InBr3 (81 mg, 0.228 mmol), 1,1-
bis(hydroxymethyl)cyclopropane (0.55 mL, 582 mg, 5.70 mmol) and DCE (11 
mL). The reaction mixture was heated at 80 °C for 4.5 days. Purification of the 
crude product by MPLC (gradient elution, 3-18% EtOAc/petrol) afforded the 
desired compounds 195 (191 mg, 35%) and 197 (142 mg, 26%), as white 
amorphous solids. 
195 
Rf 0.20 (25% EtOAc/petrol); no clear m.p. detected; [𝛼]D
30 -83° (c 0.580, EtOAc); 
λmax (EtOH)/nm 258sh; νmax/cm-1 (neat) 1701 (s, C=O), 2873, 2927 and 2980 
(w, C-H and –CH2- aliphatic), 3400 (br, O-H); 1H NMR (500 MHz; CDCl3) δH -0.16 
– -0.07 (1H, m, cyclopropyl), 0.08 – 0.16(1H, m, cyclopropyl), 0.24 – 0.35 (2H, m, 
cyclopropyl), 1.43 (1H, ABX br, OH), 1.6363 (3H, d, J = 7.3 Hz, CH3), 2.68 (1H, d, 
JAB = 9.1 Hz, CHAHBO-), 2.79 (1H, d, JAB = 9.1 Hz, CHAHBO-), 3.20 – 3.38 (2H, ABX 
m, JAB = 11.5 Hz, CH2OH), 4.1919 (1H, q, J = 7.3 Hz, CHCH3), 7.22 – 7.25 (1H, m, 
H-Ar), 7.27 –7.40 (6 H, m, H-Ar), 7.42(1H, dd, J = 1.0, 7.7 Hz, H-Ar), 7.49 (1H, 
app. t, J = 7.7 Hz, H-6), 7.53 – 7.61 (2H, m, H-Ar), 7.8383 (1H, dd, J = 1.0, 7.7 Hz, 
H-Ar); 13C NMR (125 MHz; CDCl3) δC 8.5 (CH2 cyclopropyl), 8.6 (CH2 
cyclopropyl), 20.7 (CH3), 22.1 (C q cyclopropyl), 54.3 (CHCH3), 68.1 (CH2OH), 
68.3 (CH2O-), 96.1 (C-3), 122.2 (C-Ar), 127.6 (2  C-Ar), 127.8 (2  C-Ar), 128.8 
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(2  C-Ar), 129.50 (2  C-Ar), 131.9 (C-Ar), 133.7 (C-Ar), 134.9 (C-Ar q), 135.3 
(C-Ar q), 135.7 (C-Ar q), 140.5 (C-Ar q), 143.3 (C-Ar q), 167.0 (C-1). Two 
quaternary carbons not detected; LRMS (ES+) m/z 504.4 [M+Na]+; HRMS calcd 
for C27H2635Cl2NO3 [M+H]+ 482.1284, found 482.1285; HPLC 99.5% in 0.1% 
formic acid (aq)/MeCN (Rt 9.9 min); >99.9% in 0.1% ammonia (aq)/MeCN (Rt 
9.8 min); 99.4% in isocratic 0.1% formic acid (aq)/MeCN (Rt 14.0 min). 
197 
Rf 0.14 (25% EtOAc/petrol); no clear m.p. detected; [𝛼]D
30 -9° (c 0.594, EtOAc); 
λmax (EtOH)/nm 258sh; νmax/cm-1 (neat) 1686 (s, C=O), 2874, 2930 and 2981 
(w, C-H and –CH2- aliphatic), 3400 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 0.49 
– 0.69 (4H, m, cyclopropyl), 1.85 (1H, ABX app. t, JAX = JBX = 5.9 Hz, OH), 1.93(3H, 
d, J = 7.3 Hz), 3.00 (1H, d, JAB = 9.0 Hz, CHAHBO-), 3.33 (1H, d, JAB = 9.0 Hz, 
CHAHBO-), 3.64 – 3.78 (2H, ABX dq, JAX = JBX = 5.9 Hz, JAB = 11.5 Hz, CH2OH), 4.36 
(1H, q, J = 7.3 Hz, CHCH3), 6.90 – 7.15 (9H, m, H-Ar), 7.41 (1H, dd, J= 1.0, 7.7 Hz, 
H-Ar), 7.4747 (1H, app. t, J = 7.7 Hz, H-6), 7.79 (1H, dd, J = 1.0, 7.7 Hz, H-Ar); 13C 
NMR (125 MHz; CDCl3) δC 8.9 (CH2 cyclopropyl), 9.0 (CH2 cyclopropyl), 20.2 
(CH3), 22.7 (C q cyclopropyl), 53.2 (CHCH3), 68.1 (CH2OH), 68.4 (CH2O-), 94.7 
(C-3), 122.1 (C-Ar), 127.0 (C-Ar), 127.8 (2  C-Ar), 128.0 (2  C-Ar), 128.0 (2  
C-Ar), 128.7 (2  C-Ar), 129.6 (C-Ar q), 131.8 (C-6), 133.6 (C-Ar), 134.4 (C-Ar q), 
135.1 (C-Ar q), 135.4 (C-Ar q), 140.3 (C-Ar q), 142.5 (C-Ar q), 166.6 (C-1); LRMS 
(ES+) m/z 482.4 [M+H]+; HRMS calcd for C27H2635Cl2NO3 [M+H]+ 482.1284, 
found 482.1285; HPLC 99.0% in 0.1% formic acid (aq)/MeCN (Rt 9.8 min); 
99.5% in 0.1% ammonia (aq)/MeCN (Rt 9.8 min); 97% in isocratic 0.1% formic 
acid (aq)/MeCN (Rt 12.7 min). 
6-Bromo-3-chloro-2-hydroxybenzaldehyde (290) 
 
The phenol (10.0 g, 48.2 mmol) was dissolved in chloroform (50 mL, 0.625 
mol). Water (15 mL, 0.31 mL/mol) and NaOH (12.2 g, 0.304 mol) were added in 
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one portion and the pale pink mixture was stirred at 75 °C for 3 h. The reaction 
was quenched by addition of HCl (1 M aq.) and water (50 mL) until neutral pH 
was reached. DCM (50 mL) was added and the layers were separated. The 
aqueous layer was extracted with diethyl ether (2  50 mL). The combined 
organic layers were washed with 10 % aq. NaHCO3 (50 mL), brine (50 mL), 
dried (MgSO4), filtered and evaporated. Medium pressure liquid 
chromatography (gradient elution, 0-3% EtOAc/petrol) afforded the desired 
compound 290 (2.8 g, 25%) as a pale yellow solid. Rf 0.76 (17% EtOAc/petrol); 
m.p. 81.4-84.7 °C; λmax (EtOH)/nm 271, 349; ν max/cm-1 (neat) 1640 (s, C=O); 1H 
NMR (500 MHz; CDCl3) δH 7.15 (1H, d, J = 8.4 Hz, H-5), 7.44 (1H, dd, J = 0.6, 8.4 
Hz, H-4), 10.31 (1H, s, CHO), 12.52 (1H, br, OH); 13C NMR (125 MHz; CDCl3) δC 
118.5 (C-Ar q), 124.7 (C-5), 125.7 (C-3), 137.4 (C-4), 159.7 (C-2), 197.8 (CHO) 
ppm. One quaternary carbon not detected; LRMS (ES–) m/z 233.0 and 235.0 [M-
H]–; HRMS calcd for C7H581Br35ClO2 [M+H]+ 236.9129, found 236.9133. 
(E)-N'-(6-Bromo-3-chloro-2-hydroxybenzylidene)benzohydrazide (293) 
 
The hydrazide 293 was prepared following general procedure J using aldehyde 
290 (2.50 g, 10.6 mmol), benzhydrazide (1.44 g, 10.6 mmol), and acetic acid (45 
mL). The title compound was obtained (3.03 g, 81%) as an off-white solid. Rf 
0.72 (50% EtOAc/petrol); m.p. 205.8-206.2 °C; λmax (EtOH)/nm 301, 314, 
341sh; ν max/cm-1 (neat) 1635 (s, C=O), 3060 (w, C-H str, aromatic), 3196 (br, 
OH), 3401 (br, N-H); 1H NMR (500 MHz; DMSO-d6) δH 7.25 (1H, d, J = 8.5 Hz, H-
4), 7.44 (1H, d, J = 8.5 Hz, H-5), 7.56 – 7.61 (2H, m, H-3’ and H-5’), 7.62 – 7.70 
(1H, m, H-4’), 7.94 – 8.02 (2H, m, H-2’ and H-6’), 9.02 (1H, s, C-H), 12.63 (1H, s, 
N-H), 13.54 (1H, s, O-H); 13C NMR (125 MHz; DMSO-d6) δC 117.5 (C-Ar q), 120.4 
(C-Ar q), 122.3 (C-Ar q), 124.0 (C-4), 127.7 (C-2’ and C-6’), 128.7 (C-3’ and C-5’), 
132.1(C-5), 132.5 (C-4’), 148.3 (C-1’), 154.9 (C-1), 162.8 (C=O). One quaternary 
carbon not detected; LRMS (ES+) m/z 353.2 and 355.2 [M+H]+; HRMS calcd for 
C14H1179Br35ClN2O2 [M+H]+ 352.9687, found 352.9695. 
 
 
276 
 
2-Benzoyl-6-bromo-3-chlorobenzaldehyde (294) 
 
Compound 294 was prepared according to general procedure K using the 
hydrazide 293 (3.03 g, 8.57 mmol), lead tetraacetate (4.57 g, 10.3 mmol) and 
THF (65 mL). The crude product was purified by medium pressure liquid 
chromatography (gradient elution, 0-20% EtOAc/petrol) to yield the title 
compound (2.26 g, 81%) as an off-white solid. Rf  0.49 (20% EtOAc/petrol); m.p. 
170.7-172.1 °C; λmax (EtOH)/nm 248, 314; ν max/cm-1 (neat) 1672 (vs, C=O); 1H 
NMR (500 MHz; DMSO-d6) δH 7.49 – 7.55 (2H, m, H-3’ and H-5’), 7.64 – 7.69 (1H, 
m, H-4’), 7.69 – 7.74 (2H, m, H-2’ and H-6’), 7.85 (1H, d, J = 8.6 Hz, H-4), 8.01 
(1H, d, J = 8.6 Hz, H-5), 10.15 (1H, s, CHO); 13C NMR (125 MHz; DMSO-d6) δC 
125.8 (C-Ar q), 128.4 (C-2’ and C-6’), 129.0 (C-3’ and C-5’), 130.3 (C-Ar q), 132.5 
(C-Ar q), 133.8 (C-4’), 135.6 (C-Ar q), 136.1 and 136.2 (C-4 and C-5), 140.3 (C-Ar 
q), 191.1 (CHO), 193.0 (C=O); LRMS (ES+) m/z 289.2 and 291.2 [M+H]+; HRMS 
calcd for C14H981Br35ClO2 [M+H]+ 324.9446, found 324.9447. 
2-Benzoyl-6-bromo-3-chlorobenzoic acid (295) 
 
Compound 295 was obtained following general procedure L using aldehyde 
294 (2.26 g, 6.98 mmol), sodium chlorite (0.820 g, 9.07 mmol), sulfamic acid 
(0.880 g, 9.07 mmol), MeCN (87 mL) and water (2  10 mL). The crude product 
(yellow solid; 2.60 g, 97%) was used directly in the following step without 
further purification. Rf 0.28 (10% MeOH/DCM); m.p. 189.3-190.6 °C; λmax 
(EtOH)/nm 292; νmax/cm-1 (neat)1747 (vs, C=O), 3375 (br s, O-H); 1H NMR (500 
MHz; DMSO-d6) δH 7.28-7.77 (6H, m, H-Ar), 7.85-7.97 (1H, m, H-Ar), 8.76 (1H, s, 
CO2H);13C NMR (125 MHz; CDCl3) δC 126.2 (C-Ar), 128.2 (C-Ar), 129.1 (C-Ar), 
129.2 (C-Ar), 129.3 (C-Ar), 132.3 (C-Ar), 134.4 (C-Ar), 135.6 (C-Ar), 136.9  
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(C-Ar), 192.7 (C q). Two carbons not visible; LRMS (ES–) m/z 337.1 and 339.1 
[M-H]–; HRMS calcd for C14H779Br35ClO3 [M-H]- 336.9273, found 336.9264. 
(1’R)-7-Bromo-4-chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-hydroxy-3-
phenylisoindolin-1-one (296) 
 
The isoindolinone 296 was obtained following general procedure M using acid 
295 (2.30 g, 6.77 mmol), thionyl chloride (0.98 mL, 1.61 g, 13.54 mmol), 
catalytic DMF (3 drops), (R)-4-chloro-α-methylbenzylamine (1.05 mL, 1.16 g, 
7.45 mmol), DIPEA (1.30 mL, 0.963 g, 7.45 mmol) and THF (2  8.0 mL). The 
product was obtained as a mixture of diastereoisomers (dr 1:10; white powder; 
2.56 g, 79%) after purification by MPLC (gradient elution, 0-25% EtOAc/petrol). 
Rf(1) 0.70, Rf(2) 0.57 (25% EtOAc/petrol); no clear m.p. detected; λmax (EtOH)/nm 
252sh; νmax/cm-1 (neat) 1670 and 1682 (s, C=O), 3374 (m, O-H); 1H NMR (500 
MHz; DMSO-d6) δH 1.33 (3H, d, J = 7.3 Hz, CHCH3), 1.74 (3H, d, J = 7.2 Hz, 
CHCH3), 4.36 (1H, q, J = 7.3 Hz, CHCH3)4.48 (1H, q, J = 7.2, CHCH3), 6.84 – 6.90 
(2H, m, H-Ar), 7.04 – 7.12 (2H, m, H-Ar), 7.13 – 7.31 (5H, m, H-Ar), 7.51 (1H, d, J 
= 8.5 Hz, H-5 or H-6), 7.75 (1H, d, J = 8.5 Hz, H-5 or H-6); 13C NMR (125 MHz; 
DMSO-d6) δC 19.0 (CHCH3), 50.2 (CHCH3), 88.8 (C-3), 115.5 (C-Ar q), 126.6 (2  
C-Ar), 127.4 (2  C-Ar), 128.0 (2  C-Ar), 128.1 (C-Ar), 128.3 (C-Ar), 129.2 (2  
C-Ar), 130.6 (C-Ar q), 131.1 (C-Ar q), 134.7, 135.9, 137.2 (C-Ar q), 140.2 (C-Ar 
q), 146.7 (C-Ar q), 162.8 (C-1); LRMS (ES–) m/z 476.1 [M-H]–; HRMS calcd for 
C22H1579Br35Cl2NO2 [M-H]– 473.9669, found 473.9674. 
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(1’R)-4-Chloro-2-[1’-(3’’-chlorophenyl)ethyl]-3-hydroxy-3-
phenylisoindolin-1-one (255) 
 
The isoindolinone 255 was obtained following general procedure M using acid 
183 (290 mg, 1.11 mmol), thionyl chloride (0.16 mL, 264 mg, 2.22 mmol), 
catalytic DMF (3 drops), (R)-3-chloro-α-methylbenzylamine (0.18 mL, 190 mg, 
1.22 mmol), DIPEA (0.21 mL, 158 mg, 1.22 mmol) and THF (2  1.3 mL). The 
product was obtained as a mixture of diastereoisomers (cream-colored 
amorphous solid; 339 mg, 77%) after purification by MPLC (gradient elution, 0-
33% EtOAc/petrol). Rf(1) 0.69, Rf(2) 0.54 (33% EtOAc/petrol); no clear m.p. 
detected; λmax (EtOH)/nm 259; νmax/cm-1 (neat) 1669 (s, C=O), 3208 (br, O-H); 
1H NMR (500 MHz; DMSO-d6) δH 1.36 (3H, d, J = 7.1 Hz, CH3), 1.75 (3H, d, J = 7.1 
Hz, CH3), 4.38 (1H, q, J = 7.1 Hz, CHCH3), 4.49 (1H, q, J = 7.1 Hz, CHCH3), 6.82 
(1H, t, J = 1.9 Hz, H-Ar), 6.88 (1H, dt, J = 7.6, 1.4 Hz, H-Ar), 7.06 (1H, t, J = 7.8 Hz, 
H-Ar), 7.10 (1H, ddd, J = 8.0, 2.1, 1.2 Hz, H-Ar), 7.12 – 7.28 (5H, m, H-Ar), 7.30 
(1H, t, J = 7.7 Hz, H-Ar), 7.32 – 7.43 (6H, m, H-Ar), 7.48 (1H, s, H-Ar), 7.52 (1H, t, 
J = 1.8 Hz, H-Ar), 7.55 – 7.62 (4H, m, H-Ar), 7.64 – 7.72 (2H, m, H-Ar); 13C NMR 
(125 MHz; DMSO-d6) δC 17.3 (CHCH3), 19.1 (CHCH3), 49.8 (CHCH3), 50.2 
(CHCH3), 90.5 (C-3), 90.7 (C-3), 121.2 (C-Ar), 125.9 (C-Ar), 126.0 (C-Ar), 126.4 
(C-Ar), 126.6 (C-Ar), 126.6 (C-Ar), 127.2 (C-Ar), 127.3 (C-Ar), 127.9 (C-Ar), 
128.1 (C-Ar), 128.3 (C-Ar), 128.5 (C-Ar), 128.6 (C-Ar), 129.3 (C-Ar), 129.6 (C-
Ar), 131.5 (C-Ar), 131.6 (C-Ar), 132.1 (C-Ar), 132.6 (C-Ar), 133.3 (C-Ar), 134.1 
(C-Ar), 134.4 (C-Ar), 137.6 (C-Ar), 137.7 (C-Ar), 144.1 (C-Ar), 144.2 (C-Ar), 
144.3 (C-Ar), 164.5 (C-1), 164.8 (C-1). One carbon not detected; LRMS (ES–) m/z 
396.2 [M-H]–; HRMS calcd for C22H1635Cl2NO2 [M-H]– 396.0564, found 396.0564. 
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2-Benzyl-4-chloro-3-hydroxy-3-phenylisoindolin-1-one (251) 
 
The isoindolinone 251 was obtained following general procedure M using 
benzoylbenzoic acid 183 (290 mg, 1.11 mmol), thionyl chloride (0.16 mL, 264 
mg, 2.22 mmol), catalytic DMF (3 drops), benzylamine (0.13 mL, 131 mg, 1.22 
mmol), DIPEA (0.21 mL, 158 mg, 1.22 mmol) and THF (2  1.3 mL). Purification 
by MPLC (gradient elution, 0-25% EtOAc/petrol) afforded title compound 251 
as an off-white solid (349 mg, 90%). Rf 0.43 (33% EtOAc/petrol); m.p. 183.6-
184.7 °C; λmax (EtOH)/nm 258; νmax/cm-1 (neat) 1656 (vs, C=O), 2850 and 2922 
(w, C-H and –CH2- aliphatic), 3194 (br, O-H); 1H NMR (500 MHz; DMSO-d6) δH 
4.15 (1H, d, JAB = 15.6 Hz, CHAHB), 4.38 (1H, d, JAB = 15.6 Hz, CHAHB), 7.02 – 7.17 
(5H, m, H-Ar), 7.18 – 7.34 (5H, m, H-Ar), 7.53 – 7.63 (2H, m, H-Ar), 7.70 – 7.79 
(1H, m, H-Ar); 13C NMR (125 MHz; DMSO-d6) δC 42.2 (CH2), 90.3 (C-3), 121.4 (C-
Ar), 126.4 (2  C-Ar), 127.7 (C-Ar), 127.7 (2  C-Ar), 127.8 (2  C-Ar), 128.0 (2  
C-Ar), 128.7 (C-Ar), 131.5 (C-Ar), 133.5 (C-Ar), 137.7 (C-Ar q), 137.7 (C-Ar q), 
165.4 (C-1). Three quaternary carbons not detected. LRMS (ES–) m/z 348.2 [M-
H]–; HRMS calcd for C21H1535ClNO2 [M-H]– 348.0797, found 348.0783. 
4-Chloro-2-(4’-chlorobenzyl)-3-hydroxy-3-phenylisoindolin-1-one (253) 
 
General procedure M was used to synthesize the isoindolinone 253 using 
benzoylbenzoic acid 183 (290 mg, 1.11 mmol), thionyl chloride (0.16 mL, 264 
mg, 2.22 mmol), catalytic DMF (3 drops), 4-chlorobenzylamine (0.15 mL, 173 
mg, 1.22 mmol), DIPEA (0.21 mL, 158 mg, 1.22 mmol) and THF (2  1.3 mL). 
Purification by MPLC (gradient elution, 0-33% EtOAc/petrol) afforded the title 
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compound 253 as an off-white solid (317 mg, 74%). Rf 0.46 (33% 
EtOAc/petrol); m.p. 194.0-195.5 °C; λmax (EtOH)/nm 253; νmax/cm-1 (neat) 1655 
(vs, C=O), 2924 (w, C-H and –CH2- aliphatic), 3141 (br, O-H); 1H NMR (500 MHz; 
DMSO-d6) δH 4.16 (1H, d, JAB = 15.7 Hz, CHAHB), 4.37 (1H, d, JAB = 15.7 Hz, 
CHAHB), 7.08 – 7.15 (2H, m, H-Ar), 7.16 – 7.21 (2H, m, H-Ar), 7.21 – 7.29 (4H, m, 
H-Ar), 7.29 – 7.34 (1H, m, H-Ar), 7.57 – 7.61 (2H, m, H-Ar), 7.72 – 7.78 (1H, m, 
H-Ar); 13C NMR (125 MHz; DMSO-d6) δC 41.5 (CH2), 99.5 (C-3), 121.5 (C-Ar), 
126.4 (2  C-Ar), 127.7 (2  C-Ar), 128.1 (2  C-Ar), 129.7 (2  C-Ar), 131.1 (C-
Ar q), 131.6 (C-Ar), 133.3 (C-Ar q), 133.5 (C-Ar), 136.8 (C-Ar q), 165.3 (C-1). 
Four carbons not detected; LRMS (ES–) m/z 382.3 [M-H]–; HRMS calcd for 
C21H1435Cl2NO2 [M-H]– 382.0407, found 382.0397. 
(3R,1’R)-4-Chloro-2-[1’-(3’’-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenylisoindolin-1-one (256) 
and (3S,1’R)-4-Chloro-2-[1’-(3’’-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenylisoindolin-1-one (257) 
   
Compounds 256 and 257 were obtained according to general procedure N 
using isoindolinone 255 (308 mg, 0.733 mmol), InBr3 (55 mg, 0.155 mmol), 1,1-
bis(hydroxymethyl)cyclopropane (0.37 mL, 395 mg, 3.87 mmol) and DCE (7.7 
mL). Purification by MPLC (gradient elution, 0-20% EtOAc/petrol) yielded 
isoindolinones 256 (100 mg, 27%; white amorphous solid) and 257 (140 mg, 
38%; white solid). 
256 
Rf 0.33 (33% EtOAc/petrol); no clear m.p. detected; [𝛼]D
29 +90° (c 0.706, EtOAc); 
λmax (EtOH)/nm 259;ν max/cm-1 (neat) 1343 (s), 1699 (vs, C=O), 3500 (br, O-H); 
1H NMR (500 MHz; CDCl3) δH -0.07 – 0.00 (1H, m, cyclopropyl), 0.13 – 0.21 (1H, 
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m, cyclopropyl), 0.31 – 0.40 (2H, m, cyclopropyl), 1.58 (3H, d, J = 7.3 Hz, -CH3), 
1.72 (1H, ABX br, -OH), 2.64 (1H, d, JAB = 9.1 Hz, CHAHBO-), 2.94 (1H, d, JAB = 9.1 
Hz, CHAHBO-), 3.31 (1H, ABX app. d, JAB = 11.5 Hz, CHAHB-OH), 3.46 (1H, ABX 
app. d, JAB = 11.5 Hz, CHAHB-OH), 4.20 (1H, q, J = 7.3 Hz, -CHCH3), 7.21 – 7.25 
(2H, m, H-Ar), 7.30 – 7.41 (5H, m, H-Ar), 7.43 (1H, dd, J = 7.7, 1.0 Hz, H-5), 7.49 
(1H, app. t, J = 7.7 Hz, H-6), 7.52 – 7.58 (2H, m, H-Ar), 7.83 (1H, dd, J = 1.0, 7.7 
Hz, H-7); 13C NMR (125 MHz; CDCl3) δC 8.5 (CH2 cyclopropyl), 8.5 (CH2 
cyclopropyl), 20.0 (CH3), 22.1 (C q cycloprpopyl), 53.6 (CHCH3), 68.4 and 68.4 
(CH2O- and CH2-OH), 96.4 (C-3), 122.1 (C-7), 126.3 (C-Ar), 127.7 (C-Ar), 128.2 
(C-Ar), 128.5 (C-Ar), 129.0 (C-Ar), 129.6 (C-Ar q), 130.0 (C-Ar), 130.6 (C-Ar), 
131.7 (C-6), 133.8 (C-5), 134.3 (C-Ar q), 135.2 (C-Ar q), 136.7 (C-Ar q), 140.8 (C-
Ar q), 145.1 (C-Ar q), 167.0 (C-1); LRMS (ES+) m/z 504.4 [M+Na]+; HRMS calcd 
for C27H26Cl2NO3 [M+H]+ 482.1284, found 482.1282; HPLC 98.4% in 0.1% 
formic acid (aq)/MeCN (Rt 9.7 min); 98.7% in 0.1% ammonia (aq)/MeCN (Rt 9.7 
min); 98.7% in isocratic 0.1% formic acid (aq)/MeCN (Rt 12.5 min). 
257 
Rf 0.24 (33% EtOAc/petrol); m.p. 184.9-187.4 °C; [𝛼]D
29 -3° (c 0.702, EtOAc); λmax 
(EtOH)/nm 259; ν max/cm-1 (neat) 1684 (s, C=O), 2872 and 2921 (w, aliphatic C-
H and -CH2-), 3420 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 0.51 – 0.67 (4H, m, 
cyclopropyl), 1.88 – 1.94 (4H, m, -CH3 and -OH), 3.04 (1H, d, JAB = 9.2 Hz, 
CHAHBO-), 3.32 (1H, d, JAB = 9.2 Hz, CHAHBO-), 3.70 (2H, ABX dq, JAX = JBX = 5.9 Hz, 
JAB = 11.4 Hz, CH2OH), 4.35 (1H, q, J = 7.3 Hz, -CHCH3), 6.70 (1H, app. t, J = 1.9 Hz, 
H-2’), 6.94 (1H, app. t, J = 7.7 Hz, H-5’), 7.00 (1H, m, H-Ar), 7.03 (1H, m, H-Ar), 
7.10 (4H, br, H-Ar), 7.18 – 7.23 (1H, m, H-Ar), 7.42 (1H, dd, J = 7.9, 1.1 Hz, H-5), 
7.47 (1H, dd, J = 7.9, 7.4 Hz, H-6), 7.78 (1H, dd, J = 7.4, 1.1 Hz, H-7); 13C NMR 
(125 MHz; CDCl3) δC 8.9 (CH2 cyclopropyl), 9.1 (CH2 cyclopropyl), 19.7 (CH3), 
22.7 (C q cyclopropyl), 52.3 (CHCH3), 68.3 (CH2OH), 68.5 (CH2O), 95.1 (C-3), 
122.0 (C-7), 126.1 (C-Ar), 127.1 (2  C-Ar), 128.0 (2  C-Ar), 128.2 (C-Ar), 128.8 
(C-Ar), 129.1 (C-Ar), 129.8 (C-Ar q), 131.7 (C-6), 133.4 (C-Ar q), 133.6 (C-5), 
135.4 (C-Ar q), 136.3 (C-Ar q), 140.6 (C-Ar q), 144.1 (C-Ar q), 166.5 (C-1). One 
carbon not detected; LRMS (ES+) m/z 504.4 [M+Na]+; HRMS calcd for 
 
 
282 
 
C27H26Cl2NO3 [M+H]+ 482.1284, found 482.1282; HPLC 99.8% in 0.1% formic 
acid (aq)/MeCN (Rt 9.7 min); >99.9% in 0.1% ammonia (aq)/MeCN (Rt 9.7 min); 
99.2% in isocratic 0.1% formic acid (aq)/MeCN (Rt 12.0 min). 
2-Benzyl-4-chloro-3-{[1’’’’-(hydroxymethyl)cyclopropyl]methoxy}-3-
phenylisoindolin-1-one (252) 
 
Compound 252 was obtained according to general procedure N using 
isoindolinone 251 (349 mg, 1.00 mmol), InBr3 (71 mg, 0.20 mmol), 1,1-
bis(hydroxymethyl)cyclopropane (0.48 mL, 511 mg, 5.0 mmol) and DCE (10 
mL). Purification by MPLC (gradient elution, 0-30% EtOAc/petrol) yielded the 
title compound as a white amorphous solid (300 mg, 69%). Rf 0.19 (33% 
EtOAc/petrol); m.p. 132.0-132.8 °C; λmax (EtOH)/nm 285; νmax/cm-1 (neat) 1389 
(s), 1460 (m), 1687 (vs, C=O), 1704 (s), 2875 and 2922 (w, aliphatic CH and -
CH2-), 3417 (w, O-H); 1H NMR (500 MHz; CDCl3) δH -0.09 – 0.02 (1H, m, 
cyclopropyl), 0.15 – 0.26 (1H, m, cyclopropyl), 0.29 – 0.41 (2H, m, cyclopropyl), 
1.69 (1H, ABX dd, JAX = 5.7 Hz, JBX = 6.5 Hz, -OH), 2.74 (1H, d, JAB = 9.1 Hz, 
CHAHBO-), 2.88 (1H, d, JAB = 9.1 Hz, CHAHBO-), 3.38 (2H, ABX m, , CH2-OH), 3.93 
(1H, d, JAB = 15.0 Hz, CHAHB-Ph), 4.70 (1H, d, JAB = 15.0 Hz, CHAHB-Ph), 7.13 – 
7.24 (6H, m, H-Ar), 7.30 (4H, br, H-Ar), 7.42 – 7.46 (1H, m, H-5), 7.49 (1H, t, J = 
7.7, H-6), 7.86 (1 H, dd, J 7.4, 1.0, H-7); 13C NMR (125 MHz; CDCl3) δC 8.6 (CH2 
cyclopropyl), 8.7 (CH2 cyclopropyl), 22.1 (C q cyclopropyl), 43.3 (CH2-Ar) , 68.3 
and 68.4 (CH2O- and CH2OH), 95.6 (C-3), 122.3 (C-7), 127.0 (2  C-Ar), 127.5 (C-
Ar), 128.4 (2  C-Ar), 128.5 (2  C-Ar), 128.8 (C-Ar), 129.2 (2  C-Ar), 129.8 (C-
Ar q), 131.7 (C-6), 133.9 (C-5), 134.5 (C-Ar q), 136.5 (C-Ar q), 137.6 (C-Ar q), 
141.4 (C-Ar q), 167.0 (C-1); LRMS (ES+) m/z 456.4 [M+Na]+; HRMS calcd for 
C26H25ClNO3 [M+H]+ 434.1517, found 434.1518; HPLC >99.9% in 0.1% formic 
acid (aq)/MeCN (Rt 8.9 min); 99.8% in 0.1% ammonia (aq)/MeCN (Rt 8.9 min). 
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4-Chloro-2-(4’-chlorobenzyl)-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenylisoindolin-1-one (254) 
 
The title compound was obtained following general procedure N using 
isoindolinone 253 (317 mg, 0.825 mmol), InBr3 (58 mg, 0.165 mmol), 1,1-
bis(hydroxymethyl)cyclopropane (0.40 mL, 422 mg, 4.13 mmol) and DCE (8.3 
mL). Purification by MPLC (gradient elution, 0-30% petrol/EtOAc) yielded the 
desired compound 254 (270 mg, 70%) as a white amorphous solid. Rf 0.19 
(33% EtOAc/petrol); no clear m.p detected; λmax (EtOH)/nm 252; νmax/cm-1 
(neat) 1704 (vs, C=O), 2874 and 2926 (w, aliphatic CH and -CH2-), 3400 (br, O-
H); 1H NMR (500 MHz; CDCl3) δH 0.11 (1H, m, cyclopropyl), 0.28 (1 H, m, 
cyclopropyl), 0.44 (2H, m, cyclopropyl), 1.78 (1H, ABX app. t, JAX = JBX = 6.0 Hz, -
OH), 2.79 (1H, d, JAB = 9.1 Hz, CHAHBO), 2.94 (1H, d, JAB = 9.1 Hz, CHAHBO), 3.40 – 
3.55 (2H, ABX m, CH2OH), 4.12 (1H, d, JAB = 15.0 Hz, CHAHB-Ar), 4.50 (1H, d, JAB = 
15.0 Hz, CHAHB-Ar), 7.02 – 7.15 (4H, m, H-Ar), 7.25 (5H, br, H-Ar), 7.45 (1H, m, 
H-5), 7.50 (1H, app. t, J = 7.4 Hz, H-6), 7.85 (1H, dd, J = 1.1, 7.4 Hz, H-7); 13C NMR 
(125 MHz; CDCl3) δC 8.8 (CH2 cyclopropyl), 8.8 (CH2 cyclopropyl), 22.2 (C q 
cyclopropyl), 42.5 (CH2-Ar), 68.3 (CH2OH), 68.4 (CH2O-), 95.3 (C-3), 122.3 (C-7), 
126.9 (C-Ar), 128.4 (C-Ar), 128.5 (C-Ar), 128.8 (C-Ar), 129.9 (C-Ar q), 130.6 (C-
Ar), 131.8 (C-6), 133.3 (C-Ar q), 134.0 (C-5), 134.4 (C-Ar q), 135.8 (C-Ar q), 
136.4 (C-Ar q), 141.3 (C-Ar q), 167.0 (C-1); LRMS (ES+) m/z 490.3 [M+Na]+; 
HRMS calcd for C26H24Cl2NO3 [M+H]+ 468.1128, found 468.1127; HPLC 97.8% in 
0.1% formic acid (aq)/MeCN (Rt 9.3 min); 97.7% in 0.1% ammonia (aq)/MeCN 
(Rt 9.3 min). 
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(3R,1’R)-7-Bromo-4-chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenylisoindolin-1-one (289) 
and (3S,1’R)-7-Bromo-4-chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenylisoindolin-1-one (297) 
   
The title compounds were obtained according to general procedure N using 
isoindolinone 296 (2.48 g, 5.20 mmol), InBr3 (369 mg, 1.04 mmol), 1,1-
bis(hydroxymethyl)cyclopropane (2.50 mL, 2.66 g, 26.0 mmol) and DCE 
(52mL). Purification by MPLC (gradient elution, 0-15% EtOAc/petrol) yielded 
isoindolinones 289 (1.19 g, 41%) and 297 (1.30 g, 44%) as white amorphous 
solids. 
289 
Rf 0.33 (25% EtOAc/petrol); no clear m.p. detected (melting range 78-105 °C; 
boils 130 °C); [𝛼]D
24 +75° (c 0.722, EtOAc); λmax (EtOH)/nm no maximum of 
absorption was detected; ν max/cm-1 (neat) 1703 (vs, C=O), 2880, 2937 and 
2984 (w, aliphatic CH and -CH2-); 1H NMR (500 MHz; CDCl3) δH -0.03 – 0.05 (1H, 
m, cyclopropyl), 0.14 – 0.23 (1H, m, cyclopropyl), 0.33 – 0.41 (2H, m, 
cyclopropyl), 1.57 (3H, d, J = 7.2 Hz, CH3), 1.64 (1H, ABX dd, JAX = 5.3 Hz, JBX = 6.6 
Hz, -OH), 2.68 (1H, d, JAB = 9.1 Hz, CHAHBO-), 2.85 (1H, d, JAB = 9.1 Hz, CHAHBO-), 
3.30 (1H, dd, JAX = 5.3 Hz, JAB = 11.4 Hz, CHAHBOH), 3.39 – 3.48 (1 H, dd, JAX = 6.6 
Hz, JAB = 11.4 Hz, CHAHBOH), 4.19 (1H, q, J = 7.2 Hz, CHCH3), 7.25-7.29 (3H, m, 2 
 H-Ar and H-5), 7.38 (5H, br, H-Ar), 7.54 – 7.58 (2H, m, H-Ar), 7.61 (1H, d, J = 
8.4 Hz, H-6); 13C NMR (125 MHz; CDCl3) δC 8.6 (CH2 cyclopropyl), 8.7 (CH2 
cyclopropyl), 19.9 (CH3), 22.1 (C q cyclopropyl), 53.8 (CHCH3), 68.3 (CH2OH), 
68.5 (CH2-O), 94.8 (C-3), 117.2 (C-Ar q), 128.6 (2  C-Ar), 128.8 (2  C-Ar), 129.1 
(C-Ar q), 129.2 (2  C-Ar), 129.7 (2  C-Ar), 131.6 (C-Ar q), 133.5 (C-Ar q), 134.6 
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(C-Ar), 136.3 (C-Ar q), 136.6 (C-Ar), 141.2 (C-Ar q), 143.2 (C-Ar q), 165.0 (C-1); 
LRMS (ES+) m/z 584.3 [M+Na]+; HRMS calcd for C27H2579Br35Cl2NO3 [M+H]+ 
560.0389, found 560.0390; HPLC 96.7% in 0.1% formic acid (aq)/MeCN (Rt 10.1 
min); 96.2% in 0.1% ammonia (aq)/MeCN (Rt 10.1 min). 
297 
Rf 0.23 (25% EtOAc/petrol); no clear m.p. detected; [𝛼]D
24 -75° (c 0.774, EtOAc); 
λmax (EtOH)/nm no maximum of absorption was detected; νmax/cm-1 (neat) 
1452 (s), 1493 (s), 1706 (s, C=O), 2875, 2938, and 2981 (w, aliphatic CH and -
CH2-); 1H NMR (500 MHz; CDCl3) δH 0.53 – 0.73 (4H, m, cyclopropyl), 1.86 (1H, 
ABX app. t, JAX = JBX = 5.9 Hz, -OH), 1.93 (3H, d, J = 7.3 Hz, CH3), 3.02 (1H, d, JAB = 
9.1 Hz, CHAHBO-), 3.39 (1 H, d, JAB = 9.1 Hz, CHAHBO-), 3.72 (2H, ABX m, CH2OH), 
4.38 (1H, q, J = 7.3 Hz, CHCH3), 6.86 – 6.92 (2H, m, H-Ar), 6.94 – 6.99 (2H, m, H-
Ar), 6.99 – 7.21 (4H, br, H-Ar), 7.24 (1H, m, H-Ar), 7.28 (1H, d, J = 8.5 Hz, H-5), 
7.62 (1H, d, J = 8.5 Hz, H-6); 13C NMR (125 MHz; CDCl3) δC 8.9 (CH2 cyclopropyl), 
9.1 (CH2 cyclopropyl), 19.7 (CH3), 22.7 (C q cyclopropyl), 52.4 (CHCH3), 68.1 
(CH2-OH), 68.4 (CH2OH), 93.5 (C-3), 117.2 (C-Ar q), 127.2 (2  C-Ar), 127.9 (2  
C-Ar), 128.2 (2  C-Ar), 128.8 (C-Ar), 129.2 (C-Ar q), 129.6 (2  C-Ar), 131.7 (C-
Ar q), 132.8 (C-Ar q), 134.4 (C-5), 136.0 (C-Ar q), 136.6 (C-6), 140.3 (C-Ar q), 
143.0 (C-Ar q), 164.5 (C-1); LRMS (ES+) m/z 562.3 [M+H]+; HRMS calcd for 
C27H2579Br35Cl2NO3 [M+H]+ 560.0389, found 560.0389; HPLC 98.3% in 0.1% 
formic acid (aq)/MeCN (Rt 10.1 min); 97.6% in 0.1% ammonia (aq)/MeCN (Rt 
10.1 min). 
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(3R,1’R)-4-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenyl-7-(1v-(triisopropylsilyl)-
1vH-pyrrol-3v-yl)isoindolin-1-one (298) 
 
Compound 298 was synthesized according to general procedure O using 
isoindolinone 289 (138 mg, 0.246 mmol), 1-(triisopropylsilyl)-1H-pyrrole-3-
boronic acid (86 mg, 0.320 mmol), tetrakis(triphenylphosphine)palladium (29 
mg, 0.025 mmol), Na2CO3 (2 M aq.,0.37 mL, 0.738 mmol) and acetonitrile (3.0 
mL). The crude product was purified by MPLC (gradient elution, 0-25% 
EtOAc/petrol) and the title compound was obtained as a pale yellow solid (116 
mg, 67%). Rf 0.68 (25% EtOAc/petrol); m.p. not clear meplting point detected; 
λmax (EtOH)/nm 276, 339; ν max/cm-1 (neat) 1365 (m, C=C and C=N in-plane 
vibs), 1696 (vs, C=O), 2866 and 2943 (w, aliphatic CH and -CH2-, Si-R), 3460 (br, 
O-H); 1H NMR (500 MHz; CDCl3) δH -0.05 – 0.04 (1H, m, cyclopropyl), 0.15 – 0.24 
(1H, m, cyclopropyl), 0.32 – 0.40 (2H, m, cyclopropyl), 1.14 – 1.23 (18H, m, 6  
CH3), 1.49 – 1.57 (6H, m, CHCH3 and 3  CH(CH3)2), 1.93 (1H, ABX dd, JAX = 5.6 
Hz, JBX = 6.7 Hz, OH), 2.74 (1H, d, JAB = 9.2 Hz, CHACHBO-), 2.93 (1H, d, JAB = 9.2 
Hz, CHACHBO-), 3.38 (2H, ABX dq, JAX = 5.6 Hz, JBX = 6.7 Hz, JAB = 11.4 Hz,), 4.24 
(1H, q, J = 7.3 Hz, CHCH3), 6.85 (1H, dd, J = 2.1, 2.8 Hz, H-4’’’’’ or H-5’’’’’), 6.87 
(1H, dd, J = 1.5, 2.8 Hz, H-4’’’’’ or H-5’’’’’), 7.20 – 7.25 (2H, m, H-Ar), 7.31 (1H, d, J 
= 8.4 Hz, H-5 or H-6), 7.35 (5H, br, H-Ar), 7.53 – 7.60 (3H, m, H-Ar), 7.79 (1H, dd, 
J = 1.5, 2.1 Hz, H-2’’’’’); 13C NMR (125 MHz; CDCl3) δC 8.7 (2  CH2 cyclopropyl), 
11.9 (3  CH(CH3)2), 18.1 (6  CH3), 19.8 (CHCH3), 22.1 (C q cyclopropyl), 53.2 
(CHCH3), 68.5 (CH2O-), 68.8 (CH2OH), 111.9 (C-4’’’’’ or C-5’’’’’), 124.4 (C-4’’’’’ or  
C-5’’’’’), 125.6 (C-Ar q), 127.4 (C-2’’’’’), 128.3 (C-Ar), 128.4 (C-Ar), 128.6 (C-Ar), 
129.9 (C-Ar), 132.3 (C-Ar), 133.3 (C-Ar), 134.5 (C-Ar), 142.0 (C-Ar), 142.0 (C-
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Ar). Five carbons not detected; LRMS (ES+) m/z 703.6 and 705.6 [M+H]+; HRMS 
calcd for C40H4935Cl2N2O3Si [M+H]+ 703.2884, found 703.2884. 
(3S1’R)-4-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenyl-7-(1v-(triisopropylsilyl)-
1vH-pyrrol-3v-yl)isoindolin-1-one (300) 
 
General procedure O was followed to prepare compounds 300 using 
isoindolinone 297 (150 mg, 0.267 mmol), 1-(triisopropylsilyl)-1H-pyrrole-3- 
boronic acid (93 mg, 0.347 mmol), tetrakis(triphenylphosphine)palladium (31 
mg, 0.534 mmol), Na2CO3 (2 M aq., 0.27 mL, 0.738 mmol) and acetonitrile (3.2 
mL). The crude product was purified by MPLC (gradient elution, 0-25% 
EtOAc/petrol) and the title compound was obtained as a pale yellow solid (111 
mg, 59%). Rf 0.48 (25% EtOAc/petrol); no clear m.p. detected; λmax (EtOH)/nm 
277, 339; νmax/cm-1 (neat) 1696 (vs, C=O), 2866 and 2944 (w, aliphatic CH and -
CH2-, Si-R), 3464 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 0.49 – 0.68 (4H, m, 
cyclopropyl), 1.18 (18H, dd, J = 2.2, 7.5 Hz, 6  CH3), 1.50 (3H, m, CH(CH3)2), 
1.87 (3H, d, J = 7.3 Hz, CHCH3), 2.10 (1H, ABX app. t, JAX = JBX = 6.0Hz, OH), 3.11 
(1H, d, JAB = 9.3 Hz, CHAHBO-), 3.34 (1H, d, JAB = 9.3 Hz, CHAHBO-), 3.69 (2H, qd, 
JAX = JBX = 6.0 Hz, JAB = 11.5 Hz, CH2OH), 4.36 (1H, q, J = 7.2Hz, CHCH3), 6.80 – 
6.85 (2H, m, H-4’’’’’ and H-5’’’’’), 6.86 – 6.90 (2H, m, H-Ar), 6.90 – 6.95 (2H, m, H-
Ar), 7.05 (4H, br, H-Ar), 7.16 – 7.22 (1H, m, H-Ar), 7.30 (1H, d, J = 8.4 Hz, H-5 or 
H-6), 7.55 (1H, d, J = 8.4 Hz, H-5 or H-6), 7.77 (1H, app. t, J = 1.8 Hz, H-2’’’’’); 13C 
NMR (125 MHz; CDCl3) δC 8.9 (CH2 cyclopropyl), 9.1 (CH2 cyclopropyl), 11.9 (3  
CH(CH3)2), 18.11 (6  CH3), 19.7 (CHCH3), 22.7 (C q cyclopropyl), 52.0 (CHCH3), 
68.5 (CH2O-), 68.7 (CH2OH), 111.8 (C-4’’’’’ or C-5’’’’’), 121.2 (C-Ar q), 121.7 (C-Ar 
q), 124.3 (C-4’’’’’ or C-5’’’’'), 127.3 (C-Ar), 127.5 (C-Ar), 127.6 (C-Ar), 128.0 (C-
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Ar), 128.4 (C-Ar), 129.1 (C-Ar), 129.8 (C-Ar), 132.3 (C-Ar), 133.1 (C-Ar), 137.4 
(C-Ar), 140.9 (C-Ar), 166.7 (C-1). Two carbons not detected; LRMS (ES+) m/z 
703.6 and 705.6 [M+H]+; HRMS calcd for C40H4935Cl2N2O3Si [M+H]+ 703.2884, 
found 703.2885. 
4-Chloro-2-ethyl-3-hydroxy-3-phenylisoindolin-1-one (243) 
 
Compound 243 was prepared according to general procedure M using 
benzoylbenzoic acid 183 (150 mg, 0.575 mmol), thionyl chloride (0.08 mL, 137 
mg, 1.15 mmol), DMF (catalytic, 3 drops), ethylaminee hydrochloride (52 mg, 
0.633 mmol), DIPEA (0.22 mL, 164 mg, 1.27 mmol) and THF (2  0.7 mL). 
Purification by MPLC (gradient elution, 0-20% EtOAc/petrol) yielded the title 
compound as a white solid (89 mg, 54%). Rf 0.36 (25% EtOAc/petrol); m.p. 
176.1-177.0 °C; λmax (EtOH)/nm 259; νmax/cm-1 (neat) 1667 (s, C=O), 1686 (vs, 
C=O), 2937 and 2985 (w, aliphatic CH and -CH2-), 3253 (br, O-H); 1H NMR (500 
MHz; CDCl3) δH 0.90 (3H, t, J = 7.2 Hz, CH2CH3), 2.93 – 3.06 (1H, m, CHAHBCH3), 
3.22 – 3.31 (1 H, m, CHAHBCH3), 7.15 (1H, s, OH), 7.27 – 7.39 (5H, m, H-Ar), 7.53 
– 7.60 (2H, m, H-Ar), 7.68 – 7.75 (1H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 
13.8 (CH3), 33.3 (CH2), 90.1 (C-3), 121.2 (C-Ar), 126.3 (2  C-Ar), 128.1 (2  C-
Ar), 128.5 (C-Ar q), 131.4 (C-Ar), 133.2 (C-Ar), 133.9 (C-Ar q), 138.1 (C-Ar q), 
144.8 (C-Ar q), 164.7 (C-1). One carbon not detected; LRMS (ES+) m/z 288.3 
[M+H]+; HRMS calcd for C16H1535ClNO2 [M+H]+ 288.0786, found 288.0790. 
4-Chloro-3-hydroxy-2-isopropyl-3-phenylisoindolin-1-one (245) 
 
General procedure M was followed to prepare isoindolinone 245 using 
benzoylbenzoic acid 183 (150 mg, 0.575 mmol), thionyl chloride (0.08 mL, 137 
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mg, 1.15 mmol), DMF (catalytic, 3 drops), isopropylamine (0.05 mL, 37 mg, 
0.633 mmol), DIPEA (0.11 mL, 82 mg, 0.633 mmol) and THF (2  0.70 mL). 
Purification by MPLC (gradient elution, 0-25% EtOAc/petrol) yielded the 
desired compound as a white solid (116 mg, 67%). Rf 0.24 (25% EtOAc/petrol); 
m.p. 219.4-220.4 °C; λmax (EtOH)/nm 259; νmax/cm-1 (neat) 1667 (vs, C=O), 1679 
(s, C=O), 2935 and 2980 (w, aliphatic CH and -CH2-), 3153 (br, O-H); 1H NMR 
(500 MHz; CDCl3) δH 1.02 (3H, d, J = 6.8 Hz, CH3), 1.36 (3H, d, J = 6.8 Hz, CH3), 
3.39 (1H, m, CH(CH3)2), 7.16 (1H, s, OH), 7.26 – 7.40 (5H, m, H-Ar), 7.51 – 7.58 
(2H, m, H-Ar), 7.67 (1H, dd, J = 2.2, 6.2 Hz, H-Ar); 13C NMR (125 MHz; CDCl3) δC 
19.4 (CH3), 20.5 (CH3), 43.5 (CH(CH3)2), 90.4 (C-3), 120.9 (C-Ar), 126.5 (2  C-
Ar), 127.9 (2  C-Ar), 128.0 (C-Ar), 128.4 (C-Ar q), 131.3 (C-Ar), 133.0 (C-Ar), 
134.7 (C-Ar q), 137.9 (C-Ar q), 144.5 (C-Ar q), 164.5 (C-1); LRMS (ES–) m/z 
300.2 [M-H]–; HRMS calcd for C17H1735ClNO2 [M+H]+ 302.0942, found 302.0946. 
4-Chloro-2-(cyclopropylmethyl)-3-hydroxy-3-phenylisoindolin-1-one 
(247) 
 
General procedure M was followed to synthesize isoindolinone 247 using 
benzoylbenzoic acid 183 (150 mg, 0.575 mg), thionyl chloride (0.08 mL, 137 
mg, 1.15 mmol), DMF (catalytic, 3 drops), cyclopropylmethylamine 
hydrochloride (68 mg, 0.633 mmol), DIPEA (0.22 mL, 164 mg, 1.27 mmol) and 
THF (2  0.70 mL). Purification by MPLC (gradient elution, 0-25% 
EtOAc/petrol) yielded the desired compound as a white solid (100 mg, 55%). Rf 
0.33 (25% EtOAc/petrol); m.p. 197.0-198.5 °C; λmax (EtOH)/nm 246; ν max/cm-1 
(neat) 1667 and 1686 (s, C=O), 2924, 3232 (br, O-H); 1H NMR (500 MHz; DMSO-
d6) δH -0.20 – -0.09 (1H, m, cyclopropyl), 0.06 – 0.20 (2H, m, cyclopropyl), 0.20 – 
0.27 (1H, m, cyclopropyl), 0.62 – 0.77 (1H, m, CH cyclopropyl), 2.88 (1H, ABX 
dd, JAX = 6.8 Hz, JAB = 14.4 Hz, CHAHB), 3.05 (1H, ABX dd, JBX = 7.3 Hz, JAB = 14.4 
Hz, CHAHB), 7.18 (1H, s, OH), 7.27 – 7.36 (5H, m, H-Ar), 7.54 – 7.59 (2H, m, H-Ar), 
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7.72 (1H, dd, J 5.2, 3.1, H-Ar); 13C NMR (125 MHz; DMSO-d6) δC 3.8 (CH2 
cyclopropyl), 4.4 (CH2 cyclopropyl), 10.4 (CH cyclopropyl), 43.1 (CH2), 89.9 (C-
3), 121.3 (C-Ar), 126.5 (2  C-Ar), 128.0 (2  C-Ar), 128.5 (C-Ar), 131.4 (C-Ar), 
133.3 (C-Ar), 133.7 (C-Ar q), 138.2 (C-Ar q), 144.8 (C-Ar q), 165.1 (C-1). One 
quaternary carbon was not observed by NMR; LRMS (ES+) m/z 312.2 [M+H]+; 
HRMS calcd for C18H1735ClNO2 [M+H]+ 314.0942, found 314.0946. 
4-Chloro-2-ethyl-3-{[1’’’-(hydroxymethyl)cyclopropyl]methoxy}-3-
phenylisoindolin-1-one (244) 
 
Compound 244 was obtained following general procedure N using 
isoindolinone 243 (80 mg, 0.278 mmol), indium tribromide (20 mg, 0.0556 
mmol), 1,1-bis(hydroxymethyl)cyclopropane (0.13 mL, 142 mg, 1.39 mmol) and 
DCE (2.8 mL). Purification by MPLC (gradient elution, 0-33% EtOAc/ petrol) 
yielded the desired compound as a white solid (79 mg, 76%). Rf 0.09 
(petrol/EtOAc 3:1); m.p. 130.0-130.7 °C; λmax (EtOH)/nm 259; νmax/cm-1 (neat) 
1680 (vs, C=O), 2859 and 2921 (w, aliphatic CH and -CH2-), 3421 (br, O-H); 1H 
NMR (500 MHz; CDCl3) δH 0.44 – 0.65 (4H, m, cyclopropyl), 0.95 (3H, t, J = 7.2 
Hz, CH2CH3), 1.98 (1H, ABX app. t, JAX = JBX = 6.0 Hz, OH), 3.00 (1H, d, JAB = 9.1 Hz, 
CHAHBO-), 3.12 (1H, d, JAB = 9.1 Hz, CHAHBO-), 3.26 (2H, m, CH2CH3), 3.61 – 3.70 
(2H, ABX m, CH2OH), 7.30 – 7.35 (3H, m, H-Ar), 7.37 (2H, br, H-Ar), 7.43 (1H, dd, 
J = 1.1, 7.6 Hz, H-5), 7.48 (1H, app. t, J = 7.6 Hz, H-6), 7.81 (1 H, dd, J = 1.1, 7.6, H-
7); 13C NMR (125 MHz; CDCl3) δC 8.9 (CH2 cyclopropyl), 9.2 (CH2 cyclopropyl), 
13.5 (CH2CH3), 22.5 (C q cyclopropyl), 34.4 (CH2CH3), 68.4 (CH2O- and CH2OH), 
94.8 (C-3), 122.0 (C-7), 126.8 (2  C-Ar), 128.4 (2  C-Ar), 128.8 (C-Ar), 129.8 
(C-Ar q), 131.7 (C-6), 133.6 (C-5), 135.0 (C-Ar q), 136.9 (C-Ar q), 141.2 (C-Ar q), 
166.6 (C-1); LRMS (ES+) m/z 394.4 [M+Na]+; HRMS calcd for C21H2335ClNO3 
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[M+H]+ 372.1361, found 372.1362; HPLC 98.5% in 0.1% formic acid (aq)/MeCN 
(Rt 8.0 min); 99.5% in 0.1% ammonia (aq)/MeCN (Rt 8.0 min). 
4-Chloro-3-{[1’’’-(hydroxymethyl)cyclopropyl]methoxy}-2-isopropyl-3-
phenylisoindolin-1-one (246) 
 
General procedure N was followed to synthesize compound 246 using 
isoindolinone 245 (110 mg, 0.365 mg), indium tribromide (26 mg, 0.073 
mmol), 1,1-bis(hydroxymethyl)cyclopropane (0.18 mL, 187 mg, 1.83 mmol) and 
DCE (3.7 mL), Purification by MPLC (gradient elution, 0-20% EtOAc/petrol) 
yielded the title compound (107 mg, 76%) as a white solid. Rf 0.15 (25% 
EtOAc/petrol); m.p. 128.5-129.2 °C; λmax (EtOH)/nm 259; νmax/cm-1 (neat) 1682 
(vs, C=O), 2878 and 2930 (w, aliphatic CH and -CH2-), 3398 (br, O-H); 1H NMR 
(500 MHz; CDCl3) δH 0.48 – 0.64 (4H, m, cyclopropyl), 1.01 (3H, d, J = 6.9 Hz, 
CH3), 1.48 (3H, d, J = 6.9 Hz, CH3), 2.01 (1H, app. t, JAX = JBX = 6.0, OH), 3.01 (1H, 
d, JAB = 9.2 Hz, CHAHBO-), 3.30 (1H, d, JAB = 9.2 Hz, CHAHBO-), 3.42 – 3.56 (1H, m, 
CH(CH3)2), 3.66 (2H, d, JAX = JBX = 6.0, CH2OH), 7.28 – 7.40 (5H, m, H-Ar), 7.42 
(1H, dd, J = 1.1, 7.6 Hz, H-5), 7.47 (1H, app. t, J = 7.6 Hz, H-6), 7.77 (1H, dd, J = 
1.1, 7.6 Hz, H-7); 13C NMR (125 MHz; CDCl3) δC 8.9 (CH2 cyclopropyl), 9.0 (CH2 
cyclopropyl), 19.5 (CH3), 20.4 (CH3), 22.6 (C q cyclopropyl), 44.7 (CH(CH3)2), 
68.5 (CH2O-), 68.6 (CH2OH), 95.1 (C-3), 121.7 (C-7), 126.9 (2  C-Ar), 128.3 (2  
C-Ar), 128.7 (C-Ar), 129.7 (C-Ar q), 131.6 (C-6), 133.3 (C-5), 135.8 (C-Ar q), 
137.0 (C-Ar q), 140.8 (C-Ar q), 166.2 (C-1); LRMS (ES+) m/z 408.4 [M+Na]+; 
HRMS calcd for C22H2535ClNO3 [M+H]+ 386.1517, found 386.1519; HPLC 98.8% 
in 0.1% formic acid (aq)/MeCN (Rt 8.4 min); 99.2% in 0.1% ammonia 
(aq)/MeCN (Rt 8.4 min). 
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4-Chloro-2-(cyclopropylmethyl)-3-{[1’’’’-(hydroxymethyl)cyclopropyl] 
methoxy}-3-phenylisoindolin-1-one (248) 
 
Compound 248 was obtained following general procedure N using 
isoindolinone 247 (94 mg, 0.300 mmol), indium tribromide (21 mg, 0.060 
mmol), 1,1-bis(hydroxymethyl)cyclopropane (0.14 mL, 153 mg, 1.5 mmol), and 
DCE (3.0 mL). The crude product was purified by MPLC (gradient elution, 0-
20% EtOAc/petrol) to afford the title compound as colorless crystals (101 mg, 
85%). Rf 0.15 (25% EtOAc/petrol); m.p. 91.1-92.3 °C; λmax (EtOH)/nm 259; 
νmax/cm-1 (neat) 1683 (vs, C=O), 2865 and 2914 (w, aliphatic CH and -CH2-), 
3424 (br, O-H); 1H NMR (500 MHz; CDCl3) δH -0.09 – -0.00 (1H, m, 
cyclopropylmethyl), 0.18 – 0.27 (2H, m, cyclopropylmethyl), 0.29 – 0.39 (1H, m, 
cyclopropylmethyl), 0.43 – 0.64 (4H, m, cyclopropyl), 0.71 – 0.81 (1H, m, CH 
cyclopropylmethyl), 1.99 (1H, ABX app. t, J = 6.0 Hz, OH), 3.02 (1H, d, JAB = 9.3 
Hz, CHAHB-O), 3.03 – 3.13 (2H, m, CH2CH), 3.22 (1H, d, JAB = 9.3 Hz, CHAHB-O), 
3.64 (2H, ABX m, CH2OH), 7.32 (3H, m, H-Ar), 7.38 (2H, br, H-Ar), 7.43 (1H, dd, J 
= 1.1, 7.9 Hz, H-5), 7.48 (1H, dd, J = 7.2, 7.9 Hz, H-6), 7.81 (1H, dd, J = 1.1, 7.2 Hz, 
H-7); 13C NMR (125 MHz; CDCl3) δC 4.5 (CH2 cyclopropylmethyl), 4.7 (CH2 
cyclopropylmethyl), 8.8 (CH2 cyclopropyl), 9.1 (CH2 cyclopropyl), 10.3 (CH 
cyclopropylmethyl), 22.5 (C q cyclopropyl), 44.2 (CH2CH), 68.4 (CH2-O), 68.4 
(CH2OH), 94.3 (C-3), 122.1 (C-7), 127.0 (2  C-Ar), 128.4 (2  C-Ar), 128.7 (C-
Ar), 129.8 (C-Ar q), 131.6 (C-6), 133.6 (C-5), 134.8(C-Ar q), 137.0 (C-Ar q), 
141.3 (C-9), 166.9 (C-1); LRMS (ES+) m/z 420.4 [M+Na]+; HRMS calcd for 
C23H2535ClNO3 [M+H]+ 398.1517, found 398.1520; HPLC 98.8% in 0.1% formic 
acid (aq)/MeCN (Rt 8.6 min); 99.2% in 0.1% ammonia (aq)/MeCN (Rt 8.5 min). 
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(3R,1’R)-4-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenyl-7-(1vH-pyrrol-3v-
yl)isoindolin-1-one (299) 
 
General procedure P was followed to synthesize compound 399 using 
isoindolinone 289 (101 mg, 0.144 mg), tetrabutylammonium fluoride 1 M in 
THF (0.16 mL, 0.158 mmol) and THF (930 mL). The crude product was purified 
by MPLC (gradient elution, 0-5% MeOH/DCM) to afford the desired product (61 
mg, 77%) as a pale yellow solid. Rf 0.67 (6% MeOH/DCM); no clear m.p. 
detected (dec. 116-162 °C); [𝛼]D
26 +28 (c 0.611, EtOAc); λmax (EtOH)/nm 275, 
339; νmax/cm-1 (neat) 1396 (s, C=C and C=N in-plane vibs), 1682 (vs, C=O), 2871, 
2928, and 2974 (w, aliphatic CH and -CH2-), 3345 (br, O-H and N-H); 1H NMR 
(500 MHz; CDCl3) δH -0.09 – -0.02 (1H, m, cyclopropyl), 0.15 – 0.20 (1H, m, 
cyclopropyl), 0.32 – 0.39 (2H, m, cyclopropyl), 1.53 (3H, d, J = 7.3 Hz, CH3), 1.81 
– 1.92 (1H, ABX m, -OH), 2.72 (1H, d, JAB = 9.2 Hz, CHAHBO-), 2.95 (1H, d, JAB = 9.2 
Hz, CHAHBO-), 3.28 – 3.46 (2H, ABX m, CH2OH), 4.23 (1H, q, J = 7.3 Hz, CHCH3), 
6.71 (1H, td, J = 1.6, 2.7 Hz, H-4’’’’’ or H-5’’’’’), 6.89 (1H, td, J = 2.0, 2.7 Hz, H-4’’’’’ 
or H-5’’’’’), 7.22-7.26 (2H, m, H-Ar), 7.31 – 7.42 (6H, m, H-Ar), 7.53 – 7.59 (3H, m, 
H-Ar), 7.84 (1H, m, H-2’’’’’), 8.45 (1H, br, NH); 13C NMR (125 MHz; CDCl3) δC 8.7 
(CH2 cyclopropyl), 8.7 (CH2 cyclopropyl), 20.1 (CH3), 22.1 (C q cyclopropyl), 
53.4 (CHCH3), 68.5 (CH2O-), 68.7 (CH2OH), 109.7 (C-4’’’’’ or C-5’’’’’), 118.2 (C-4’’’’’ 
or C-5’’’’’), 119.2 (C-Ar q), 121.0 (C-2’’’’’), 126.1 (C-Ar q), 128.4 (2  C-Ar), 128.6 
(2  C-Ar), 128.7 (2  C-Ar), 129.0 (C-Ar), 129.7 (2  C-Ar), 132.5 (C-5 or C-6), 
133.1 (C-Ar q), 133.5 (C-5 or C-6), 134.4 (C-Ar q), 137.4 (C-Ar q), 141.9 (C-Ar q), 
142.0 (C-Ar q), 167.4 (C-1). Two carbons not detected; LRMS (ES–) m/z 545.3 
[M-H]–; HRMS calcd for C31H27Cl2N2O3 [M-H]– 545.1404, found 545.1405; HPLC 
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98.5% in 0.1% formic acid (aq)/MeCN (Rt 9.8 min); 97.2% in 0.1% ammonia 
(aq)/MeCN (Rt 9.8 min). 
(3S,1’R)-4-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenyl-7-(1vH-pyrrol-3v-
yl)isoindolin-1-one (301) 
 
General procedure P was used to synthesize 301 using isoindolinone 299 (92 
mg, 0.131 mmol), tetrabutylammonium fluoride 1 M in THF (0.14 mL, 0.144 
mmol), and THF (8.0 mL). Purification by MPLC (gradient elution, 0-5% 
MeOH/DCM) yielded the title compound (53 mg, 74 %) as an ochre solid. Rf 0.52 
(6% MeOH/DCM); no clear m.p. detected (dec. 118-156 °C); [𝛼]D
26 -215 (c 0.641, 
EtOAc); λmax (EtOH)/nm 275, 341; νmax/cm-1 (neat) 1399 (s, C=C and C=N in-
plane vibs), 1682 (vs, C=O), 2873, 2927, and 2980 (w, aliphatic CH and -CH2-), 
3332 (br, O-H and N-H); 1H NMR (500 MHz; CDCl3) δH 0.50 – 0.69 (4H, m, 
cyclopropyl), 1.88 (3H, d, J = 7.3 Hz, CH3), 2.06 (1H, ABX app. t, JAX = JBX = 5.5 Hz, 
OH), 3.10 (1H, d, JAB = 9.2Hz, CHAHBO-), 3.33 (1H, d, JAB = 9.2 Hz, CHAHBO-), 3.70 
(2H, dq, JAX = JBX = 5.5 Hz, JAB = 11.4 Hz, CH2OH), 4.39 (1H, q, J = 7.3 Hz, CHCH3), 
6.67 – 6.72 (1H, m, H-4’’’’’ or H-5’’’’’), 6.84 – 6.90 (3H, m, H-Ar), 6.90 – 6.96 (2H, 
m, H-Ar), 6.97 – 7.22 (5H, m, H-Ar), 7.34 (1H, d, J = 8.5 Hz, H-5), 7.56 (1H, d, J = 
8.5 Hz, H-6), 7.78 – 7.83 (1H, m, H-2’’’’’), 8.45 (1 H, br, NH); 13C NMR (125 MHz; 
CDCl3) δC 9.0 (CH2 cyclopropyl), 9.1 (CH2 cyclopropyl), 19.9 (CH3), 22.7 (C q 
cyclopropyl), 52.0 (CHCH3), 68.5 (CH2O-), 68.6 (CH2OH), 93.5 (C-3), 109.7 (C-
4’’’’’ or C-5’’’’’), 118.2 (C-4’’’’’ or C-5’’’’’), 121.0 (C-2’’’’’), 126.2 (C-Ar q), 127.2 (2  
C-Ar), 127.8 (2  C-Ar), 128.0 (2  C-Ar), 128.4 (C-Ar), 129.2 (C-Ar q), 129.5 (2  
C-Ar), 132.4 (C-Ar q), 132.5 (C-5 or C-6), 133.3 (C-5 or C-6), 134.3 (C-Ar q), 
137.1 (C-Ar q), 140.9 (C-Ar q), 141.7 (C-Ar q), 166.9 (C-1). One carbon not 
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detected; LRMS (ES+) m/z 547.4 [M+H]+; HRMS calcd for C31H29Cl2N2O3 [M+H]+ 
547.1550, found 547.1548; HPLC 96.5% in 0.1% formic acid (aq)/MeCN (Rt 9.9 
min); 95.0% in 0.1% ammonia (aq)/MeCN (Rt 9.9 min). 
(3R,1’R)-4-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenyl-7-(1vH-pyrazol-3v-
yl)isoindolin-1-one (302) 
 
General procedure O was followed to synthesized compound 302 using 
isoindolinone 289 (80 mg, 0.143), 1H-pyrazol-3-yl boronic acid hydrate (24 mg, 
0.215 mmol), tetrakis(triphenylphosphine)palladium (17 mg, 0.0143 mmol), 
Na2CO3 (2 M aq., 0.64 mL, 1.29 mmol) and acetonitrile (1.7 mL). The crude 
product was purified by MPLC (gradient elution, 0-40% EtOAc/petrol) and the 
title compound was obtained as a white solid (59 mg, 76%). Rf 0.06 (25% 
EtOAc/petrol); m.p. 201.2-202.4 °C; [𝛼]𝐷
24 +30° (c 0.239, EtOAc); λmax 
(EtOH)/nm 279, 322; νmax/cm-1 (neat) 1676 (vs, C=O), 2873, 2927, and 2974 (w, 
aliphatic CH and -CH2-), 3335 (br, O-H and N-H); 1H NMR (500 MHz; CDCl3) δH -
0.15 – -0.24 (1H, m, cyclopropyl), 0.03 – -0.05 (1H, m, cyclopropyl), 0.21 – 0.12 
(2H, m, cyclopropyl), 1.33 (3H, d, J = 7.2 Hz, CH3), 1.45 (1H, ABX m, -OH), 2.52 
(1H, d, JAB = 9.1 Hz, CHAHBO-), 2.71 (1H, d, JAB = 9.1 Hz, CHAHB-O), 3.12 (1H, dd, 
JAX = 4.9 Hz, JAB = 11.5 Hz, CHAHBOH), 3.24 (1H, dd, JAX = 6.5 Hz, JAB = 11.5 Hz, 
CHAHBOH), 4.08 (1H, q, J = 7.2 Hz, CHCH3), 6.59 (1H, d, J = 2.0 Hz, H-4’’’’’), 7.09 – 
7.05 (2H, m, H-Ar), 7.17 (5H, br, H-Ar), 7.24 (1H, d, J = 8.5 Hz, H-5 or H-6), 7.37 – 
7.32 (2H, m, H-Ar), 7.47 (1H, d, J = 2.0 Hz, H-5’’’’’), 7.66 (1H, d, J = 8.5 Hz, H-5 or 
H-6), 14.47 (1 H, br, NH); 13C NMR (125 MHz; CDCl3) δC 8.6 (CH2 cyclopropyl), 
8.7 (CH2 cyclopropyl), 19.6 (CH3), 22.1 (C q cyclopropyl), 53.8 (CHCH3), 68.3  
(CH2O-), 68.5 (CH2OH), 95.8 (C-3), 104.6 (C-4’’’’’), 126.7 (C-Ar q), 128.5 (C-Ar), 
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128.6 (2  C-Ar), 128.8 (2  C-Ar), 129.0 (C-Ar), 129.2 (2  C-Ar), 129.7 (2  C-
Ar), 130.6 (C-5 or C-6), 133.6 (C-Ar q), 134.5 (C-5 or C-6), 136.1 (C-Ar q), 139.4 
(C-Ar q), 140.4 (C-Ar q), 140.6 (C-5’’’’’), 142.5 (C-Ar q), 168.2 (C-1). One 
quaternary carbon not detected; LRMS (ES+) m/z 548.4 [M+H]+; HRMS calcd for 
C30H28Cl2N3O3 [M+H]+ 548.1502, found 548.1500; HPLC 97.5% in 0.1% formic 
acid (aq.)/MeCN (Rt 9.9 min); 94.1% in 0.1% ammonia (aq.)/MeCN (Rt 9.9 min). 
(R)-4-Chloro-2-((R)-1-(4-chlorophenyl)ethyl)-3-((1-(hydroxymethyl) 
cyclopropyl)methoxy)-3-phenyl-7-(1H-pyrazol-4-yl)isoindolin-1-one 
(303) 
 
Compound 303 was obtained following general procedure O using 
isoindolinone 289 (80 mg, 0.143 mmol), 1H-pyrazole-4-boronic acid (24 mg, 
0.215 mmol), tetrakis(triphenylphosphine)palladium (17 mg, 0.0143 mmol), 
Na2CO3 (2 M aq., 0.64 mL, 1.29 mmol) and acetonitrile (1.7 mL). The crude 
product was purified by reverse phase column chromatography (gradient 
elution, 0-70% acetonitrile/water +0.1% formic acid v/v) and the title 
compound was obtained as a cream-colored solid (111 mg, 59%). Rf 0.18 (33% 
EtOAc/petrol); 0.54 (MeCN + 0.1% formic acid v/v); m.p. 120.2-121.7 °C; [𝛼]D
24 
+42° (c 0.228, EtOAc); λmax (EtOH)/nm 267, 319; νmax/cm-1 (neat) 1694 (vs, 
C=O), 2875, 2935, and 2972 (w, aliphatic CH and -CH2-), 3198 (br, O-H); 1H NMR 
(500 MHz; CDCl3) δH -0.04 – 0.04 (1H, m, cyclopropyl), 0.17 – 0.25 (1H, m, 
cyclopropyl), 0.34 – 0.42 (2H, m, cyclopropyl), 1.55 (3H, d, J = 7.3 Hz, CHCH3), 
2.75 (1H, d, JAB = 9.1 Hz, CHAHBO-), 2.95 (1H, d, JAB = 9.1 Hz, CHAHBO-), 3.34 (1H, 
d, JAB = 11.5 Hz, CHAHBOH), 3.44 (1H, d, JAB = 11.5 Hz, CHAHBOH), 4.25 (1H, q, J = 
7.3 Hz, CHCH3), 7.24 – 7.29 (2H, m, H-Ar), 7.38 (5H, br, H-Ar), 7.41 (1H, d, J = 8.3 
Hz, H-5 or H-6), 7.51 – 7.56 (2H, m, H-Ar), 7.59 (1H, d, J = 8.3 Hz, H-5 or H-6), 
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8.36 (2H, br, H-3’’’’’ and H-5’’’’’); 13C NMR (125 MHz; CDCl3) δC 8.6 (CH2 
cyclopropyl), 8.7 (CH2 cyclopropyl), 19.9 (CH3), 22.1 (C q cyclopropyl), 53.4 
(CHCH3), 68.4 (CH2O-), 68.5 (CH2OH), 95.0 (C-3), 127.4 (2  C-Ar), 128.5 (2  C-
Ar), 128.7 (2  C-Ar), 128.9 (C-Ar), 129.4 (C-Ar q), 129.6 (2  C-Ar), 132.0 (C-5 
or C-6), 133.3 (C-Ar q), 133.8 (C-5 or C-6), 137.0 (C-Ar q), 141.5 (C-Ar q), 142.3 
(C-Ar q), 167.1 (C-1). Four carbons not visible; LRMS (ES+) m/z 548.5 [M+H]+; 
HRMS calcd for C30H26Cl2N3O3 [M-H]- 546.1357, found 546.1357; HPLC 94.8% in 
0.1% formic acid (aq.)/MeCN (Rt 9.1 min); 94.8% in 0.1% ammonia (aq.)/MeCN 
(Rt 9.1 min). 
 (R)-1-(1-(4-Chlorophenyl)ethyl)-3,4-dimethyl-1H-pyrrole-2,5-dione 
(226) 
 
General procedure Q was used to synthesize compound 226 using 2,3-dimaleic 
anhydride (250 mg, 1.98 mmol), (R)-4-chloro-α-methylbenzylamine (308 mg, 
1.98 mmol, 0.28 mL) and THF (1.0 mL). The reaction mixture was refluxed for 
34 h. Medium pressure liquid chromatography (gradient elution, 0-20% 
EtOAc/petrol) afforded the desired compound as a colorless oil (311 mg, 59%). 
Rf 0.67 (25% EtOAc/petrol); λmax (EtOH)/nm 247sh; νmax/cm-1 (neat) 1696 (vs, 
C=O); 1H NMR (500 MHz; CDCl3) δH 1.78 (3H, d, J = 7.3 Hz, CHCH3), 1.92 (6H, s, 
CH3), 5.29 (1H, q, J = 7.3 Hz, CHCH3), 7.24 – 7.30 (2H, m, H-Ar), 7.34 – 7.39 (2H, 
m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 8.8 (2  CH3), 17.8 (CHCH3), 49.0 
(CHCH3), 128.7 (2  C-Ar), 128.9 (2  C-Ar), 133.5 (C-Ar q), 137.2 (2  =C-CH3), 
139.3 (C-Ar q), 172.0 (2  C=O). 
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4-Chloro-2-(cyclohexylmethyl)-3-hydroxy-3-phenylisoindolin-1-one (249) 
 
General procedure M was followed to synthesize isoindolinone 249 using 
benzoylbenzoic acid 183 (85 mg, 0.326 mmol), thionyl chloride (0.05 mL, 78 
mg, 0.652 mmol), catalytic DMF (3 drops), (aminomethyl)cyclohexane (0.05 mL, 
41 mg, 0.359 mmol), DIPEA (0.06 mL, 46 mg, 0.359 mmol) and THF (2  0.4 
mL). The crude product was purified by MPLC (gradient elution, 0-25% 
EtOAc/petrol) to obtain the racemic 249 as an off-white solid (89 mg, 77%). Rf 
0.50 (33% EtOAc/petrol); m.p. 171.9-172.5 °C; λmax (EtOH)/nm 259; νmax/cm-1 
(neat) 1673 (vs, C=O), 2848 and 2919 (w, aliphatic CH and -CH2-), 3330 (br, O-
H); 1H NMR (500 MHz; DMSO-d6) δH 0.65 – 1.09 (5H, m, Hax), 1.15 – 1.30 (1H, m, 
CH-CH2N), 1.43 – 1.62 (5H, m, Heq), 2.72 (1H, ABX dd, JAB = 13.8 Hz, JAX = 7.8 Hz, 
CHAHB-cyclohexyl), 3.12 (1H, ABX dd, JAB = 13.8 Hz, JAX = 7.2 Hz, CHAHB-N), 7.15 
(1H, s, OH), 7.24 – 7.37 (5H, m, H-Ar), 7.53 – 7.60 (2H, m, H-Ar), 7.71 (1H, m, H-
Ar); 13C NMR (125 MHz; CDCl3) δC δ C (126 MHz, DMSO) 25.3 (CH2), 25.4 (CH2), 
25.9 (CH2), 30.5 (CH2), 30.6 (CH2), 36.2 (CHCH2N), 44.7 (CH2N), 90.2 (C-3), 
121.3 (C-Ar), 126.2 (3  C-Ar), 128.1 (2  C-Ar), 128.5 (C-Ar q), 131.4 (C-Ar), 
133.2 (C-Ar), 133.7 (C-Ar q), 138.3 (C-Ar q), 144.7 (C-Ar q), 165.4 (C-1); LRMS 
(ES–) m/z 354.4 [M-H]–; HRMS calcd for C21H21ClNO2 [M-H]– 354.1266, found 
354.1252. 
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4-Chloro-2-(cyclohexylmethyl)-3-{[1’’’’-(hydroxymethyl)cyclopropyl] 
methoxy}-3-phenylisoindolin-1-one (250) 
 
The desired compound 250 was obtained following a modified general 
procedure N and using isoindolinone 249 (80 mg, 0.225 mmol), InBr3 (160 mg, 
0.450 mmol, 2.0 equiv.), 1,1-bis(hydroxymethyl)cyclopropane (0.11 mL, 115 
mg, 1.125 mmol), and DCE (2.25 mL). Purification by MPLC (gradient elution, 0-
25% EtOAc/petrol) yielded the racemic isoindolinone 250 as a white 
amorphous solid (68 mg, 69%). Rf 0.31 (33% EtOAc/petrol); no clear m.p. 
detected; λmax (EtOH)/nm 259; νmax/cm-1 (neat) 1686 (vs, C=O), 2849 and 2920 
(m, aliphatic CH and -CH2-), 3419 (br, OH); 1H NMR (500 MHz; CDCl3) δH 0.39 – 
0.68 (4H, m, cyclopropyl), 0.73 – 1.13 (6H, m, CHax), 1.40 – 1.69 (5H, m, CHeq), 
2.01 (1H, app. t, JAX = JBX = 6.0 Hz, OH), 2.94 – 3.10 (4H, m, CH2-N and CH2O-), 
3.57 – 3.72 (2H, m, CH2OH), 7.32 (5H, br, H-Ar), 7.44 (dd, J = 1.2, 7.6 Hz, 1H, H-
5), 7.48 (1H, app. t, J = 7.6 Hz, H-6), 7.80 (1H, dd, J = 1.2, 7.6 Hz, H-7); 13C NMR 
(125 MHz; CDCl3) δC 8.8 (CH2 cyclopropyl), 9.3 (CH2 cyclopropyl), 22.5 (C q 
cyclopropyl), 25.8 (CH2 cyclohexyl), 25.9 (CH2 cyclohexyl), 26.4 (CH2 
cyclohexyl), 31.2 (CH2 cyclohexyl), 31.5 (CH2 cyclohexyl), 37.0 (CH-CH2N), 45.6 
(CH2-C6H11), 68.5 (CH2OH), 68.5 (CH2O-), 95.0 (C-3), 122.1 (C-7), 126.6 (C-Ar), 
128.4 (C-Ar), 128.8 (C-Ar), 129.8 (C-Ar q), 131.7 (C-6), 133.6 (C-5), 135.0 (C-Ar 
q), 137.4 (C-Ar q), 141.1 (C-Ar q), 167.2 (C-1); LRMS (ES+) m/z 462.5 [M+Na]+; 
HRMS calcd for C26H31ClNO3 [M+H]+ 440.1987, found 440.1983; HPLC 99.0% in 
0.1% formic acid (aq.)/MeCN (Rt 9.8 min); 99.3% in 0.1% ammonia (aq.)/MeCN 
(Rt 9.8 min). 
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(3R,1’R)-4-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-methoxy-3-
phenylisoindolin-1-one (233) and (3S,1’R)-4-Chloro-2-[1’-(4’’-
chlorophenyl)ethyl]-3-methoxy-3-phenylisoindolin-1-one (234) 
   
Compounds 233 and 234 were obtained according to a modified general 
procedure N using isoindolinone 198 (98 mg, 0.246 mmol), InBr3 (174 mg, 
0.492 mmol), methanol (0.05 mL, 39 mg, 1.225 mmol) and DCE (2.5 mL). The 
reaction mixture was heated at 80 °C for 1 h. Purification by MPLC (gradient 
elution, 0-4% EtOAc/petrol) yielded isoindolinones 233 (40 mg, 39%; colorless 
oil) and 234 (33 mg, 33%; colorless oil). 
233 
Rf 0.70 (25% EtOAc/petrol); [𝛼]D
24 +175° (c 0.410, EtOAc); λmax (EtOH)/nm 259; 
νmax/cm-1 (neat) 1699 (vs, C=O), 2832, 2933, and 2973 (w, aliphatic CH and -
CH2-). 1H NMR (500 MHz; CDCl3) δH 1.61 (3H, d, J = 7.3 Hz, CHCH3), 2.65 (3H, s, 
OCH3), 4.22 (1H, q, J = 7.3 Hz, CHCH3), 7.27 (2H, m, H-Ar), 7.32 – 7.38 (5H, m, H-
Ar), 7.39 (1H, dd, J = 1.1, 7.7 Hz, H-5), 7.45 (1H, app. t, J = 7.7 Hz, H-6), 7.57 – 
7.63 (2H, m, H-Ar), 7.77 (1H, dd, J = 1.1, 7.7 Hz, H-7); 13C NMR (125 MHz; CDCl3) 
δC 18.7 (CHCH3), 51.2 (OCH3), 52.8 (CHCH3), 96.7 (C-3), 121.8 (C-7), 127.3 (2  
C-Ar), 128.3 (2  C-Ar), 128.5 (2  C-Ar), 128.8 (C-Ar), 129.9 (C-Ar q), 130.0 (2  
C-Ar), 131.5 (C-6), 133.3 (C-Ar q), 133.5 (C-5), 135.5 (C-Ar q), 136.8 (C-Ar q), 
140.5 (C-Ar q), 140.6 (C-Ar q), 166.8 (C-1); LRMS (ES+) m/z 412.4 [M+H]+; 
HRMS calcd for C23H20Cl2NO2 [M+H]+ 412.0866, found 412.0858; HPLC 99.6% in 
0.1% formic acid (aq.)/MeCN (Rt 10.6 min); 99.6% in 0.1% ammonia 
(aq.)/MeCN (Rt 10.7 min). 
234 
Rf 0.62 (25% EtOAc/petrol); [𝛼]D
24 +71° (c 0.380, EtOAc); λmax (EtOH)/nm 
259sh; νmax/cm-1 (neat) 1699 (vs, C=O), 2831, 2933, and 2970 (w, aliphatic CH 
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and -CH2-); 1H NMR (500 MHz; CDCl3) δH 1.84 (3H, d, J = 7.3 Hz, CHCH3), 3.13 
(3H, s, OCH3), 4.45 (1H, q, J = 7.3 Hz, CHCH3), 6.86 – 6.93 (2H, m, H-Ar), 6.94 – 
7.01 (2H, m, H-Ar), 7.14 (4H, br, H-Ar), 7.19 – 7.25 (1H, m, H-Ar), 7.41 (1H, dd, J 
= 1.1, 7.6 Hz, H-5), 7.46 (1H, app. t, J = 7.6, H-6), 7.77 (1H, dd, J = 1.1, 7.3 Hz, H-
7); 13C NMR (125 MHz; CDCl3) δC 19.1 (CHCH3), 51.2 (OCH3), 51.6 (CHCH3), 96.0 
(C-3), 121.8 (C-7), 127.3 (2  C-Ar), 127.8 (2  C-Ar), 128.0 (2  C-Ar), 128.6 (C-
Ar), 129.6 (2  C-Ar), 130.0 (C-Ar q), 131.6 (C-6), 132.7 (C-Ar q), 133.5 (C-5), 
135.6 (C-Ar q), 136.6 (C-Ar q), 140.3 (C-Ar q), 140.5 (C-Ar q), 166.6 (C-1); LRMS 
(ES+) m/z 412.4 [M+H]+; HRMS calcd for C23H20Cl2NO2 [M+H]+ 412.0866, found 
412.0856; HPLC 98.7% in 0.1% formic acid (aq.)/MeCN (Rt 10.4 min); 97.6% in 
0.1% ammonia (aq.)/MeCN (Rt 10.5 min). 
(1’R)-1-[1’-(4’’-Chlorophenyl)ethyl]-5-hydroxy-3,4-dimethyl-5-phenyl-1H-
pyrrol-2(5H)-one (227) 
 
General procedure R was followed to prepare 227 using the imide 226 (114 
mg, 0.432 mmol), phenylmagnesium bromide (1.0 M in THF, 1.30 mL, 1.30 
mmol), and THF (0.9 mL). Purification by MPLC (gradient elution 0-26% 
EtOAc/petrol) yielded the desired product 227 (white solid; 80 mg, 54%) as a 
mixture of diastereoisomers. Rf(1) = 0.49 and Rf(2) = 0.23 (petrol/EtOAc 3:1; 
UV254 nm, and KMnO4); no clear m.p. detected; λmax (EtOH)/nm 253; νmax/cm-1 
(neat) 1655 (vs, C=O), 2581, 2919 and 2981 (w, aliphatic CH and -CH2-), 3189 
(br, O-H); 1H NMR (500 MHz; CDCl3) δH 1.57 – 1.61 (6H, m, CHCH3 and CH3-C=), 
1.61 – 1.63 (3H, m, CH3=), 1.64 (3H, d, J = 7.3 Hz, CHCH3), 1.83 (3H, m, CH3-C=), 
1.83 – 1.86 (3H, m, CH3), 1.87 (1H, s, OH), 2.02 – 2.07 (1H, m, OH), 4.33 (1H, q, J 
= 7.3 Hz, CHCH3), 4.61 (1H, q, J = 7.3, CHCH3), 6.95 – 7.01 (2H, m, H-Ar), 7.02 – 
7.08 (2H, m, H-Ar), 7.18 – 7.25 (7H, m, H-Ar), 7.28 – 7.44 (5H, m, H-Ar), 7.44 – 
7.49 (2H, m, H-Ar). 13C NMR (125 MHz; CDCl3) δC 8.5 (CH3-C=), 10.0 (CH3-C=), 
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18.7 (CHCH3), 19.8 (CHCH3), 51.4 (CHCH3), 52.2 (CHCH3), 93.5 (C-3), 126.3 (C-
Ar), 126.5 (C-Ar), 128.0 (C-Ar), 128.4 (C-Ar), 128.5 (C-Ar), 128.6 (C-Ar), 128.7 
(C-Ar), 129.2 (C-Ar), 129.3 (C-Ar), 129.5 (C-Ar), 136.9 (C-Ar), 137.0 (C-Ar), 
140.8 (C-Ar), 141.9 (C-Ar), 151.7 (C-Ar), 151.8 (C-Ar), 171.1 (C-3), 171.2 (C-3); 
LRMS (ES–) m/z 340.3 [M-H]–; HRMS calcd for C20H1935ClNO2 [M-H]– 340.1110, 
found 340.1098. 
(1’R)-2-[1’-(4’’-Chlorophenyl)ethyl]-4,5,6,7-tetrahydro-1H-isoindole-
1,3(2H)-dione (230) 
 
The imide 230 was obtained following general procedure Q using 3,4,5,6-
tetrahydrophthalic anhydride (250 mg, 1.64 mmol), (R)-4-chloro-α-
methylbenzylamine (0.23 mL, 255 mg, 1.64 mmol) and THF (0.8 mL). 
Purification by MPLC (gradient elution, 0-10% EtOAc/petrol) yielded the 
desired compound 230 (341 mg, 72%) as a pale yellow oil. Rf 0.76 (25% 
EtOAc/petrol); λmax (EtOH)/nm 277sh; νmax/cm-1 (neat) 1697 (vs, C=O), 2936 
(w, aliphatic CH and -CH2-); 1H NMR (500 MHz; CDCl3) δH 1.76 (4H, m, 2  CH2), 
1.81 (3H, d, J = 7.3 Hz, CHCH3), 2.31 (4H, m, 2  CH2), 5.31 (1 H, q, J = 7.3 Hz, 
CHCH3), 7.29 – 7.33 (2H, m, H-Ar), 7.37 – 7.42 (2H, m, H-Ar); 13C NMR (125 
MHz; CDCl3) δC 17.7 (CHCH3), 19.9 (2  CH2), 21.3 (2  CH2), 48.6 (CHCH3), 128.6 
(2  C-Ar), 128.8 (2  C-Ar), 133.3 (C-Ar q), 139.3 (C-Ar q), 141.5 (2  CH2C=), 
170.9 (2  C=O). 
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(1’R)-2-[1-(4-Chlorophenyl)ethyl]-3-hydroxy-3-phenyl-2,3,4,5,6,7-
hexahydro-1H-isoindol-1-one (231) 
 
General procedure R was followed to synthesize 231 using the imide 230 (325 
mg, 1.12 mmol), phenylmagnesium bromide 1.0 M in THF (3.4 mL, 3.36 mmol), 
and THF 2.2 mL). The crude product was purified by MPLC (gradient elution, 0-
25% EtOAc/petrol) to afford the title compound (293 mg, 71%; white 
amorphous solid) as a mixture of diastereoisomers. Rf(1) = 0.49 and Rf(2) = 0.23 
(25% EtOAc/petrol); no clear m.p. detected; λmax (EtOH)/nm 253;νmax/cm-1 
(neat) 1653 (vs, C=O), 2857 and 2931 (w, aliphatic CH and -CH2-), 3230 (br, O-
H); 1H NMR (500 MHz; CDCl3) δH 1.49 – 1.84 (16H, m, 2  CH3 and 5  CH2, 2  
OH), 2.09 – 2.14 (4H, m, 2  CH2), 2.14 – 2.38 (4H, m, 2  CH2), 4.38 (1H, q, J = 
7.3 Hz, CHCH3), 4.64 (1H, q, J = 7.3 Hz, CHCH3), 6.99 – 7.04 (1H, m, H-Ar), 7.06 – 
7.10 (1H, m, H-Ar), 7.22 – 7.26 (2H, m, H-Ar), 7.26 – 7.28 (2H, m, H-Ar), 7.35 – 
7.47 (5H, m, H-Ar), 7.47 – 7.52 (2H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 18.8 
(CHCH3), 19.9 (CHCH3), 19.9 (CH2), 20.7 (CH2), 22.0, 22.0 (CH2), 22.1 (CH2), 51.2 
(CHCH3), 51.9 (CHCH3), 126.2 (C-Ar), 126.4 (C-Ar), 128.0 (C-Ar), 128.4 (C-Ar), 
128.5 (C-Ar), 128.6 (C-Ar), 128.7 (C-Ar), 129.4 (C-Ar), 129.5 (C-Ar), 132.3 (C-
Ar), 132.9 (C-Ar), 137.0 (C-Ar), 142.0 (C-Ar), 155.8 (C-Ar), 155.9 (C-Ar), 170.6 
(C-Ar q); LRMS (ES–) m/z 366.3 [M-H]– ; HRMS calcd for C22H2135ClNO2 [M-H]– 
366.1266, found 366.1255. 
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(3R,1’R)-1-[1’-(4’’-Chlorophenyl)ethyl]-5-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3,4-dimethyl-5-phenyl-1H-pyrrol-
2(5H)-one (223) and (3S,1’R)-1-[1’-(4’’-Chlorophenyl)ethyl]-5-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3,4-dimethyl-5-phenyl-1H-pyrrol-
2(5H)-one (224) 
   
A modified general procedure N was used to synthesize compounds 223 and 
224 using isoindolinone 227 (75 mg, 0.219 mmol), indium tribromide (155 mg, 
0.438 mmol), 1,1-bis(hydroxymethyl)cyclopropane (0.11 mL, 112 mg, 1.095 
mmol) and DCE (2.2 mL). Purification by MPLC (gradient elution, 0-26% 
EtOAc/petrol) yielded the desired isoindolinones 223 (35 mg, 38%; white 
amorphous solid) and 224 (28 mg, 30%; white solid). 
223 
Rf 0.26 (25% EtOAc/petrol); no clear m.p. detected; [𝛼]D
26 +108° (c 0.434, 
EtOAc); λmax (EtOH)/nm 258sh; νmax/cm-1 (neat) 1673 and 1687 (vs, C=O), 
2873, 2920, and 2973 (w, aliphatic CH and -CH2-), 3407 (br, O-H) cm-1; 1H NMR 
(500 MHz; CDCl3) δH 0.03 – 0.21 (2H, m, cyclopropyl), 0.33 – 0.45 (2H, m, 
cyclopropyl), 1.51 – 1.59 (6H, m, =C-CH3 and CHCH3), 1.65 (1H, ABX m, OH), 
1.89 (3H, m, =C-CH3), 2.58 (1H, d, JAB = 9.5 Hz, CHAHBO-), 2.99 (1H, d, JAB = 9.5 
Hz, CHAHBO-), 3.24 (1H, ABX dd, JAX = 4.0 Hz, JAB = 11.2 Hz, CHAHBOH), 3.48 (1H, 
ABX dd, JBX = 5.8 Hz, JAB = 11.2 Hz, CHAHBOH), 4.07 (1H, q, J = 7.3 Hz, CHCH3), 
7.19 – 7.25 (2H, m, H-Ar), 7.38 (5H, m, H-Ar), 7.44 – 7.51 (2H, m, H-Ar); 13C NMR 
(125 MHz; CDCl3) δC 8.6 (CH3), 8.7 (CH2 cyclopropyl), 8.8 (CH2 cyclopropyl), 
10.3 (CH3), 20.1 (CHCH3), 22.2 (C q cyclopropyl), 53.4 (CHCH3), 67.6 (CH2O-), 
68.6 (CH2OH), 97.5 (C-3), 126.4 (2  C-Ar), 128.6 (2  C-Ar), 128.7 and 128.8 (3 
 C-Ar), 129.4 (2  C-Ar), 131.2 (C-3 or C-4), 133.0 (C-Ar q), 137.3 (C-Ar q), 
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142.4 (C-Ar q), 149.3 (C-3 or C-4), 172.0 (C-1); LRMS (ES+) m/z 448.5 [M +Na]+; 
HRMS calcd for C25H2935ClNO3 [M+H]+ 426.1830, found 426.1823; HPLC 94.1% 
in 0.1% formic acid (aq.)/MeCN (Rt 9.3 min); 95.0% in 0.1% ammonia 
(aq.)/MeCN (Rt 9.3 min). 
224 
Rf 0.16 (25% EtOAc/petrol); m.p. 131.6-133.0 °C; [𝛼]D
26 +10° (c 0.406, EtOAc); 
λmax (EtOH)/nm 252sh; νmax/cm-1 (neat) 1671 (vs, C=O), 2874 and 2921 (w, 
aliphatic CH and -CH2-), 3396 (m, O-H) cm-1; 1H NMR (500 MHz; CDCl3) δH 0.48 – 
0.69 (4H, m, cyclopropyl), 1.48 (3H, m, =C-CH3), 1.78 (3H, d, J = 7.3 Hz, CHCH3), 
1.84 (1H, ABX m, OH), 1.86 – 1.93 (3H, m, =C-CH3), 3.20 (1H, d, J AB = 9.5 Hz, 
CHAHBO-), 3.30 (1H, d, J AB = 9.5 Hz, CHAHBO-), 3.62 (1H, dd, JAX = 5.0 Hz, JAB = 
11.3 Hz, CHAHBOH), 3.72 (1H, dd, JBX = 5.5 Hz, JAB = 11.3 Hz, CHAHBOH), 4.20 (1H, 
q, J = 7.3 Hz, CHCH3), 6.86 – 6.92 (2H, m, H-Ar), 6.92 – 6.98 (2H, m, H-Ar), 7.09 
(4H, br, H-Ar), 7.16 (1H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 8.5 (CH3), 9.0 
(CH2 cyclopropyl), 9.1 (CH2 cyclopropyl), 10.4 (CH3), 20.1 (CHCH3), 22.7 (C q 
cyclopropyl), 52.2 (CHCH3), 67.4 (CH2O-), 68.4 (CH2OH), 96.1 (C-3), 126.5 (2  
C-Ar), 127.8 (2  C-Ar), 128.2 (2  C-Ar), 128.4 (C-Ar), 129.3 (2  C-Ar), 131.5 
(C-3 or C-4), 132.4 (C-Ar q), 136.7 (C-Ar q), 141.6 (C-Ar q), 148.8 (C-3 or C-4), 
171.6 (C-1); LRMS (ES+) m/z 448.5 [M +Na]+; HRMS calcd for C25H2935ClNO3 
[M+H]+ 426.1830, found 426.1821; HPLC 96.6% in 0.1% formic acid 
(aq.)/MeCN (Rt 9.3 min); 97.8% in 0.1% ammonia (aq.)/MeCN (Rt 9.3 min). 
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(3R,1’R)-2-[1’-(4’’-Chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenyl-2,3,4,5,6,7-hexahydro-
1H-isoindol-1-one (224) and (3S,1’R)-2-[1’-(4’’-chlorophenyl)ethyl]-3-
{[1’’’’-(hydroxymethyl)cyclopropyl]methoxy}-3-phenyl-2,3,4,5,6,7-
hexahydro-1H-isoindol-1-one (232) 
   
A modified general procedure N was used to synthesize compounds 224 and 
232 using isoindolinone 230 (108 mg, 0.294 mmol), indium tribromide (208 
mg, 0.588 mmol), 1,1-bis(hydroxymethyl)cyclopropane (0.14 mL, 150 mg, 1.47 
mmol) and DCE (2.9 mL). Purification by MPLC (gradient elution, 0-10% 
EtOAc/petrol) yielded the desired isoindolinones 224 (37 mg, 28%; colorless 
oil, solidified to a white solid) and 232 (18 mg, 14%; white amorphous solid). 
224 
Rf 0.22 (25% EtOAc/petrol); m.p. 141.3-142.9 °C; [𝛼]D
26 +86° (c 0.454, EtOAc); 
λmax (EtOH)/nm 252sh; νmax/cm-1 (neat) 1669 (vs, C=O), 2883, 2942, and 2986 
(w, aliphatic CH and -CH2-), 3499 (m, O-H); 1H NMR (500 MHz; CDCl3) δH -0.04 – 
0.07 (2H, m, cyclopropyl), 0.24 – 0.33 (2H, m, cyclopropyl), 1.45 (3H, d, J = 7.3 
Hz, CH3), 1.48 – 1.68 (6H, m, 5  alkyl protons and OH), 1.81 – 1.92 (1H, m, alkyl 
proton), 2.12 – 2.30 (2H, m, alkyl protons), 2.48 (1H, d, JAB = 9.5 Hz, CHAHBO-), 
2.98 (1H, d, JAB = 9.5 Hz, CHAHBO-), 3.15 (1H, ABX dd, JAX = 4.5 Hz, JAB = 11.3 Hz, 
CHAHBOH), 3.38 (1H, ABX dd, JAX = 6.5 Hz, JAB = 11.3 Hz, CHAHBOH), 3.99 (1H, q, J 
= 7.3 Hz, CHCH3), 7.10 – 7.15 (2H, m, H-Ar), 7.22 – 7.33 (5H, m, H-Ar), 7.35 – 
7.40 (2H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 8.7 (CH2 cyclopropyl), 8.8 (CH2 
cyclopropyl), 20.1 (CH3), 20.2 (CH2), 21.3 (CH2), 21.9 (CH2), 22.0 (CH2), 22.2 (C q 
cyclopropyl), 53.2 (CHCH3), 67.8 (CH2O-), 68.6 (CH2OH), 97.1 (C-3), 126.3 (2  
C-Ar), 128.5 (2  C-Ar), 128.7 and 128.8 (3  C-Ar), 129.5 (2  C-Ar), 133.0 (C-Ar 
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q), 134.6 (C-5 or C-6), 137.3 (C-Ar q), 142.5 (C-Ar q), 153.4 (C-5 or C-6), 171.4 
(C-1); LRMS (ES+) m/z 474.4 [M +Na]+; HRMS calcd for C27H3135ClNO3 [M+H]+ 
452.1987, found 452.1976; HPLC 95.6% in 0.1% formic acid (aq.)/MeCN (Rt 9.7 
min); 96.1% in 0.1% ammonia (aq.)/MeCN (Rt 9.7 min). 
232 
Rf 0.11 (25% EtOAc/petrol); no clear m.p. detected; [𝛼]D
26 +16° (c 0.205, EtOAc); 
λmax (EtOH)/nm 252sh; νmax/cm-1 (neat) 1669 and 1686 (vs, C=O), 2860 and 
2928 (w, aliphatic CH and -CH2-), 3383 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 
0.46 – 0.70 (4H, m, cyclopropyl), 1.57 – 1.76 (5H, m, 2  CH2 and -OH), 1.77 (3H, 
d, J = 7.3 Hz, CH3), 1.82 – 2.04 (2H, m, CH2), 2.25 – 2.35 (2H, m, CH2), 3.22 – 3.36 
(2H, AB q, JAB = 9.5 Hz, CH2O-), 3.61 (1H, d, JAB = 11.3 Hz, CHAHBOH), 3.72 (1H, d, 
JAB = 11.3 Hz, CHAHBOH), 4.22 (1H, q, J = 7.3 Hz, CHCH3), 6.86 – 6.92 (2H, m, H-
Ar), 6.92 – 6.98 (2H, m, H-Ar), 7.00 – 7.14 (4H, m, H-Ar), 7.14 – 7.20 (1H, m, H-
Ar); 13C NMR (125 MHz; CDCl3) δC 9.0 (CH2 cyclopropyl), 9.1 (CH2 cyclopropyl), 
20.0 (CH2), 20.1 (CH3), 21.4 (CH2), 21.9 (CH2), 22.0 (CH2), 22.7 (C q cyclopropyl), 
51.9 (CHCH3), 67.7 (CH2O-), 68.5 (CH2OH), 95.8 (C-3), 126.5 (2  C-Ar), 127.8 (2 
 C-Ar), 128.2 (2  C-Ar), 128.4 (C-Ar), 129.3 (2  C-Ar), 132.3 (C-Ar q), 134.9 
(C-Ar q), 136.7 (C-Ar q), 141.7 (C-Ar q), 152.9 (C-Ar q), 171.0 (C-1); LRMS (ES+) 
m/z 452.5 [M+H]+; HRMS calcd for C27H3135ClNO3 [M+H]+ 452.1987, found 
452.1977; HPLC 97.3% in 0.1% formic acid (aq.)/MeCN (Rt 9.7 min); 98.6% in 
0.1% ammonia (aq.)/MeCN (Rt 9.7 min). 
Methyl 3-(benzyloxy)isoxazole-5-carboxylate (273) 
 
To a suspension of methyl 3-hydroxy-5-isoxazolecarboxylate (1.00 g, 7.00 
mmol) in acetonitrile (19 mL, 2.7 mL/mmol), K2CO3 (1.93 g, 14.0 mmol) was 
added in one portion. The reaction mixture was stirred at 70 °C for 1 h and 
benzyl bromide (1.25 mL, 1.80 g, 10.5 mmol) was added portionwise over 30 
min. The mixture was stirred at 70 ° C for 3 hours and at RT overnight before 
being filtered through a Celite cartridge. The solvent was removed in vacuo and 
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the crude product was purified by MPLC (gradient elution, 0-20% 
EtOAc/petrol) to obtain the title compound (1.34 g, 82%) as a colorless oil 
which solidified upon storage at RT. Rf 0.64 (25% EtOAc/petrol); m.p. 37.4-
37.7°C (lit.172 43 °C); λmax (EtOH)/nm no maximum of absorption was observed; 
νmax/cm-1 (neat) 1736 (s, C=O); 1H NMR (500 MHz; CDCl3) δH 3.95 (3H, s, CH3), 
5.32 (2H, s, CH2), 6.57 (1H, s, H-4), 7.34 – 7.43 (3H, m, H-Ar), 7.43 – 7.47 (2H, m, 
H-Ar); 13C NMR (125 MHz; CDCl3) δC 53.0 (CH3), 72.3 (CH2), 101.1 (C-4), 128.5 
(C-Ar), 128.8 (C-Ar), 128.9 (C-Ar), 135.3 (C-Ar), 157.2 (C-3), 160.5 (C-5), 171.5 
(CO2CH3); HRMS calcd for C12H12NO4 [M+H]+ 234.0761, found 234.0764. 
Spectral data are consistent with those reported in the literature.172 
[3-(Benzyloxy)isoxazol-5-yl]methanol (274) 
 
Sodium borohydride (168 mg, 4.45 mmol) was added carefully to a cooled 
(0 °C) solution of the ester 273 (416 mg, 1.78 mmol) in methanol (12.8 mL, 7.2 
mL/mmol). The reaction mixture was allowed to warm up to RT, stirred 
overnight. HCl (1 M aq., 5 mL) and was stirred at RT for 30 min. The product 
was extracted with DCM (3  40 mL) and the combined organic layers were 
washed with brine (25 mL), dried (MgSO4), filtered and evaporated. Purification 
by MPLC (0-40% EtOAc/petrol) yielded the title compound as a colorless oil 
(337 mg, 92%). Rf 0.24 (25% EtOAc/petrol); λmax (EtOH)/nm 257; νmax/cm-1 
(neat) 3361 (O-H); 1H NMR δH (500 MHz; CDCl3) δ H (500 MHz, CDCl3) 1.94 (1H, 
br, OH), 4.67 (2H, s, CH2OH), 5.27 (2H, s, CH2O), 5.92 (1H, s, H-4), 7.32 – 7.48 
(5H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 57.1 (CH2OH), 71.8 (CH2O), 93.7 (C-
4), 128.4 (2  C-Ar), 128.7 (C-Ar), 128.8 (2  C-Ar), 135.8 (C-Ar q), 171.8 (C-3), 
172.2 (C-5); HRMS calcd for C11H12NO3 [M+H]+ 206.0812, found 206.0811. 
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{1-{[(tert-Butyldiphenylsilyl)oxy]methyl}cyclopropyl}methanol (283) 
 
Under an inert atmosphere, 1,1-bis(hydroxymethyl)cyclopropane (1.02 mL, 1.5 
g, 14.7 mmol) was dissolved in DCM (15 mL, 1.0 mL/mmol) and triethylamine 
(1.23 mL, 0.89 g, 8.82 mmol) was added. The clear solution was cooled to 0 °C 
and a solution of TBDPSCl (1.91 mL, 2.02 g, 7.35 mmol) in DCM (2 mL) was 
added dropwise. The reaction mixture was allowed to warm up to RT and 
stirred for 2 h. Saturated NaHCO3 (aq., 4 mL) was added to the reaction mixture 
and the layers were separated. The aqueous phase was extracted with DCM (2  
30 mL) and the combined organic layers were washed with water (45 mL) and 
brine (45 mL), dried (MgSO4) and the solvent was removed in vacuo. 
Purification by MPLC (gradient elution, 0-60% EtOAc/petrol) yielded the 
desired compound 283 (2.47 g, 99%) as a colorless oil. Rf 0.65 (25% 
EtOAc/petrol); λmax (EtOH)/nm 264; νmax/cm-1 (neat) 2857 2930 and 3070 (w, 
aliphatic CH and -CH2-), 3412 (br, O-H); 1H NMR (500 MHz; CDCl3) δH δ H 0.32 – 
0.39 (2H, m, cyclopropyl), 0.45 – 0.53 (2H, m, cyclopropyl), 1.07 (9H, s, 3  CH3), 
2.56 (1H, ABX app. t, JAX = JBX = 5.6 Hz, OH), 3.57 – 3.66 (4H, m, 2  CH2), 7.34 – 
7.49 (6H, m, H-Ar), 7.62 – 7.73 (4H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 8.9 
(2  CH2 cyclopropyl), 19.3 (C(CH3)3), 24.2 (C q cyclopropyl), 27.0 (3  CH3), 
69.5 (CH2), 70.5 (CH2), 127.9 (2  C-Ar), 130.0(C-Ar), 133.3 (C-Ar q), 135.8 (2  
C-Ar); HRMS calcd for C21H29O2 [M+H]+ 341.1931, found 341.1936. 
[3-(Benzyloxy)isoxazol-5-yl](methoxy)methyl acetate (279) 
 
Under an inert atmosphere, DIBAL (1 M in cyclohexanes, 4.3 mL, 4.3 mmol) was 
added dropwise to a solution of 273 (250 mg, 1.07 mmol) in DCM (6.4 mL, 6.0 
mL/mmol) cooled at -78 °C The solution was stirred at -78 °C for 1.5 h. Pyridine 
(0.26 mL, 254 mg, 3.21 mmol), a solution of DMAP (261 mg, 2.14 mmol) in DCM 
(3.2 mL) and acetic anhydride (0.61 mL, 655 mg, 6.42 mmol) were added 
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sequentially dropwise. The reaction mixture was stirred at -78 °C for 15 h, at 
0 °C for 30 min and quenched by addition of sat. aq. NH4Cl (10 mL) and sat. aq. 
Rochelle salt solution (7.5 mL). The mixture was allowed to warm up to RT and 
stirred until the layers separated. The aqueous layer was extracted with DCM (4 
 10 mL); the combined organic layers were washed with ice-cooled potassium 
hydrogen sulfate (aq. 1 M, 2  10 mL), sat. aq. NaHCO3 (3  10 mL) and brine (10 
mL), dried (MgSO4), filtered and evaporated. Purification on amine silica 
(gradient elution, 0-15% EtOAc/petrol) yielded the desired α-acetoxy ether 279 
(99 mg, 33%) as a colorless oil. Rf 0.84 (50% EtOAc/petrol); λmax (EtOH)/nm 
257; νmax/cm-1 (neat)1745 (m, C=O); 1H NMR (500 MHz; CDCl3) δH 2.21 (3H, s, 
O-CH3), 3.57 (3H, s, CO-CH3), 5.30 (2H, s, CH2), 6.07 (1H, s, H-4), 6.70 (1H, s, O-
CH-O), 7.33 – 7.52 (5H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 21.0 (OCH3), 
56.9(CO-CH3), 71.9 (CH2), 90.8 (O-CH-O), 94.9 (C-4), 128.4 (2  C-Ar), 128.7 (C-
Ar), 128.7 (2  C-Ar), 135.7 (C-Ar q), 167.9 (C q), 170.0 (C q), 171.4 (C q); LRMS 
(ES+) m/z 300.2 [M+Na]+ ; HRMS calcd for C14H16N1O5 [M+H]+ 278.1023, found 
278.1026. 
3-(Benzyloxy)isoxazole-5-carboxylic acid (284) 
 
The ester 273 (620 mg, 2.66 mmol) was dissolved in THF (25 mL) and LiOH 
(aq. 2 M, 25 mL) was added in one portion. The reaction mixture was stirred for 
45 min and acidified by addition of HCl (aq. 1 M) to pH 3. Ethyl acetate was 
added and the layers were separated. The aqueous layer was extracted with 
ethyl acetate (2  40 mL). The combined organic layers were washed with brine 
(30 mL), dried (MgSO4), filtered and the solvent was removed in vacuo. The 
product (white solid; 0.56 mg, 96%) was used directly in the following step 
without further purification. Rf 0.01 (10% MeOH/petrol); m.p. 124.4-126.0 °C; 
λmax (EtOH)/nm no maximum of absorption; νmax/cm-1 (neat) 1706 (s, C=O), 
2900 (br, O-H); 1H NMR (500 MHz; DMSO-d6) δH 5.30 (2H, s, CH2), 6.99 (1H, s, H-
4), 7.27 – 7.60 (5H, m, H-Ar), 14.35 (1H, s, OH); 13C NMR (125 MHz; DMSO-d6) δC 
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71.7 (CH2), 100.3 (C-4), 128.4 (2  C-Ar), 128.5 (2  C-Ar), 128.5 (C-Ar), 135.5 
(C-Ar q), 157.5 (C q), 161.6 (C q), 171.3 (CO2H); LRMS (ES–) m/z 218.1 [M-H]–; 
HRMS calcd for C11H8NO4 [M-H]– 218.0459, found 218.0455. 
3-(Benzyloxy)-5-(methoxymethyl)isoxazole (280) and 3-
(benzyloxy)isoxazole-5-carbaldehyde (281) 
   
Under an inert atmosphere, triethylsilane (0.07 mL, 52 mg, 0.450 mmol) was 
added to a solution of the α-acetoxyether 279 (50 mg, 0.180 mmol) in DCM (3.6 
mL, 20 mL/mmol) cooled at -78 °C. Boron trifluoride etherate (0.06 mL, 64 mg, 
0.450 mmol) was added dropwise and the mixture was stirred ar -78 °C for 50 
min. Upon completion of the reaction, the reaction mixture was partitioned 
between NaHCO3 (sat. aq., 5 mL) and petrol (10 mL) and the aqueous layer was 
back-extracted with petrol (10 mL). The combined organic layers were dried 
(MgSO4), filtered and evaporated. Purification by MPLC afforded the desired 
ether 280 (8 mg, 20%) and the aldehyde 281 (14 mg, 38%), both as colorless 
oils. 
280 
Rf 0.58 (25% EtOAc/petrol); λmax (EtOH)/nm 257; νmax/cm-1 (neat) 2932 (w, 
aliphatic CH and -CH2-); 1H NMR (500 MHz; CDCl3) δH 3.42 (3H, s, CH3), 4.43 
(2H, s, CH2-OCH3), 5.27 (2H, s, CH2-Ph), 5.87 – 5.95 (1H, m, H-4), 7.30 – 7.54 (5H, 
m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 59.0 (CH3), 65.8 (CH2-OCH3), 71.8 (CH2-
Ph), 94.7 (C-4), 128.4 (2  C-Ar), 128.7 (C-Ar), 128.8 (2  C-Ar), 135.9 (C-Ar q), 
170.3 (C-3 or C-5), 171.8 (C-3 or C-5); LRMS (ES+) m/z 220.2 [M+H]+; HRMS 
calcd for C12H14NO3 [M+H]+ 220.0968, found 220.0968. 
281 
Rf 0.53 (25% EtOAc/petrol); λmax (EtOH)/nm 257sh; νmax/cm-1 (neat) 1703 (s, 
C=O); 1H NMR (500 MHz; CDCl3) δH 5.34 (2H, s, CH2), 6.60 (1H, s, H-4), 7.31 – 
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7.54 (5H, m, H-Ar), 9.84 (1H, s, CHO); 13C NMR (125 MHz; CDCl3) δC 72.6 (CH2), 
100.1 (C-4), 128.5 (2  C-Ar), 128.8 (2  C-Ar), 129.0(C-Ar), 135.2 (C-Ar q), 
166.0 (-C-3 or C-5), 171.6 (C-3 or C-5), 178.8 (CHO); HRMS calcd for C11H10NO3 
[M+H]+ 204.0655, found 204.0651. 
{1-{[(tert-Butyldiphenylsilyl)oxy]methyl}cyclopropyl}methyl 3-
(benzyloxy)isoxazole-5-carboxylate (284) 
 
To a cooled (0 °C) solution of 284 (1.27 g, 5.79 mmol) in THF (4.6 mL, 0.8 
mL/mmol), a solution of thionyl chloride (0.84 mL, 1.38 g, 11.6 mmol) in THF 
(2.3 mL, 0.4 mL/mmol) was added followed by a catalytic amount of DMF (1-3 
drops); the solution was stirred at RT for 4 h and evaporated. The residue was 
redissolved in THF (5.8 mL, 1.2 mL/mmol), and 283 (2.17 g, 6.17 mmol) and 
DIPEA (1.11 mL, 0.82 g, 6.37 mmol) were added dropwise. The solution was 
stirred at RT overnight; Upon completion of the reaction, ethyl acetate (10 mL) 
was added to the mixture and the layers were separated. The aqueous layer was 
extracted with EtOAc (2  10 mL) and the combined organic layers were dried 
(MgSO4), filtered and the solvent was removed in vacuo. The crude product was 
purified by MPLC (gradient elution, 0-6% EtOAc/petrol) to afford the desired 
product as a colorless oil (2.25 g, 72%). Rf 0.69 (17% EtOAc/petrol); νmax/cm-1 
(neat) 1733 (m, C=O), 2856, 2930 and 3069 (w, aliphatic CH and -CH2-); 1H 
NMR (500 MHz; CDCl3) δH 0.45 – 0.64 (4H, m, cyclpropane), 1.05 (9H, s, 3  
CH3), 3.59 (2H, s, CH2-OTBDPS), 4.35 (2H, s, CH2-OC=O), 5.33 (2H, s, CH2-Ph), 
6.46 (1H, s, H-4), 7.31 – 7.53 (11H, m, H-Ar), 7.59 – 7.70 (4H, m, H-Ar); 13C NMR 
(125 MHz; CDCl3) δC 9.0 (CH2 cyclopropyl), 19.5 (C q), 22.0 (C q), 27.0 (3  CH3), 
66.6 (CH2-OTBDPS), 69.8 (CH2-OC=O), 72.2 (CH2-Ph), 100.9 (C-4), 127.8 (C-Ar), 
128.5 (C-Ar), 128.8 (C-Ar), 128.8 (C-Ar), 129.8 (C-Ar), 133.6 (C-Ar), 135.5 (C-
Ar), 135.7 (C-Ar), 156.9 (C-3 or C-5), 160.7 (C-3 or C-5), 171.4 (CO2R); HRMS 
calcd for C32H36NO5Si [M+H]+ 542.2357, found 542.2350. 
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[3-(Benzyloxy)isoxazol-5-yl]{{1-[[(tert-
butyldiphenylsilyl)oxy]methyl]cyclopropyl}methoxy}methyl acetate 
(286) 
 
Under an inert atmosphere, DIBAL (1 M in cyclohexanes, 7.20 mL, 7.20 mmol) 
was added dropwise to a solution of 284 (1.30 g, 2.40 mmol) in DCM (14.4 mL, 
6.0 mL/mmol) cooled at -78 °C The solution was stirred at -78 °C for 1.5 h. 
Pyridine (0.58 mL, 570 mg, 7.20 mmol), a solution of DMAP (586 mg, 4.80 
mmol) in DCM (7.2 mL) and acetic anhydride (1.36 mL, 1.47 g, 14.4 mmol) were 
added dropwise. The reaction mixture was stirred at -78 °C for 15 h, at 0 °C for 
30 min and quenched by addition of sat. aq. NH4Cl (20 mL) and sat. aq. Rochelle 
salt solution (15 mL). The mixture was allowed to warm up to RT and stirred 
until the layers separated. The aqueous layer was extracted with DCM (4  20 
mL); the combined organic layers were washed with ice-cooled potassium 
hydrogen sulfate (aq. 1 M, 2  20 mL), sat. aq. NaHCO3 (3  20 mL) and brine (20 
mL), dried (MgSO4), filtered and evaporated. Purification on previously 
neutralized silica (gradient elution, 0-30% EtOAc/petrol) yielded the desired α-
acetoxyether 286 (1.40 g, quant.) as a colorless oil. Rf 0.56 (17% EtOAc/petrol); 
λmax (EtOH)/nm 259; νmax/cm-1 (neat) 1750 (m, C=O), 2856, 2930 and 3070 (w, 
aliphatic CH and -CH2-); 1H NMR (500 MHz; CDCl3) δH 0.37 – 0.53 (4H, m, 
cyclopropyl), 1.05 (9H, s, 3  CH3), 2.12 (3H, s, CH3CO), 3.58 (2H, AB q, J = 10.2 
Hz, CH2OSi), 3.76 (2H, AB q, J = 9.6 Hz, CH2C-OAc), 5.28 (2H, s, CH2Ph), 5.97 (1H, 
s, H-4), 6.76 (1H, s, OCHOAc), 7.31 – 7.49 (11H, m, H-Ar), 7.65 (4H, m, H-Ar); 13C 
NMR (125 MHz; CDCl3) δC 8.3 (CH2 cyclopropyl), 8.6 (CH2 cyclopropyl), 19.5 (C q 
cyclopropyl), 21.2 (CH3CO), 22.4 (C(CH3)3), 27.0 (3  CH3), 66.4 (CH2OSi), 71.9 
(CH2Ph), 73.7 (CH2C-OAc), 90.0 (OCHOAc), 94.8 (C-4), 127.8 (2  C-Ar), 127.8 (2 
 C-Ar), 128.4 (2  C-Ar), 128.7 (C-Ar), 128.7 (2  C-Ar), 129.8 (C-Ar), 133.8 (2  
C-Ar), 133.8 (2  C-Ar), 135.7 (C-Ar), 135.7 (C-Ar), 135.8 (C-Ar), 168.3 (OCO), 
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170.1 (C-5), 171.4 (C-3); LRMS (ES+) m/z 608.5 [M+Na]+; HRMS calcd for 
C34H40NO6Si [M+H]+ 586.2619, found 586.2593. 
3-(Benzyloxy)-5-{{[1-[((tert-
butyldiphenylsilyl)oxy)methyl]cyclopropyl]methoxy}methyl}isoxazole 
(287) 
 
TMSOTf was dissolved in DCM; the solution was cooled to 0 °C and 
triethylsilane was added, followed by a solution of the acetal 286 in DCM. The 
reaction mixture was stirred for 30 min and quenched with saturated NaHCO3 
aq., extracted with Et2O (3  20 mL), dried (MgSO4) and the solvent was 
removed in vacuo. Purification on pre-neutralized silica (gradient elution 0-6% 
EtOAc/petrol) yielded the desired ether 287 (312 mg, 69%) as a colorless oil. Rf 
0.80 (25% EtOAc/petrol); λmax (EtOH)/nm 264; νmax/cm-1 (neat) 2855, 2929 
and 3069 (w, aliphatic CH and -CH2-); 1H NMR (500 MHz; CDCl3) δH 0.44 (4H, s, 
cyclopropyl), 1.06 (9H, s, 3  CH3), 3.53 (2H, s, CH2OSi), 3.61 (2H, s, CH2OCH2-
isoxazole), 4.47 (2H, s, CH2-isoxazole), 5.27 (2H, s, CH2Ph), 5.89 (1H, s, H-4), 
7.31 – 7.53 (11H, m, H-Ar), 7.61 – 7.73 (4H, m, H-Ar); 13C NMR (125 MHz; CDCl3) 
δC 8.3 (CH2-cyclopropyl), 19.5 (C q cyclopropyl), 22.5 (C(CH3)3), 27.0 (3  CH3), 
64.2 (CH2-isoxazole), 66.6 (CH2OCH2-isoxazole), 71.7 (CH2Ph), 74.8 (CH2OSi), 
94.4 (C-4), 127.8 (4  C-Ar), 128.3 (2  C-Ar), 128.6(C-Ar), 128.7 (2  C-Ar), 
129.7 (2  C-Ar), 133.9 (C-Ar q), 135.7 (4  C-Ar), 135.9 (C-Ar q), 170.8 (C-5), 
171.8 (C-3); LRMS (ES+) m/z 482.4 [M+H]+ ; HRMS calcd for C32H38NO4Si 
[M+NH4]+ 528.2565, found 528.2560. 
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{1-{[(3-(Benzyloxy)isoxazol-5-yl)methoxy]methyl}cyclopropyl}methanol 
(277) 
 
Compounds 277 was obtained following general procedure P using isoxazole 
287 (305 mg, 0.578 mmol), TBAF (1 M in THF, 0.87 mL, 0.87 mmol) and THF 
(23 mL). Purification by MPLC (gradient elution, 0-70% EtOAc/petrol) yielded 
the title compound as a yellow oil (164 mg, 98%). Rf 0.31 (50% EtOAc/petrol); 
λmax (EtOH)/nm 257; νmax/cm-1 (neat) 3432 (OH); 1H NMR (500 MHz; CDCl3) δH 
0.44 – 0.65 (4H, m, cyclopropyl), 3.54 (2H, s, CH2OH), 3.58 (2H, s, CH2OCH2-
isoxazole), 4.55 (2H, s, CH2-isoxazole), 5.29 (2H, s, CH2Ph), 5.96 (1H, s, H-4), 
7.32 – 7.55 (5H, m); 13C NMR (125 MHz; CDCl3) δC 9.0 (CH2 cyclopropyl), 22.7 (C 
q cyclopropyl), 64.3 (CH2-isoxazole), 68.5 (CH2OCH2-isoxazole), 71.8 (CH2 
benzylic), 76.9 (CH2OH), 94.7 (C-4), 128.4 (2  C-Ar), 128.7 (C-Ar), 128.8 (2  C-
Ar), 135.8 (C-Ar q), 170.2 (C-5), 171.8 (C-3); HRMS calcd for C16H23O4N2 
[M+NH4]+ 307.1652, found 307.1656. 
(3R,1’R)-4-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-(2’’’’-hydroxyethoxy)-3-
phenylisoindolin-1-one (235) and (3S,1’R)-4-chloro-2-[1’-(4’’-
chlorophenyl)ethyl]-3-(2’’’’-hydroxyethoxy)-3-phenylisoindolin-1-one 
(238) 
   
Compounds 235 and 238 were synthesized following general procedure N 
using isoindolinone 198 (250 mg, 0.628 mmol), InBr3 (45 mg, 0.126 mmol), 1,2-
ethanediol (0.175 mL, 195 mg, 3.14 mmol) and dichloroethane (6.3 mL). 
Purification by MPLC (gradient elution, 0-40% EtOAc/petrol) yielded the two 
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diastereoisomers as white amorphous solids (235 139 mg, 50%; 238 124 mg, 
45%). 
235 
Rf 0.29 (25 %EtOAc/petrol); m.p. 136.8-137.6 °C; [α]24D +155° (c 0.422, EtOAc); 
λmax (EtOH)/nm 259; νmax/cm-1 (neat) 1683 (s, C=O), 2932 (w, aliphatic CH2), 
3384 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 1.61 (3H, d, J = 7.3 Hz, CH3), 1.71 
(1H, ABX dd, J = 4.4, 8.2 Hz, OH), 2.70 – 2.88 (2H, m, OCH2CH2OH), 3.35 – 3.54 
(2H, ABX m, OCH2CH2OH), 4.21 (1H, q, J 7.3 Hz, CHCH3), 7.26 – 7.29 (2H, m, H-
Ar), 7.34 – 7.44 (6H, m, 5  H-Ar and H-5), 7.48 (1H, app. t, J = 7.7 Hz, H-6), 7.55 
– 7.61 (2H, m, H-Ar), 7.79 (1H, dd, J = 1.0, 7.7 Hz, H-7); 13C NMR (125 MHz; 
CDCl3) δC 19.4 (CHCH3), 53.3 (ArCHCH3), 61.4 (OCH2CH2OH), 65.0 (OCH2CH2OH), 
96.3 (C-3), 122.0 (C-7), 128.5 (2  C-Ar), 128.6 (C-Ar), 129.0 (C-Ar), 129.7 (2  
C-Ar), 129.7 (C-Ar q), 131.8 (C-6), 133.4 (C-Ar q), 133.8 (C-5), 135.2 (C-Ar q), 
136.5 (C-Ar q), 140.6 (C-Ar q), 141.1 (C-Ar q), 166.8 (C-1). One carbon not 
detected; LRMS (ES+) m/z 442.3 [M+H]+; HRMS calcd for C24H2235Cl2NO3 [M+H]+ 
442.0971, found 442.0967; HPLC 96.4% in 0.1% formic acid (aq)/MeCN (Rt 9.1 
min); 96.3% in 0.1% ammonia (aq)/MeCN (Rt 9.1 min). 
238 
Rf 0.09 (25 %EtOAc/petrol); m.p. 155.6-156.9 °C; [α]24D +56° (c 0.674, EtOAc); 
λmax (EtOH)/nm 254; νmax/cm-1 (neat) 1681 (vs, C=O), 2870 and 2930 (w, 
aliphatic CH and -CH2-), 3364 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 1.87 (3H, 
d, J = 7.3 Hz, CHCH3), 2.05 (1H, ABX dd, J =  5.5, 6.4 Hz, OCH3), 3.10 – 3.21 (1H, m, 
OCHAHBCH2OH), 3.44 – 3.55 (1H, m, OCHAHBCH2OH), 3.77 – 3.95 (2H, m, 
OCH2CH2OH), 4.43 (1H, q, J = 7.3 Hz, CHCH3), 6.82 – 6.92 (2H, m, H-Ar), 6.93 – 
7.00 (2H, m, H-Ar), 7.13 (4H, br, H-Ar), 7.19 – 7.25 (1H, m, H-Ar), 7.42 (1H, dd, J 
= 1.1, 7.7 Hz, H-5), 7.48 (1H, app. t, J = 7.7 Hz, H-6), 7.78 (1H, dd, J = 1.1, 7.7, H-
7); 13C NMR (125 MHz; CDCl3) δC 19.5 (CHCH3), 52.0 (CHCH3), 61.8 
(OCH2CH2OH), 65.1 (OCH2CH2OH), 95.3 (C-3), 121.9 (C-7), 127.2 (2  C-Ar), 
127.9 (2  C-Ar), 128.1 (2  C-Ar), 128.7 (C-Ar), 129.5 (2  C-Ar), 129.8 (C-Ar q), 
131.8 (C-6), 132.7 (C-Ar q), 133.7 (C-5), 135.3 (C-Ar q), 136.2 (C-Ar q), 140.3 (C-
Ar q), 140.5 (C-Ar q), 166.5 (C-1); LRMS (ES+) m/z 442.3 [M+H]+; HRMS calcd 
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for C24H2235Cl2NO3 [M+H]+ 442.0971, found 442.0967; HPLC 98.9% in 0.1% 
formic acid (aq)/MeCN (Rt 9.0 min); 99.1% in 0.1% ammonia (aq)/MeCN (Rt 9.0 
min). 
(3R,1’R)-4-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-(3-hydroxypropoxy)-3-
phenylisoindolin-1-one (236) and (3S,1’R)-4-chloro-2-[1-(4-
chlorophenyl)ethyl]-3-(3’’’’-hydroxypropoxy)-3-phenylisoindolin-1-one 
(241) 
   
Compounds 236 and 241 were synthesized following general procedure N 
using isoindolinone 198 (200 mg, 0.502 mmol), InBr3 (35 mg, 0.100 mmol), 1,3-
propanediol (0.18 mL, 191 mg, 2.51 mmol) and dichloroethane (5.0 mL). The 
two diastereoisomers were separated by MPLC (gradient elution, 0-45% 
EtOAc/petrol) to obtain 236 as a white amorphous solid (113 mg, 49%) and 
241 as a white solid (84 mg, 37%). 
236 
Rf 0.26 (25 %EtOAc/petrol); no clear m.p. detected; [α]24D +153° (c 0.584, 
EtOAc); λmax (EtOH)/nm 259; νmax/cm-1 (neat) 1684 (s, C=O), 2878 and 2932 (w, 
aliphatic CH and CH2), 3389 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 1.39 – 1.51 
(1H, m, CHAHB), 1.52 – 1.68 (5H, m, CH3, CHAHB, and OH), 2.73 – 2.90 (2H, m, 
CH2), 3.56 – 3.75 (2H, m, CH2OH), 4.19 (1H, q, J = 7.3 Hz, CHCH3), 7.26 – 7.30 
(2H, m, H-Ar), 7.32 – 7.43 (6H, m, 5  C-Ar and C-5), 7.47 (1H, app. t, J = 7.6 Hz, 
H-6), 7.56 – 7.63 (2H, m, H-Ar), 7.79 (1H, dd, J = 1.1, 7.5 Hz, H-7); 13C NMR (125 
MHz; CDCl3) δC 19.4 (CHCH3), 31.7 (OCH2CH2CH2OH), 53.2 (CHCH3), 60.9 
(OCH2CH2CH2OH), 61.5 (OCH2CH2CH2OH), 96.3 (C-3), 122.0 (C-7), 127.1 (C-Ar), 
128.5 (2  C-Ar), 128.6 (2  C-Ar), 128.9 (2  C-Ar), 129.6 (C-Ar q), 129.7 (2  C-
Ar), 131.6 (C-6), 133.3 (C-Ar q), 133.6 (C-5), 135.2 (C-Ar q), 136.7 (C-Ar q), 
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140.7 (C-Ar q), 141.3 (C-Ar q), 166.8 (C-1); LRMS (ES+) m/z 456.4 [M+H]+; 
HRMS calcd for C25H2435Cl2NO3 [M+H]+ 456.1128, found 456.1125;HPLC 99.4% 
in 0.1% formic acid (aq)/MeCN (Rt 9.3 min); 99.4% in 0.1% ammonia 
(aq)/MeCN (Rt 9.3 min). 
241 
Rf 0.12 (25 %EtOAc/petrol); no clear m.p. detected; [α]24D +54° (c 0.609, EtOAc); 
λmax (EtOH)/nm 254; νmax/cm-1 (neat) 1684 (s, C=O), 2878 and 2933 (w, 
aliphatic CH and CH2), 3405 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 1.75 (1H, 
ABX app. t, J = 5.6 Hz, OH), 1.85 (3H, d, J = 7.3 Hz, CH3), 1.87 – 2.04 (2H, m, CH2), 
3.17 (1H, m, CHAHB), 3.49 (1H, dt, m, CHAHB), 3.86 – 3.97 (2H, m, CH2), 4.42 (1H, 
q, J = 7.3 Hz, CHCH3), 6.84 – 6.91 (2H, m, H-Ar), 6.93 – 7.01 (2H, m, H-Ar), 7.13 
(4H, br, H-Ar), 7.19 – 7.25 (1H, m, H-Ar), 7.42 (1H, dd, J = 1.1, 7.7 Hz, H-5), 7.47 
(1H, app. t, J = 7.7 Hz, H-6), 7.77 (1H, dd, J = 1.1, 7.3 Hz, H-7); 13C NMR (125 
MHz; CDCl3) δC 19.4 (CHCH3), 32.3 (OCH2CH2CH2OH), 51.8 (CHCH3), 60.8 
(OCH2CH2CH2OH), 61.3 (OCH2CH2CH2OH), 95.4 (C-3), 121.9 (C-7), 127.2 (2  C-
Ar), 127.9 (2  C-Ar), 128.1 (2  C-Ar), 128.7 (C-Ar), 129.5 (2  C-Ar), 129.8 (C-
Ar q), 131.7 (C-6), 132.7 (C-Ar q), 133.5 (C-5), 135.4 (C-Ar q), 136.6 (C-Ar q), 
140.3 (C-Ar q), 140.8 (C-Ar q), 166.5 (C-1); LRMS (ES+) m/z 456.4 [M+H]+; 
HRMS calcd for C25H2435Cl2NO3 [M+H]+ 456.1128, found 456.1124; HPLC 97.4% 
in 0.1% formic acid (aq)/MeCN (Rt 9.2 min); 97.6% in 0.1% ammonia 
(aq)/MeCN (Rt 9.3 min). 
(3R,1’R)-2-{[7-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-oxo-1-
phenylisoindolin-1-yl]oxy}acetic acid (237) 
 
General procedure S was followed to synthesize the acid 237 using the alcohol 
235 (139 mg, 0.314 mmol), sodium periodate (276 mg, 1.29 mmol), RuCl3 · H2O  
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(6.5 mg, 0.0314), ethyl acetate (0.45 mL), acetonitrile (0.45 mL) and water (0.79 
mL). Purification by MPLC (gradient elution, 1-25% EtOAc/petrol + 0.1% acetic 
acid) yielded the title compound as a white amorphous solid (76 mg, 53%). Rf 
0.28 (33% EtOAc/petrol, 0.1% formic acid); no clear m.p. detected; [α]26D +180° 
(c 0.543, EtOAc); λmax (EtOH)/nm 259; ν max/cm-1 (neat) 1667 (s, C=O), 1703 (s, 
C=O), 2932 (w, C-H), 3000 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 1.63 (3H, d, J 
= 7.2 Hz, CH3), 3.28 (1H, d, JAB = 15.5 Hz, CHAHB), 3.42 (1H, d, JAB = 15.5 Hz, 
CHAHB), 4.27 (1H, q, J = 7.2 Hz, CHCH3), 7.20 – 7.26 (2H, m, H-Ar), 7.34 – 7.46 
(6H, m, H-Ar), 7.50 (1H, app. t, J = 7.7 Hz, H-6), 7.54 – 7.65 (2H, m, H-Ar), 7.81 
(1H, dd, J = 1.0, 7.7 Hz, H-7); 13C NMR (125 MHz; CDCl3) δC 19.0 (CHCH3), 53.2 
(CHCH3), 60.6 (OCH2CO2H), 96.1 (C-3), 122.2 (C-7), 127.2 (2  C-Ar), 128.6 (2  
C-Ar), 128.8 (2  C-Ar), 129.2 (C-Ar), 129.7 (2  C-Ar), 130.0 (C-Ar q), 132.2 (C-
6), 133.6 (C-Ar q), 134.0 (C-5), 135.0(C-Ar q), 135.7 (C-Ar q), 139.7 (C-Ar q), 
140.5 (C-Ar q), 166.7 (C-1), 172.4 (CO2H); LRMS (ES–) m/z 454.2 [M-H]–; HRMS 
calcd for C24H1835Cl2NO4 [M-H]– 454.0618, found 454.0603; HPLC 97.8% in 
0.1% formic acid (aq)/MeCN (Rt 9.2 min); 99.0% in 0.1% ammonia (aq)/MeCN 
(Rt 4.7 min). 
(3S,1’R)-2-{[7-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-oxo-1-
phenylisoindolin-1-yl]oxy}acetic acid (239) 
 
General procedure S was followed to synthesize the acid 239 using the alcohol 
238 (124 mg, 0.280 mmol), sodium periodate (246 mg, 1.15 mmol), RuCl3 · H2O  
(5.8 mg, 0.0280), ethyl acetate (0.40 mL), acetonitrile (0.40 mL) and water (0.70 
mL). Purification by MPLC (gradient elution, 1-25% EtOAc/petrol + 0.1% acetic 
acid) yielded the title compound as a white amorphous solid (89 mg, 70%). Rf 
0.23 (33% EtOAc/petrol + 0.1% formic acid); no clear m.p. detected; [α]26D +77° 
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(c 0.460, EtOAc); λmax (EtOH)/nm 252sh; νmax/cm-1 (neat) 1667 (s, C=O), 1702 
(s, C=O), 2935 and 2977 (w, C-H), 3000 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 
1.79 (3H, d, J = 7.3 Hz, CHCH3), 3.79 (1H, d, JAB = 15.7 Hz, CHAHB), 3.91 (1H, d, JAB 
= 15.7 Hz, CHAHB), 4.58 (1H, q, J = 7.3 Hz, CHCH3), 6.86 – 6.94 (2H, m, H-Ar), 6.93 
– 7.02 (2H, m, H-Ar), 7.16 (4H, br, H-Ar), 7.22 – 7.26 (1H, m, H-Ar), 7.45 (1H, dd, 
J = 1.0, 7.7 Hz, H-5), 7.52 (1H, app. t, J = 7.7 Hz, H-6), 7.81 (1H, dd, J = 7.4 Hz, 1.0, 
H-7); 13C NMR (125 MHz; CDCl3) δC 19.6 (CHCH3), 52.0 (CHCH3), 60.8 
(OCH2CO2H), 95.5 (C-3), 122.2 (C-7), 127.2 (2  C-Ar), 128.0 (2  C-Ar), 128.3 (2 
 C-Ar), 129.0 (C-Ar), 129.5 (2  C-Ar), 130.0 (C-Ar q), 132.3 (C-6), 132.9 (C-Ar 
q), 134.0 (C-5), 135.1 (C-Ar q), 135.5 (C-Ar q), 139.7 (C-Ar q), 139.9 , 166.6 (C-
1), 172.3 (CO2H); LRMS (ES+) m/z 456.3 [M+H]+; HRMS calcd for C24H1835Cl2NO4 
[M-H]- 454.0618, found 454.0602; HPLC 97.1% in 0.1% formic acid (aq)/MeCN 
(Rt 9.2 min); 97.8% in 0.1% ammonia (aq)/MeCN (Rt 4.8 min). 
(3R,1’R)-3-{[7-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-oxo-1-
phenylisoindolin-1-yl]oxy}propanoic acid (240) 
 
General procedure S was followed to synthesize the acid 240 using the alcohol 
236 (13 mg, 0.248 mmol), sodium periodate (218 mg, 1.02 mmol), RuCl3 · H2O 
(5.0 mg, 0.0248), ethyl acetate (0.35 mL), acetonitrile (0.35 mL) and water (0.62 
mL). Purification by MPLC (gradient elution, 1-25% EtOAc/petrol + 0.1% acetic 
acid) yielded the title compound as a white amorphous solid (71 mg, 61%). Rf 
0.28 (33% EtOAc/petrol, 0.1% formic acid); no clear m.p. detected; [α]26D +161° 
(c 0.595, EtOAc); λmax (EtOH)/nm 246; νmax/cm-1 (neat) 1688 (s, C=O), 1732 (s, 
C=O), 2937 (w, C-H), 3213 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 1.62 (3H, d, J 
= 7.3 Hz, CH3), 2.16 (1H, AA’BB’ m, CHAHA’), 2.27 – 2.37 (1H, AA’BB’ m, CHAHA’), 
2.83 – 2.93 (1H, AA’BB’ m, CHBHB’), 3.01 – 3.11 (1H, AA’BB’ m, CHBHB’), 4.18 (1H, 
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q, J = 7.3 Hz, CHCH3), 7.26 – 7.30 (2H, m, H-Ar), 7.35 (5H, br, H-Ar), 7.40 (1H, dd, 
J = 1.0, 7.7 Hz, H-5), 7.47 (1H, app. t, J = 7.7 Hz, H-6), 7.55 – 7.61 (2H, m, H-Ar), 
7.79 (1H, dd, J = 1.0, 7.7 Hz, H-7); 13C NMR (125 MHz; CDCl3) δC 19.5 (CHCH3), 
34.0 (OCH2CH2CO2H), 53.3 (CHCH3), 59.1 (OCH2CH2CO2H), 96.3 (C-3), 121.9 (C-
7), 127.1 (2  C-Ar), 128.4 (2  C-Ar), 128.7 (2  C-Ar), 128.9 (C-Ar), 129.6 (2  
C-Ar), 130.0 (C-Ar q), 131.7 (C-6), 133.4 (C-Ar q), 133.8 (C-5), 135.1 (C-Ar q), 
136.5 (C-Ar q), 140.5 (C-Ar q), 141.4 (C-Ar q), 167.0 (C-1), 175.9 (COOH); LRMS 
(ES+) m/z 470.3 [M+H]+; HRMS calcd for C25H2035Cl2NO4 [M-H]- 468.0775, found 
468.0762; HPLC 98.2% in 0.1% formic acid (aq)/MeCN (Rt 9.2 min); 99.8% in 
0.1% ammonia (aq)/MeCN (Rt 4.8 min). 
(3S,1’R)-3-{[7-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-oxo-1-
phenylisoindolin-1-yl]oxy}propanoic acid (242) 
 
General procedure S was followed to synthesize the acid 242 using the alcohol 
241 (84 mg, 0.184 mmol), sodium periodate (161 mg, 0.754 mmol), RuCl3 · H2O 
(4 mg, 0.0184), ethyl acetate (0.26 mL), acetonitrile (0.26 mL) and water (0.46 
mL). Purification by MPLC (gradient elution, 1-25% EtOAc/petrol + 0.1% acetic 
acid) yielded the title compound as a white amorphous solid (50 mg, 58%). Rf 
0.23 (33% EtOAc/petrol)0.1% formic acid); m.p. 147.3-148.7 °C; [α]26D +44° (c 
0.543, EtOAc); λmax (EtOH)/nm 247sh; νmax/cm-1 (neat) 1659 (s, C=O), 1736 (s, 
C=O), 2922 (w, C-H), 3068 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 1.81 (3H, d, J 
= 7.2 Hz, CH3), 2.53 – 2.80 (2H, AA’BB’ m, CHAHA’), 3.23 (1H, AA’BB’ m, CHBHB’), 
3.58 (1H, m, AA’BB’, CHBHB’), 4.35 (1H, q, J = 7.2 Hz, CHCH3), 6.77 – 6.86 (2H, m, 
H-Ar), 6.86 – 6.93 (2H, m, H-Ar), 7.01 (4H, br, H-Ar), 7.08 – 7.16 (1H, m, H-Ar), 
7.33 (1H, dd, J = 1.0, 7.7 Hz, H-5), 7.40 (1H, app. t, J = 7.7 Hz, H-6), 7.71 (1H, dd, J 
= 1.0, 7.7 Hz, H-7); 13C NMR (125 MHz; CDCl3) δC 19.6 (CHCH3), 34.5 
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(OCH2CH2CO2H), 52.0 (CHCH3), 59.0 (OCH2CH2CO2H), 95.3 (C-3), 121.9 (C-7), 
127.2 (2  C-Ar), 127.9 (2  C-Ar), 128.0 (2  C-Ar), 128.6 (C-Ar), 129.5 (2  C-
Ar), 130.0 (C-Ar q), 131.8 (C-6), 132.7 (C-Ar q), 133.7 (C-5), 135.3 (C-Ar q), 
136.2 (C-Ar q), 140.4 (C-Ar q), 140.5 (C-Ar q), 166.6 (C-1), 175.8 (COOH); LRMS 
(ES+) m/z 470.3 [M+H]+; HRMS calcd for C25H20Cl2NO4 [M-H]- 468.0775, found 
468.0762; HPLC 99.2% in 0.1% formic acid (aq)/MeCN (Rt 9.2 min); 99.5% in 
0.1% ammonia (aq)/MeCN (Rt 5.0 min). 
3-(Benzyloxy)-5-{bis{[1-[((tert-
butyldiphenylsilyl)oxy)methyl]cyclopropyl]methoxy}methyl}isoxazole 
(288) 
 
At -78 °C and under an inert atmosphere, triethylsilane was added to a solution 
of 286 in DCM. Boron trifluoride etherate was added dropwise and the solution 
was stirred at -78 °C for 20 min. Petrol (40 mL) was added at - 78 ° C followed 
by saturated NaHCO3 (aq., 20 mL). The aqueous layer was extracted with DCM 
(40 mL). The combined organic layers were washed with brine (40 mL), dried 
(MgSO4), filtered and evaporated. Purification by MPLC (gradient elution, 
0620% EtOAc/petrol) yielded the by-product 288 (colorless oil, 0.54 g, 
35%), the aldehyde 281 (colorless oil, 210 mg, 58%) and the desired product 
287 (colorless oil, 57 mg, 6%). Rf 0.21 (petrol); λmax (EtOH)/nm 264; νmax/cm-1 
(neat) 2856, 2930 and 3070 (w, aliphatic CH and -CH2-); 1H NMR (500 MHz; 
CDCl3) δH 0.34 – 0.45 (8H, m, 4  CH2 cyclopropyl), 1.04 (18H, s, 6  CH3), 3.50 
(4H, dd, J = 3.6, 10.2 Hz, 2  CH2OSi), 3.64 (4H, dd, J = 10.2, 19.5 Hz, CH2OCH2-
isoxazole), 5.26 (2H, s, CH2Ph), 5.56 (1H, s, OCHO), 5.91 (1H, s, H-4), 7.29 – 7.50 
(17H, m, H-Ar), 7.58 – 7.70 (8H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 8.1 (2  
CH2 cyclopropyl), 8.5 (2  CH2 cyclopropyl), 19.5 (2  C q cyclopropyl), 22.3 (2  
C(CH3)3), 27.0 (6  CH3), 66.5 (CH2OSi), 69.8 (CH2O-CH-isoxazole), 71.7 (CH2Ph), 
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94.8 (C-4), 95.4 (OCHO), 127.8 (6  C-Ar), 128.3 (2  C-Ar), 128.6 (C-Ar), 128.7 
(2  C-Ar), 129.7 (2  C-Ar), 133.9 (C-Ar q), 135.7 (2  C-Ar), 135.8 (2  C-Ar), 
136.0 (C-Ar q), 170.1 (C-5), 171.4 (C-3); HRMS calcd for C53H67N2O6Si2 
[M+NH4]+ 883.4532, found 883.4534. 
(1’R)-4-Chloro-3-hydroxy-2-[1’-(4’’-methoxyphenyl)ethyl]-3-
phenylisoindolin-1-one (258) 
 
General procedure M was followed to synthesize isoindolinone 258 using the 
acid 183 (150 mg, 0.575 mmol), thionyl chloride (0.08 mL, 137 mg, 1.15 mmol), 
catalytic DMF (3 drops), (R)-(+)-1-(4-methoxyphenyl)ethylamine (0.09 mL, 96 
mg, 0.633 mmol), DIPEA (0.22 mL, 164 mg, 1.27 mmol) and THF (2  0.7 mL). 
Purification by MPLC (gradient elution, 0-40% EtOAc/petrol) yielded the title 
compound (pale yellow oil, solidified upon storage at RT; 210 mg, 93%) as a 
mixture of diastereoisomers (dr 63:37). Rf(1) 0.30; Rf(2) 0.23 (25% 
EtOAc/petrol); m.p. 149.5-150.8; λmax (EtOH)/nm 260; νmax/cm-1 (neat) 1671 
(C=O), 3222 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 1.56 (3H, d, J = 7.3 Hz), 1.75 
(1H, d, J = 7.3 Hz), 3.01 (1H, s, OH), 3.06 (1H, s, OH), 3.71 (H, s, OCH3), 3.76 (3H, 
s, OCH3), 4.43 (1H, q, J = 7.3 Hz, CHCH3), 4.70 (1H, q, J = 7.2 Hz, CHCH3), 6.56 – 
6.61 (2H, m, H-Ar), 6.74 – 6.82 (2H, m, H-Ar), 6.83 – 6.90 (2H, m, H-Ar), 7.24 
(1H, m, H-Ar), 7.27 – 7.32 (2H, m, H-Ar), 7.34 – 7.45 (9H, m, H-Ar), 7.48 (2H, s, 
H-Ar), 7.52 – 7.57 (2H, m, H-Ar, H-Ar), 7.70 (2 H, m, H-Ar); 13C NMR (125 MHz; 
CDCl3) δC 18.2 (CHCH3), 19.6 (CHCH3), 51.5 (CHCH3), 52.0 (CHCH3), 55.3 (OCH3), 
55.4 (OCH3), 91.7 (C-3), 91.9 (C-3), 113.1 (C-Ar), 113.6 (C-Ar), 121.8 (C-Ar), 
121.8 (C-Ar), 127.0 (C-Ar), 127.1 (C-Ar), 128.3 (C-Ar), 128.4 (C-Ar), 128.7 (C-
Ar), 128.8 (C-Ar), 129.4 (C-Ar), 129.4 (C-Ar), 129.4 (C-Ar), 131.4 (C-Ar), 131.4 
(C-Ar), 133.3 (C-Ar), 133.6 (C-Ar), 134.5 (C-Ar), 134.6 (C-Ar), 136.9 (C-Ar), 
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158.7 (C-Ar), 165.8 (C-Ar); LRMS (ES+) m/z 394.3 [M+H]+ ; HRMS calcd for 
C23H1935ClNO3 [M-H]- 392.1059, found 392.1064. 
(3R,1’R)-4-Chloro-3-{[1’’’’-(hydroxymethyl)cyclopropyl]methoxy}-2-[1’-
(4’’-methoxyphenyl)ethyl]-3-phenylisoindolin-1-one (259) and (3S,1’R)-4-
chloro-3-{[1’’’’-(hydroxymethyl)cyclopropyl]methoxy}-2-[1’-(4’’-
methoxyphenyl)ethyl]-3-phenylisoindolin-1-one (260) 
   
General procedure N was followed to obtain 259 and 260 using isoindolinone 
258 (180 mg, 0.457 mmol), InBr3 (32 mg, 0.0914 mmol), 1,1-
bis(hydroxymethyl)cyclopropane (0.22 mL, 234 mg, 2.29 mmol) and DCE (4.6 
mL). The reaction mixture was heated at 80 °C for 4 h. Purification by semi-
preparative HPLC (55% MeCN/H2O + 0.1% formic acid) yielded the desired 
compounds 259 (white amorphous solid; 66 mg, 30%) and 260 (colorless oil; 
43 mg, 20%). 
259 
Rf 0.32 (50% EtOAc/petrol); no clear m.p. detected; [α]22D +122° (c 0.643, 
EtOAc); λmax (EtOH)/nm 260; νmax/cm-1 (neat) 1686 and 1696 (s, C=O), 2874, 
2932 and 3001 (w, aliphatic CH and -CH2-), 3046 (br, O-H); 1H NMR (500 MHz; 
CDCl3) δH -0.01 – 0.08 (1H, m, cyclopropyl), 0.12 – 0.23 (1H, m, cyclopropyl), 
0.29 – 0.41 (2H, m, cyclopropyl), 1.56 (3H, d, J = 7.3 Hz, CH3), 1.72 (1H, ABX app. 
t, J = 5.5 Hz, OH), 2.72 (1H, d, JAB = 9.1 Hz, CHAHBO-), 2.81 (1H, d, JAB = 9.1 Hz, 
CHAHB-O), 3.33 (1H, dd, JAX = 5.5 Hz, JAB = 11.6 Hz, CHAHBOH), 3.38 (1H, dd, JBX = 
5.5 Hz, JAB = 11.6 Hz, CHAHBOH), 3.78 (3H, s, OCH3), 4.18 (1H, q, J = 7.3 Hz, 
CHCH3), 6.80 – 6.87 (2H, m, H-Ar), 7.37 (5H, br, H-Ar), 7.41 (1H, d, J = 7.7 Hz, H-
5), 7.47 (1H, t, J = 7.7 Hz, H-6), 7.51 – 7.57 (2H, m, H-Ar), 7.81 (1H, d, J = 7.7 Hz, 
H-7); 13C NMR (125 MHz; CDCl3) δC 8.6 (CH2 cyclopropyl), 8.7 (CH2 cyclopropyl), 
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20.5 (CHCH3), 22.1 (C q cyclopropyl), 53.5 (CHCH3), 55.5 (OCH3), 68.5 (CH2OH), 
68.6 (CH2O-), 96.4 (C-3), 113.9 (2  C-Ar), 121.9 (C-7), 127.2 (2  C-Ar), 128.5 (2 
 C-Ar), 128.9 (2  C-Ar), 129.2 (2  C-Ar), 129.5 (C-Ar q), 131.6 (C-6), 133.6 (C-
5), 135.5 (C-Ar q), 135.5 (C-Ar q), 137.0 (C-Ar q), 140.9 (C-Ar q), 159.0 (C-Ar q), 
166.9 (C-1); LRMS (ES+) m/z 500.4 [M+Na+]; HRMS calcd for C28H29ClNO4 
[M+H]+ 478.1780, found 478.1776; HPLC 99.4% in 0.1% formic acid (aq)/MeCN 
(Rt 9.2 min); 99.4% in 0.1% ammonia (aq)/MeCN (Rt 9.2 min). 
260 
Rf 0.32 (50% EtOAc/petrol); [α]D
22 +44° (c 0.562, EtOAc); λmax (EtOH)/nm 260; 
νmax/cm-1 (neat) 1683 and 1694 (s, C=O), 2781, 2930 and 3069 (w, aliphatic CH 
and -CH2-), 3407 (br, O-H); 1H NMR (500 MHz; CD3OD) δH 0.46 – 0.65 (4H, m, 
cyclopropyl), 1.88 (3H, d, J = 7.2 Hz, CHCH3), 2.81 (1H, d, JAB = 9.0, CHAHBO-), 
3.50 (1H, d, JAB = 11.1 Hz, CHAHBOH), 3.56 (1H, d, JAB = 9.0 Hz, CHAHBO-), 3.66 
(3H, s, OCH3), 3.83 (1H, d, JAB = 11.1 Hz, CHAHBOH), 4.43 (1H, q, J = 7.2 Hz, 
CHCH3), 6.44 – 6.55 (2H, m, H-Ar), 6.79 – 6.88 (2H, m, H-Ar), 7.08 (4H, br, H-Ar), 
7.13 – 7.22 (1H, m, H-Ar), 7.49 (1H, dd, J = 0.7, 7.7 Hz, H-5), 7.55 (1H, app. t, J = 
7.7 Hz, H-6), 7.76 (1H, dd, J = 0.7, 7.7 Hz, H-7); 13C NMR (125 MHz; CDCl3) δC 8.9 
(CH2 cyclopropyl), 9.1 (CH2 cyclopropyl), 19.9 (CHCH3), 22.7(C q cyclopropyl), 
52.1 (CHCH3), 55.3 (OCH3), 68.4 (CH2OH), 68.6 (CH2O-), 95.3 (C-3), 113.0 (2  C-
Ar), 121.9 (C-7), 127.3 (2  C-Ar), 128.0 (2  C-Ar), 128.5 (C-Ar), 129.3 (2  C-
Ar), 129.7 (C-Ar q), 131.6 (C-6), 133.4 (C-5), 134.3 (C-Ar q), 135.6 (C-Ar q), 
136.5 (C-Ar q), 140.7 (C-Ar q), 158.4 (C-Ar q), 166.4 (C-1); LRMS (ES+) m/z 
500.4 [M+Na]+; HRMS calcd for C28H2935ClNO4 [M+H]+ 478.1780, found 
478.1775; HPLC 96.5% in 0.1% formic acid (aq)/MeCN (Rt 9.0 min); 97.4% in 
0.1% ammonia (aq)/MeCN (Rt 9.0 min). 
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(3R,1’R)-3-{{1’’’’-[[(3-(Benzyloxy)isoxazol-5-
yl)methoxy]methyl]cyclopropyl}methoxy}-4-chloro-2-[1’-(4’’-
chlorophenyl)ethyl]-3-phenylisoindolin-1-one (278) and (S)-3-{{1’’’’-[[(3-
(benzyloxy)isoxazol-5-yl)methoxy]methyl]cyclopropyl}methoxy}-4-
chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-phenylisoindolin-1-one (275) 
   
A modified general procedure N was followed to obtain 278 and 275 using the 
isoindolinone 198 (254 mg, 0.638 mmol), the alcohol 277 (277 mg, 0.957 
mmol, 2.0 equiv.), InBr3 (45 mg, 0.128 mmol) and DCE (2  3.2 mL). The 
reaction mixture was heated at 80 °C for 3 h. Purification by MPLC (gradient 
elution, 0-15% EtOAc/petrol) yielded the desired compounds 278 (156 mg, 
37%) and 275 (180 mg, 42%) as colorless oils. 
278 
Rf 0.46 (25% EtOAc/petrol); λmax (EtOH)/nm 258; νmax/cm-1 (neat) 1699 (vs, 
C=O), 2871, 2933 and 3064 (w, aliphatic CH and -CH2-); 1H NMR (500 MHz; 
CDCl3) δH -0.02 – 0.05 (1H, m, cyclopropyl), 0.09 – 0.24 (1H, m, cyclopropyl), 
0.24 – 0.41 (2H, m, cyclopropyl), 1.56 (3H, d, J = 7.3 Hz, CHCH3), 2.50 (1H, d, JAB 
= 9.1 Hz, CHAHBO-isoindolinone), 2.95 (1H, d, JAB = 9.1 Hz, CHACHBO-
isoindolinone), 3.03 (1H, d, JAB = 9.6 Hz, CHAHBOCH2-isoxazole), 3.65 (1H, d, JAB = 
9.6 Hz, CHAHBOCH2-isoxazole), 4.21 (1H, q, J = 7.3 Hz, CHCH3), 4.29 – 4.41 (2H, 
AB q, JAB = 13.6 Hz, CH2-isoxazole), 5.25 (2H, s, CH2Ph), 5.78 (1H, s, H-4’), 7.19 – 
7.25 (2H, m, H-Ar), 7.29 – 7.47 (12H, m, H-Ar), 7.47 – 7.53 (2H, m, H-Ar), 7.78 
(1H, dd, J = 1.1, 7.4 Hz, H-Ar); 13C NMR (125 MHz; CDCl3) δC 8.1 (CH2 
cyclopropyl), 8.8 (CH2 cyclopropyl), 19.9 (CHCH3), 19.9 (C q cyclopropyl), 53.2 
 
 
327 
 
(CHCH3), 64.0 (CH2-isoxazole), 66.5 (CH2O-isoindolinone), 71.7 (CH2Ph), 74.9 
(CH2OCH2-isoxazole), 94.5 (C-4’), 96.2 (C-3), 121.8 (C-Ar), 127.2 (C-Ar), 128.4 
(C-Ar), 128.4 (C-Ar), 128.6 (C-Ar), 128.6 (C-Ar), 128.7 (C-Ar), 128.8 (C-Ar), 
129.6 (C-Ar), 129.8 (C-Ar), 131.6 (C-Ar), 133.2 (C-Ar), 133.7 (C-Ar), 135.2 (C-
Ar), 137.0 (C-Ar), 141.1 (C-Ar), 141.5 (C-Ar), 167.0 (C-1), 170.6 (C-5’), 171.7 (C-
3’). One carbon not detected; LRMS (ES+) m/z 669.5 [M+H]+ ; HRMS calcd for 
C38H3535Cl2N2O5 [M+H]+ 669.1918, found 669.1917. 
275 
Rf 0.36 (25% EtOAc/petrol); λmax (EtOH)/nm 258; νmax/cm-1 (neat)1698 (vs, 
C=O), 2871, 2932, and 3064 (w, aliphatic CH and -CH2-); 1H NMR (500 MHz; 
CDCl3) 0.46 – 0.68 (4H, m, cyclopropyl), 1.88 (3H, d, J = 7.3 Hz, CHCH3), 2.86 (1H, 
d, JAB = 9.1 Hz, CHAHBO-isoindolinone), 3.40 (1H, d, JAB = 9.1 Hz, CHAHBO-
isoindolinone), 3.55 (1H, d, JAB = 9.7 Hz, CHAHBOCH2-isoxazole), 3.70 (1H, d, JAB = 
9.7 Hz, CHAHBOCH2-isoxazole), 4.35 (1H, d, J = 7.3 Hz, CHCH3), 4.44 – 4.59 (2H, 
m, CH2-isoxazole), 5.24 (2H, s, CH2Ph), 5.88 (1H, s, H-4’), 6.84 – 6.91 (2H, m, H-
Ar), 6.91 – 6.96 (2H, m, H-Ar), 7.08 (4H, br, H-Ar), 7.15 – 7.21 (1H, m, H-Ar), 
7.31 – 7.48 (7H, m, H-Ar), 7.75 (1H, dd, J = 1.0, 7.5 Hz, H-Ar); 13C NMR (125 MHz; 
CDCl3) δC 9.0 (CH2 cyclopropyl), 9.1 (CH2 cyclopropyl), 19.7 (CHCH3), 20.5 (C q 
cyclopropyl), 52.1 (CHCH3), 64.1 (CH2-isoxazole), 66.8 (CH2O-isoindolinone), 
71.7 (CH2Ph), 75.0 (CH2OCH2-isoxazole), 94.7 (C-4’), 94.9 (C-3), 121.8 (C-Ar), 
127.3 (C-Ar), 127.8 (C-Ar), 128.0 (C-Ar), 128.4 (C-Ar), 128.5 (C-Ar), 128.7 (C-
Ar), 128.7 (C-Ar), 129.4 (C-Ar), 129.5 (C-Ar), 129.8 (C-Ar), 131.6 (C-Ar), 132.6 
(C-Ar), 133.5 (C-Ar), 135.4 (C-Ar), 135.8 (C-Ar), 136.6 (C-Ar), 140.7 (C-Ar), 
140.8 (C-Ar), 166.5 (C-1), 170.5 (C-5’), 171.7 (C-3’); LRMS (ES+) m/z 669.5 
[M+H]+ ; HRMS calcd for C38H35Cl2N2O5 [M+H]+ 669.1918, found 669.1906. 
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4-Chloro-3-hydroxy-2-[1’-(4’’-nitrophenyl)ethyl]-3-phenylisoindolin-1-
one (268) 
 
General procedure M was followed to obtain isoindolinone 268 using the acid 
183 (223 mg, 0.855 mmol), thionyl chloride (0.12 mL, 203 mg, 1.71 mmol), 
catalytic DMF (3 drops), 4-nitrobenzylamine hydrochloride (177 mg, 0.941 
mmol), DIPEA (0.33 mL, 243 mg, 1.88 mmol) and THF (2  1.0 mL). Purification 
by MPLC (gradient elution, 0-80% EtOAc/petrol) yielded the desired product 
268 (0.26 g, 77%) as a pale yellow solid. Rf 0.14 (25% EtOAc/petrol); m.p. 
210.1-211.4°C; λmax (EtOH)/nm 271; νmax/cm-1 (neat) 1510 (s, NO2), 1660 and 
1680 (s, C=O), 3206 (br, O-H); 1H NMR (500 MHz; DMSO-d6) δH 4.31 (1H, d, JAB = 
16.3 Hz, CHACHB), 4.52 (1H, d, JAB = 16.3 Hz, CHACHB), 7.24 (5H, m, H-Ar), 7.34 – 
7.41 (3H, m, H-Ar and OH), 7.59 – 7.64 (2H, m, H-Ar), 7.78 (1H, dd, J = 2.5, 5.9 
Hz, H-Ar), 7.97 – 8.03 (2H, m, H-Ar); 13C NMR (125 MHz; DMSO-d6) δC 41.6 
(CH2), 90.3 (C-3), 121.6 (C-Ar), 122.9 (2  C-Ar), 126.4 (2  C-Ar), 128.1 (2  C-
Ar), 128.2 (C-Ar), 128.7 (C-Ar), 128.8 (2  C-Ar), 131.7 (C-Ar), 133.2 (C-Ar), 
133.7 (C-Ar), 137.4 (C-Ar), 144.7 (C-Ar q), 145.8 (C-Ar q), 146.2 (C-Ar q), 165.5 
(C-1); LRMS (ES–) m/z 393.2 [M-H]–; HRMS calcd for C21H14ClN2O4 [M-H]– 
393.0648, found 393.0639. 
(1’R)-4-Chloro-3-hydroxy-3-phenyl-2-(1-phenylethyl)isoindolin-1-one 
(217) 
 
General procedure M was followed to obtain isoindolinone 217 using the acid 
183 (150 mg, 0.575 mmol), thionyl chloride (0.08 mL, 137 mg, 1.15 mmol), 
catalytic DMF (3 drops), (R)-(+)-α-methylbenzylamine (0.08 mL, 77 mg, 0.633 
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mmol), DIPEA (0.11 mL, 82 mg, 0.633 mmol) and THF (2  0.7 mL). Purification 
by MPLC (gradient elution, 0-10% EtOAc/petrol) yielded the desired product 
217 (182 mg, 87%; dr 59:41) as a yellow oil which solidified upon storage at 
RT. Rf(1) 0.47; Rf(2) 0.39 (25% EtOAc/petrol); m.p. 133.0-133.8°C; λmax 
(EtOH)/nm 259; νmax/cm-1 (neat) 1669 (vs, C=O), 3218 (br, O-H); 1H NMR (500 
MHz; CDCl3) δH 1.58 (3H, d, J = 7.3 Hz, CHCH3), 1.80 (3H, d, J = 7.3 Hz, CHCH3), 
2.94 (1H, s, OH), 3.18 (1H, s, OH), 4.46 (1H, q, J = 7.3 Hz, CHCH3), 4.74 (1H, q, J = 
7.3 Hz, CHCH3), 6.95 – 7.02 (2H, m, H-Ar), 7.03 – 7.11 (3H, m, H-Ar), 7.17 – 7.24 
(3H, m, H-Ar), 7.24 – 7.32 (2H, m, H-Ar), 7.34 – 7.45 (9H, m, H-Ar), 7.48 (4H, br, 
H-Ar), 7.55 – 7.64 (2H, m, H-Ar), 7.68 – 7.76 (1H, m, H-Ar); 13C NMR (125 MHz; 
CDCl3) δC 18.2 (CH3), 19.6 (CH3), 52.1 (CHCH3), 52.6 (CHCH3), 91.7 (C-3), 91.9 
(C-3), 121.8 (C-Ar), 121.9 (C-Ar), 126.9 (C-Ar), 127.0 (C-Ar), 127.1 (C-Ar), 127.4 
(C-Ar), 127.9 (C-Ar), 128.0 (C-Ar), 128.1 (C-Ar), 128.2 (C-Ar), 128.4 (C-Ar), 
128.4 (C-Ar), 128.7 (C-Ar), 128.8 (C-Ar), 129.4 (C-Ar), 129.5 (C-Ar), 131.4 (C-
Ar), 133.6 (C-Ar), 133.7 (C-Ar), 134.4 (C-Ar), 134.4 (C-Ar), 136.8 (C-Ar), 136.9 
(C-Ar), 141.3 (C-Ar), 142.4 (C-Ar), 143.8 (C-Ar), 165.9 (C-1); LRMS (ES–) m/z 
362.2 [M-H]–; HRMS calcd for C22H17ClNO2 [M-H]– 362.0953, found 362.0946. 
(3S,1’R)-4-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-{{1’’’’-[[(3-
hydroxyisoxazol-5-yl)methoxy]methyl]cyclopropyl}methoxy]-3-
phenylisoindolin-1-one (276) 
 
Under an inert atmosphere, a solution of 275 (40 mg, 0.0597 mmol) in DCM 
(0.14 mL) was added to a suspension of Pd(OAc)2 (0.6 mg, 0.0030 mmol), 
triethylamine (0.01 mL, 8.5 mg, 0.0836 mmol) and triethylsilane (0.4 µL, 0.3 mg, 
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0.0030 mmol) in DCM (0.27 mL) and the mixture was stirred at RT for 18 h. 
Upon completion of the reaction, the mixture was quenched with saturated 
NH4Cl (aq., 1.2 mL) and extracted with EtOAc (3  5 mL). The combined organic 
layers were washed with brine, filtered over a Thiol MP SPE cartridge, dried 
(MgSO4) and concentrated in vacuo. Purification by MPLC (gradient elution, 0-
88% EtOAc/petrol + 0.1% formic acid) yielded the desired product 276 (18 mg, 
52%) as a colorless oil. Rf 0.51 (50% EtOAc/petrol + 0.1% formic acid); no clear 
m.p. detected; [α]D
22 +53 (c 0.577, EtOAc); λmax (EtOH)/nm 258; νmax/cm-1 (neat) 
1689 (s, C=O), 2627, 2799 and 2869 (w, aliphatic CH and -CH2-), 3000 (br, O-H); 
1H NMR (500 MHz; CDCl3) δH 0.50 – 0.66 (4H, m, cyclopropyl), 1.88 (3H, d, J = 
7.3 Hz, CHCH3), 2.90 (1H, d, JAB = 9.1 Hz, CHAHBO-), 3.36 (1H, d, JAB = 9.1 Hz, 
CHAHBO-), 3.58 (1H, d, JAB = 9.7 Hz, CHAHB-OCH2), 3.65 (1H, d, JAB 9.7 Hz, CHAHB-
OCH2), 4.33 (1H, q, J = 7.3 Hz, CHCH3), 4.44 – 4.57 (2H, m, OCH2-isoxazole), 5.90 
(1H, s, H-4’), 6.83 – 6.90 (2H, m, H-Ar), 6.90 – 6.96 (2H, m, H-Ar), 7.02 (4H, br, 
H-Ar), 7.15 – 7.21 (1H, m, H-Ar), 7.39 (1H, dd, J = 1.0, 7.7 Hz, H-5), 7.45 (1H, app. 
t, J = 7.7 Hz, H-6), 7.76 (1H, dd, J = 1.0, 7.7 Hz, H-7); 13C NMR (125 MHz; CDCl3) 
δC 8.9 (CH2 cyclopropyl), 8.9 (CH2 cyclopropyl), 19.5 (CHCH3), 20.3 (C q 
cyclopropyl), 51.9 (CHCH3), 63.9 (isoxazole-CH2-O), 66.6 (CH2O-), 75.0 (CH2-
OCH2), 94.8 (C-4’), 95.1 (C-3), 121.7 (C-7), 127.1 (2  C-Ar), 127.7 (2  C-Ar), 
127.8 (2  C-Ar), 128.4 (C-Ar), 129.3 (2  C-Ar), 129.7 (C-Ar q), 131.5 (C-6), 
132.4 (C-Ar q), 133.4 (C-5), 135.2 (C-Ar q), 136.4 (C-Ar q), 140.6 (C-Ar q), 166.5 
(C-1), 170.2 (C-5’), 170.8 (C-3’) ppm. One quaternary carbon not detected; 
LRMS (ES+) m/z 579.4 [M+H]+; HRMS calcd for C31H2935Cl2N2O5 [M+H]+ 
579.1448, found 579.1444; HPLC 96.3% in 0.1% formic acid (aq)/MeCN (Rt 9.9 
min); 96.5% in 0.1% ammonia (aq)/MeCN (Rt 5.8 min). 
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4-Chloro-3-{[1’’’’-(hydroxymethyl)cyclopropyl]methoxy}-2-(4’’-
nitrobenzyl)-3-phenylisoindolin-1-one (269) 
 
General procedure N was followed to obtain 269 using the isoindolinone 186 
(370 mg, 0.937 mmol), 1,1-bis(hydroxymethyl)cyclopropane (0.45 mL, 479 mg, 
4.69 mmol.), InBr3 (66 mg, 0.187 mmol) and DCE (9.5 mL). The reaction mixture 
was heated at 80 °C for 5 h. Purification on C18 silica (gradient elution, 5-90% 
MeCN/H2O + 0.1% formic acid) yielded the desired compound 269 (0.370 g, 
82%) as a pale yellow oil. Rf 0.34 (5% MeOH/DCM); m.p. 174-176 °C; λmax 
(EtOH)/nm 269; νmax/cm-1 (neat) 1342 (vs, NO2), 1699 (s, C=O), 2872, 2922 and 
3077 (w, aliphatic CH and -CH2-), 3419 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 
0.14 – 0.25 (1H, m, cyclopropyl), 0.31 – 0.44 (1H, m, cyclopropyl), 0.44 – 0.57 
(2H, m, cyclopropyl), 1.76 (1H, t, J = 5.4 Hz, OH), 2.93 (1H, d, JAB = 9.1 Hz, 
CHAHBO-), 2.96 (1H, d, JAB = 9.1 Hz, CHAHBO-), 3.54 (2H, d, J = 5.4 Hz, CH2OH), 
4.44 (1H, d, JAB = 15.2 Hz, CHAHB-Ar), 4.51 (1H, d, JAB = 15.2 Hz, CHAHB-Ar), 7.19 
(5H, m, H-Ar), 7.21 – 7.25 (2H, m, H-Ar), 7.48 (1H, dd, J = 1.1, 7.7 Hz, H-5), 7.53 
(1H, t, J = 7.7 Hz, H-6), 7.86 (1H, dd, J = 1.1, 7.7 Hz, H-7), 7.92 – 7.98 (2H, m, H-
Ar); 13C NMR (125 MHz; CDCl3) δC 8.8 (CH2 cyclopropyl), 8.9 (CH2 cyclopropyl), 
22.4 (C q cyclopropyl), 42.2 (CH2-Ar), 68.1(CH2OH), 68.3 (CH2O-), 94.9 (C-3), 
122.4 (C-7), 123.4 (2  C-Ar), 126.8 (2  C-Ar), 128.5 (2  C-Ar), 129.0 (C-Ar), 
129.9 (2  C-Ar), 130.1 (C-Ar), 132.0 (C-6), 134.2 (C-5), 136.3 (C-Ar q), 141.1 (C-
Ar q), 144.5 (C-Ar q), 147.1 (C-Ar q), 167.0 (C-1). One quaternary carbon not 
detected; LRMS (ES–) m/z 477.3 [M-H]–; HRMS calcd for C26H2435ClN2O5 [M+H]+  
479.368, found 479.1366; HPLC 96.3% in 0.1% formic acid (aq)/MeCN (Rt 8.7 
min); 96.9% in 0.1% ammonia (aq)/MeCN (Rt 8.7 min). 
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(3R,1’R)-4-Chloro-3-{[1’’’’-(hydroxymethyl)cyclopropyl]methoxy}-3-
phenyl-2-(1’-phenylethyl)isoindolin-1-one (218) and (3S,1’R)-4-chloro-3-
{[1’’’’-(hydroxymethyl)cyclopropyl]methoxy}-3-phenyl-2-(1’-
phenylethyl)isoindolin-1-one (219) 
   
General procedure N was followed to obtain 218 and 219 using the 
isoindolinone 217 (160 mg, 0.440 mmol), 1,1-bis(hydroxymethyl)cyclopropane 
(0.21 mL, 225 mg, 2.20 mmol.), InBr3 (31 mg, 0.0880 mmol) and DCE (4.4 mL). 
The reaction mixture was heated at 80 °C for 18 h. The diastereoisomers were 
separated by MPLC (gradient elution, 0-2% MeOH/DCM) to yield the desired 
compound 219 (42 mg, 21%) as white amorphous solid. The isoindolinone 218 
was further purified on C18 silica (gradient elution, 10-80% MeCN/H2O + 0.1% 
formic acid) to afford the pure compound (39 mg, 20%) as a colorless oil. 
218 
Rf 0.52 (5% MeOH/DCM); Rf 0.41 (80% MeCN/H2O + 0.1% formic acid); [α]D
22 
+105° (c 0.474, EtOAc); λmax (EtOH)/nm 258; νmax/cm-1 (neat) 1689 and 1699 
(s, C=O), 2873, 2933, 3002 and 3063 (w, aliphatic CH and -CH2-), 3407 (br, O-
H); 1H NMR (500 MHz; CDCl3) δH -0.15 – -0.06 (1H, m, cyclopropyl), 0.07 – 0.17 
(1H, m, cyclopropyl), 0.30 (2H, m, cyclopropyl), 1.58 (1H, dd, J = 5.6, 6.8 Hz, OH), 
1.61 (3H, d, J = 7.3 Hz, CHCH3), 2.69 (1H, d, JAB = 9.1 Hz, CHAHBO-), 2.81 (1H, d, 
JAB = 9.1 Hz, CHAHBO-), 3.24 – 3.36 (2H, m, CH2OH), 4.20 (1H, q, J = 7.3 Hz, 
CHCH3), 7.22 – 7.25 (1H, m, H-Ar), 7.29 – 7.35 (2H, m, H-Ar), 7.38 (5H, br, H-Ar), 
7.42 (1H, dd, J = 0.9, 7.7 Hz, H-5), 7.48 (1H, app. t, J = 7.7 Hz, H-6), 7.56 – 7.62 
(2H, m, H-Ar), 7.83 (1 H, dd, J = 0.9, 7.7 Hz, H-7); 13C NMR (125 MHz; CDCl3) δC 
8.5 (CH2 cyclopropyl), 8.6 (CH2 cyclopropyl), 20.6 (CHCH3), 22.1 (C q 
cyclopropyl), 54.3 (CHCH3), 68.3 (CH2OH), 68.4 (CH2O-), 96.5 (C-3), 122.0 (C-7), 
127.2 (2  C-Ar), 127.5 (C-Ar), 127.9 (2  C-Ar), 128.5 (2  C-Ar), 128.7 (2  C-
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Ar), 128.9 (C-Ar), 129.6 (C-Ar q), 131.6 (C-6), 133.6 (C-5), 135.4 (C-Ar q), 137.0 
(C-Ar q), 140.9 (C-Ar q), 143.5 (C-Ar q), 167.1 (C-1); LRMS (ES+) m/z 470.4 
[M+Na]+; HRMS calcd for C27H2735ClNO3 [M+H]+ 448.1674, found 448.1665; 
HPLC 98.8% in 0.1% formic acid (aq)/MeCN (Rt 9.3 min); 98.7% in 0.1% 
ammonia (aq)/MeCN (Rt 9.3 min). 
219 
Rf 0.38 (5% MeOH/DCM); m.p. 183-185 °C; [α]D
22 -10° (c 0.464, EtOAc); λmax 
(EtOH)/nm 259; νmax/cm-1 (neat) 1684 (vs, C=O), 2870 and 2914 (w, aliphatic 
CH and -CH2-), 3509 (m sharp, O-H); 1H NMR (500 MHz; CDCl3) δH 0.46 – 0.70 
(4H, m, cyclopropyl), 1.92 (3H, d, J = 7.3 Hz, CHCH3), 1.94 – 1.99 (1H, m, OH), 
3.05 (1H, d, JAB = 9.2 Hz, CHAHBO-), 3.33 (1H, d, JAB = 9.2 Hz, CHAHBO-), 3.64 – 
3.79 (2H, m, CH2OH), 4.43 (1H, q, J = 7.3 Hz, CHCH3), 6.90 – 7.12 (9H, m, C-Ar), 
7.13 – 7.19 (1H, m, C-Ar), 7.41 (1H, dd, J = 0.7, 7.6 Hz, H-5), 7.46 (1H, app. t, J = 
7.6 Hz, H-6), 7.78 (1H, dd, J = 0.7, 7.6 Hz, H-7); 13C NMR (125 MHz; CDCl3) δC 8.9 
(CH2 cyclopropyl), 9.1 (CH2 cyclopropyl), 20.0 (CHCH3), 22.7 (C q cyclopropyl), 
52.9 (CHCH3), 68.4 (CH2OH), 68.6 (CH2-O), 95.3 (C-3), 121.9 (C-7), 126.8 (2  C-
Ar), 127.2 (2  C-Ar), 127.8 (2  C-Ar), 127.9 (2  C-Ar), 128.5 (C-Ar), 129.7 (C-
Ar q), 131.6 (C-6), 133.5 (C-5), 135.5 (C-Ar q), 136.4 (C-Ar q), 140.7 (C-Ar q), 
142.2 (C-Ar q), 166.6 (C-1). One quaternary carbon not detected; LRMS (ES+) 
m/z 448.3 [M+H]+; HRMS calcd for C27H2735ClNO3 [M+H]+ 448.1674, found 
448.1672; HPLC 98.6% in 0.1% formic acid (aq)/MeCN (Rt 9.2 min); 99.0% in 
0.1% ammonia (aq)/MeCN (Rt 9.2 min). 
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(3R,1’R)-4-Chloro-2-[1’-(4’’-chlorophenyl)ethyl]-3-{{1-[[(3-
hydroxyisoxazol-5-yl)methoxy]methyl]cyclopropyl}methoxy}-3-
phenylisoindolin-1-one (164) 
 
Under an inert atmosphere, a solution of 278 (141 mg, 0.211 mmol) in DCM 
(0.49 mL) was added to a suspension of Pd(OAc)2 (2.4 mg, 0.0106 mmol), 
triethylamine (0.04 mL, 29.9 mg, 0.295 mmol) and triethylsilane (1.6 µL, 1.2 mg, 
0.0106 mmol) in DCM (0.95 mL) and the mixture was stirred at RT for 7 h. Upon 
completion of the reaction, the mixture was quenched with saturated NH4Cl 
(aq., 5 mL) and extracted with EtOAc (3  15 mL). The combined organic layers 
were washed with brine, filtered over a Thiol MP SPE cartridge, dried (MgSO4) 
and concentrated in vacuo. Purification by MPLC (gradient elution, 0-80% 
EtOAc/petrol + 0.1% formic acid) yielded the desired product 164 (32 mg, 
26%) as a colorless oil. Rf 0.44 (50% EtOAc/petrol + 0.1% formic acid); no clear 
m.p. detected; [α]D
22 +104 (c 0.341, EtOAc); λmax (EtOH)/nm 253; νmax/cm-1 
(neat) 1699 (s, C=O), 2867 and 2932 (w, aliphatic CH and -CH2-), 3000 (br, OH); 
1H NMR (500 MHz; CDCl3) δH -0.01 – 0.09 (1H, m, cyclopropyl), 0.12 – 0.22 (1H, 
m, cyclopropyl), 0.26 – 0.40 (2H, m cyclopropyl), 1.56 (3H, d, J = 7.3 Hz, CHCH3), 
2.47 (1H, d, JAB = 9.2 Hz, CHAHB-O), 2.97 (1H, d, JAB = 9.2 Hz, CHAHB-O), 3.00 (1H, 
d, JAB = 9.6 Hz, CHAHB-OCH2), 3.66 (1H, d, JAB = 9.6 Hz, CHAHB-OCH2), 4.21 (1H, q, 
J = 7.3 Hz, CHCH3), 4.28 – 4.41 (2H, m, OCH2-isoxazole), 5.79 (1 H, s, H-4 
isoxazole), 7.20 – 7.25 (2 H, m, H-Ar), 7.35 (5 H, br, Ph), 7.39 (1 H, dd, J 7.9, 0.8, 
H-5), 7.46 (1 H, app. t, J 7.8, H-6), 7.47 – 7.54 (2 H, m, H-Ar), 7.80 (1 H, dd, J 7.5, 
0.8, H-7); 13C NMR (125 MHz; CDCl3) δC 8.1 (CH2 cyclopropyl), 8.9 (CH2 
cyclopropyl), 19.9 (CHCH3), 53.2 (CHCH3), 63.9 (isoxazole-CH2-O), 66.46 (CH2-
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O), 75.1 (CH2-OCH2), 95.0 (C-4’), 96.2 (C-3), 121.9 (C-7), 127.2 (2  C-Ar), 128.4 
(2  C-Ar), 128.6 (2  C-Ar), 128.8 (C-Ar), 129.6 (2  C-Ar), 129.8 (C-Ar), 131.6 
(C-6), 133.2 (C-Ar q), 133.8 (C-5), 135.2 (C-Ar q), 137.0 (C-Ar q), 141.0 (C-Ar q), 
141.5 (C-Ar q), 167.1 (C-1), 170.5 (C-5’), 170.9 (C-3 isoxazole). One quaternary 
carbon not detected; LRMS (ES+) m/z 579.4 [M+H]+; HRMS calcd for 
C31H2935Cl2N2O5 [M+H]+ 579.1448, found 579.1443; HPLC 95.9% in 0.1% formic 
acid (aq)/MeCN (Rt 9.9 min); 96.8% in 0.1% ammonia (aq)/MeCN (Rt 5.7 min). 
(1’R)-2-[1’-(4’’-chlorophenyl)ethyl]-3-hydroxy-3-phenylisoindolin-1-one 
(220) 
 
General procedure M was followed to obtain isoindolinone 220 using the acid 
189 (150 mg, 0.663 mmol), thionyl chloride (0.10 mL, 157 mg, 1.33 mmol), 
catalytic DMF (3 drops), (R)-4-chloro-α-methylbenzylamine (0.10 mL, 113 mg, 
0.729 mmol), DIPEA (0.13 mL, 94 mg, 0.729 mmol) and THF (2  0.8 mL). 
Purification by MPLC (gradient elution, 0-25% EtOAc/petrol) yielded the 
desired product 220 (206 mg, 85%; dr 50:50) as a white solid. Rf(1) 0.71; Rf(2) 
0.53 (33% EtOAc/petrol); m.p. 162.9-164.9 °C; λmax (EtOH)/nm 253sh; νmax/cm-
1 (neat) 1660 (vs, C=O), 3218 (br, O-H); 1H NMR (500 MHz; DMSO-d6) δH 1.45 
(3H, d, J = 7.2 Hz, CHCH3), 1.74 (3H, d, J = 7.1 Hz, CHCH3), 4.41 (1H, q, J = 7.2 Hz, 
CHCH3), 4.54 (1H, q, J = 7.1 Hz, CHCH3), 7.01 – 7.06 (2H, m, H-Ar), 7.10 – 7.15 
(2H, m, H-Ar), 7.21 – 7.25 (3H, m, H-Ar), 7.25 – 7.36 (6H, m, H-Ar), 7.38 (4H, m, 
H-Ar), 7.47 – 7.59 (7H, m, H-Ar), 7.65 – 7.73 (2H, m, H-Ar); 13C NMR (125 MHz; 
DMSO-d6) δC 17.7 (CH3), 19.7 (CH3), 49.9 (CHCH3), 50.5 (CHCH3), 90.9 (C-3), 
91.0 (C-3), 122.2 (C-Ar), 122.3 (C-Ar), 122.9 (C-Ar), 126.2 (C-Ar), 126.3 (C-Ar), 
127.4 (C-Ar), 127.5 (C-Ar), 128.0 (C-Ar), 128.3 (C-Ar), 129.2 (C-Ar), 129.3 (C-
Ar), 130.9 (C-Ar), 131.0 (C-Ar), 131.2 (C-Ar), 132.5 (C-Ar), 140.0 (C-Ar), 141.2 
(C-Ar), 149.0 (C-Ar), 166.0 (C-1), 166.5 (C-1); LRMS (ES+) m/z 364.3 [M+H]+; 
HRMS calcd for C22H1735ClNO2 [M-H]- 362.0953, found 362.0955. 
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(3R,1’R)-2-[1’-(4’’-Chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenylisoindolin-1-one (221) 
and (3S,1’R)-2-[1’-(4’’-chlorophenyl)ethyl]-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenylisoindolin-1-one (222) 
   
General procedure N was followed to obtain 221 and 222 using the 
isoindolinone 220 (200 mg, 0.550 mmol), 1,1-bis(hydroxymethyl)cyclopropane 
(0.26 mL, 281 mg, 2.75 mmol.), InBr3 (39 mg, 0.110 mmol) and DCE (5.5 mL). 
The reaction mixture was heated at 80 °C for 18 h. The diastereoisomers were 
separated by MPLC (gradient elution, 0-20% EtOAc/petrol) to yield the desired 
compounds 221 (81 mg, 33%) and 222 (51 mg, 21%) as white amorphous 
solids. A mixture of the two compounds was also recovered (57 mg, 23%). 
221 
Rf 0.33 (33% EtOAc/petrol); no clear m.p. detected; [α]D
22 +102 (c 0.694, EtOAc); 
λmax (EtOH)/nm 253; νmax/cm-1 (neat) 1681 and 1695 (vs, C=O), 2875, 2933, 
2978 and 3060 (w, aliphatic CH and -CH2-), 3396 (br, O-H); 1H NMR (500 MHz; 
CDCl3) δH -0.02 – 0.08 (2H, m, cyclopropyl), 0.27 – 0.41 (2H, m, cyclopropyl), 
1.63 – 1.65 (1H, ABX m, OH), 1.66 (3H, d, J = 7.2 Hz, CHCH3), 2.56 (1H, d, JAB = 9.5 
Hz, CHAHBO-), 2.74 (1H, d, JAB = 9.5, CHAHB-O), 3.26 (1H, dd, JAX = 5.3 hz, JAB = 
11.3 Hz, CHAHBOH), 3.41 (1H, dd, JBX = 6.1 Hz, JAB = 11.3 Hz, CHAHBOH), 4.24 (1H, 
q, J = 7.3 Hz, CHCH3), 7.03 – 7.12 (1H, m, H-4), 7.22 – 7.29 (2H, m, H-Ar), 7.31 – 
7.39 (3H, m, H-Ar), 7.43 (2H, br, H-Ar), 7.46 – 7.52 (2H, m, H-5 and H-6), 7.54 – 
7.61 (2H, m, H-Ar), 7.85 (1H, m, H-7); 13C NMR (125 MHz; CDCl3) δC 8.7 (CH2 
cyclopropyl), 8.7 (CH2 cyclopropyl), 20.1 (CHCH3), 22.2 (C q cyclopropyl), 53.6 
(CHCH3), 68.2 (CH2-O), 68.4 (CH2OH), 96.6 (C-3), 123.0 (C-7), 123.4 (C-4), 126.6 
(2  C-Ar), 128.6 (2  C-Ar), 128.8 (2  C-Ar), 128.8 (C-Ar), 129.7 (2  C-Ar), 
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129.9 (C-5 or C-6), 132.6 (C-Ar q), 132.9 (C-5 or C-6), 133.2 (C-Ar q), 138.9 (C-
Ar q), 141.9 (C-Ar q), 145.3 (C-Ar q), 168.5 (C-1). One quaternary carbon not 
detected; HRMS calcd for C27H2735ClNO3 [M+H]+ 448.1674, found 448.1667; 
HPLC 96.7% in 0.1% formic acid (aq)/MeCN (Rt 9.4 min); 96.4% in 0.1% 
ammonia (aq)/MeCN (Rt 9.4 min). 
222 
Rf 0.23 (33% EtOAc/petrol); no clear m.p. detected; [α]D
22 -5 (c 0.750, EtOAc); 
λmax (EtOH)/nm 259; νmax/cm-1 (neat) 1680 and 1695 (vs, C=O), 2873, 2928 and 
3070 (w, aliphatic CH and -CH2-), 3386 (br, O-H); 1H NMR (500 MHz; CDCl3) δH 
0.35 – 0.45 (1H, m, cyclopropyl), 0.47 – 0.53 (1H, m, cyclopropyl), 0.53 – 0.63 
(2H, m, cyclopropyl), 1.82 (1H, t, J = 5.7 Hz, OH), 1.90 (3H, d, J = 7.3 Hz, CHCH3), 
2.96 (1H, d, JAB = 9.5 Hz, CHAHBO-), 3.31 (1H, d, JAB = 9.5 Hz, CHAHB-O), 3.64 (2H, 
d, J = 5.7 Hz, CH2OH), 4.40 (1H, q, J = 7.3 Hz, CHCH3), 6.89 – 7.00 (4H, m, H-Ar), 
7.02 – 7.15 (5H, m, 4  H-Ph and H-4), 7.17 (1H, m, H-Ph), 7.44 – 7.52 (2H, m, H-
5 and H-6), 7.79 – 7.89 (1H, m, H-7); 13C NMR (125 MHz; CDCl3) δC 8.9 (CH2 
cyclopropyl), 9.0 (CH2 cyclopropyl), 20.0 (CHCH3), 22.7 (C q cyclopropyl), 52.3 
(CHCH3), 68.0 (CH2O-), 68.3 (CH2OH), 95.4 (C-3), 123.1 (C-7), 123.4 (C-4), 127.0 
(2  C-Ar), 127.9 (2  C-Ar), 128.1 (2  C-Ar), 128.5 (C-Ar), 129.5 (2  C-Ar), 
130.0 (C-5 or C-6), 132.6 (C-Ar q), 132.8 (C-5 or C-6), 138.3 (C-Ar q), 141.2 (C-
Ar q), 145.0 (C-Ar q), 168.2 (C-1). Two carbons not detected; HRMS calcd for 
C27H2735ClNO3 [M+H]+ 448.1674, found 448.1671; HPLC 99.0% in 0.1% formic 
acid (aq)/MeCN (Rt 9.4 min); 98.1% in 0.1% ammonia (aq)/MeCN (Rt 9.4 min). 
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2-(4’’-Aminobenzyl)-4-chloro-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenylisoindolin-1-one (270) 
 
A solution of 269 (50 mg, 0.104 mmol) in ethanol (3.5 mL, 34 mL/mmol) and 
THF (1.6 mL, 15 mL/mmol) was passed over a 10% Pd/C catalyst cartridge 
embedded in a Thales H-cube. Flow rate, H2 pressure, at RT (full H2 mode, 2 h 
45 min). Upon completion of the reaction, the solvent was removed in vacuo. 
The crude product was purified by MPLC (gradient elution on amine silica 
from .0-50% EtOAc/petrol) to obtain the title compound as an off-white solid 
(28 mg, 60%). Rf 0.32 (75% EtOAc/petrol); no clear m.p. detected; λmax 
(EtOH)/nm no maximum of absorption; νmax/cm-1 (neat) 1685 (vs, C=O), 3356 
(m, NH2); 1H NMR (500 MHz; CDCl3) δH 0.06 – 0.15 (1H, m, cyclopropyl), 0.23 – 
0.31 (1H, m, cyclopropyl), 0.34 – 0.42 (2H, m, cyclopropyl), 2.76 – 2.84 (2H, m, 
CH2O-), 3.33 – 3.46 (2H, m, CH2OH), 3.60 (2H, br, NH2), 3.79 (1H, d, J = 14.9 Hz, 
CHAHB-Ar), 4.61 (1H, d, J = 14.9 Hz, CHAHB-Ar), 6.49 – 6.56 (2H, m, H-Ar), 6.98 – 
7.06 (2H, m, H-Ar), 7.32 (5H, br, H-Ar), 7.42 (1H, dd, J = 7.7, 1.1 Hz, H-5), 7.47 
(1H, d, J = 7.7 Hz, H-6), 7.84 (1 H, dd, J = 7.7, 1.1 Hz, H-7); 13C NMR (125 MHz; 
CDCl3) δC 8.7 (CH2 cyclopropyl), 8.8 (CH2 cyclopropyl), 22.2 (C q cyclopropyl), 
42.8 (CH2-Ar), 68.4 (CH2O- and CH2OH), 95.6 (C-3), 114.9 (2 C-Ar), 122.2 (C-7), 
127.0 (2  C-Ar), 127.4 (C-Ar), 128.4 (2  C-Ar), 128.7 (2 C-Ar), 129.7 (C-Ar q), 
130.4 (2  C-Ar), 131.6 (C-6), 133.7 (C-5), 134.7 (C-Ar q), 136.7 (C-Ar q), 141.4 
(C-Ar q), 145.8 (C-Ar q),166.92 (C-1); LRMS (ES+) m/z 471.1 [M+Na]+ ; HRMS 
calcd for C26H2635ClN2O3 [M+H]+ 449.1626, found 449.1627; HPLC 96.2% in 
0.1% formic acid (aq)/MeCN (Rt 6.1 min); 87.5% in 0.1% ammonia (aq)/MeCN 
(Rt 7.6 min). 
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(1’R)-4-Chloro-3-hydroxy-2-[1’-(4’’-nitrophenyl)ethyl]-3-
phenylisoindolin-1-one (265) 
 
General procedure M was followed to synthesize isoindolinone 265 using the 
acid 183 (292 mg, 1.12 mmol), thionyl chloride (0.16 mL, 266 mg, 2.24 mmol), 
catalytic DMF (3 drops), (R)-α-methyl-4-nitrobenzylamine hydrochloride (250 
mg, 1.23 mmol), DIPEA (0.43 mL, 318 mg, 2.46 mmol) and THF (2  1.3 mL). 
Purification by MPLC (gradient elution, 0-80% EtOAc/petrol) yielded the title 
compound (dr 53:47; 0.40 g, 87%) as an off-white solid. Rf(1) 0.32; Rf(2) 0.16 
(25% EtOAc/petrol); m.p. 204.0-206.6 °C; λmax (EtOH)/nm 272; νmax/cm-1 (neat) 
1514 (m, NO2), 1658 and 1675 (m, C=O), 3213 (br, O-H); 1H NMR (500 MHz; 
DMSO-d6) δH 1.41 (3H, d, J = 7.2 Hz, CHCH3), 1.79 (3H, d, J = 7.2 Hz, CHCH3), 4.51 
(1H, q, J= 7.2 Hz, CHCH3), 4.66 (1H, q, J = 7.2 Hz, CHCH3), 7.12 – 7.31 (7H, m, H-
Ar), 7.31 – 7.46 (5H, m, H-Ar), 7.47 (1H, s, H-Ar), 7.52 (1H, s, H-Ar), 7.56 – 7.65 
(4H, m, H-Ar), 7.68 (1H, dd, J = 2.1, 6.4 Hz, H-Ar), 7.70 – 7.78 (3H, m, H-Ar), 7.86 
– 7.94 (2H, m, H-Ar), 8.09 – 8.17 (2H, m, H-Ar); 13C NMR (125 MHz; DMSO-d6) δC 
17.3 (CH3), 19.3 (CH3), 49.7 (CHCH3), 50.2 (CHCH3), 90.5 (C-3), 121.3 (C-Ar), 
122.6 (C-Ar), 122.9 (C-Ar), 126.4 (C-Ar), 126.6 (C-Ar), 127.9 (C-Ar), 128.2 (C-
Ar), 128.3 (C-Ar), 128.6 (C-Ar), 131.6 (C-Ar), 131.6 (C-Ar), 133.5 (C-Ar), 133.9 
(C-Ar), 134.2 (C-Ar), 137.5 (C-Ar), 137.6 (C-Ar), 144.2 (C-Ar), 145.9 (C-Ar), 
149.6 (C-Ar), 149.7 (C-Ar), 164.5 (C-1), 165.1 (C-1); LRMS (ES–) m/z 407.3 [M-
H]–; HRMS calcd for C22H16ClN2O4 [M-H]– 407.0804, found 407.0795. 
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(3R,1’R)-4-Chloro-3-{[1’’’’-(hydroxymethyl)cyclopropyl]methoxy}-2-[1’-
(4’’-nitrophenyl)ethyl]-3-phenylisoindolin-1-one (261) and (3S,1’R)-4-
chloro-3-{[1-(hydroxymethyl)cyclopropyl]methoxy}-2-[1-(4-
nitrophenyl)ethyl]-3-phenylisoindolin-1-one (266) 
   
General procedure N was followed to obtain 261 and 266 using the 
isoindolinone 265 (342 mg, 0.837 mmol), 1,1-bis(hydroxymethyl)cyclopropane 
(0.40 mL, 428 mg, 4.19 mmol.), InBr3 (59 mg, 0.167 mmol) and DCE (8.4 mL). 
The reaction mixture was heated at 80 °C for 18 h. The diastereoisomers were 
separated by MPLC (gradient elution, 0-30% EtOAc/petrol) to yield the desired 
compounds 261 (155 mg, 37%) and 266 (224 mg, 54%) as off-white 
amorphous solids. 
261 
Rf 0.70 (50% EtOAc/petrol); no clear m.p. detected; [α]D
29 +128 (c 0.434, EtOAc); 
λmax (EtOH)/nm 269; νmax/cm-1 (neat) 1519 (s, NO2), 1698 (s, C=O), 2874, 2935 
and 3002 (w, aliphatic CH and -CH2-), 3408(br, O-H); 1H NMR (500 MHz; CDCl3) 
δH -0.05 – 0.04 (1H, m, cyclopropyl), 0.23 – 0.32 (1H, m, cyclopropyl), 0.37 – 
0.54 (2H, m, cyclopropyl), 1.69 (3H, d, J = 7.3 Hz, CHCH3), 1.80 (1H, br, OH), 2.80 
(1H, d, J = 9.1 Hz, CHAHBO-), 3.00 (1H, d, J = 9.1 Hz, CHAHB-O), 3.41 (1H, d, J = 
11.5 Hz, CHAHB-OH), 3.54 (1H, d, J = 11.5 Hz, CHAHB-OH), 4.51 (1H, q, J = 7.3 Hz, 
CHCH3), 7.48 (5H, br, H-Ar), 7.55 (1H, dd, J = 7.7, 1.1 Hz, H-5), 7.61 (1H, app. t, J 
= 7.7, H-6), 7.82 – 7.89 (2H, m, H-Ar), 7.93 (1H, dd, J = 7.7, 1.1 Hz, H-7), 8.21 – 
8.29 (2H, m, H-Ar); 13C NMR (125 MHz; CDCl3) δC 8.6 (CH2 cyclopropyl), 8.7 (CH2 
cyclopropyl), 19.5 (CHCH3), 22.2 (C q cyclopropyl), 53.1 (CHCH3), 68.2 (CH2-
OH), 68.6 (CH2-O), 96.4 (C-3), 122.2 (C-7), 123.8, 127.1 (2  C-Ar), 128.6 (2  C-
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Ar), 129.1 (2  C-Ar), 129.1 (C-Ar), 129.8 (C-Ar q), 131.9, 134.0 (C-5), 134.9 (C-
Ar q), 136.5 (C-Ar q), 140.8 (C-Ar q), 147.3 (C-Ar q), 167.1 (C-1); LRMS (ES+) 
m/z 515.3 [M+Na]+; HRMS calcd for C27H2635ClN2O5 [M+H]+ 493.1525, found 
493.1522; HPLC 96.7% in 0.1% formic acid (aq)/MeCN (Rt 8.8 min); 96.7% in 
0.1% ammonia (aq)/MeCN (Rt 8.8 min). 
266 
Rf 0.50 (50% EtOAc/petrol); no clear m.p. detected; [α]D
29 +31 (c 0.462, EtOAc); 
λmax (EtOH)/nm 271; νmax/cm-1 (neat) 1516 (s, NO2), 1696 and 1698 (s, C=O), 
2872, 2932 and 3002 (w, aliphatic CH and -CH2-), 3395 (br, O-H); 1H NMR (500 
MHz; CDCl3) δH; 0.48 – 0.60 (2H, m, cyclopropyl), 0.60 – 0.72 (2H, m, 
cyclopropyl), 1.84 (1H, app. t, J = 5.6 Hz, OH), 1.96 (3H, d, J = 7.2 Hz, CHCH3), 
3.02 (1H, d, J = 9.1 Hz, CHAHBO-), 3.39 (1H, d, J = 9.1 Hz, CHAHBO-), 3.67 (1H, dd, J 
= 11.4, 5.6 Hz, CHAHB-OH), 3.77 (1H, dd, J = 11.4, 5.6 Hz, CHAHB-OH), 4.49 (1H, q, 
J = 7.3 Hz, CHCH3), 7.07 (4H, br, H-Ar), 7.10 – 7.15 (2H, m, H-Ar), 7.15 – 7.20 
(1H, m, H-Ar), 7.45 (1H, dd, J = 7.7, 1.5 Hz, H-5), 7.50 (1H, app. t, J = 7.7 Hz, H-6), 
7.80 (1H, dt, J = 7.7, 1.5 Hz, H-7), 7.81 – 7.86 (2 H, m, H-Ar); 13C NMR (125 MHz; 
CDCl3) δC 8.9 (CH2 cyclopropyl), 9.1 (CH2 cyclopropyl), 19.6 (CHCH3), 22.7 (C q 
cyclopropyl), 52.1 (CHCH3), 68.1 (CH2-OH), 68.4 (CH2-O), 95.0 (C-3), 122.0 (C-7), 
123.1 (2  C-Ar), 127.0 (2  C-Ar), 128.2 (2  C-Ar), 128.8 (2  C-Ar), 128.9 (C-
Ar), 129.9 (C-Ar q), 131.9 (C-6), 133.8 (C-5), 135.1 (C-Ar q), 136.4 (C-Ar q), 
140.4 (C-Ar q), 146.7 (C-Ar q), 149.6 (C-Ar q), 166.7 (C-1); LRMS (ES+) m/z 
515.2 [M+Na]+; HRMS calcd for C27H2635ClN2O5 [M+H]+ 493.1525, found 
493.1520; HPLC 98.9% in 0.1% formic acid (aq)/MeCN (Rt 9.0 min); 99.1% in 
0.1% ammonia (aq)/MeCN (Rt 9.0 min). 
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(3R,1’R)-2-[1’-(4’’-Aminophenyl)ethyl]-4-chloro-3-{[1’’’’-
(hydroxymethyl)cyclopropyl]methoxy}-3-phenylisoindolin-1-one (262) 
 
A solution of 261 (72 mg, 0.146 mmol) in ethanol (5.0 mL, 34 mL/mmol) and 
THF (2.2 mL, 15 mL/mmol) was passed over a 10% Pd/C catalyst cartridge 
embedded in a Thales H-cube. Flow rate, H2 pressure, at RT (full H2 mode, 2 h 
45 min). Upon completion of the reaction, the solvent was removed in vacuo. 
The crude product (white solid; 371 mg, 96%) was purified by MPLC (gradient 
elution on amine silica from .0-50% EtOAc/petrol) to obtain the title compound 
as a yellow oil (67 mg, 99%). Rf 0.16 (50% EtOAc/petrol); [α]D
27 +122 (c 0.356, 
EtOAc); λmax (EtOH)/nm no maximum of absorption; νmax/cm-1 (neat) 1684 (vs, 
C=O), 2871, 2927 and 3000 (w, aliphatic CH and -CH2-), 3356 (m, NH2); 1H NMR 
(500 MHz; CDCl3) δH -0.04 – 0.05 (1H, m, cyclopropyl), 0.11 – 0.17 (1H, m, 
cyclopropyl), 0.22 – 0.29 (2H, m, cyclopropyl), 1.45 (3H, d, J = 7.3 Hz, CHCH3), 
2.64 (1H, d, J = 9.1 Hz, CHAHBO-), 2.73 (1H, d, J = 9.1 Hz, CHAHBO-), 3.18 – 3.32 
(2H, m, CH2OH), 3.54 (2H, br, NH2), 4.01 (1H, q, J = 7.3 Hz, CHCH3), 6.48 – 6.58 
(2H, m, H-Ar), 7.22 – 7.34 (8H, m, 7  H-Ar, H-5), 7.34 – 7.41 (1H, app. t, J = 7.7 
Hz, H-6), 7.71 (1H, dd, J = 7.7, 1.0 Hz, H-7); 13C NMR (125 MHz; CDCl3) δC 8.6 
(CH2 cyclopropyl), 8.6 (CH2 cyclopropyl), 20.5 (CHCH3), 22.1 (C q cyclopropyl), 
53.6 (CHCH3), 68.3 (CH2-OH and CH2O-), 96.3 (C-3), 114.9 (2  C-Ar), 121.8 (C-
Ar), 127.0 (2  C-Ar), 128.3 (2  C-Ar), 128.7 (C-Ar), 128.9 (2  C-Ar), 129.4 (C-
Ar q), 131.4 (C-Ar), 133.2 (C-Ar q), 133.4 (C-Ar), 135.5 (C-Ar q), 136.9 (C-Ar q), 
140.8 (C-Ar q), 145.6 (C-Ar q), 166.8 (C-1); LRMS (ES+) m/z 482.4 [M+Na]+ 
485.4; HRMS calcd for C27H2835ClN2O3 [M+H]+ 463.1783, found 463.1781; HRMS 
calcd for C26H2635ClN2O3 [M+H]+ 449.1626, found 449.1627; HPLC 95.7% in 
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0.1% formic acid (aq)/MeCN (Rt 6.6 min); 90.1% in 0.1% ammonia (aq)/MeCN 
(Rt 7.5 min). 
N-{4-{[7-Chloro-1-[(1’’’’-(hydroxymethyl)cyclopropyl)methoxy]-3-oxo-1-
phenylisoindolin-2-yl]methyl}phenyl}-1,1,1-trifluoromethanesulfonamide 
(271) 
 
Aniline 270 (45 mg, 0.100 mmol) was dissolved in DCM (0.4 mL, 4mL/mmol) 
and DIPEA (0.05 mL, 39 mg, 0.300 mmol) was added at 0 C followed by Tf2O 
(25.5 µl, 42 mg,0.150 mmol). The mixture was stirred at 0 C for 10 min and at 
RT for 45 min. A solution of NaOH in MeOH (2.5 M, 0.2 mL) and the solution was 
stirred for 30 min at RT. The mixture was partitioned between DCM (5 mL) and 
HCl (aq., 1 M, 2 mL). The aqueous layer was extracted with DCM (5ml) and the 
combined organic layers were washed with HCl (aq., 1 M, 2 mL), brine (5 mL), 
dried (MgSO4) and the solvent was removed in vacuo. The crude product was 
purified by MPLC (gradient elution on amine silica from .0-55% EtOAc/petrol) 
to obtain the title compound as a yellow oil (12 mg, 21%). Rf 0.30 (50% 
EtOAc/petrol); λmax (EtOH)/nm no maximum of absorption; νmax/cm-1 (neat) 
1210 (s, C-F), 1375 (s, SO2str), 1683 (s, C=O), 2780, 2876 and 2921 (w, aliphatic 
CH and -CH2-), 3495 (br, O-H); 1H NMR (500 MHz; CDCl3) δH -0.03 – 0.05 (1H, m, 
cyclopropyl), 0.14 – 0.20 (1H, m, cyclopropyl), 0.27 – 0.34 (2H, m, cyclopropyl), 
1.67 (1H, br, OH), 2.72 (1H, d, J = 9.1 Hz, CHAHBO-), 2.79 (1H, d, J = 9.1 Hz, 
CHAHBO-), 3.31 (1H, d, J = 11.5 Hz, CHAHBOH), 3.37 (1H, d, J = 11.5 Hz, 
CHAHBOH), 4.09 (1H, d, J = 15.1 Hz, CHAHB-Ar), 4.33 (1H, d, J = 15.1 Hz, CHAHB-
Ar), 6.87 – 6.93 (2H, m, H-Ar), 6.96 – 7.02 (2H, m, H-Ar), 7.05 – 7.12 (5H, m, H-
Ar), 7.32 (1H, dd, J = 7.7, 1.0 Hz, H-5), 7.37 (1H, d, J 7.7 Hz, H-6), 7.72 (1H, dd, J 
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7.7, 1.0 Hz, H-7).; 13C NMR (125 MHz; CDCl3) δC 8.7 (CH2 cyclopropyl), 8.7 (CH2 
cyclopropyl), 22.2 (C q cyclopropyl), 42.5 (CH2-Ar), 68.2 (CH2OH), 68.4  
(CH2O-), 95.4 (C-3), 118.7, 121.3, 122.4, 123.4, 126.8, 128.5, 129.0, 130.0, 130.1, 
132.0, 133.5, 134.1, 136.1, 141.2, 167.4 (C-1); LRMS (ES–) m/z 579.3 [M-H]–; 
HRMS calcd for C27H24ClF3N2O5S [M+NH4]+ 598.1385, found 598.1371; HPLC 
95.9% in 0.1% formic acid (aq)/MeCN (Rt 8.9 min); 97.7% in 0.1% ammonia 
(aq)/MeCN (Rt 5.4 min). 
(3R,1’R)-N-{4-{1-[7-chloro-1-[(1-(hydroxymethyl)cyclopropyl)methoxy]-
3-oxo-1-phenylisoindolin-2-yl]ethyl}phenyl}-1,1,1-
trifluoromethanesulfonamide (263) 
 
Aniline 262 (40 mg, 0.0864 mmol) was dissolved in DCM (0.35 mL, 4mL/mmol) 
and DIPEA (44 µL, 33 mg, 0.259 mmol) was added at 0 C followed by Tf2O (35 
µl, 60 mg,0.216 mmol). The mixture was stirred at 0 C for 10 min and at RT for 
45 min. A solution of NaOH in MeOH (2.5 M, 0.2 mL) and the solution was 
stirred for 30 min at RT. The mixture was partitioned between DCM (5 mL) and 
HCl (aq., 1 M, 2 mL). The aqueous layer was extracted with DCM (5mL) and the 
combined organic layers were washed with HCl (aq., 1 M, 2 mL), brine (5 mL), 
dried (MgSO4) and the solvent was removed in vacuo. The crude product was 
purified by MPLC (gradient elution on amine silica from .0-55% EtOAc/petrol) 
to obtain the title compound as a yellow oil (8 mg, 16%). Rf 0.34 (50% 
EtOAc/petrol); λmax (EtOH)/nm no maximum of absorption; νmax/cm-1 (neat) 
1213 (s, C-F), 1374 (s, SO2str), 1677 (s, C=O), 2930 (w, aliphatic CH and -CH2-), 
3030 (br, O-H); 1H NMR (500 MHz; CDCl3) δH -0.04 – 0.04 (1H, m, cyclopropyl), 
0.13 – 0.23 (1H, m, cyclopropyl), 0.29 – 0.40 (2H, m, cyclopropyl), 1.53 (3H, d, J 
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= 7.2 Hz, CHCH3), 2.75 (1H, d, J = 9.1 Hz, CHAHBO-), 2.91 (1H, d, J = 9.1 Hz, 
CHAHBO-), 3.28 (1H, d, J = 11.5 Hz, CHAHBOH), 3.43 (1H, d, J = 11.5 Hz, HAHBOH), 
4.28 (1H, q, J = 7.2 Hz, CHCH3), 7.20 – 7.25 (2H, m, H-Ar), 7.29 – 7.40 (5H, m, H-
Ar), 7.44 (1H, dd, J = 7.7, 1.0 Hz, H-5), 7.50 (1H, d, J = 7.7 Hz H-6), 7.54 – 7.59 
(2H, m, H-Ar), 7.87 (1H, dd, J = 7.7, 1.0 Hz, H-7); 13C NMR (125 MHz; CDCl3) δC 
8.4 (CH2 cyclopropyl), 8.5 (CH2 cyclopropyl), 19.9 (CHCH3), 22.0 (CHCH3), 53.2  
(CHCH3), 68.3 (CH2-OH), 68.4 (CH2-O), 96.6 (C-3), 122.2 (C-7), 123.6 (2  C-Ar), 
127.1 (2  C-Ar), 128.6 (2  C-Ar), 129.1 (C-Ar q), 129.2 (2  C-Ar), 129.7, 131.9 
(C-6), 133.6 (C-Ar q), 134.0 (C-5), 134.9 (C-Ar q), 136.4 (C-Ar q), 140.8 (C-Ar q), 
141.7 (C-Ar q), 167.4 (C-1); LRMS (ES–) m/z 593.3 [M-H]–; HRMS calcd for 
C27H24ClF3N2O5S [M+NH4]+ 612.1541, found 612.1538. 
 Structural biology experimental 9.4
9.4.1 General procedures 
Media supplementation 
All cultures were supplemented with an antibiotic, according to the antibiotic 
selectivity of the pGEX-6P-1 vector and E. coli strain used during recombinant 
protein expression. During IPTG-based induction of protein expression, the 
lactose analogue IPTG was added to the culture to induce protein expression. 
Appropriate amounts of IPTG (200 mM) and ampicillin (50 mg/mL) were 
dissolved in sterile 18.2 MΩ/cm H2O, before storing at -20 °C until required. 
Chloramphenicol (34 mg/mL) was dissolved in 100% ethanol and stored at -
20 °C. 
mHBS buffer 
To prepare the mHBS buffer, 20 mL of aq. NaCl (5 M), 5 mL of aq. DTT (1 M) and 
20 mL of aq. HEPES (1 mM, pH 7.4) were used in 1 L of solution and the pH was 
brought to 7.4 by addition of aq. NaOH (10 M). The buffer was filtered and 
degassed before use and, if required, stored at 4 °C for no longer than one week. 
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Glutathione elution buffer 
To prepare the glutathione elution buffer, glutathione (0.123g) was dissolved in 
mHBS (20 mL) and the pH was brought to 7.4 by addition of aq. NaOH (10 M). 
The buffer was stored at 4 °C and used immediately after preparation. 
Polyacrylamide gel electrophoresis 
SDS-PAGE was used for protein identification and semi-quantitative analysis. 
Pre-cast 12-well acrylamide gels (RunBlue; 12% for GST-MDMX/GST-MDM2 
and 16% for MDMX/MDM2) were used with SDS run buffer (RunBlue). Samples 
were mixed with SDS loading buffer (RunBlue) and denatured at 100 °C for  
5 min before being loaded onto the gel. PageRuler pre-stained protein ladder 
(10-170 kDa, Thermo Scientific) was used. Electrophoresis was carried out at 
180 V and gels were stained with InstantBlue™ protein stain. 
9.4.2 Expression from MDMX and MDM2 gene constructs 
Transformation of competent RosettaTM BL21(DE3) pLysS E. coli 
To allow protein expression, the pre-prepared pGEX-6P-1 plasmid encoding for 
the desired construct (provided by Jane Endicott and Martin Noble) was 
transformed into chemically competent RosettaTM BL21 (DE3) pLysS E. coli. 
Competent cells were mixed with 1 µL of plasmid and incubated on ice for 30 
min. The cells were transferred to a water bath at 42 °C for 30 sec, before 
incubating on ice for 2 min. The cells were recovered through aseptic addition 
of 200 µL super optimal broth with catabolite repression (SOC) medium and 
incubated at 37 °C, 200 rpm for 1 h. The recovered cells were aseptically plated 
onto LB-agar plates supplemented with ampicillin and chloramphenicol and 
incubated overnight at 37 °C to allow growth of transformed bacterial colonies. 
Recombinant MDMX expression following IPTG induction 
Transformed RosettaTM BL21(DE3) pLysS E. coli colonies were used to inoculate 
starter cultures containing 10 mL of Terrific Broth (TB), supplemented with 
ampicillin (20 µL) and chloramphenicol (10 µL). The starter cultures were 
incubated overnight at 37 °C, 200 rpm before aseptic transfer of a 1% (v/v) 
inoculum into an appropriate volume of expression media, supplemented with 
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antibiotics. The culture was incubated at 37 °C, 160 rpm and the optical density 
(OD) of the culture was monitored by spectrometry during growth. Once an 
OD600 nm of 0.6-1.0 was reached, 200 mM IPTG (1 mL) was added to the culture 
to induce protein expression. The culture was incubated at 20 °C, 160 rpm 
overnight. 
Recombinant MDM2 expression following IPTG induction 
BL21 (DE3) E. coli glycerol stocks for  MDM217−125
K51A  and MDM217−125
E69K70A were 
prepared previously by Judith Reeks and stored at -80 °C. A glycerol stock of 
BL21 (DE3) pLysS E. coli for MDM217−108
E69K70A was prepared and stored similarly. 
Transformed BL21 E. coli cells were inoculated in starter cultures containing 10 
mL of LB, supplemented with ampicillin (20 µL) (BL21 (DE3)) or ampicillin (20 
µL) and chloramphenicol (10 µL) (BL21 (DE3) pLysS). The starter cultures were 
incubated overnight at 37 °C, 200 rpm, before aseptic transfer of a 1% (v/v) 
inoculum into an appropriate volume of expression media, supplemented with 
chloramphenicol (1 mL) and/or ampicillin (1 mL). The culture was incubated at 
37 °C, 160 rpm, whilst the optical density of the culture was monitored during 
growth. Once an OD600 nm of 0.6-1.0 was reached, 200 mM IPTG (1 mL) was 
added to the culture to induce protein expression. The culture was incubated at 
20 °C, 160 rpm overnight. 
Cell harvesting 
Following culture, the E. coli cells were harvested by centrifugation (5000  g, 
15 min, 4°C) to give a pellet which was resuspended in mHBS supplemented 
with a protease inhibitor tablet (Roche; 1 tablet/40 mL), flash-frozen in dry ice 
and stored at -20 °C until further use. 
9.4.3 Protein purification 
The resuspended cell pellets were thawed under running water and lysozyme 
(400 µL of 25 mg/mL stock), RNAase A (200 µL of 10 mg/mL stock), DNAase I 
(200 µL of 2 mg/mL stock) and MgCl2 (100 µL of 2 M stock) were added before 
sonication (30% amplitude; 20 sec on/40 sec off intervals for 15 min) whilst on 
ice. The lysed cells were centrifuged (45,000 × g, 60 min, 4°C) and the 
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supernatant (cell-free extract, CFE) was decanted from the pellet and retained. 
Diluted CFE samples were heated at 100 °C for 5 min and then analyzed by SDS-
PAGE to establish whether the target protein had been overexpressed. 
The supernatant was incubated overnight at 4 °C with glutathione Sepharose 4B 
resin (GE Healthcare, bed volume 2 mL). The mixture was loaded by gravity 
flow into a column and washed twice with mHBS (15 mL). The GST-MDMX (or 
GST-MDM2) was eluted with a fresh solution of glutathione in mHBS (20 mL). 
3C protease (50:1 protein:3C protease by weight) was added to cleave MDMX or 
MDM2 from the GST tag and the mixture was incubated overnight at 4 °C. The 
desired protein was separated from the GST tag using gel filtration 
chromatography (Äkta Superdex 75 26/60, isocratic flow of mHBS, Äkta FPLC 
Chromatographic system, UV absorbance 280 nm). 
The protein concentration was measured using a UV-vis spectrophotometer 
NanoDrop 2000 (Thermo Scientific). 
9.4.4 Protein preparation for crystallography 
The purified protein was incubated overnight at 4 °C with a 1.5× molar excess of 
inhibitor (20 mM stock in DMSO). Protein mixtures were concentrated using 
Amicon® Ultra-15 (Millipore) centrifugal filter devices (5000 × g, 4 °C) to a 
concentration between 5 and 10 mg/mL, if possible. 
Crystallization trays were set up in 2-subwell 96-well plates by pipetting 
commercial screens (JCSG+ from Molecular Dimensions and the AmSO4 Suite 
from Qiagen) from deep well blocks prior to protein addition. Protein mixture 
and precipitant were mixed in the subwells by a Mosquito® robot (100 + 100 
nL, 200 + 100 nL, precipitant:protein) using the sitting drop method. Plates 
were sealed and stored in the Minstrel (Rigaku) automated high-throughput 
monitoring system at 4 °C for up to five weeks. Crystals were transferred into a 
solution of 70% precipitant, 30% ethylene glycol, flash cooled in liquid nitrogen 
and shipped to Diamond Light Source (Oxford, UK) for data collection. 
9.4.5 HTRF assay 
The assay was set up and optimized by Judith Reeks and Santosh Adhikari. 
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The inhibitor solutions (20 mM solution in DMSO) were dispensed in an Echo 
qualified 384-well low dead volume microplate source plate using a multi-
channel pipette. 
Buffer A (50 mM Tris at pH 7.4, 100 mM NaCl, 100 μg/mL BSA, 1 mM DTT) and 
buffer B (50 mM Tris at pH 7.4, 100 mM NaCl, 100 μg/mL BSA) were prepared 
fresh. The inhibitors were dispensed into a 384-well black low-binding round 
bottom assay plate (Corning) using a Echo® Liquid Handler 550 (Labcyte), 
starting at 500 μM inhibitor (final assay concentration) and decreasing over a 
semi-log scale. Each well was backfilled with DMSO to a final volume of 250 nL 
and each condition was in duplicate.  
IP3 peptide (300 µM in DMSO) was diluted in buffer A supplemented with 4.2 % 
DMSO to obtain a 500 nM solution and was added to all the wells on the assay 
plate (6 µL). GST-MDMX22-111 (107 µM stock) was diluted with buffer A, first to 
1.07 µM and subsequently to 25 nM and was added to the plate (4 µL). Positive 
(peptide, MDMX and DMSO; no inhibitor) and negative (peptide, buffer A and 
DMSO; no protein or inhibitor) controls were included. The plate was incubated 
on a shaking platform for 1 h. The final concentrations were as follows: 10 nM 
GST-MDMX, 300 nM IP3 peptide, 5 % DMSO. A solution of Tb-anti-GST-antibody 
(3.3 µM stock) was prepared in buffer B (20 nM) and added to each well (10 µL) 
of the assay plate followed by 45 min incubation on the shaker. The plate was 
read using PHERAstar FS (BMG Labtech) microplate reader. 
9.4.6 Differential scanning fluorimetry (DSF) 
The inhibitor solutions (20 mM solution in DMSO) were dispensed in an Echo 
Qualified 384-well low dead volume source plate using a multi-channel pipette. 
The inhibitors were dispensed in 45 nL aliquots in triplicate in a 384-well 
MicroAmp optical assay plate (Life Technologies) using the Echo® Liquid 
Handler 550 (Labcyte). Positive controls include known inhibitors (WT-p53, 
RO-2443, RO-5963, WK298). Negative controls include the absence of inhibitor 
(replaced by DMSO), the absence of protein (replaced by mHBS) and the 
absence of both (replaced by DMSO and mHBS). The plate was prepared by 
adding solutions of MDMX (final concentration 30 µM), SYPRO® Orange 
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(Invitrogen; 1:1000 dilution), 4% DMSO and mHBS to bring the reaction volume 
to 15 µL per well. The final inhibitor concentration was 60 µM. The plate was 
heated from 25 to 95 °C with a heating rate of 3 °C/min using a ViiATM 7 Real-
Time PCR System (Applied Biosystems). The fluorescence intensity was 
measured and the melting points were calculated using an Excel-based DSF 
analysis transformation tool downloaded from 
ftp://ftp.sgc.ox.ac.uk/pub/biophysics (Frank H. Neisen, SGC, Oxford). Data were 
compiled using GraphPad Prism v6. 
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APPENDICES 
Appendix A - Small molecule crystal structures 
Crystal data and structure refinement for 199 
Identification code  rjg130003 
Chemical formula (moiety) C27H25Cl2NO3 
Chemical formula (total) C27H25Cl2NO3 
Formula weight  482.38 
Temperature  120(2) K 
Radiation, wavelength  synchrotron, 0.6889 Å 
Crystal system, space group  monoclinic, P21 
Unit cell parameters a = 8.718(5) Å  = 90° 
 b = 13.802(7) Å  = 
90.290(6)° 
 c = 40.35(2) Å  = 90° 
Cell volume 4854(4) Å
3
 
Z 8 
Calculated density  1.320 g/cm
3
 
Absorption coefficient  0.274 mm1 
F(000) 2016 
Crystal colour and size colourless, 0.150  0.100  0.020 mm3 
Reflections for cell refinement 9961 ( range 2.3 to 26.4°) 
Data collection method Rigaku Saturn 724+ on kappa 
diffractometer 
 wide-frame  scans 
 range for data collection 1.0 to 26.5° 
Index ranges h 11 to 11, k 17 to 14, l 51 to 50 
Completeness to  = 24.4° 99.2 %  
Reflections collected 37658 
Independent reflections 17481 (Rint = 0.0461) 
Reflections with F
2
>2 16747 
Absorption correction none 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0731, 28.8171 
Data / restraints / parameters 17481 / 1819 / 1191 
Final R indices [F
2
>2] R1 = 0.1039, wR2 = 0.2652 
R indices (all data) R1 = 0.1070, wR2 = 0.2679 
Goodness-of-fit on F
2
 1.103 
Absolute structure parameter 0.07(2) 
Extinction coefficient 0.036(3) 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 1.11 and 1.06 e Å3 
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Crystal data and structure refinement for 208 
Identification code  rjg130002 
Chemical formula (moiety) C27H25Cl2NO3·0.5CH2Cl2 
Chemical formula (total) C27.50H26Cl3NO3 
Formula weight  524.84 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, C2 
Unit cell parameters a = 24.1233(10) Å  = 90° 
 b = 11.1421(5) Å  = 
113.934(6)° 
 c = 11.1318(5) Å  = 90° 
Cell volume 2734.8(2) Å
3
 
Z 4 
Calculated density  1.275 g/cm
3
 
Absorption coefficient  0.363 mm1 
F(000) 1092 
Crystal colour and size  0.30  0.30  0.20 mm3 
Reflections for cell refinement 15660 ( range 3.7 to 28.6°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.1 to 28.6° 
Index ranges h 31 to 31, k 14 to 14, l 14 to 14 
Completeness to  = 25.0° 99.8 %  
Reflections collected 31840 
Independent reflections 6227 (Rint = 0.0292) 
Reflections with F
2
>2 5891 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.8988 and 0.9309 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0602, 1.9405 
Data / restraints / parameters 6227 / 1 / 329 
Final R indices [F
2
>2] R1 = 0.0391, wR2 = 0.1027 
R indices (all data) R1 = 0.0420, wR2 = 0.1057 
Goodness-of-fit on F
2
 1.037 
Absolute structure parameter  0.01(5) 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.67 and 0.39 e Å3 
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Appendix B - Crystallization conditions giving crystals 
Summary of the selected crystals for attempted data collection. 
 
Construct Inhibitor Screen/conditions 
MDM2 c1 
306 
Ammonium sulfate suite 
A9 2:1 (0.2 M ammonium iodide, 2.2 M 
ammonium sulfate) 
Ammonium sulfate suite 
C10 2:1 (0.2 M Potassium thiocyanate, 2.2 M 
ammonium sulfate) 
MDM2 c2 
Ammonium sulfate suite 
C6 1:1 (0.2 M potassium iodide, 2.2 M 
ammonium sulfate) 
MDM2 c1 159 
C7 1:1 (0.2 M potassium nitrate, 2.2 M 
ammonium sulfate) 
 
Appendix C - Construct sequences 
Non-native amino acids recognized by 3C protease are highlighted in green. 
Human MDMX18-111 uncleaved 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLP
YYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYS
KDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPM
CLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVL
FQGPLGSRISPGQINQVRPKLPLLKILHAAGAQGEMFTVKEVMHYLGQYIMVKQLY
DQQEQHMVYCGGDLLGELLGRQSFSVKDPSPLYDMLRKNLVTLAT 
Human MDMX18-111 cleaved 
GPLGSRISPGQINQVRPKLPLLKILHAAGAQGEMFTVKEVMHYLGQYIMVKQLYDQ
QEQHMVYCGGDLLGELLGRQSFSVKDPSPLYDMLRKNLVTLAT 
Molecular weight: 11070.9 Da 
Extinction coefficient: 7450 M-1 cm-1 
Human MDMX22-111 uncleaved 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLP
YYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYS
KDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPM
CLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVL
FQGPLGSGQINQVRPKLPLLKILHAAGAQGEMFTVKEVMHYLGQYIMVKQLYDQQE
QHMVYCGGDLLGELLGRQSFSVKDPSPLYDMLRKNLVTLAT 
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Human MDMX22-111 cleaved 
GPLGSGQINQVRPKLPLLKILHAAGAQGEMFTVKEVMHYLGQYIMVKQLYDQQEQH
MVYCGGDLLGELLGRQSFSVKDPSPLYDMLRKNLVTLAT 
Molecular weight: 10617.4 Da 
Extinction coefficient: 7450 M-1 cm-1 
Human MDMX26-111 uncleaved  
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLP
YYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYS
KDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPM
CLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVL
FQGPLGSQVRPKLPLLKILHAAGAQGEMFTVKEVMHYLGQYIMVKQLYDQQEQHMV
YCGGDLLGELLGRQSFSVKDPSPLYDMLRKNLVTLAT 
Human MDMX26-111 cleaved  
GPLGSQVRPKLPLLKILHAAGAQGEMFTVKEVMHYLGQYIMVKQLYDQQEQHMVYC
GGDLLGELLGRQSFSVKDPSPLYDMLRKNLVTLAT 
Molecular weight: 10204.9 Da 
Extinction coefficient: 7450 M-1 cm-1 
Human 𝐌𝐃𝐌𝟐𝟏𝟕−𝟏𝟐𝟓
𝐊𝟓𝟏𝐀 uncleaved 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLP
YYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYS
KDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPM
CLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVL
FQGPLGSSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMAEVLFYLGQYIMTKR
LYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTS
VSEN 
Human 𝐌𝐃𝐌𝟐𝟏𝟕−𝟏𝟐𝟓
𝐊𝟓𝟏𝐀  cleaved 
GPLGSSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMAEVLFYLGQYIMTKRLY
DEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVS
EN 
Molecular weight: 12874.7 Da 
Extinction coefficient: 10430 M-1 cm-1 
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Human 𝐌𝐃𝐌𝟐𝟏𝟕−𝟏𝟎𝟖
𝐄𝟔𝟗𝐊𝟕𝟎𝐀 uncleaved 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLP
YYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYS
KDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPM
CLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVL
FQGPLGSSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKR
LYDAAQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLV 
Human 𝐌𝐃𝐌𝟐𝟏𝟕−𝟏𝟎𝟖
𝐄𝟔𝟗𝐊𝟕𝟎𝐀 cleaved 
GPLGSSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLY
DAAQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLV 
Molecular weight: 11067.9 Da 
Extinction coefficient: 10430 M-1 cm-1 
Human 𝐌𝐃𝐌𝟐𝟏𝟕−𝟏𝟐𝟓
𝐄𝟔𝟗𝐊𝟕𝟎𝐀 uncleaved 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLP
YYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYS
KDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPM
CLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVL
FQGPLGSSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKR
LYDAAQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTS
VSEN 
Human 𝐌𝐃𝐌𝟐𝟏𝟕−𝟏𝟐𝟓
𝐄𝟔𝟗𝐊𝟕𝟎𝐀 cleaved 
GPLGSSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLY
DAAQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVS
EN 
Molecular weight: 12816.7 Da 
Extinction coefficient: 10430 M-1 cm-1 
Sequence alignments for MDM2, 𝐌𝐃𝐌𝟐𝟏𝟕−𝟏𝟐𝟓
𝐊𝟓𝟏𝐀  and MDMX 
MDM2 
MDM217−125
K51A  
MDMX 
MCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTM 50 
-----------GPLGSSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTM 39 
MTSFSTSAQCSTSDSACRISPG-QINQVRPKLPLLKILHAAGAQGEMFTV 49 
KEVLFYLGQYIMTKRLYDEKQQHIVYCNSDLLGDLFGVPSFSVKEHRKIY 100 
AEVLFYLGQYIMTKRLYDEKQQHIVYCNSDLLGDLFGVPSFSVKEHRKIY 89 
KEVMHYLGQYIMVKQLYDQQEQHMVYCGGDLLGELLGRQSFSVKDPSPLY 99 
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TMIYRNLVVVN--------------------------------------- 111 
TMIYRNLVVVN--------------------------------------- 100 
DMLRKNLVTLATATTDAAQT------------------------------ 119 
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